AU2015224425A1 - Fused benzoxazepinones as ion channel modulators - Google Patents

Abstract

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula 1: wherein Z1, Z2, Z3 , Z4, X, Y, R2 R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Description

P/001011 Reguation 3.2 AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Fused benzoxazepinones as ion channel modulators The following statement is a full description of this invention, including the best method of performing it known to us: FUSED BENZOXAZEPINONES AS ION CHANNEL MODUIATORS Cross-Reference to Related Applications [0001] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional 5 Application Serial Numbers 61/503,980, filed on July 1,2011 and 61/582,160, filed on December 30, 2011, the entirety of which are both incorporated herein by reference. Field [0002] The present disclosure relates to novel compounds and to their use in the treatment of various diseases, including cardiovascular diseases and diabetes. The 10 disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions comprising such compounds. Background [0003] The late sodium current (INaL) is a sustained component of the fast Na+ current of cardiac myocytes and neurons. Many common neurological and cardiac conditions are 15 associated with abnormal (INaL) enhancement, which contributes to the pathogenesis of both electrical and contactile dysfinction in mammals. See, for example, Pathophysiology and Pharmacology of the Cardiac "Late Sodium Current", Pharmacology and Therapeutics 119 (2008) 326-339. Accordingly, compounds that selectively inhibit (INaL) in mammals am useful in treating such disease states. 20 [0004 One example of a selective inhibitor of(INaL) is RANEXA, a compound approved by the FDA for the treatment of chronic stable angina pectoris. RANEXA has also been shown to be useful for the treatment of a variety of cardiovascular diseases, including ischemia-reperfusion injury, arrhythmia and unstable angina, and also for the treatment of diabetes. It would be desirable to provide novel compounds that selectively 25 inhibit ([NaL) in mammals and that have the similar or improved selectivity over peak INa inhibition of the cardiac sodium channel as RANEXA. 1A Summary [0005] Accordingly, typical embodiments the present disclosure provide novel compounds that function as late sodium channel blockers. In one embodiment, the disclosure provides compounds of Formula I: ZI Y-N -'2 R3 I I Z2 x R 4 5 wherein: Z' and Z 2 are each independently selected from the group consisting of CR 7 and N; 10 Z and Z 4 are each independently selected from the group consisting of CR 7 , C-Q

R

1 and N, provided that one of Z 3 and Z 4 is C-Q-R' and the other of Z 3 and Z4 is

CR

7 or N and further provided that only one of Z 1 , Z 2 and Z4 is N; X is -O- or -NR-; Y is -C(O)-, -C(R") 2 -or -S(O) 2 -; 15 Q is a covalent bond, -O-Co-z alkylene, -NR 11 -Co-2 alkylene, C2 alkylene,

C

2 alkenylene or C 2 alkynylene; R is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently 20 selected from the group consisting of halo, -NO 2 , -CN, -SF 5 , -Si(CH3)3, -O-Rao, -S-R0, -C(0)-Re, -C(O)-Oleo, -N(R2)(e), -C(O)-N(R)(e), -N(Ra)-C(0)-R?2, -N(Re)-C(O)-OR?2, -N(e)-S(0)2-R2, -S(O)2-Re, -O

S(O)

2 -RY, -S(O)2-N(R)(RM), C 1

.

4 alkyl, C 2

.

4 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 25 wherein said C 1 .- alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group 2 consisting of halo, -NO 2 , aryl, heterocyclyl, heteroaryl, C 1

.

4 alkyl,

C

1 .s haloalkyl, cycloalkyl, -N(R 2 o)(2), -C(O)-0, -C(O)-OR' 0 ,

-C(O)-N(R

2 )(Re), -CN and -O-R 0 ;

R

2 is -C 1 i alkylene-R, -L-R, -L-C 1 .- alkylene-R 5 , -C 1 .- alkylene-L-R or -C 14 5 alkylene-L-C 1 .- alkylene-R 5 ; wherein each -C.6 alkylene is optionally substituted by one substituent independently selected from the group consisting of C2 alkynyl,.halo,

-NO

2 , -CN, -0- 0 ', -N(RaXR 22 ), -C(O)-R 0 , -C(O)-OR 26 , -C(O) N(R)(R), -N(R 2 )-S(0) 2 -R, cycloalkyl, aryl, heteroaryl or 10 heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 .6 alkyl, C 2 .M alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, 15 -N(R 2 )('R), -C(O)-R, -C(O)-OR t , -C(O)-N(R 2 )(Re), -CN and -O-R"; L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(O) 2 NH-, -C(O)NH-, or -NHC(O)-; provided that when Y is -C(') 2 -, then R 2 is -L-R 5 , -L-CI. alkylene-R 5 , -C 14 alkylene 20 L-R 5 or -C..s alkylene-L-Cl- alkylene-R' and L is not -C(0)-; and when R 2 is -L-R0 or -L-C 1 .- alkylene-R 5 , then L is not -0-, -S-, -NHS(O) or -NHC(O)-; each R3 is independently hydrogen, deuterium, C1.6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 25 wherein said C 1

.

4 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(t)(Re), -C(O)-R 2 , -0(O)-OR, -C(O)-N(R)(R 2 ), -CN and -0-R; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are 30 optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 3 C1.4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

20 )R), -C(O)-R 20 , -C(O)-OR20, -C(O)-N(R 20 )(Re), -CN and

-O-R

2 0 ; and wherein said C1.4 alkyl, aralkyl, cycloalkyl, aryl, 5 heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2 0 Re),

-C(O)-R

20 , -C(O)-OR 20 , -C(O)-N(R 2 0 Re 2 ), -CN and -0 e13; 10 or when Y is -C(O)-, then R 2 and one of R? can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C1.4 alkyl,

-O-R

20 , -N(R 2 0 )(R), -N(R 20 )-C(O)-OR20 and -C(O)-OR20; and 15 wherein said C1.4 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; each R 4 is independently hydrogen, deuterium, C1.4 alkyl, -C(O)- 26,

-C(O)-N(R

2

')(R

2 t), cycloalkyl, aryl, heteroaryl or heterocyclyl; 20 wherein said C1.4 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2h(R"), -C(O)- 20 ,

-C(O)-OR

20 , -C(O)-N(R 2 0 )(R3), -CN and -0-R 2 0 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are 25 optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1.4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

20 )(R), -C(O)-R 20 , -C(O)-OR 20 , -C(O)-N(R 20 )Re), -CN and

-O-R

20 ; and 30 wherein said C1.4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted 4 with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , -N(e)(e), -C(O)-R o, -C(O)-OR?', -C(O)-N(Re)(R), -CN and -O-R; 5 or two B3 or two R 4 together with the carbon atom to which they are attached form an oxo;

R

5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from 10 the group consisting of C 1 .6 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R3), -N(R3)-S(O) 2

-R

0 , -N(R20_ C(O)-R?, -C(O)-R 2 0 , -C(O)-OR 2 0 , -C(O)-N(R)(R 2 ), -CN, oxo and -0 R20 wherein said C 1 -6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl 15 are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

1

.

4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -CO)-R?, -C(O)-00, -C(O)-N(R)R 2 e), -CN and -0-R 0 ; and wherein said C 14 6 alkyl, cycloalkyl, aryl, heterocyclyl or 20 heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO2, -CF 3 , -N(Rt)(Re), -C(O) R2, -C(O)-0R 0 , -C(O)-N(R 2 )(Rt), -CN, -S(O) 2 -R and -O-R 2; 25 R is hydrogen, C 1

.

4 alkyl or cycloalkyl; wherein said C 1 .6 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , -N(R 2

)(R

2 ), -C(O)-R 20 , -C(O)-OR, -C(O)-N(R 2 )(R), -CN and 30 R' is hydrogen, halo, -O-k 20 or C 14 6 allkyl R is hydrogen or C 1 alkyl; 5 R20 and R2 are in each instance independently selected from the group consisting of hydrogen, C1 alkyl, Cm alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the CI4 alkyl, C2 alkenyl, C2 alkynyl, cycloalkyl, heterocyclyl, 5 aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2

R

26 , -CN, C13 alkoxy, -CF 3 , -OCF3, -OCH 2

CF

3 , -C(O)-NH2, aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with CA 10 alkyl or cycloalkyl; or when R 20 and R 2 are attached to .a common nitrogen atom R0 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , 15 -S(O) 2

R

26 , -CN, C1-3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 2 6 is independently selected from the group consisting of hydrogen, C1.4 alkyl, aryl and cycloalkyl; wherein the CIA alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting 20 of hydroxyl, halo, Cj4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof; provided that when Y is -C(O)-, X is -0-, each R 4 is hydrogen, R 2 and R 3 together with the atom to which they are attached form a piperazine which is optionally 25 substituted with tert-butoxycarbonyl and Q is a bond, then R 1 is not unsubstituted phenyl or morpholinyl; and that when Y is -S(0) 2 -, X is -0-, R2 is benzyl, each R? is hydrogen, Z 4 is C-Q-R, Q is a bond and R' is aryl or heteroaryl, then both R are hydrogen. 6 [00061 In certain embodiments, the disclosure provides compounds of Formula IA: R2 (R10)n Cy% Q N N

(R

17 )m R4 R 4 IA wherein: 5 Cy is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; Q is a covalent bond, -0-Co- 2 alkylene, -NR 1 -Co.2 alkylene, C 2 alkylene,

C

2 alkenylene or C 2 alkynylene; m is 0, 1, 2 or 3; n is 0, 1,2, 3,4 or 5; 10 each R' 0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH 3

)

3 , -0-Rr, -S-R, -C(0)-R2 0 , -C(O)-0R 0 , -N(R 2

')R

2 "), -C(O) N(R2)(R), -N(R)-C(O)-R 2, -N(e)-C(O)-OR , -N(Ra)-S(O)2-RE,1-S(O)2 R2, -)-S(O) 2 - , -S(0)-N(R)p(RE), C 14 alkyl, C 2 4 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 15 wherein said C 14 alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , aryl, heterocyclyl, heteroaryl, C- alkyl, C 1

.

3 haloalkyl, cycloalkyl,

-N(R

2

)(R

2 ), -C(O)-R 0 , -C(O)-03% -C(O)-N(R)(R), -CN and -0-R; 20 R 2 is -C 14 alkylene-R 5 , -L-R 5 , -L-C 14 alkylene-R 5 , -C 1 4 alkylene-L-R' or -C 14 alkylene-L-C 34 alkylene-R; wherein each -C 1 4 alkylene is optionally substituted by one substituent independently selected from the group consisting of C 24 alkynyl, halo,

-NO

2 , -CN, -O-R , -N(R)(Re), -C(O)-R 0 , -C(0)-OR 2 , -C(O) 25 N(R)(R), -N(R 2 )-S(0) 2 -R , cycloaLkyl, aryl, heteroaryl or heterocyclyl; and 7 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 14 alkyl, C 24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, 5 -N(R )(Re), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R)(Re), -CN and 00 L is -0-, -S-, -C(O)-, -NIS(O)2-, -S(0)2NH-, -C(O)NH- or -NHC(O)-; provided that when R is -L-R' or -L-C 1 4 alkylene-R, then L is not -0-, -S-, -NHS(0) 2 - or -NHC(O)-; and 10 each R3 is independently hydrogen, deuterium, C 14 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 14 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R 2 , 15 -C(O)-0R 0 , -C(O)-N(R)(R), -CN and -O-R 0 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo,. -NO 2 ,

C

14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 20 -N(Rt)(R 2 ), -C(O)-R, -C(O)-OR 0 , -C(O)-N(RY)(R), -CN and -O-R; and wherein said C 14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected 25 from the group consisting of halo, -NO 2 , -N(R)(R), -C(O)-R, -C(O)-0R, -C(O)-N(R")(R), -CN and -0

R

0 or R 2 and one of R3 can join together with the atom to which they are attached to form a heterocyclyl; 8 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of CI.. alcyl,

-O-R

20 , -N(R)(R), -N(Rn)-C(O)-ORO and -C(O)-OR 0 ; and wherein said Ci- alkyl is optionally substituted with one, two or 5 three substituents independently selected from the group consisting of halo and heteroaryl; each Re is independently hydrogen, deuterium, Ci4 alkyl, -C(O)-OR 6 , -C(O)-N(R)(R), cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said Ci- alkyl is optionally substituted with one, two or three 10 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R?), -C(O)-R,

-C(O)-OR

0 , -C(O)-N(kR(), -CN and -O-Ra; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 15 independently selected from the group consisting of halo, -NO 2 , C4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(R"), -C(O)-R 0 , -C(O)-OR 0 , -C(0)-N(R)(R 2 ),.-CN and

-O-R

0 ; and wherein said CI alkyl, aralkyl, cycloalkyl, aryl, 20 heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO2, -N(R 2)(R?2), -C(0)-R ', -C(O)-Oea, -C(O)-N( R (R), -CN and -0-R?; 25 R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C14 alkyl, C2-4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R 2 ), -N(R)-S(O) 2 -Rr, -N(R 30 C(O)-R 2 , -C(O)-RO, -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN, oxo and -0 RE; 9 wherein said C1.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Cj.4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), 5 -C(O)-Re, -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -O-R; and wherein said CI-4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(Re), -C(0) 10 Re, -C(O)-OR, -C(O)-N(R)(R 2 e), -CN, -S(0) 2

-R

0 and

-O-R

0 ; R7 is halo, -O-R 0 or C1-6 alkyl; Ra and R? are in each instance independently selected from the group consisting of hydrogen, C 1

-

6 alkyl, Cu, alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl 15 and heteroaryl; wherein the C1.4 alkyl, C2-4 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, acylamino, oxo, -NO2 -S(0) 2 Re 6 , -CN, C1.3 alkoxy, -CF 3 , 20 -OCF 3 , -OCH 2

CF

3 , -C(0)-NHl 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with CiA alkyl or cycloalkyl; or when R 2 and R are attached to a common nitrogen atom R 20 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 25 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CIA alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

6 , -CN, C-a alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C14 alkyl, aryl and cycloaLkyl 10 wherein the C 1 .4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of 5 stereoisomers or tautomer thereof; provided that when each R is hydrogen, R 2 and R 3 together with the atom to which they are attached fbrm a piperazine which is optionally substituted with tert-butoxycarbonyl, Q is a bond and Cy is phenyl or morpholinyl, then n is 1, 2, 3,4 or 5. 10 [00071 Some embodiments provide a method of using the compounds of Formula 1, IA, IB, U, IIA, IIB, III, 1IA, IV, V, VI, Vi, VIA, MX, X, XII or XIII, or additional Formula(s) described throughout, in the treatment of a disease or condition in a mammal that is amenable to treatment by a late sodium channel blocker. Such diseases include cardiovascular diseases such as atrial and ventricular arrhythmias, heart failure (including 15 congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischenia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease and intermittent. claudication. Such diseases may also include diabetes and conditions related to-diabetes, 20 e.g. diabetic peripheral neuropathy. Such diseases may also include conditions affecting the neuromuscular system resulting in pain, seizures or paralysis. Therefore, it is contemplated that the compounds of the disclosure and their phannaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers and/or tautomer forms are potentially of use as medicaments for the treatment of the aforementioned diseases. 25 [0008] In certain embodiments, the disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the disclosure (e.g. a compound of Formula I or additional Formulas described throughout), and at least one pharmaceutically acceptable excipient. [0009J In certain embodiments, the compound is: 30 4-((3-methyloxetan-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (11-1); 11 4-(2-(pyrrolidin-1 -ylethy1)-7-(4-Qrif luomomethoxy)pheny1)-3,4 dihydrobenzo[t][1,4]oxazepin-5(2B)-onie (11-3); 4-((5-cyolobutyl- 1,3,4-oxdiaol-2-yl)nefyi)-7-(4-Qtrifluomomethoxy)pheayl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5(211)-one (11-4); 5 4-((2,3-dihydrobenzo*][1,4]dioxin-6-y1)methl)-7-(4-(trifluoromethoxy)pheny1)-,4 dihydrobenzo[f][ I ,4]oxazepin-5(2H)-one (11-5); 4-(quinolin-2-ylmetliyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fjl,4]oxazepin-5(2H)-one (11-7); (R)-2-(pyrinii-2-ylmethyl)-8-(4-Qrifluowomethyl)phenyl)-3,4, 12, 12a-tetrahydmo-1H 10 benzofpyrazino[2,1-c] [1 ,4]oxazepin-6(2H)-one (11-8); 4-(cyclopropylmethiyl)-7-(4-(trifluoromethoxy)phenyI)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(21-1)-onie (11-10); (S--ehl4(yiii--hntyl--4(ilooehlpey)34 dihydrobenzo[fjl,4]oxazepin-5(21-one (11-12); 15 (R)-3-inethyl-4-(pyrimidin-2-ylmethyl)-7-(4-(tiluoromethyl)phenyl)-3,4 dihydiobenzo[f][1,4]oxazepin-5(2H)-one (11-13); 6-((5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dlhiydrobenz[fl[A]oxazepim.4(5H) yl)methayl)piooliuonitrle (H1-14); 7-(4-(trfluoromethoxy)phenyl)-4-((6-(trfluoronxethyl)pyridin-2-yl)methy9)-3,4 20 dihydrobenzo[fjl ,4]oxazepin-5(211-oue (H15i); 7-(4-(trifluoromethoxy)phenyl)-4-((6-(tifluoromethyl)pyridin-3-yl)niethyl)-3,4 dihydrobenzo[fi[1,4]oxazepin-5(2fl-one (11I-16); 4-((6-methylpyridin-2-yl)znethyl)-7-(4-(trilluoromethoxy)phenyl)-3,4 dihydrobenzo[fj [1 ,4]oxazepin-S(211)-oue (H-17); 25 (2R, 1 laS)-2-amino-7-(4-(tritluoromethyl)phenyl)-2,3,1 1,11 a tewrahydrzobenzo[t]pyrrolo[21-c( 1 ,4]oxazepin-5Q 11)-one (11-21); (R)-2-(2,2-clifluoroethyl.)-8-(4-(trifluoromethyl)phenyl)-3,4, 12,1 2a-tetrahiydro-1IH benzo[t]pyrazino [2, 1-c]f1,4]oxazepin-6(2U)-one (11-22); 12 (R)Kj-2-ethyl-8-(4-(trif luoromethyl)phenyl)-3,4, 12, 12a-tetrahydro-11I benzo[f]pyrazino[2,1-g][1 ,4]oxezepin-6(211)-one (11-23); (S)-2-(2,2-difluoroethyl)-8-(4-(trifuowznethyl)phenyl)-3,4,12, 12a-tetrahydro-1H benzo[flpyrazino[2,1-c][1 ,4]oxazepin-6(211'-aae (11-24); 5 (S)-2-eothyl-8-(4-(trifluoromethyl)pheuyl)-3,4, 12,12a-tetrahydmo-IH benzo[f~pyrazino[2,1-o,][1 ,4]oxazepin-6(2H)-one (11-25); 4-(pyrazin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(2I)-one (11-31); 4-((5-methyloxazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 10 dihych'obenzo[f][1 1 4]oxazepin-5(2H-)-one (11-33); 7-(t~ifluoromethoxy)phenyl)-(2(2,5,-rimethy.1,3-dioxan.2yl)ethyl)>3,4. dihydrobenzo[fj[1 ,4]oxezepin-5(21-1)-one M1-35); tert-butyl (2R,1laR)-5-oxo-7-(4-(trif'luoromethyl)phenyt)-1,2,3,5,1 1,11 a hexahydrobenzo [fjpyrrola[2,1-c [ 1,4joxazepin-2-ylcarbamate (11-39); 15 4-((5-(pyridin-2-yI)isoxazol-3-yl)methyl)-7-(4-(tiifluoromettoxy)pheayl)-3,4 dihydrobenzo~fJ[1 ,4)oxazepia-5(2H-)-one (11-41); 4-((4,6-dimnethoxypyrimidin-2-yl)metiyl)-7-(4-(trifluaorometltoxy)phenyl)-3,4 dihydrobenzo[fl[1 ,4)oxazepin-5(24)-oae (11-42); ethyl 3-((5-oxo-7-(4-}trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4oxazepin-4(5H) 20 yl)methyl)benzoate (H1-43); 4-(2-(pyrimidin-2-yl)etkyl)-7-(4-(trifluowomethoxy)pheuyl)-3,4 dihydrobeazo[f][1 ,4]oxazepin-5(211)-one (0-44); 4-(3,4-diftuorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f 1,4]oxazepin 5(211)-one (11-45); 25 4-(2-chlorobenzyl)-7-(4-(rifluoromethoxy)phenyl)-3,4-diiydrobenzol] [1 ,4]oxazepin 5(211-one (1147); 4-(2,6-dichlarobenzy1)-7.-(4-(frifluomomethoxy)pheny)-3,4 dihydrobenzo [I][1 ,4]oxazepin-5(2H)-one (1148); 13 4-(2,6-ditluorobenzyl)-7-(4-(triftuoroniethoxy)phenyl)-3,4-dihydrobenzo[fJ [1 ,4]oxazeprn 5(211)-one (11-49); 4-(2-(lH-pyrazol-I -yl)ethyl)-7-(4-(trifluoromethoxy)phenyt)-3,4 dihydrobenzol[fjll,4]oxazepin-5(211-oue (11-50); 5 (28,11 aS)-2-amino-7-(4-(trifluoromethyl)phenyl)-2,3,1 1,11 a tefrahydrobenzoffpyrrolo[2,1 -oJ[1 ,4]oxazepin-5(1 11)-one (11-51); 4-(2-(PYridina-2-yl)ethyl)-7-(4-(trifluoinmethoxy)phenyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one (11-54); 4-(2-fhaorobenzyl)-7-(4-(frifluoromethoxy)phenyl)-3,4-dihydrobenzo[fj[ 1,4]oxazepin 10 5(211)-one (H-57); (R)-7-(4-(trifluoroniethyl)phenyl)-2,3,1 1,1 la-tetrahydrobenzo[flpynolo[2,1 c][I 1 4]ozaepin-5(IU)-one (U1-59); 4-(prnidin-2-ylmnethyl)-7-(4-(trifluoromethy)phenyl)-3,4 dihydrobenzo( ]I,4oxazepin-5(2H)-one (11-61); 15 4-(4-fluorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,A-dihydrobenzo[fJ[1 ,4]oxazepin 5(210-one (H1-62); 4-((1-methyl- 1H-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1 ,4]oxazepiu-5 (210-one (H-64); 4-((5-chloropyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 20 dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one (H-65); 4-(pyridiu-4-YlmethYl)-7-(4-(tiifluoronaethoxy)phenyl)-3,4 dihydrobenzorfj[1 ,4]oxazepin-5(2H)-one (11-67); 4-((5-oyclopropyl-1 ,3,4-oxadiazol-2-yl)methyl)-7-(4-(tifluownzethoxy)phenyl)-3,4 dihydrobenzo[f] [1 ,4]oxazepin-5(2ff)-one (11-68); 25 4-(2-Q(yrimidin-2-yloxy)ethyl)-7-(4-Qrifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,A]oxazepin-5(211)-one (11-69); 4-(pyriclin-3-ylniethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1 A]oxazepin-5(2H1)-one (11-70); 14 4-(pyridin-2-ylmethyl)-7-QI-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one (11-72); 4-(pyrirnidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenza[fJ[1 ,4]oxazepin-5(2H)-one (11-73); 5 4-((3-methylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H1)-oDne (11-75); (R)-2-(2,2,2-friflnoroethyl)-8-Q1-(trifluoromethyl)phenyl)-34, 2,12a-tetalydro-1H benzo[f]pyrazino[2,1-o) [1 ,4]oxazepin-6(211)-one (H-83); 4-(pyrimidin-2-ylmethyl)-7-p-tolyl-3,4-diydrobenazo[f][1,4oxazepin-5(2H)-one (1U-87); 10 7-(4-cblorophenyl)-4-(pyimidin-2-ylmethyl)-3,--diaydrobenzo[fJ[1,4]oxazepiu-5(2H) one (11-88); 7-$--isopropylphenyl)-4-(pyrimidin-2-yhnethyl)-3,4-dihydrobenz[][1 ,4]oxazepin 5(241-one- (11-89); 7-(4-ethylpheuyl)A-(pyrimiidin-2-ymethyl)-3,4-dihydrobenzo[f][ 1,4]oxazepin-5(2E1')-one 15 (H-91); 7-(4-oyolopropylpheay)-4-(pyriniidia-2-ylmethy1)-3,A-dihydrobenzo[f] [1 ,4]oxazepin 5(213)-one (11-92); dihydrobenzo[f][1 ,4]oxazepin-5(2H')-one (11-95); 20 7-(4-isobutoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,+dihyliobenzo[fJ[1,4]oxazepin 5(211)-one (11-97); 7-(4-tert-bntylpheny1)-4-(pyrimidin-2-ylmethiyl)-3,4-dihydrobenzo[fjfi,4Joxazepin 5(211)-one (11-98); 7-(4-cyclopropoxypheayl)-4-(pyrimidin-2-ylmiethyl)-3,4-dihydrobenzo[][ 1,4]oxazepin 25 5(211-one (11-1 02); 7-(4-fluorophenyl)-4-(pyrimidin-2-yhnethy)-3,4-dihydrobenzo[f] [1 ,4]oxazepin-5(211) one (11- 104); 7-(2-fluoro-4-(trifluoromethyl)phenyl)-4-(pyrimidin-2-ymethyl)-3,4 dihydrobenzolfJ[1 5 4joxazepin-5(211I)-one (11-105); 15 7-(3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)-4-(pyrimidin-2-ylniethyl)3,4 dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one (11-106); 4-(pyrimidin-2-ylmethyl)-7-(4-(2,,2,2-trifluoroethoxy)phenyl)-3,4 dihydrobenzo[fjl[1 A]oxazepin-5(2H)-orie (11-107); 5 7-(2-chlom-4-(trifluoromethyl)phenyl)-44(yrimidin-2-ymehiyl)-3,4 dihydrobenzo[fJ[1 ,4]oxazepiu-5(2H)-ane (11-1 10); 7-(4-(trifluoromthoxy)phenyl)-4-((4-(trifluoromethy)pyrixidin-2-yl)methyl)-3,4 dihydrobenzo[fJ[1 ,4]oxazepin-5(2H)-oae (11-113); 7-(4-(trifluoromethoxy)pheaiyl)-4-((5-(6-(tifluoromethyl)pyidin-3-y)pyriniidin-2 10 y1)methyl)-3,4-dihydmrbenzo[fl[1,4]oxazepin-5(2H)-one (11-115); 7-(4-chlow-2-fluorophenyl)-4-(yrimidin-2-ylmethy)-3,4-dihydrobenzo[f] [1 ,4]oxazejpin 5(210-one ([1-117); 1 -(4-(5-oxo-4-(pyrimidin-2-yhnethyl)-2,3,4,5-terahydrobenzo[fJ [1 ,4]oxazepin-7 yl)phenyl)o~yolopentaneoarbonitrile (11-122); 15 7-(4-ethoxyphenyl)-4-(pyrimidin-2-ylmethiyl)-3,4-dihydrobenzo[f)[1 ,4]oxazepin-5(21TJ one (11-123); 7-(4-(difluoromethyl)phenyl)-4-{pyrimidin.2-ylethyl)>3,4 dihydrobenazo[fJ[1I,4]oxazepin-5(2H)-one (11-124); 4-(imidazo[1I,2-alpyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 20 dihydrobenzoff][ 1,4)oxazepin-5(2H)-one (01-129); 4-((4-morpholinopyrimidin-2-yl)methyl)-7-(4-(trifhxoromethoxy)pheayl)-3,4 cliydrobenzo[fj[ 1,4]oxazepin-5(211)-one (H-133); 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[] (I,4]oxazepin-5(2ff)-one (11-134); 25 4-(imfdazo[1,2-a]pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[fljl ,4]oxazepiu-5(2fl)-one (11-135); 7-(3-fluoro-4-(frifluomomethy)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydmobenzo[ff 1 ,4]oxazepin-5(211)-one (11-136); 16 4-4(4-methoxypyrimidin-2-yl~methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydmobcnzo [f][ 1,4]oxazepin-5(211'-one (fl-I 137); 4-((4-methylpyrimidin-2-yl)methyi)-7-(4-(trifl-uoromethoxy)phenyl)-3,4 dihydrobeuzo[fJ[I ,4]oxazepin-5(211)-one (11-138); 5 4-((4-(piperidin-1-ylpyriidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyL)-3,4 dihyclrobenzo[f][1 ,4]oxazepin-:5(2H)-one (11-139); 4-((4-(dimethylarnino)pyrirnidiu-2-yl)methyl)-7-(4-(trifluoromethoxy)pheayl)-3,4 dihydmobenzo[f][ 1,4]oxazepin-5(2H)-oae (11-140); 4-benzy1-7-(4-(ffifluoromethy1)pheny1)-3,4-dihydmobenzo[fJ(1,4]oxazepin-5(2HM-one (11 10 141); 4-((3-methoxypyridin-2-yl)methyl)-7-(4-Qxritluoromethoxy)phenyl)-3,4 dihydrobenazo~fJ[1 ,4]oxazepin-5(211)-one (11-143); 7-(4-(oyclobutylmethoxy)phenyl)4-(pyrimidin-2-ymethyl)-3,4 dihydrobenzo[fj) ,4]oxazepin-5(2H)-one (11-144); 15 7-(2-nethyl-4-Qzrifl-uoromethyl)phenyl)-4-(pyriniidin-2-ylmethyl)-3,4 dihydrobenzo[fj]jl,4]oxazepin-5(21i)-one (11-145); 7-(2-methyl-4-(trifluormcthoxy)pheayfr-4-(pyimidin-2-ymethyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(2Hi)-one (11-146); 4-(( 1-(dilluoromethyl)- 1H-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3A4 20 dihydrobenzo[f][ 1,4]oxazepin-5(2H)-one (11-147); 7-(4-(trifluoromethoxy)phenyl)-4-((3-(trifluoromethy)-1H-pyrazol-1-yl)nethyl)-34 dihydrobenzo[fl[ 1,4]oxazepia-5(211}.one (11-148); 4-(pyriniidin-2-ylmethlyl)-7-{4-(2,2,2-trifluoroethyl)pheayfr-3,4 dihydrobenzo[fjl ,4]oxazepin-5(211)-one (11-150); 25 44(yridi-2-ymethyl)-7-(4-(2,2,2-rifluoroethyl)phenyl)-3,4 dihydrobenzo[fJ[1,4]oxazepin-5(211)-oae (11-151); 4-((1-oyolopeaty1-1H-pyrazo1-3-y)methyl)-7-(4-(ftifuowomethoxy)pheny1)-3,4 dihydrobenzolf ll ,4]oxazepina-5(211)-one (1I-152); 17 4-((l1-ethyl-1IH-pyrazo1-3-y)methyl)-7-(4-(frifluorometbaoxy)pheuyl)-3,4 dihydrobenzo[fJ[ 1,4]oxazepin-5(23)-one (11-153); 4-((1-methyl-1 I-imidazolA-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[t][1 ,4]oxazepin-5(2H)-one (H-154); 5 4-((4-methyl-IH-pyrazol-1-yl)methyl)-7-(4-(tdifluoromethoxy)pheny[)-3,4 dihydrobeirzo[ff 1 ,4]oxazepin-5(211-one (11-155); 4-((4-ohloro-1 E-pyrazol-1-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dih~ydrobenzo[fJ[ 1,4] oxazepin-5(211)-one (11-156); 7-(4-(diflnoroniethyl)phenyl)A-(pyidin-2-ymethyl)-3,4-dihydroberzo[f] [1 ,4]oxazepin 10 5(210-one ([1-157); 7-(4-chloro-3-fluorophenyl)-4-(pyiddin-2-ylmethyl)-3,4-dihydrobenzo[f] [1 ,4]oxazepin 5(211)-one (1H-158); 7-(4-(difluoromethoxy)phenyl)-4-(pyridin-2-ylmnethyl)-3,4-dibydrobenzo[f][ 1,4]oxazepin 5(211)-one (H-159); 15 4-((1-methyl-1H-pyrazol-4-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[ ]1 ,4]oxazepin-5(2W)-one (H-160); 4-(pyrinidin-2-ylmethyl)-7-(2,3,4-trifluorophenyl)-3 ,4-dihydrobenzo[f] [1,4]oxazepin 5(213)-one (11-162); 7-(3,4-difluoropheuyl)-4-(pyriwidiu-2-ylmetbyl)-3,4-dihydrob enzo[fJ[1,4]oxazepin 20 5(2F0-one (R-163); 4-((3-fluoropyridin-2-yI)methyl)-7-(4-(trifluommethoxy)phenyl)-3,4 dihydrobenzof[1 ,4]oxazepin-5(2H1)-one (11-164); 4-benzyL-9-fluoro-7-(4-(trifluowomethoxy)phenyl)-3,4-dihydrobenzo[fl[1,4]oxazepin 5(213)-one (01-165); 25 4-beizyL-9-fluoro-7-(4-(trifluoromethyl)phenyi)-3,4-dihydrobenzo[f][1,4]oxazepin 5(213)-one (1-166); 4-benzyl-8-flnoro-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydroberizo[f][1,4]oxazepin 5(211)-one (B-167); 18 4-benzyl-8-fluoiv-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[fJ[1 ,4)oxazepin 5(211)-one (H-168); 7-(4--chlaiv-3-fluorophenyl)A4-((3-fluoropyridin-2-yI)methyl)-3,4 dihydrobenzo[f)[1,4]oxazepin-5(2H)-one (H-169); 5 7-(2-fluoro-4-(tifluoronethylpheny)4-((3-fluoropyridin-2-yl)methy)-3,4 dihydrobeizo~f][1 ,4]oxazepin-5(211)-one (U-170); 4-(5-oxo-4-(pyrirnidiu-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[fJ[ 1,4]oxazepin-7-yl)phenyl trifluowomethanesulfonate (11-17 1); 4-((5-meth~ylpyrazin-2-yl)metiyl)-7-Qt-(ffiluoromethoxy)pheuyl)-3,4 10 dihydrobenzofj( 1,4]oxazepin-5(2H)-oae (H1-172); 2,2,3,3-tetradeutero-4-(pyrimidin-2-ymethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(211)-one (11-174); 4-{(6-methylpyrazin-2-yI)mnethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydroberizof[1,4)oxazepin-5(211)-one (H-175); 15 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethyl)phenyl)-3,4 diliydrobenzo[f'J[1,4]oxazepin-5(2B)-one (11-176);) N-(2-(5-oxo-7-(4-(trifluoromethoxy)pheayl)-2,3-dihydrobenzo[fJ[l,4]oxazepinA(5if yl)ethyl)benzenesulfonamide (11-177); N-(2-(5-oxo-7-(4-Qtrifluoromethoxy)plieayl)-2,3 -diliydrobenzo [f][ 1,4]oxazepi4(5fl 20 yl)etbhyl)cyolopropanesulfonamide (11-179); 4-((1 -meffiyl-IH-imidazol-2-yl)methyl)-7-(4-Qrifluomometioxy)phenyD-3,4 dihydrobenzo[f][1 ,4)oxazepin-5(:2R)-one (11-186); 4-((1-benzyl-111-imidazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo~fJ[1 ,4]oxazepin-5(21T)-one (11-187); 25 4-(irnidazofl1,2-a~pyridiu-2-ylmethyl)-7-(4-(trifiuomomethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(211)-one (11-189); N-oyclopropyl-3-(5-oxo-7-(4-(frifluioromethoxy)phenyl)-2,3 dihydrobenzo[t][1 ,4]oxazepin-4(5H)-yl)propane-1 -sulfonamide (11-190); 19 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobeizo[fJ[1,4oxazepin-4(5T) yl)ethyl)pyuiniidine-2-oarboxamide (11-192); 7-(4-(4-fluorophenoxy)phenyl)-4-(pyzimfdin-2-ylmethyl)-3,4 dihydrobeazo[fj[1,4]oxazepin-5(2H)-oue (11-193); 5 7-$-pheuoxypheuyl)4-(pyrinidin-2-ylmethyl)-3,4-dihydwbenzo[f][1,4]oxazepin-5(2H) one (11-194); 7-(3-phenoxypheuy1)-4-(pymidi-2-ylmethiyi)-3,4-dihydrobeno[f]f1,4]oxazepin-5(2H) one (11-195); 7-(4-tert-butyloyolohex-1-enyl)-4-(pyrinidin-2-ylrnethyl)-3,4 10 dihydrobenzo[fj[ 1,4]oxazepin-5(2U)-oue (V-I); 7-oyclohexenyl-4-(pyimidin-2-ylmethyl)-3,4-dihydrobez[fJ[1,4]oxazepin-5(211)-one (V-3); 7-(4-methylcyclohex-1-enyl)-4-(pyimicliu-2-yhnethyl)-3,4 dihydrobenzo[f] [1 ,4]oxazepin-5(211)-one (V-5); 15 7-(2-tert-butoxypyridin-4-yl)-4-(pyridin-2-ylnethyl)-3,4-dihydrobenzo[f][1 ,4loxazepin 5(2H-)-one (VIA4); 7-(1-methyl-2-oxo-1,2-dihydropyridiu-4-yl)-4-(pyridin-2-ymethyl)-3,4 dihyclobenzo[f [1,4]oxazepin-5(2H)-one (VI-12); 4-pyidin-2-yimethyl)-7-(5-(tifluoromethyl)pyridin-2-yl)-3,4 20 dihydrobenzo[fJ[L,4]oxazepin-5(211)-oue (VI-26); 7-(2-isopropyltbiazolA-yl)4-(pyridin-2-ymethyl)-3,4-dihydrobenzo[f] [l,4oxazepin 5(211)-one (VI-30); 4-(Pyridin-2-ylmthy)-7-($-(trifluoromethy1)thiophen-2-y)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2fl)-one (VI-3 1); 25 7-(5-c-yclopropyltbiophen-2-yl)A-(pyxidinL-2-yhnethyl)-3,4 dihydrobenzolf][1 ,4]oxazepin-5(2H)-one (VI-32); 7-(5-cyclopropylthiophen-2-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzolffjl,4]oxazepin-5(2H1)-one (VI-3 6); and 20 4-(pyriniidin-2-ylmethyl)-7-(5-(tilaoromethyl)thiophen-2-yl)-3,4 dihiydrobenzo[ql[1 ,4]oxazepia-5(211)-one (VI-37); 4-(pyrimidin-2-ylnethyl)-7-((4-(trifluorometlioxy)phenyl)ethynyl)-3,4 dihydrobenzo[f [1 ,4loxazepin-5(2H7)-one (VILI-4); 5 7-(phenylethynyl)4-(pyrimidin-2-ymethyl)-3,4-dihydrobezo[fJ[1 ,4]oxazepiu-5(2H)-one ('JiltS); 4-(pyrimidin-2-ylmethyl)-7-((4-(trifluoromethyl)phenyl)ethyuayl)-3,4 dihydrobenzo[q][1 ,4]oxazepin-5(211-one (VflhI-6); 4-(jpyridin-2-ylmethy)-7-(4-(trifluoromethy)phenethy)-3,4 10 dihydrobenzo~fJ[ 1 A]oxazepin-5(21JJ-one (VIil-7); 4-(,pyimidin-2-ylmethyl)-7-(4-(frifluoromethyl)phenethyl)-3,4 dihydrobenzo[fJ[1 ,4]oxazepin-5(211)-one (VIII-8); 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluommethyl)phenethyl)-3,4 dihydrobenzoffl[1 ,4]oxazepin-5 (211)-one (VIII-9); 15 (E)-4-beuzyl-7-(4-(trifluoromethyl)styiyl)-3,4-dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one (VIlI-lO); and 4-benzyl-7-(4-(frifluoromethyl)phenethyl)-3,4-diiydrobenzoifl[1 ,4]oxazepin-5(2H)-one (VMil 1); 2-((pyrimidiu-2-yl)rnethyl)-8-(4-(trifluoromethyl)phenyl)-3 4-dihydro-211 20 benzo jb] [1,4,5]oxatbiazepin-sulfoae (JX-2); 2-((5-chloropyrimuidin-2-yl)rnethyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-21 benzo[b][1,4,5]oxathiazepin-sulfbne QIX-3); 4-(2-(benzyloxy)ethyl)-1 -methyl-7-(4-Qtrifluoromethoxy)phenyl)-3,4-dibhydro-1H benzo~e][ 1,4]diazepine-2,5-dione (X-7); 25 4-b enzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-IH-benzo[e]f 1,4]diazepine-2.,5-dione 4-benzyl-1-mnethyl-7-(4-Qxrifluoromethyl)pheayl)-3,4-dihydro-1H-beuzo~e] (1,4jdiazepine 2,5-dione (X-1 1); 21 5-benzyl-8-(4-(trifluoromethyl)phenyl)-4H-benzo[flinidazo[1,2-a][1,4]diazepin-6(5I) one (-12); 4-b nzy-7-(4-(trifluoromethioxy~pheny1)-3,4-dihycdropyrido[4,3-f][1,4]oxazepin-5(2H) one (XMI-1); 5 4-benzyl-7-(4-(trifluoromethoxy)pheny)-3,4-diiydropyrilo[2,3-f][1 ,4]axazepin-5(2HI) one (XIEI-2); 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydropyrido[2,3-fJ[1,4]oxazepin-5(21)-one QXIIP3); 4-(pyrimidia-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyt)-3,4-dihydropyrido[4,3 10 fJ[1,4]oxazepin-5(2fl)-one (XII-5); 4-((4-methylpyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido [4,3-fl [1,4]oxazepin-5(211)-one (XU-8); 4-(oyolopropylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3 fI [1 ,4]oxazepin-5(2H)-ane (XII-9); 15 4-((3-methoxypyxidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido[4,3-f] [l,4]oxazepin-5(21*)-one (Xfl-10); 4-((3-fl-uoropyridin-2-yl)methyl)-7-(4-(triftuoromethoxy)phenyl)-3,4-dihydropyrido4,3 f]fl,4]oxazepin-5(2H)-one (XI-i 1); 4-((4-methoxypyrimidin-2-yl)methyl)-7-(4-(trifiuoromethoxy)phenyl)-3,4 20 dihydropyrido[4,3-fj 1,4]oxazepiu-5(2H)-one (XII-14); 4-(,pyrimidiu-2-ylmethyl)-7-(4-(friftuoromethoxy)phenylamino)-3,4 diliydrobenzoffl[1 ,4]oxazepin-5(2H)-one (XI1I-1); 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenoxy)-3,4 dihydrobenzo[fJ[I ,4]oxazepin-5(211-one (XIII-2); 25 4-(pyrmidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenylwnino)-3,4 diliydnobenz[f][1,4]oxazpin-5(2fl1)-one (XIII-3); 4-(pyridin-2-yhnethyl)-7-(4-(trifluoromethoxy)phenylaniino)-3,4 dihydrobenz[fl[1 ,4]oxazepin-5(2I Waone (XII-4); 22 4-(pyridin-2-yethyl)-7-(4-(trifluoromethyl)phenylamino)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(211)-one (XIII-6); or 7-(methyl(4-(trifluoromethoxy)phenyl)amin)-4(pyrimidin-2-ymethy)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (XII-10); 5 or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0010] In other embodiments, the compound is: 4-(2,2-difluoroethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[fj[1,4]oxazepin 5(2H)-one (II-6); 10 4-(2-methoxyethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H1)-one (1I-11); (R)-3-methyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (11-19); 4-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[fJ[1,4]oxazepin-5(2H)-one 15 (II-46); (S)-3-isopropyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H) one (11-77); 3-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (I-142); 20 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepin-4(5H) yl)ethyl)ethanesulfonamide (11-178); or 4-(3-(azetidin-1-ylsulfonyl)propyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (11-191); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or 25 tautomer thereof [0011] In other embodiments, the compound is: pyrimidin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) yl)methanone (III-1); 23 phenyl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[J[1 ,4]oxazepin-4(SH') yl)methanone (111-4); (1-methylcyclopropyl)(7-{4-(trifluoromethoxy)phlenyl)-2,3 dihydrobenzo[f][ 1,4]oxazepin-4(511)-yl)methanone (11-10); 5 (3,3-difluorocyclobutyl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo (fl (1,4]oxazepin-4(5H)-yl)rnetlione (11- 11); (1-methyl-1H-pyrazol-4-yl)(7-(-rifluoromnethoxy)phenyl)-2,3 dihydrobenzo[ ]1,4]oxazepiu-4(5H)-y)methaaone (111-12); (1 H-pyrazol-3-yl)(7-(4-(trifluorcmetkoxy)phenyl)-2,3-dihydrobenzo[f] [1,4]oxazepin 10 4(5HI)-yl)methanone (HI1- 15); pyrazin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f] [1,4]oxazepin-4(5H) yl)methanone (111-23); pyridazin-3-yl(7-(4-(rifluoxnmethoxy)phenyl)-2,3-lihycknbenzo[f] [1 ,4]oxazevin-4(5U) yI)methanone (M1-24); 15 2-(pyridin-2-yl)-I-(7-(4-(tdfluoromethyl)pheayl)-2,3-dihydrobenzo[f] [1 ,4]oxazepiu 4(5Hi)-yI)ethanone (M1-29); 2-(pyrimidin-2-yl)- 1-(7-$--(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1 ,4]oxazepin 4(511)-yl)ethanone (111-30); (1-meth~yl-JH-imidazol-5-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 20 dihydrobenzo(f][1 ,4]oxezepin-4(5H)-yl)methanone (111-32); (lIH-imidazol-2-yl)(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5E)-yl)rnethanone (111-33); (1-methyl-1H-imidazol-2-yl)(7-(4-(trifluoroznethyl)pheny)-2,3 dlihycrobenzo[t][ 1,4] oxazepin-4(5H)-yl)methanone (111-37); 25 (R)-(2-methyl-7-(4-(trifluoromethloxy)phenyl)-2,3-dihydrobenz[fJ[1 ,4]oxazepin-4(5H) yl)(pyrimidin-2-yl)methanone (111-38); tert-butyl 2-(7-(4-Qrtitluoromethyl)phenyl)-2,3,45-tetrahydrobenzo~fJ[1,4]oxazepiue-4 carbonyl)-5,6-dihydroixnidazo[1,2-a]pyrazine-7(SH)-carboxylate (111-40); 24 (LH-1,2,4-triazol-3-yl)(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepin 4(5H)-yl)methanone (III-50); or (1,5-dimethyl-1H-pyrazol-3-yl)(7-(4-(irifluoromethoxy)phenyl)-2,3 dihydrobenzo[fJ[1,4]oxazepin-4(5H)-yl)methanone (III-58); 5 or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0012] The inventions of this disclosure are described throughout In addition, specific embodiments of the invention are as disclosed herein. 10 Detailed Description L Definitions and General Parameters [0013] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. 15 [00141 The term alkyll" refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms, or from 1 to 15 carbon atoms, or from I to 10 carbon atoms, or from 1 to 8 carbon atoms, or from I to 6 carbon atoms, or from 1 to 4 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-decyl, tetradecyl, and the like. 20 [0015] The term "substituted alkyl" refers to: 1) an alkyl group as defined above, having 1, 2, 3, 4 or 5 substituents, (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, 25 alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl,-S(O)-heteroaryl, -S(0)2-alkyl, 30 -S(O) 2 -cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O) 2 -heteroaryl. Unless 25 otherwise constrained by the definition, all substituents may optionally be further substituted by 1,2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalIyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).Ra, in which Ra 5 is alkyl, aryl or heteroaryl and n is 0, 1 or 2; or 2) an alkyl group as defined above that is interrupted by 1-10 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently chosen from oxygen, sulfur and NRa, where Ra is chosen from hydrogen, allyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally further substituted 10 by alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)aRa, in which Ra is alkyl, aryl or heteroaryl and n is 0, 1 or 2; or 3) an alkyl group as defined above that has both 1, 2, 3, 4 or 5 substituents as 15 defined above and is also interrupted by 1-10 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above. [0016] The term "lower alkyl" refers to a monoradical branched or unbranched saturated hydrocarbon chain having 1, 2, 3, 4, 5 or 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t 20 butyl, n-hexyl, and the like. [00171 The term "substituted lower alkyl" refers to lower alkyl as defined above having 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents), as defined for substituted alkyl or a lower alkyl group as defined above that is interrupted by 1, 2, 3, 4 or 5 atoms as defined for substituted alkyl or a lower alkyl group as defined above that has 25 both 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1, 2, 3, 4 or 5 atoms as defined above. [00181 The term "alkylene" refers to a diradical of a branched or unbranched saturated hydrocarbon chain, in some embodiments, having from 1 to 20 carbon atoms (e.g. 1-10 carbon atoms or 1, 2, 3, 4, 5 or 6 carbon atoms). This term is exemplified by groups such 30 as methylene (-CH 2 -), ethylene (-CH2CH 2 -), the propylene isomers (e.g., -CH 2

CH

2

CH

2 and -CH(CH3)CH 2 -), and the like. 26 [00191 The term 'lower alkylene"refers to a diradical of a branched or unbranched saturated hydrocarbon chain, in some embodiments, having 1, 2, 3, 4, 5 or 6 carbon atoms. [0020] The term "substituted alkylene" refers to an alkylene group as defined above 5 having 1 to 5 substituents (in some embodiments, 1,2 or 3 substituents) as defined for substituted alkyl. [00211 The term "aralkyl"refers to an aryl group covalently linked to an alkylene group, where aryl and alkylene are defined herein. "Optionally substituted aralkyl" refers to an optionally substituted aryl group covalently linked to an optionally substituted 10 alkylene group. Such aralkyl groups are exemplified by benzyl, phenylethyl, 3-(4 methoxyphenyl)propyl, and the like. [0022] The term "aralkyloxy" refers to the group -0-aralkyl. "Optionally substituted aralkyloxy" refers to an optionally substituted aralkyl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are exemplified by benzyloxy, 15 phenylethyloxy, and the like. [00231 The term "alkenyl" refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from I to 6 carbon carbon double bonds, e.g. 1, 2 or 3 carbon-carbon double bonds. In some embodiments, 20 alkenyl groups include ethenyl (or vinyl, i.e. -CH=CH 2 ), 1-propylene (or allyl, i.e.

-CH

2

CH=CH

2 ), isopropylene (-C(CH 3

)=CH

2 ), and the like. [0024] The term "lower alkenyl"refers to alkenyl as defined above having from 2 to 6 carbon atoms. [0025] The term "substituted alkenyl" refers to an alkenyl group as defined above 25 having I to 5 substituents (in some embodiments, 1, 2 or 3 substituents) as defined for substituted alkyl. [0026] The term "alkenylene" refers to a diradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from I to 6 carbon 30 carbon double bonds, e.g. 1, 2 or 3 carbon-carbon double bonds. 27 [00271 The term "alkynyl" refers to a monoradical of an unsaturated hydrocarbon, in some embodiments, having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon triple bonds e.g. 1, 2 or 3 carbon-carbon triple bonds. In some embodiments, alkynyl groups 5 include ethynyl (-C=C1), propargyl (or propynyl, i.e. -C=CCH 3 ), and the like. [0028] The term "substituted alkynyl" refers to an alkynyl group as defined above having 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents) as defined for substituted alkyl. [00291 The term "alkynylene" refers to a diradical of an unsaturated hydrocarbon, in 10 some embodiments, having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon triple bonds e.g. 1, 2 or 3 carbon-carbon triple bonds. [0030] The term "hydroxy" or "hydroxyl" refers to a group -OH. [0031] The term "alkoxy" refers to the group R-O-, where R is alkyl or -Y-Z, in which 15 Y is alkylene and Z is alkenyl or alkynyl, where alkyl, alkenyl and alkynyl are as defined herein. In some embodiments, alkoxy groups are alkyl-O- and includes, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexyloxy, 1,2-dimethylbutoxy, and the like. [0032] The term "lower alkoxy" refers to the group R-Q- in which R is optionally 20 substituted lower alkyl. This term is exemplified by groups such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, n-hexyloxy, and the like. [00331 The term "substituted alkoxy"refers to the group R-O-, where R is substituted alkyl or -Y-Z, in which Y is substituted alkylene and Z is substituted alkenyl or substituted alkynyl, where substituted alkyl, substituted alkenyl and substituted alkynyl 25 are as defined herein. [00341 The term "C1.3 haloalkyl" refers to an alkyl group having from 1 to 3 carbon atoms covalently bonded to from 1 to 7, or from 1 to 6, or from 1 to 3, halogen(s), where alkyl and halogen are defined herein. In some embodiments, C 1 a haloalkyl includes, by way of example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 2,2 30 difluoroethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, 3,3-difluoropropyl, 3-fluoropropyl. 28 [0035J The term "cycloalkyl'refers to cyclic alkyl groups of from 3 to 20 carbon atoms, or from 3 to 10 carbon atoms, having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like or multiple ring structures 5 such as adamantanyl and bicyclo[2.2.1]hcptanyl or cyclic alkyl groups to which is fused an aryl group, for example indanyl, and the like, provided that the point of attachment is through the cyclic alkyl group. [0036] The term "cycloalkenyl" refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings and having at least one 10 double bond and in some embodiments, from 1 to 2 double bonds. [0037] The terms "substituted cycloalkyl" and "susbstituted cycloalkenyl" refer to cycloalkyl or cycloalkenyl groups having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, 15 acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido,.cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloallcyl, -S(O)-heterocyclyl, -S(O)-aryl,-S(O) 20- heteroaryl, -S(O)z-alkyl, -S(O)z-cycloalkyl, -S(0)-heterocyclyl, -S(O)2-aryl and -S(O)2 heteroaryl. The term "substituted cycloalkyl" also includes cycloalkyl groups wherein one or more of the annular carbon atoms of the cycloalkyl group has an oxo group bonded thereto. 1n addition, a substituent on the cycloalkyl or cycloalkenyl may be attached to the same carbon atom as, or is geminal to, the attachment of the substituted cycloalkyl or 25 cycloalkenyl to the 6,7-ring system. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1,2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen,

CF

3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O),Ra, in which R is alkyl, aryl or heteroaryl and n is 0, 1 or 2. 30 [0038] The term "cycloalkoxy" refers to the group cycloalkyl-O-. [0039] The term "substituted cycloalkoxy" refers to the group substituted cycloalkyl-0-. [00401 The term "cycloalkenyloxy"refers to the group cycloalkenyl-O-. 29 [0041] The term "substituted cycloalkenyloxy" refers to the group substituted cycloalkenyl-O- [0042] The term "ary" refers to an aromatic carbocyclic group of 6 to 20 carbon atoms having a single ring (e-g., phenyl) or multiple rings (e.g., biphenyl) or multiple condensed 5 (fused) rings (e.g., naphthyl, fluorenyl and anthryl). In some embodiments, aryls include phenyl, fluorenyl, naphthyl, anthryl, and the like. [0043] Unless otherwise constrained by the definition for the aryl substituent, such aryl groups can optionally be substituted with 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, 10 alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, 15 alkoxyamino, nitro, -S(Q)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl,-S(O) heteroaryl, -S(O) 2 -alkyl, -S(O) 2 -cycloalkyl, -S(0)2-heterocyclyl, -S(O)2-aryl and -S(O)2 heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, allkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted 20 amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).Ra, in which a is alkyl, aryl or heteroaryl and n is 0, 1 or 2. [00441 The term "aryloxy" refers to the group aryl-O- wherein the aryl group is as defined above, and includes optionally substituted aryl groups as also defined above. The term "arylthio" refers to the group R-S-, where R is as defined for aryl. 25 [00451 The term "heterocyclyl," "heterocycle," or "heterocyclic" refers to a monoradical saturated group having a single ring or multiple condensed rings, having from 1 to 40 carbon atoms and from 1 to 10 hetero atoms, and from 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring. In some embodiments, the heterocyclyl," "heterocycle," or "heterocyclic" group is linked to the 30 remainder of the molecule through one of the heteroatoms within the ring. [00461 Unless otherwise constrained by the definition for the heterocyclic substituent, such heterocyclic groups can be optionally substituted with 1 to 5 substituents (in some 30 embodiments, 1, 2 or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, 5 heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl,-S(O) heteroaryl, -S(O) 2 -alkyl, -S(0)a-cycloalkyl, -S(0)z-heterocyclyl, -S(O)2-aryl and -S(O) 2 heteroaryl. In addition, a substituent on the heterocyclic group maybe attached to the 10 same carbon atom as, or is geminal to, the attachment of the substituted heterocyclic group to the 6,7-ring system. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen,

CF

3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and 15 -S(O).R, in which R! is alkyl, aryl or heteroaryl and n is 0, 1 or 2. Examples of heterocyclics include tetrahydrofuranyl, morpholino, piperidinyl, and the like. [00471 The term "heterocyclooxy" refers to the group -0-heterocyclyl. [00481 The term "heteroaryl" refers to a group comprising single or multiple rings comprising I to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen 20 and sulfur within at least one ring. The term "heteroaryl" is generic to the terms "aromatic heteroaryl" and "partially saturated heteroaryl". The term "aromatic heteroaryl" refers to a heteroaryl in which at least one ring is aromatic, regardless of the point of attachment. Examples of aromatic heteroaryls include pyrrole, thiophene, pyridine, quinoline, pteridine. 25 [00491 The term "partially saturated heteroaryl" refers to a heteroaryl having a structure equivalent to an underlying aromatic heteroaryl which has had one or more double bonds in an aromatic ring of the underlying aromatic heteroaryl saturated. Examples of partially saturated heteroaryls include dihydropyrrole, dihydropyridine, chroman, 2-oxo-1,2 dihydropyridin-4-yl, and the like. 30 [00501 Unless otherwise constrained by the definition for the heteroaryl substituent, such heteroaryl groups can be optionally substituted with 1 to 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting alkyl, alkenyl, 31 alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, 5 aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl,-S(O) heteroaryl, -S(O)2-alkyl, -S(O)2-cycloalkyl, -S(0)2-heterocyclyl, -S(0)2-aryl and -S(0)2 heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, 10 carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).R, in which Ra is alkyl, aryl or heteroaryl and n is 0, 1 or 2. Such heteroaryl groups can have a single ring (e.g., pyridyl or fiuryl) or multiple condensed rings (e.g., indolizinyl, benzothiazole or benzothienyl). Examples of nitrogen heterocyclyls and heteroaryls include, but are not 15 limited to, pyrrole, inidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalaziue, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, scri dine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, and the like as well as N-alkoxy 20 nitrogen containing heteroaryl compounds. [00511 The term "heteroaryloxy"refers to the group heteroaryl-O-. [00521 The term "amino" refers to the group -NH2. [0053] The term "substituted amino" refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, 25 heteroaryl and heterocyclyl provided that both R groups are not hydrogen or a group -Y Z, in which Y is optionally substituted alkylene and Z is alkenyl, cycloalkenyl or alcynyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, 30 cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).Ra, in which R! is alkyl, aryl or heteroaryl and n is 0, 1 or 2. 32 [00541 The tenn "alkyl amine'refers to R-NH 2 in which R is optionally substituted alkyl. [0055] The term "dialkyl amine" refers to R-NHR in which each R is independently an optionally substituted alkyl. 5 [0056] The term "trialkyl amine" refers to NR in which each R is independently an optionally substituted alkyl. [00571 The term "cyano" refers to the group -CN. 0 e [0058] The term "azido" refers to a group -N=N=N. [0059J The term "keto" or "oxo" refers to a group =0. 10 [0060] The term "carboxy" refers to a group -C(O)-OH. [00611 The term "ester" or "carboxyester"refers to the group -C(O)OR, where R is alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, which may be optionally further substituted by alkyl, alkoxy, halogen, CF 3 , amino, substituted amino, cyano or -S(O)Ra, in which R is alkyl, aryl or heteroaryl and n is 0, 1 or 2. 15 [00621 The term "acyl" denotes the group -C(O)R, in which R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or hetemaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, 20 cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).Ra, in which R is alkyl, aryl or heteroaryl and n is 0, 1 or 2. [0063] The term "carboxyaLkyl"refers to the groups -C(0)0-alkyl or-C(0)0 cycloalkyl, where alkyl and cycloalkyl are as defined herein, and may be optionally further substituted by alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, 25 hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).R, in which R is alkyl, aryl or heteroaryl and n is 0, 1 or 2. [00641 The term "aminocarbonyl"refers to the group -C(O)NRR where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, or where both R groups are joined to form a heterocyclic group (e.g., morpholino). Unless otherwise 30 constrained by the definition, all substituents may optionally be further substituted by 1, 2 33 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)R', in which Ra is alkyl, aryl or heteroaryl and n is 0, 1 or 2. 5 [0065] The term "acyloxy" refers to the group -OC(O)-R, in which R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyaiyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, 10 cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).Ra, in which R! is alkyl, aryl or heteroaryl and n is 0, 1 or 2. [0066] The term "acylamino"refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further 15 substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O)aR", in which R is ailyl, aryl or heteroaryl and n is 0, 1 or 2. [0067] The term "alkoxycarbonylamino" refers to the group -N(Rd)C(O)OR in which R 20 is alkyl and Rd is hydrogen or alkyl. Unless otherwise constrained by the definition, each alkyl may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alikynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O),R', in which R" is alkyl, aryl or heteroaryl and n is 0, 1 or 2. 25 100681 The term "aminocarbonylamino" refers to the group -NR"C(O)NRR, wherein R* is hydrogen or alkyl and each R is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, 30 alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).R", in which R! is alkyl, aryl or heteroaryl and n is 0, 1 or 2. [0069] The term "thiol"refers to the group -SH. 34 [0070] The term "thiocarbonyl" refers to a group -S. [00711 The term "alkylthio" refers to the group -S-alkyl. [0072J The term "substituted alkylthio" refers to the group -S-substituted alkyl. [00731 The term "heterocyclylthio" refers to the group -S-heterocyclyl. 5 [0074] The term "arylthio" refers to the group -S-aryl. [0075] The term "heteroarylthiol" refers to the group -S-heteroaryl wherein the heteroaryl group is as defined above including optionally substituted heteroaryl groups as also defined above. [0076] The term "sulfoxide" refers to a group -S(O)R, in which R is alkyl, cycloalkyl, 10 heterocyclyl, aryl or heteroaryl. "Substituted sulfoxide"refers to a group -S(O)R, in which R is substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl or substituted heteroaryl, as defined herein. [0077] The term "sulfone" refers to a group -S(O) 2 R, in which R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. "Substituted sulfone"refers to a group -S(0) 2 R, in which 15 R is substituted alkyl, substituted cycloalkyl, substituted heterocyclyl, substituted aryl or substituted heteroaryl, as defined herein. [0078] The term "aminosulfonyl" refers to the group -S(O) 2 NRR, wherein each R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further 20 substituted by 1, 2 or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -S(O).Ra, in which Ra is alkyl, aryl or heteroaryl and n is 0, 1 or 2. [0079] The term "hydroxyamino" refers to the group -NHOH. 25 [00801 The term "alkoxyamino"refers to the group -NHOR in which R is optionally substituted alkyl. [0081] The term "halogen" or "halo" refers to fluoro, bromo, chloro and iodo. [0082] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where 30 said event or circumstance occurs and instances in which it does not. 35 [0083] A "substituted" group includes embodiments in which a monoradical substituent is bound to a single atom of the substituted group (e.g. forming a branch), and also includes embodiments in which the substituent may be a diradical bridging group bound to two adjacent atoms of the substituted group, thereby forming a fused ring on the 5 substituted group. [00841 Where a given group (moiety) is described herein as being attached to a second group and the site of attachment is not explicit, the given group may be attached at any available site of the given group to any available site of the second group. For example, a "lower alkyl-substituted phenyl", where the attachment sites are not explicit, may have 10 any available site of the lower alkyl group attached to any available site of the phenyl group. In this regard, an "available site" is a site of the group at which a hydrogen of the group may be replaced with a substituent. [0085] It is understood that in all substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl 15 having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, etc.) are not intended for inclusion herein. Also not included are infinite numbers of substituents, whether the substituents are the same or different. In such cases, the maximum number of such substituents is three. Each of the above definitions is thus constrained by a limitation that, for example, substituted aryl groups 20 are limited to -substituted aryl-(substituted aryl)-substituted aryl. [0086] A compound of a given formula (e.g. the compound of Formula I, which also includes Formula IA, IB, II, IIA, III, IA, IV, V, VI, VIII, VIIIA, IX, X, XI and XIII) is intended to encompass the compounds of the disclosure, and the pharmaceutically acceptable salts, pharmaceutically acceptable esters, isomers, tautomers, solvates, 25 isotopes, hydrates, polymorphs, and prodrugs of such compounds. Additionally, the compounds of the disclosure may possess one or more asymmetric centers, and can be produced as a racemic mixture or as individual enantiomers or diastereoisomers. The number of stereoisomers present in any given compound of a given formula depends upon the number of asymmetric centers present (there are 2" stereoisomers possible where n is 30 the number of asymmetric centers). The individual stereoisomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis or by resolution of the compound by conventional means. The individual stereoisomers (including individual enantiomers and diastereoisomers) as well as racemic 36 and non-racemic mixtures of stereoisomers are encompassed within the scope of the present disclosure, all of which are intended to be depicted by the structures of this specification unless otherwise specifically indicated. [0087] "Isomers" are different compounds that have the same molecular formula. 5 Isomers include stereoisomers, enantiomers and diastereomers. [0088] "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. [0089] 'Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. The 10 term "(1)" is used to designate a racemic mixture where appropriate. [0090] "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. [0091] The absolute stereochemistry is specified according to the Cahn Ingold Prelog R S system. When the compound is a pure enantiomer the stereochemistry at each chiral 15 carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown are designated (+) or (-) depending on the direction (dextro- or laevorotary) that they rotate the plane of polarized light at the wavelength of the sodium D line. [0092] Some of the compounds exist as tautomeric isomers. Tautomeric isomers are in 20 equilibrium with one another. For example, aide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic 25 acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers. Non-limiting examples of amide-comprising and imidic acid-comprising tautomers are shown below: O HO 21 NH Z- N N

Z

4 Z4o 37 [00931 The term "therapeutically effective amount' refers to an amount that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the 5 disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. [00941 The term "polymorph"refers to different crystal structures of a crystalline compound. The different polymorphs may result from differences in crystal packing (packing polymorphism) or differences in packing between different conformers of the 10 same molecule (conformational polymorphism). [00951 The term "solvate" refers to a complex formed by the combining of a compound of Formula I, IA, IB, II, HA, 11B,111, IIA, IV, V, VI, VIII, VIHLA, IX, X, XI or XIII and a solvent. [0096 The term "hydrate" refers to the complex formed by the combining of a 15 compound of Formula I, IA, IB, IH, TEA, 1B,1I1, IA, IV, V, VI, VHI, VDIA, IM, X, XHi or XlI and water. [00971 The-term "prodrug"refers to compounds of Formula I, IA, B, 11, HA, IIB, I1, IA, IV, V, VI, VIII, VHIA, IX, X, XII or XMI that include chemical groups which, in vivo, can be converted and/or can be split off from the remainder of the molecule to 20 provide for the active drug, a pharmaceutically acceptable salt thereof or a biologically active metabolite thereof. [00981 Any formula or stmcture given herein, including Formula I, IA, IB,1, HA, IIB, I, IRA, IV, V, VI, VIII, VHIA, IX, X, XI or XII compounds, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. 25 Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3fH (tritium), 11 C, 13 C, "C, 15N, 30 "F, 3 1 P, 32 P, 3 S, MCI and 12I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as H, 13 C and 1 4 C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, 38 reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients. [0099] The disclosure also included compounds of Formula I, IA, IB11, IIA, JIB, III, 5 IIA, IV, V, VI, VIII, VIlA, IX, X, XII or XIII in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half life of any compound of Formula I when administered to a mammal. See, for example, Foster, '"Deuterium Isotope Effects in Studies of Drug 10 Metabolism", Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium. [0100] Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacoidnetics) properties, relating to 15 distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An 'F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof 20 can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound of Formula I. [0101] The concentration of such a heavier isotope, specifically deuterium, may be 25 defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as "I" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically 30 designated as a deuterium (D) is meant to represent deuterium. 39 [0102] The term "treatment" or "treating"means administration of a compound of the invention, by or at the direction of a competent caregiver, to a mammal having a disease for purposes including: (i) preventing the disease, that is, causing the clinical symptoms of the disease 5 not to develop; (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, that is, causing the regression of clinical symptoms. [01031 In many cases, the compounds of this disclosure are capable of forming acid 10 and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. [0104] The term pharmaceuticallyy acceptable salt" of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition 15 salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted 20 alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted 25 cycloalkenyl amine, trisubstituted cycloalkenyl marines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of ailcyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, 30 cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group. Amines are of general structure 40 N(R")(R)(Rf), wherein mono-substituted amines have 2 of the three substituents on nitrogen (R', R0 and R) as hydrogen, di-substituted amines have 1 of the three substituents on nitrogen (R, R' and R) as hydrogen, whereas tri-substituted mines have none of the three substituents on nitrogen (R , R0 and R 2 ) as hydrogen. R, 0n 5 and 2 are selected from a variety of substituents such as hydrogen, optionally substituted alkyl, aryl, heteroayl, cycloalkyl, cycloalkenyl, heterocyclyl and the like. The above-mentioned amines refer to the compounds wherein either one, two or three substituents on the nitrogen are as listed in the name. For example, the term "cycloalkenyl amine" refers to cycloalkenyl-NH 2 , wherein "cycloalkenyl" is as defined 10 herein. The term "diheteroarylamine" refers to NH(heteroaryl) 2 , wherein "heteroaryl" is as defined herein and so on. [0105J Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, 15 caffeine, procaine, hydrabamne, choline, betaine, ethylenediamine, glucosamine, N alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N ethylpiperidine, and the like. [0106] Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, 20 hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. 25 [0107] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active 30 ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. 41 [01081 "Coronary diseases" or "cardiovascular diseases" refer to diseases of the cardiovasculature arising from any one or more than one of, for example, heart failure (including congestive heart failure, diastolic heart failure and systolic heart failure), acute heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmias, angina 5 (including exercise-induced angina, variant angina, stable angina, unstable angina), acute coronary syndrome, diabetes and intermittent claudication. [0109] "Intermittent claudication"means the pain associated with peripheral artery disease. "Peripheral artery disease" or PAD is a type of occlusive peripheral vascular disease (PVD). PAD affects the arteries outside the heart and brain. The most common 10 symptom of PAD is a painful cramping in the hips, thighs or calves when walking, climbing stairs or exercising. The pain is called intermittent claudication. When listing the symptom intermittent claudication, it is intended to include both PAD and PVD. [01101 Arrhythmia refers to any abnormal heart rate. Bradycardia refers to abnormally slow heart rate whereas tachycardia refers to an abnormally rapid heart rate. As used 15 herein, the treatment of arrhythmia is intended to include the treatment of supra ventricular tachycardias such as atrial fibrillation, atrial flutter, AV nodal reentrant tachycardia, atrial tachycardia and the ventricular tachycardias (VTs), including idiopathic ventricular tachycardia, ventricular fibrillation, pre-excitation syndrome and Torsade de Pointes (TdP). 20 2. Nomenclature [01111 Names of compounds of the present disclosure are provided using ACD/Name software for naming chemical compounds (Advanced Chemistry Development, Inc., Toronto, Canada). Other compounds or radicals may be named with common names or 25 systematic or non-systematic names. The naming and numbering of the compounds of the disclosure is illustrated with a representative compound of Formula I:

F

3 CO 0 N N which is named 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 30 dihydrobenzolf][1,4]oxazepin-5(2H)-one. 42 3. Compounds (0112] Accordingly, typical embodiments the present disclosure provide novel compounds that function as late sodium channel blockers. In one embodiment, the 5 disclosure provides compounds of Formula I: Z 1 Y-_ N OOR aR Z' C R ~z2 x" Z2 X - - R4 R4 wherein: Z' and Z 2 are each independently selected from the group consisting of CR 7 and 10 N;

Z

3 and Z4 are each independently selected from the group consisting of CR?, C-Q R and N, provided that one of Z 3 and Z4 is C-Q-R' and the other of Z 3 and Z 4 is CR' or N and TRther provided that only one of Z', Z 2 and t' is N; X is -O- or -NR6-; 15 Y is -C(O)-, -C(R") 2 - or -S(0)2-; Q is a covalent bond, -0-Co- 2 alkylene, -NRu-Co.

2 alkylene, C 2 alkylene,

C

2 alkenylene or C 2 alkynylene; RI' is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are 20 optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CN, -SF 5 , -Si(CH 3

)

3 , -0-R0, -S-R0, -C(O)-R2, -C(O)-OR20, -N(Re)(R), -C(O)-N(Ro)(R2 -N(R2)-C(0)-R?2, -N(R20)C(O)-OR 2, -N(R20)-S(O)2-R26, -S(O)2-R0, -O S(O)2-R2O, -S(O)2-N(R 20 )(Re), C 1 .6 alkyl, C2.4 alkenyl, C 2

.

4 alkynyl, 25 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C,.6 alkyl, C 2

.

4 alkenyl, C 2

.

4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two 43 or three substituents independently selected from the group consisting of halo, -NO 2 , aryl, heterocyclyl, heteroaryl, CI- alkyl,

CI-

3 haloalkyl, cycloalkyl, -N(R 2 )(R?), -C(O)-R 0 , -C(O)-OR 0 , -C(O)-NW(R ), -CN and -O-R; 5 R2 is -C 1 4 alkylene-, -L-R, -L- alkylene-R 5 , -C 1

.

6 alkylene-L-R or -C 14 alkylene-L-C 1 4 alkylene-R 5 ; wherein each -C 14 alkylene is optionally substituted by one substituent independently selected from the group consisting of C 2 4 alkynyl, halo, -NO2, -CN, -0-R?,-NR)(' , -C(O)-R', -C(O)-ORe, -C(O) 10 N(R3)(R3), -N(Rt)-S(O)-R 2 , cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Ci- alkyl, C 24 15 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(Re), -C(O)-R 2 , -C(O)-OR, -C(O)-N(R 2 )(), -CN and 00 L is -0-, -S-, -C(O)-, -NHS(O)r, -S(0) 2 NH-, -C(O)NH-, or -NHC(O)-; provided that 20 when Y is -C(R 1

)

2 -, then R2 is -L-R, -L-C 14 alkylene-R 5 , -C14 alkylene 1,-R or -Ci. alkylene-L-C 14 alkylene-R 5 and L is not -C(0)-; and when R2 is -L-R' or -L-CI 4 alkylene-R', then L is not -0-, -S-, -NHS(O) 2 or -NHC(O)-; each R is independently hydrogen, deuterium, Ci 4 alkyl, cycloalkyl, aryl, 25 heteroaryl or heterocyclyl; wherein said Ci- alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-Ra, -C(O)-OR, -C(O)-N(R)(R 2 ), -CN and -O-R 0 ; 30 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 44 independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(Re), -C(O)-R 2 , -C(O)-OR, -C(O)-N(R)(Re), -CN and -O-R0; and 5 wherein said C 14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R)(R), -C(O)-Re, -C(O)-OR, -C(O)-N(R2)(R), -CN and -0 10 or when Y is -C(O)-, then R2 and one of R3 can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 14 alkyl, 15 -O-R?, -N(R 2

)(R

2 ), -N(R 2

)-C(O)-OR

0 and -C(O)-OR; and wherein said C 14 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; each Ris independently hydrogen, deuterium, C 14 alkyl, -C(O)-OR 6 , 20 -C(O)-N(R2(Rt), cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 1 - alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(0)-R 2 ,

-C(O)-OR

0 , -C(O)-N(R 20 )(R), -CN and -0-R?0; 25 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO2,

C

14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Ro 2 ) ), -C(O)-R 2 , -C(O)-O1&, -C(O)-N(R 2 'e)), -CN and 30 -O-RO; and 45 wherein said C 1

.

4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , 5 -N(R)(RR), -C(O)-R , -C(O)-OR2, -C(O)-NR)(e), -CN and -O-Ra; or two RW or two R 4 together with the carbon atom to which they are attached form an oxo; RW is cycloalkyl, aryl, heteroaryl or heterocyclyl; 10 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of CI. alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Rt)(R"), -N(R )-S(0)rR 0 , -N(R 2

)

C(O)-R , -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R)(R 2 ), -CN, oxo and -0 15 R2; wherein said C1. alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

1 -6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R), 20 -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -O-Ra; and wherein said C1.4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(RE), -C(O) 25 R 0 , -C(O)-0R 0 , -C(O)-N(R)(R), -CN, -S(O) 2

-R

20 and

R

6 is hydrogen, C 1

.

6 alkyl or cycloalkyl; wherein said C 1

.

4 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 30 -NO2, -N(R 2 )(RW ), -C(O)-R 0 , -C(O)-0R 0 , -C(O)-N(R )(R), -CN and 46 R7 is hydrogen, halo, -O-20 or C 1 6 alkyl; R" is hydrogen or C 1

.

4 alkyl; R2 and R22 are in each instance independently selected from the group consisting of hydrogen, C1.6 alkyl, C2.6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl 5 and heteroaryl; wherein the C.. alkyl, C2.6 alkenyl, C2.4 alkynyl, cycioalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1.4 alkyl, acylamino, oxo, -NO 2 , -S(O)2R26, -CN, C 1

.

3 alkoxy, -CF 3 , 10 -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with CI 4 alkyl or cycloalky; or when R 2 0 and R2 are attached to a common nitrogen atom R 20 and R 2 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 15 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1

.

4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

26 , -CN, CI3 alkoxy, -CF 3 , -OCF3, aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C.4 alkyl, aryl and cycloalkyl; 20 wherein the C1.4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, C.4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof; 25 provided that when Y is -C(O)-, X is -0-, each R is hydrogen, R 2 and R 3 together with the atom to which they are attached form a piperazine which is optionally substituted with tert-butoxycarbonyl and Q is a bond, then Ri 1 is not unsubstituted phenyl or morpholinyl; and that when Y is -S(0)2-, X is -0-, R 2 is benzyl, each R2 is hydrogen, Z is C-Q-R', Q is a bond and Ri is aryl or heteroaryl, then both R 30 are hydrogen. 47 [0113] In another embodiment, the disclosure provides compounds of Formula I: R2 zeY N Z1 R3 R 4 wherein: 5 Z' and Z 2 are each independently selected from the group consisting of CR 7 and N;

Z

3 and Z 4 are each independently selected from the group consisting of CR 7 , C-Q R' and N, provided that one of Z and Z 4 is C-Q-R' and the other of ZA and Z is

CR

7 or N and further provided that only one of Z', Z2 and Z' is N; 10 X is -O- or -NRi-; Y is -C(O)-; Q is a covalent bond, -O-Co-2 alkylene, -NR-Co- 2 alkylene, C 2 alkylene,

C

2 alkenylene or C 2 alkynylene; R' is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; 15 wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of halo, -N02, -CN, -SFs, -Si(CH 3

)

3 , -O-Ra, -S-R 2 , -C(O)-R 20 , -C(O)-OR 2 0, -N(R 2

)(R

2 ), -C(O) N(Re)(R), -N(Re)-C(O)-R ', -N(Ra)-(O)-OR 22, -N(Re)-S(0)rRe, 20 -S(O)-R 20 , -O-S(O) 2 -R2, -S(0) 2 -N(R)(Re), C 1

.

4 alkyl, C 2

.

4 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C2.

4 alkyl, C 2

.

4 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group 25 consisting of halo, -NO 2 , aryl, heterocyclyl, heteroaryl, C 1 .6 alkyl, C13 haloalkyl, cycloalkyl, -N(R 2 )(R), -C(O)-R 0 , -C(O)-OR,

-C(O)-N(R

20 XRa), -CN and -O-Ra; 48 R2 is -C 1 4 alkylene-R, -L-R 5 , -L-C, 4 alkylene-R 5 , -C 14 alkylene-IRor -C4 alkylene-L-C4 alkylene-R 5 ; wherein each -CIa alkylene is optionally substituted by one substituent independently selected from the group consisting of C24 alkynyl, halo, 5 -NO 2 , -CN, -O-R, -N(R 2 )(R), -C(O)-R 2 , -C(O)-ORe, -C(O) N(R)(RO), -N(R 2

)-S(O)

2 -R, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents 10 independently selected from the group consisting of C14 alkyl, C 24 alkynyl, halo, -NO2, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R)(Re), -CN and -O-R0; L is -0-, -S-, -C(0)-, -NHS(0) 2 -, -S(0) 2 NH-, -C(O)NH- or -NHC(O)-; provided 15 that when R3 is -I-R 5 or -L-C 14 alkylene-R', then L is not -0-, -S-,

-NHS(O)

2 - or -NHC(O)-; and each R3 is independently hydrogen, deuterium, C 14 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1. aLkyl is optionally substituted with one, two or three 20 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(RY)(R), -C(O)-R3, -C(O)-03 4 , -C(O)-N(R 0

)(R

2 ), -CN and -0-R; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally hitter substituted with one, two or three substituents 25 independently selected from the group consisting of halo, -NO 2 , C14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(R), -C(O)-R, -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -0-R; and wherein said C1 alkyl, aralkyl, cycloalkyl, aryl, 30 heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected 49 from the group consisting of halo, -NO 2 , -N(R 2 0 )RE),

-C(O)-R

20 , -C(O)-ORw, -C(O)-N(R")(R), -CN and -0 or R 2 and one ofR 3 can join together with the atom to which they are attached to 5 form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 .6 alkyl, -O-R, -N(R 2 )(RP), -N(R 2 )-C(O)-OR and -C(O)-OR 0 ; and wherein said C14 alkyl is optionally substituted with one, two or 10 three substituents independently selected from the group consisting of halo and heteroaryl; each R is independently hydrogen, deuterium, CI.4 alkyl, -C(O)-OR 26 , -C(O)-N(Rn)(R2l, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1.- alkyl is optionally substituted with one, two or three 15 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -C(O)-Rt

-C(O)-OR

0 , -C(O)-N(Re)(Re), -CN and -O-R 0 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 20 independently selected from the group consisting of halo, -NO 2 , C13 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(R), -C(O)-RO, -C(O)-OR 2 , -C(O)-N(R 2 )(Re), -CN and -O-R0; and wherein said C3 alkyl, aralkyl, cycloalkyl, aryl, 25 heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , -N(R)(R"), -C(O)-R, -C(O)-OR", -C(O)-N(Ra 2 4), -CN and -0-R"; 30 or two R 3 or two R 4 together with the carbon atom to which they are attached form an oxo; 50 R5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 14 alkyl, C2.4 alkynyl, halo, -NO 2 , cycloalkyl, 5 aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -N(R2)-S(O)2-R 0 , -N(R ) C(O)-Re, -C(O)-Re, -C(O)-OR, -C(0)-N(R 0 )(Re 2 ), -CN, oxo and -0 wherein said C 14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 10 independently selected from the group consisting of halo, -NO 2 ,

C

1 . alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re),

-C(O)-R

0 , -C(Q)-OP7, -C(O)-N(Rf)(R), -CN and -0-RP; and wherein said C 14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 15 or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(RY)(RE), -C(0)

R

2 0 , -C(O)-OR 0 , -C(O)-N(R 2 )(R), -CN, -S(Q) 2 -Ra and R is hydrogen, Cz- alkyl or cycloalkyl; 20 wherein said C 14 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , -N(R 2 )(R), -C(O)-R? 2 , -C(O)-OR 2 , -C(O)-N(R 2 )(Re), -CN and -0- 0 ; R7 is hydrogen, halo, -O-R0 or CI-6 alkyl; 25 R" is hydrogen or C 4 alkyl R and R? are in each instance independently selected from the group consisting of hydrogen, Cx- alkyl, C224 alkenyl, C2- alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C14 alkyl, C24 alkenyl, C2. ailcynyl, cycloalkyl, heterocyclyl, 30 aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, 51 halo, C 1 4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 R?, -CN, C 1

-

3 alkoxy, -CF 3 ,

-OCF

3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C 1 4 alkyl or cycloalkyl; or 5 when R2 0 and R2 are attached to a common nitrogen atom R 20 and R 2 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Cia alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

2 , -CN, C 3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and 10 each R? 6 is independently selected from the group consisting of hydrogen, C 1 4 alkyl, aryl and cycloalkyl; wherein the C 1 4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; 15 or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof; provided that when X is -0-, each R 4 is hydrogen, R 2 and R 3 together with the atom to which they are attached form a piperazine which is optionally substituted with tert-butoxycarbonyl and Q is a bond, then R 1 is not unsubstituted phenyl or 20 morpholinyl. [0114] In another embodiment, the disclosure provides compounds of Formula I: 1 Y N II Z) R3 ZX, R4 R4 wherein ZiZ, ZX, R3 and R4 are as defined herein; 25 Y is -C(RI)2-; R2 is -IrRs, -L-C1.6 alklene-RW, -CQ.6 alkylene-L-R or -CI-6 alkylene-L-1 alkylene-RW; 52 wherein each -C 14 alkylene is optionally substituted by one substituent independently selected from the group consisting of C2.4 alkynyl, halo,

-NO

2 , -CN, -0-R, -N(R 2 )(Rt), -C(O)-R 2 , -C(O)-OR 2 , -C(O) N(RW)RE), -N(R 2

)-S(O)

2 -R, cycloalkyl, aryl, heteroaryl or 5 heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of CI-4 alkyl, C 2 -4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, 10 -N(R 2 )(R), -C(O)-R, -C(O)-OR, -C(O)-N(R 2 )(R), -CN and L is -0-, -S-, -NHS(0) 2 -, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-; and R' is hydrogen or C1 4 alkyl. [01151 In yet another embodiment, the disclosure provides compounds of Formula I: Z3 Z1 01R2 R

Z

1 Ys /N s- NNR II Z2 xR R4 15 R4 wherein Z', Z 2 , 3 , 4X, , It 3 and R 4 are as defined herein; and Y is -S(0)2-; provided that when X is -0-, R 2 is benzyl, each Rt is hydrogen, Z 4 is C-Q-RI, Q is 20 a bond and RI is aryl or heteroaryl, then both R 4 are hydrogen. [01161 In some embodiments, RI is aryl, cycloalkyl, cycloalkenyl or heteroaryl; wherein said aryl, cycloalkenyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -O-RO, -C(O)-RaO, -C(0)-OR20, -N(Ra)(R2), -N(Rn)-C(O)-R 2, -N(R2)-C(O) 25 OR, -S(Q)R-P, -O-S(O)-R 0 , C 1

.

4 alkyl, cycloalkyl and heterocyclyl; and 53 wherein said C 14 alkyl or cycloalkyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -CN and -O-R 0 . [0117] In some embodiments, each R? is independently hydrogen, deuterium or C1 5 alkyl. [0118] In some embodiments, each R4 is independently hydrogen, deuterium or C 14 alkyl. (0119] In some embodiments, R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted 10 with one, two or three substituents independently selected from the group consisting of C 1 . alkyl, halo, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(R), -C(O)-R t , -C(O)-Ot 1 , -C(O)-N(R)(Rne), -CN, oxo and -O-R 2D; wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 15 independently selected from the group consisting of halo, C1 alkyl, aryl, heterocyclyl and heteroaryl; and wherein said C1 alkyl is optionally further substituted with one, two or three halo. [0120] In some embodiments, R2 and one of R3 can join together with the atom to which 20 they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 - alkyl, -0 R0, -N(R 2 )(R) and -C(O)-OR2; and wherein said C 14 alkyl is optionally substituted with one, two or three 25 substituents independently selected from the group consisting of halo and heteroaryl. [0121] In certain embodiments of each of the formulas disclosed herein, each -C14 alkylene of R2 is unsubstituted -C1 alkylene. [0122] In certain embodiments, the compound is not tert-butyl 6-oxo-8-phenyl 30 3,4,12,12a-tetrahydro-LH-benzo[flpyrazino[2,1-c][1,4]oxazepine-2(6H)-carboxylate, tert 54 butyl 6-oxo-9-phenyl-3,4,12,12a-tetrahydro-1H-benzo[fJpyrazino[2,1-c][1,4]oxazepine 2(6H)-carboxylate, 8-phenyl-3,4,12,12a-tetrahydro-1H-benzo[f]pyrazino[2,1 c]jl,4]oxazepin-6(2H)-one, 9-phenyl-3,4,12,12a-tetrahydro-1H-benzo[fJpyrazino[2,1 c][l,4]oxazepin-6(2)-one, 8-morpholino-1,2,3,4,12,12a 5 hexahydrobenzo[e]pyrazino[1,2-a]azepin-6(11H)-one, tert-butyl 8-morpholino-6-oxo 3,4,6,11,12,12a-hexahydrobenzo[e]pyrazino[1,2-a]azepine-2(lH)-carboxylate, tert-butyl 2-morpholino-12-oxo-5,6,6a,7,9,10-hexahydropyrazino[1,2-a]pyrido[3,2-e]azepine 8(12H)-carboxylate, 2-morpholino-6,6a,7,8,9,10-hexahydropyrazino[1,2-a]pyrido[3,2 e]azepin-12(5H)-one, 2-morpholino-8,9,10,1Oa,11,12-hexahydropyrazino[1,2 10 a]pyrido[2,3-e]azepin-5(7H)-one or tert-butyl 2-morpholino-5-oxo-7,8, 10,1 Oa,1 1,12 hexahydropyrazino[1,2-a]pyrido[2,3-e]azepine-9(5H)-carboxylate. [01231 In alternative embodiments, the disclosure provides compounds of Formula I: Z3- NRR3 R 3 R4 R4 15 wherein: Z and Z 2 are each independently selected from the group consisting of CR 7 and N;

Z

3 and Z are each independently selected from the group consisting of CR 7 , C-Q RI and N, provided that one of Z 3 and Z 4 is C-Q-R' and the other of Z and Z 4 is 20 CR 7 or N and further provided that only one of Z', Z 2 and Z 4 is N; X is -O- or -NR-; Y is -C(O)-, -C(R") 2 - or -S(0)2-; Q is a covalent bond, -O-Co-2 alkylene, -NR"-C-2 alkylene or C2 ailcynylene; R is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; 25 wherein said aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CN, -SF 5 , -Si(CH3) 3 , -O-R", -- R-, -C(O)-R, -C(O)-OR?, -N(R)(Re), -C(O)-N(R 2 )e), 55

-N(R

20 )-C(O)-R2, -N(R)-C(O)-ORP 2 , -N(e)-S(O) 2 -R2, -S(O)2-R , -o

S(O)-R

0 , -S(O)2-N(R)(Ra), C 1 -6 alkyl, C 2

.

4 alkenyl, C2.4 alkynyl, cycloalkyl, aryl, hetemaryl and heterocyclyl; and wherein said C 1

.

4 alkyl, C24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, 5 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , phenyl, heterocyclyl, heteroaryl, Cj-6 alkyl, cycloalkyl, -N(Re)(e), -C(0)-R"', -C(O)-Oea, -C(O)

N(R

2 )(e), -CN and -O-R 0 ; 10 R 2 is -C 1

.

4 alkylene-R, -L-R 5 , -L-CI-6 alkylene-R 5 , -C 1

.

4 alkylene-L-R or -C 1 .6 alkylene-L-C 1 4 alkylene-R; L is -O-, -S-, -C(O)-, -NHS(O)2-, -S(0)2NH-, -C(O)NI- or -NHC(O)-; provided that when Y is -C(R1)2-, then R2is -L-R', -L-C 1

.

4 alkylene-R, -C 1

.

6 alkylene-L-R or -C 1

.

6 alkylene-L-C 1 .6 alkylene-R 5 ; 15 each R 3 is independently hydrogen, deuterium, C1-15 alkyl, cycloalkyl, aryl; heteroaryl or heterocyclyl; wherein said CI- 1 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R), -C(O)-R 0 , 20 -C(O)-R, -C(O)-N(R')(R), -CN and -O-RO wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally fRther substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Ci.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 25 -N(R)(Re), -C(O)-RO, -C(O)-OR", -C(O)-N(R )(Ra 2 ), -CN and -O-R0; and wherein said C 1 .6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected 30 from the group consisting of halo, -NO 2 , -N(Ra)(Ra), 56

-C(O)-R

2 , -C(O)-OR, -C(O)-N(R)(Re), -CN and -0 RP2 or when Y is -C(O)-, then R2 and one of R 3 can join together with the atom to which they are attached to form a heterocyclyl; 5 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C14s alkyl, -O-R 4 , -N(R")(R 2 ), -N(R 2 )-C(O)-0R 0 and -C(0)-OR 2 ; and wherein said C -Is alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting 10 of halo and heteroaryl; each R 4 is independently hydrogen, deuterium, Ci..s alkyl, C 14 alkoxy, -C(0)

OR

26 , -C(O)-N(R)(R 2 ), -N(R 2 )-S(O)2-R 0 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C-5 alkyl is optionally substituted with one, two or three 15 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R), -C(O)-R?, -C(O)-OR2, -C(O)-N(R 2 )(R2), -CN and -0-R?); wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 20 independently selected from the group consisting of halo, -NO 2 , C1.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(RW)(R

2 ), -C(O)-R3, -C(O)-OR 2 , -C(O)-N(R 2 )(R), -CN and -0-R 2 ; and wherein said C1.6 alkyl, aralkyl, cycloalkyl, aryl, 25 heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 ,

-N(R)(R

2 ), -C(O)-R, -C(O)-OR, -C(0)-N(R)(R2), -CN and -O-R; 30 or two R 3 or two R 4 together with the carbon atom to which they are attached form an oxo; 57 RW is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1- alkyl, C 2 4 alkynyl, halo, -NO 2 , cycloalkyl, 5 aryl, heterocyclyl, heteroaryl, -N(R 2

)(R

2 ), -N(R 2

)-S(O)

2

-R

0 , -N(RO)

C(O)-R

2 , -C(O)-I, -C(O)-OR, -C(O)-N(R 2 )(Re), -CN and -O-R; wherein said Ci6 alkyl, cycloalkyl, aryl, heterocyclyl or heternaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 10 C 1

.

4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )Re ), -C(O)-R, -C(O)-ORr, -C(O)-N(R 2 )(Re), -CN and -O-R; and wherein said C1.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group 15 consisting of halo, aryl, -NO 2 , -CF 3 , -N(R)(Re), -C(O)

R

2 , -C(O)-OR, -C(O)-N(R3)(R 2 ), -CN, -S(0)2-Ra and -0-It ; R is hydrogen, C1.i5 alkyl, -C(O)- 2 , -C(O)-OR 6 , cycloalkyl, aryl, heteroaryl or heterocyclyl; 20 wherein said C145 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -C(O)-R 2 ,

-C(O)-OR

0 , -C(O)-N(R 2 )(R), -CN and -O-Re wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are 25 optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

1 -6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R)(R

2 ), -C(O)-R , -C(Q)-ORO 2 , C(O)-N(R)(R 2 ), -CN and -0-Re; and 30 wherein said C- alky], aralkyl, cycloalkyl, aryl, heterocyclyl or hetero aryl are optionally further substituted 58 with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 20

)(R

2 ),

-C(O)-R

20 , -C(O)-0R 20 , -C(O)-N(R 20 )(RE ), -CN and -O

R

2 0 ; 5 R 7 is hydrogen, halo or C1.6 alkyl; R is hydrogen or C14 alky];

R

20 and R2 are in each instance independently selected from the group consisting of hydrogen, Ci-is alkyl, C 2

-

1 5 alkenyl, C2-1s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 10 wherein the Ci-15 alkyl, C2-15 alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, acylamino, oxo, -NO 2 , -S(0) 2

R

26 , -CN, CI3 alkoxy, -CF 3 , -OCF3, -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and 15 heteroaryl; and wherein said heteroaryl is optionally further substituted with Cia alkyl or cycloalkyl; or when R 0 and R 2 are attached to a common nitrogen atom RI 20 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 20 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

2 t, -CN, C13 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 2 6 is independently selected from the group consisting of hydrogen, C 14 alkyl, aryl and cycloalkyl; and 25 wherein the C14 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, CIA alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof; 30 provided that when Y is -C(O)-, X is -0-, each R is hydrogen, R 2 and R together with the atom to which they are attached form a piperazine which is optionally substituted 59 with tert-butoxycarbonyl and Q is a bond, then R is not unsubstituted phenyl or morpholinyl; and that when Y is -S(0) 2 -, X is -0-, R 2 is benzyl, each R 3 is hydrogen, 2 is C-Q-R 1 , Q is a bond and RI is aryl or heteroaryl, then both R4 are hydrogen. [0124] In some embodiments, R' is aryl, cycloalkyl, cycloalkenyl or heteroaryl; 5 wherein said aryl, cycloalkenyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -0-R', -C(0)-R?2, -C(O)-O20, -N()(R), -N(R)-C(O)-R, -N(Ra)-C(O)

OR

2 , -S(O) 2

-R

2 , -O-S(0)2-R 20 , Ca4 alkyl, cycloalkyl and heterocyclyl; and wherein said C1.

6 alkyl or cycloalkyl are optionally substituted with one, 10 two or three substituents independently selected from the group consisting of halo, -CN and -O-R 0 [0125] In some embodiments, each R 3 is independently hydrogen, deuterium or C1.15 alkyl. [0126] In some embodiments, each R is independently hydrogen, deuterium or C1-15 15 alkyl. (01271 In some embodiments, R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Cw. alkyl, halo, cycloalkyl, aryl, heterocyclyl, heteroaryl, 20 -N(R 2

)(R

2 ), -C(O)-It, -C(O)-OR 0 , -C(0)-N(R)R), -CN and -0-R 2 ; wherein said C.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, C1- alkyl, aryl, heterocyclyl and heteroaryl; and 25 wherein said C14 alkyl is optionally further substituted with one, two or three halo. [0128] In some embodiments, Y is -C(O)- and R 2 and one of R 3 can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three 30 substituents independently selected from the group consisting of C.15 alkyl, -0-Re, -N(RaXn) and -C(O)-ORe; and 60 wherein said C 1

.

5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl. [0129] In some embodiments, the disclosure provides compounds of Formula IA: (R1O)n C4 Q 5 R4 IA wherein: Cy is aryl, cycloalkyl, cycloalkenyl, heterocyclyl or heteroaryl; Q is a covalent bond, -O-Co.

2 alkylene, -NR"-Co-2 alkylene, C2 alkylene, 10 C 2 alkenylene or C2 alkynylene; m is 0, 1, 2 or 3; n is 0, 1, 2, 3, 4 or 5; each R 0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH31)3, -0-R0, -S-R0, -C(0)-R ', -C(O)-OR O, -N(e)(Re), -C(0) 15 N(R2)(R2), -N(R)-C(O)-R 2, -N(R)-C(O)-OR?2, -N(Re)-S(O)2-R -S(O)2

R

20 , -0-S(O) 2 -R2 0 , -S(0) 2 -N(R)(Re), C 14 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said CI 4 alkyl, C24 alkenyl, C2-4 ailcynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 20 substituents independently selected from the group consisting of halo,

-NO

2 , aryl, heterocyclyl, heteroaryl, C14 alkyl, Ci-3 haloalkyl, cycloalkyl,

-N(R

2 )(R), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R)(R22), -CN and -O-R? 0 ;

R

2 is -C1-6 alkylene-R 5 , -L-R 5 , -L-C 1

.

4 alkylene-R, -C14 alkylene-L-R or -C1. alkylene-L-C 1 .- alkylene-R'; 25 wherein each -C1.4 alkylene is optionally substituted by one substituent independently selected from the group consisting of C24 alkynyl, halo,

-NO

2 , -CN, -O-R 0 , -N(R)(Ra), -C(O)-R 2 , -C(O)-OR 2 6 , -C(O) 61 N(R20)(R2 ), -N(R)-S(O) 2 -R, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents 5 independently selected from the group consisting of C14 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(Re), -C(O)-RO, -C(O)-OR 2 , -C(O)-N(R")(Re), -CN and -O-RaD L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(0) 2 NH-, -C(0)NH- or -NHC(O)-; provided 10 that when R 2 is -L-R 5 or -L-C 14 alkylene-R, then L is not -0-, -S-, -NHS(0)2- or -NHC(O)-; and each Ra is independently hydrogen, deuterium, C14 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said Ci alkyl is optionally substituted with one, two or three 15 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R")(R), -C(O)-0,

-C(O)-OR

0 , -C(O)-N(R")(RW), -CN and -0-Ra?; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 20 independently selected from the group consisting of halo, -NO 2 , C1- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(Re), -C(O)-R, -C(O)-OR 0 , -C(O)-N(ReXR), -CN and -O-R0; and wherein said C14 alkyl, aralkyl, cycloalkyl, aryl, 25 heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R)(Re), -C(O)-RO, -C(O)-OR, -C(O)-N(R)e 0 ), -CN and -0 R?'; 30 or R2 and one of R can join together with the atom to which they are attached to form a heterocyclyl; 62 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 4 alkyl,

-O-R

0 , -N(R 2

)(R

2 ), -N(R)-C(O)-OR 0 and -C(O)-OR0; and wherein said Ci- alkyl is optionally substituted with one, two or 5 three substituents independently selected from the group consisting of halo and heteroaryl; each R is independently hydrogen, deuterium, C14 alkyl, -C(O)-OR,

-C(O)-N(R

2 )(R) ), cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 14 alkyl is optionally substituted with one, two or three 10 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -C(O)-R 2 -C(O)-OR?, -C(O)-N(R")(R), -CN and -0-Ra; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 15 independently selected from the group consisting of halo, -NO2, Ci 4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R 2 ), -C(O)-R 0 , -C(O)-0R 0 , -C(O)-N(R)(R), -CN and -0-R 0 ; and wherein said CI 4 alkyl, aralkyl, cycloalkyl, aryl, 20 heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , -N(R)(Re), -C(0)-Rr, -C(0)-OR0, -C(0)-N(Ra 2)) -CN and -0-R 20 ; 25 IRS is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 - alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(RX ), -N(R")-S(O) 2 -R, -N(R) 30 C(O)-R, -C(O)-R2, -C(O)-OR 0 , -C(O)-N(R")(Re), -CN, oxo and -0 a 63 wherein said C 14 alkyl, cycloalkyl, aryl, heterocyclyl or heteraryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(RW) 0 Re), 5 -C(O)-R 2 , -C(o)-OR 2 , -C(O)-N(R)(R), -CN and -O-Re; and wherein said C, 4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 0 )(R), -C(O) 10 Re, -C(O)-OR 0 , -C(O)-N(Re)(Re), -CN, -S(O) 2 -R and -0-Re;

R

17 is halo, -0-R" or C 1

.

4 alkyl; R? and R2 are in each instance independently selected from the group consisting of hydrogen, C 1 .6 alkyl, C2-6 alkenyl, C 2 .6 alkynyl, cycloalkyl, heterocyclyl, aryl 15 and heteroaryl; wherein the C 14 alkyl, C2, alkenyl, C 2 6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkyl, acylamino, oxo, -NO2, -S(0) 2

R

6 , -CN, C1.3 alkoxy, -CF 3 , 20 -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with Cr4 alkyl or cycloalkyl; or when R 2 " and R are attached to a common nitrogen atom R and R may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 25 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

6 , -CN, C 1

-

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C1A alkyl, aryl and cycloalkyl; 64 wherein the C.. alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C14 alkoxy, -CF 3 and -OCFa; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of 5 stereoisomers or tautomer thereof; provided that when each R is hydrogen, R 2 and R 3 together with the atom to which they are attached form a piperazine which is optionally substituted with tert-butoxycarbonyl, Q is a bond and Cy is phenyl or morpholinyl, then n is 1, 2, 3,4 or 5. 10 [0130J In certain embodiments, the disclosure provides compounds of Formula II: (R)-- | O R2 N'R // R3 (RI7)m R4 II wherein: mis 0, 1,2 or 3; 15 n is 0, 1, 2,3,4 or 5; each R 10 is independently selected from the group consisting of halo, -NO 2 , -CN, -SF, -Si(CH 3

)

3 , -Q-R 2 , -S-R 0 , -C(O)-Ra, -C(O)-OY, -N(R')(R), -C(O) N(R)(Re), -N(R 2 )-C(O)-R?, -N(R 0

)-C(O)-OR

22 , -N(Re)-S(O)2-R 6 , -S(O)2 R*, -O-S(O)2-Ra, -S(O) 2 -N(tR7)( , C1. alkyl, C24 alkenyl, C24 alkynyl, 20 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1.4 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , aryl, heterocyclyl, heteroaryl, C1-6 akyl, C1-3 haloallcyl, cycloalkyl, 25 -N(R)(R 2 ), -C(O)-R 0 , -C(O)-0R 0 , -C(O)-N(R 2 )(R2), -CN and -O-R; R2 is -C16 alkylene-R', -L-R, -L-C1.e alkylene-R, -C1.4 alkylene-L-R or -C1.6 alkylene-L-C 1

.

4 alkylene-R 5 ; wherein each -C1.4 alkylene is optionally substituted by one substituent independently selected from the group consisting of C2.4 alkynyl, halo, 65

-NO

2 , -CN, -O-R, -N(Re)(R), -C(O)-R 2 , -C(O)-OR 2 , -C(O)

N(R

2 )(R), -N(R 2 )-S(O)rR2, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are 5 optionally substituted with one, two or three substituents independently selected from the group consisting of C1.6 alkyl, C24 alcynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2)(R), -C(O)-R, -C(O)-OR 0 , -C(O)-N(R2)(e), -CN and 10 L is -0-, -S-, -C(O)-, -NHS(O)2-, -S(O)2NH-, -C(O)NH- or -NHC(O)-, provided that when R 2 is -L-R 5 or -L-C 1 .- alkylene-RW, then L is not -O-, -S-, -NHS(O) 2 - or -NHC(O)-; each 3 is independently hydrogen, deuterium, C1.6 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; 15 wherein said Ci4 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R, -C(O)-ORo, -C(O)-N(R)(Re), -CN and -O-R; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are 20 optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1.s alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(Re), -C(O)-R, -C(O)-OR 2 , -C(Q)-N(R 2 )(Re), -CN and -O-R; and 25 wherein said C1.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2 )(R),

-C(O)-R

0 , -C(O)-OR 0 , -C(O)-N(R 2 )(RW ), -CN and -0 30 66 or R 2 and one of R can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1

.

4 alkyl, 5 -0-R 2 , -N(Rt)(e), -N(Rn)-C(O)-OI& and -C(O)-OR ; and wherein said C 1 4 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; each R is independently hydrogen, deuterium, Ci- alkyl, -C(O)-0R, 10 -C(O)-N(R)(R 2 ), cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 1 alyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R"), -C(O)-R, -C(O)-0R 0 , -C(O)-N(Ra) 2 R), -CN and -0- 0 ; 15 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(Rt), -C(O)-t 0 , -C(O)-OR 2 0, -C(O)-N(R 2 )(e), -CN and 20 -O-R; and wherein said C 14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , 25 -N(R 2 )(R), -C(O)-R, -C(O)-O0, -C(O)-N(Re)(RO), -CN and -0-R 0 R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from 30 the group consisting of Ci- alkyl, C2.4 alkynyl, halo, -NO2, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(Re), -N(R>)-S(O)2-Ra, -N(R) 67

C(O)-R

2 , -C(O)-R, -C(O)-OR, -C(O)-N(R)(Re), -CN, oxo and -0 R20 wherein said Ci alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally father substituted with one, two or three substituents 5 independently selected from the group consisting of halo, -NO 2 , Ci- alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -C(O)-R?, -C(O)-OR , -C(O)-N(R 20 )Re), -CN and -0-R 0 ; and wherein said C14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 10 or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF3, -N(R 2 0 R), -C(0)

RI

2 , -C(O)-OR, -C(O)-N(R)(R 2 e), -CN, -S(0) 2

-R

0 and -0-R; R is halo, -0-t 0 or Ci 4 alkyl; 15 R 2 and Rm are in each instance independently selected from the group consisting of hydrogen, CI.6 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C14 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three 20 substituents independently selected from the group consisting of hydroxyl, halo, Cia alkyl, acylamino, oxo, -NO 2 , -S(O) 2

R

2 , -CN, CI.3 alkoxy, -CF 3 ,

-OCF

3 , -OCH2CF 3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said hetemaryl is optionally further substituted with C14 alkyl or cycloalkyl; or 25 when R 0 and R 2 are attached to a common nitrogen atom R 0 and 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(0) 2 Re, -CN, C1-3 alkoxy, -CF 3 , -OCF3, aryl, heteroaryl and cycloalkyl; and 30 each R2 6 is independently selected from the group consisting of hydrogen, CIA alkyl, aryl and cycloalkyl; 68 wherein the CiA alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, C1.4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of 5 stereoisomers or tautomer thereof; provided that when is 0, each R4 is hydrogen, R? and R? together with the atom to which they are attached form a piperazine which is optionally substituted with tert-butoxycarbonyl and Q is a bond, then n is 1, 2 or 3. [0131] In some embodiments, R2 is -C4 alkylene-R' or -C 14 alkylene-L-R. 10 [0132] In some embodiments, each -C14 alkylene of R2 is optionally substituted by one substituent independently selected from the group consisting of C 2 4 alkynyl, halo, -NO2, -CN, -0-Re, -N(R)(Re), -C(0)-R0, -C(0)-OR?4, -C(0)-N(R)(R2), -N(Ra)-S(0)2 R?, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally 15 substituted with one, two or three substituents independently selected from the group consisting of C1- alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -C(O)-R 0 , -C(O)-OR, -C(O)

N(R

2 )(Re), -CN and -o- 0 . [01331 In some embodiments, each -C1 6 alkylene of R2 is unsubstituted. 20 [01341 In some embodiments, R 5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Ci alkyl, halo, cycloalkyl, heterocyclyl, heteroaryl, -N(R2)(R), -C(O)-OR 2 , -CN and -0-R 0 ; 25 wherein said C 1 -6 alkyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, C1. alkyl and aryl; and wherein said Ci 4 alkyl is optionally further substituted with one, two or three halo. 30 [0135J In some embodiments, R2 and one of R3 can join together with the atomto which they are attached to form a heterocyclyl; 69 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 14 alkyl, -O-R20, -N(R 2 0 )(R2) and -C(O)-OR 2 0 ; and wherein said C 1 . alkyl is optionally substituted with one, two or 5 three substituents independently selected from the group consisting of halo and heteroaryl. [0136] In some embodiments, R 2 is OC-1, F F F CF C 0 C1 \ Ice \ N, 10 - N'O---N N NN N CF N N NN N N-. N N N 70 F 0 N N O N NFF NO N N-N NN N FN N -.. F N N N-N _1N N 1 [3 NO ie t 2 o k I N F N~>~ f N . X each R 10 is independently selected from the group consisting of halo, -O-R( 2 o, -O-.

S(O)

2

-R

20 , C 14 ailkyl and cycloalkyl; and wherein said alkyl and cycioalkyl are optionally substituted with one, two or three halo or -CN; and 71 R20 is independently selected from the group consisting of C 1 - alkyl, cycloalkyl and ary; and wherein the alkyl and aryl are optionally substituted with one, two or three halo or cycloalkyl. 5 [0138] In some embodiments, n is 1, 2 or 3; and each R 0 is independently 2-fnoro, 3 fluoro, 4-fluoro, 2-chloro, 4-chloro, 2-methyl, 4-methyl, 4-ethyl, 4-isopropyl, 4-tert-butyl, 4-difluoromethyl, 4-trifluoromethyl, 4-cyclopropyl, 4-isobutoxy, 4-difluoromethoxy, 4 trifluoromethoxy, 4-(2,2,2-trifluoroethoxy), 4-trifluoromethylsulfoxyl, 4-(2,2,2 trifluoroethyl), 4-cyclopropoxy, 4-cyclobutylmethoxy, 4-fluorophenoxy, 4-phenoxy or 3 10 phenoxy. [0139] In some embodiments, each R3 is independently hydrogen, deuterium or CI4 alkyl optionally substituted with heteroaryl; or R2 and one of R3 can join together with the atom to which they are attached to form a heterocyclyl; 15 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 14 alkyl,

-N(R

20

)(R

2 2 ) and -N(R 2 )-C(O)-0R 20 ; and wherein said C 1

.

6 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting 20 of halo and heteroaryl; and R20 and R are in each instance independently selected from the group consisting of hydrogen, C 1 - alkyl and heteroaryl. [01401 In some embodiments, each R is independently hydrogen, deuterium or CI alkyl optionally substituted with heteroaryl; and 25 each R is independently hydrogen, deuterium or C1 alkyl optionally substituted with heteroaryl. [01411 In some embodiments, each R is independently hydrogen, deuterium or C1 alkyl optionally substituted with heteroaryl; m is 0 or 1; and 30 RV is halo. 72 [0142] In some embodiments, each R 3 is independently hydrogen, deuterium, methyl, isopropyl or pyridin-2-ylmethyl m is 0 or 1; and

R

7 is fluoro. 5 [01431 In some embodiments, each R 4 is independently hydrogen, deuterium or C14 alkyl. [01441 In some embodiments, each R is independently hydrogen, deuterium or C14 alkyl optionally substituted with heteioaryl; or R2 and one of R 3 can join together with the atom to which they are attached to 10 form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 alkyl,

-N(R)W(R

2 ) and -N(R 2

)-C(O)-OR

20 ; and wherein said Ci- alkyl is optionally substituted with one, two or 15 three substituents independently selected from the group consisting of halo and heteroaryl and each 4 is independently hydrogen, deuterium or C14 alkyl optionally substituted with heteroaryl. [01451 In certain embodiments, the disclosure provides compounds of Formula IIA:

(R

1

O

1 ,R2 N R4

OR

20 R4 IIA wherein: nis0, 1,2or3; each .

0 is independently selected from the group consisting of halo, -NO 2 , -CN, 25 -SF5, -Si(CH3)3, -O-Re, -S-RaD, -C(O)-RaO, -C(O)-ORO, -N(RW)R), -C(O) N(R")(R), -N(Ra-C(O)-Ra2, -N(Ra)-C(0)-ORe, -N(Ra)-S(0)2-Re, -S(O)2 RY, -O-S(O)2-R 0 , -S(O) 2

-N(R

2 )(Re), CJ46 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryL, heteroaryl and heterocyclyl; and 73 wherein said Ci- alkyl, C24 alkenyl, C- 2 4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , aryl, heterocyclyl, heteroaryl, C6 alkyl, CI-a haloalkyl, cycloalkyl, 5 -N(R Re 2 ), -C(O)-R, -C(O)-0R2 0 , -C(O)-N(R 20 )Re), -CN and -O-R;

R

2 is -C 14 alkylene-R, -L-R 5 , -I-C 14 alkylene-R', -C1-s alkylene-L-R or -C 14 alkylene-L-Ci6 alkylene-R 5 ; L is -0-, -S-, -C(O)-, -NHS(O)2-, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-, provided that when R2 is -LR or -LC 1

.

6 alkylene-R 5 , then L is not -o-, -S-, -NHS(O)2- or 10 -NHC(O)-; each R3 is independently hydrogen or Ci 4 alkyl; each R4 is independently hydrogen or CI- alkyl; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally 15 substituted with one, two or three substituents independently selected from the group consisting of C 1 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R? 2 ), -N(Rm)-S(0) 2

-R

0 , -N(O) C(O)-R?, -C(O)-R 0 , -C(O)-OR , -C(O)-N(R 2 )(Re), -CN, oxo and -0 20 20 wherein said C 14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , CIs alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R) ), -C(O)-R, -C(O)-0R 2 , -C(O)-N(R)(R), -CN and -O-R; and 25 wherein said Ci4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -N02, -CF 3 , -N(R)(RW), -C(O) R?, -C(O)-OR 0 , -C(O)-N(R)R 2 ), -CN, -S(0) 2 -Ra and 30 -0-R; 74 R and R 2 are in each instance independently selected from the group consisting of hydrogen, Ci- alkyl, C 2

-

6 alkenyl, C 2

.

6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the CI6 alkyl, C 2 4 alkenyl, C2 alkynyl, cycloalkyl, heterocyclyl, 5 aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CiA alkyl, acylamino, oxo, -NOz, -S(O)2RE, -CN, Ct.

3 alkoxy, -CF 3 ,

-OCF

3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with CI 4 10 alkyl or cycloalkyl; or when R 20 and RF are attached to a common nitrogen atom R 0 and Re may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci 4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , 15 -S(O)2Re, -CN, C 1

-

3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; and each R is independently selected from the group consisting of hydrogen, C 14 alkyl, aryl and cycloalkyl; wherein the C 14 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting 20 of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [01461 In certain embodiments, the disclosure provides compounds of Formula iB:

(RI

1 ) - O R2 N. NR 25 JIB wherein: nis 0, 1,2 or 3; each R10 is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH 3

)

3 , -O-R20, -S-R2, -C(O)-R 0 , -C(O)-0 0 , -N(R 2

)(R

22 ), -C(O) 30 N(Ra ), -N(R 2 )-C(O)-R, -N(R)-C(O)-OR 2 , -N(R)-S(O)2-R, -S(0)2 75

R

20 , -O-S(0) 2

-R

20 , -S(0)2-N(R)(Re 2 ), C1. alkyl, C, alkenyL C2 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; wherein said C-6 alkyl, C24 alkenyl, C2u alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 5 substituents independently selected from the group consisting of halo,

-NO

2 , aryl, heterocyclyl, heteroaryl, Ci-o alkyl, C1 haloalkyl, cycloalkyl,

-N(R

2 )(R), -C(O)-R 0 , -C(O)-OR 0 , -C(O)-N(R 2 e)(R), -CN and -O-R 20 ; R2 is -C1.6 alkylene-R 5 ; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; 10 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Cs6 alkyl, C24 alkynyl, halo, -NO 2 , -N(Re)(Re), -N(RO)-S(O)2RO, -N(a)-C(0)-R?2, -C(0)-R0, -C(O)-O00, -C(O)

N(R

2 )(RY), -CN, oxo and -O-R; and 15 wherein said C 1 . alkyl is optionally further substituted with one,, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2

)(R

2 ), -C(Q)-R, -C(O)-ORO,

-C(O)-N(R

2 )(R), -CN and -O-R; R and R are in each instance independently selected from the group consisting 20 of hydrogen, C14 alkyl, C 2 .6 alkenyl, C 2 4 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C1 alkyl, C2.6 alkenyl, C2.6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, 25 halo, Ci 4 alkyl, acylamino, oxo, -NO 2 , -S(0) 2

R

6 , -CN, CIa alkoxy, -CF 3 ,

-OCF

3 , -OCH 2

CF

3 and -C(O)-NH 2 ; or when R 0 and R are attached to a common nitrogen atom R 0 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of 30 hydroxyl, halo, C14 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO2, -S(Oh 2 , -CN, 0-3 alkoxy, -CF 3 and -OCF 3 ; and 76 each R is independently selected from the group consisting of hydrogen, C 14 alkyl, aryl and cycloalkyl; wherein the CIA alkyl, aryl and cycloalkyl maybe further substituted with from I to 3 substituents independently selected from the group consisting 5 of hydroxyl, halo, CIA alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0147] In some embodiments, n is 1, 2 or 3; and each RIO is independently selected from the group consisting of halo, -O-Re, -0 10 S(0) 2

-R

0 , C 14 alkyl and cycloalkyl; and wherein said alkyl and cycloalkyl are optionally substituted with one, two or three halo or -CN; and RaY is CI.6 alkyl, cycloalkyl or aryl; and wherein the alkyl and aryl are optionally substituted with one, two or three 15 halo or cycloalkyl. [0148] In some embodiments, n is 1, 2 or 3; and each RIO is independently 2-fluoro, 3 fluoro, 4-fluoro, 2-chloro, 4-chloro, 2-methyl, 4-methyl, 4-ethyl, 4-isopropyl, 4-tert-butyl, 4-difluoromethyl, 4-trifluoromethyl, 4-cyclopropyl, 4-isobutoxy, 4-difluoromethoxy, 4 trifluoromethoxy, 4-(2,2,2-trifluoroethoxy), 4-trifluoromethylsulfoxyl, 4-(2,2,2 20 trifluoroethyl), 4-cyclopropoxy, 4-cyclobutylmethoxy, 4-fluorophenoxy, 4-phenoxy or 3 phenoxy. [0149] In some embodiments, the compound is selected from the group consisting of: 4-((3-methyloxetan-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (11-1); 25 4-(2-(pyrrolidin-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fl[1,4]oxazepin-5(2H)-one (II-3); 4-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (11-4); 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 30 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (1-5); 77 4-(quinolin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fJl1 ,4]oxazepin-5(211)-one (H-7); (R)-2-(pyrimidin-2-ylmethyl)-8-(4-(trifl-uoinmethyl)pheny)-3,4,12, 12a-tetrahydmo- 11 benzo[flpyrazino[2,1-c][l,4]oxazepin-6(211)-one (11-8); 5 4-(cyclopropylmethyl)-7-(4-(trifluoromethoxy)pheayl)-3,4 dihydrobenzo[fJ[I ,4]oxazepin-5(2Hi)-one (11-10); (S)-3-methy1-4-(pyrimfidin-2-yhmethy)-7-(4-(tifiuoomethy)pheny)-3,4 dihydrobenzo[fJ[1 ,4]oxazephn-5(2Hi)-one (11-12); (R)-3-nethyb.4-(yrimdin-2-ymethy)-7-(4-ziluoromethy)pheny)-3,4 10 dihydrobenzolf][1 ,4]oxazePin-5(21{)-one (11-13); 6-{(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(511 yl)methyl)picolinonitle (11-14); 7-(4-(trifluowomethoxy)phenyl)-4-((6-(trifluoromethy)pyridin-2-yl)methyl)-3,4 dihydrobenzo[fJ[1,4]oxazepin-5(2H-)-one (11-15); 15 7-(4-(trifluoromethoxy)phenyl)-4-((6-(triluoromethyl)ptcini-3-yl)methyl)-3,4 dtydrobenzo[fJ[1 ,4]oxazepin-5(2H)-one (11-16); 4-((6-methylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)pheayl)-3,4 dihydrobcnzoffl[1,4]oxazepin-5(211-one (fl-17); (21(41 aS)-2-amino-7-(4-(trifluoivmethiyl)phenyl)-2,3,1 1,11 a 20 tetahydrobnom[flpynolo[2,1-c][ 1,4]oxazepin-5(LH)-one (11-2 1); (R)-2-(2,2-difiuoroethyl)-8-(4-(tifluoromethyl)phenyl)-3,4, 2,12a-tetahydro-1H benazo~fpyrazino[2,1-o] [i,4]oxazepin-6(21-1)-oae (H-22); (R)-2-ethy1-8-(4-(trifluoromethylphenyl)-3 ,4, 12, 12 a-tetraliydro-1H benzo[fjpyrazino[2,1-c][1,4]oxazepin-6(2H)-ouc (11-23); 25 (S)-2-(2,2-difluoroethyl)-8-(4-(tritluoixmetkyl)phenyl)-3,4, 12,1 2a-tetrahydro-1H bezrzo[f'Jpyrazino [2, 1-cJ[1,4]oxazepin-6(2H)-one (11-24); (S)-2-ethyl-8-(4-(tifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1H benzo[flpyraziuo[2, 1-o][1l4joxazepin-6(2HJ-one (H1-25); 78 4-(pyrazin-2-ylmethy1)-7-(4-(trifluowomethoxy)pheny1)-3,4 dihydrobenzo[fJ 1 ,4]oxazepin-5(2H)-one (11-3 1); 4-((5-methiyloxazol-2-yl)meffiyl)-7-(4-(triftuoromethoxy)phenyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5(2B)-one (11-33); 5 7-(4-(trifluoromethoxy)phenyl-42-(2,5,5-trimethy-1 ,3-dioxan-2-yl)ethyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5(2H-one (H-35); tert-butyl (2Rl I aR)-5-oxo-7-(4-(trfluomomethyl)phenyl)-I,2,3,5,1 1,1 Ia hexahydrobenzoffpyrrolo[2,1 -o][1,4]oxazepin-2-ylcarbamate (11-39); 4-((5-(pyridin-2-yl)isoxazol-3-yl)methyl)-7-(4-(trifluomomethoxy)phenyl)-3,4 10 dihydrobenzo[fJ[1 ,4]oxazepin-5(2Hi)-one (11-41); 4-((4,6-dimethoxypyrinildin-2-yl)metkyl)-7-(4-Qrifluoromethoxy)phenyl)-3 ,4 dihydrobenzo[f [ 1,4]oxazepin-5(2H)-one (11-42); ethfyl 3-((5-oxo-7-(4-(frifluoromethoxy)phenyi)-2,3Adihydrobenzo[f]1 ,4]oxazepin4(511) yl)methyl)benzoate (11-43); 15 4-(2-(pyriniidin-2-yl)ethyl)-7-(4-(trifluoromethoxy)pheatyl)-3,4 diliydrobenzo[f][1 ,4]oxazepin-5(211)-one (H-44); 4-(3,4-difluorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[][1,4]oxazepin 5(211)-one (11-45); 4-(2-chlorobenzy1)-7-(4-(trifluoromethoxy)pheny1)-3,4-dilhydrobenzo[f][1,4Joxazepin 20 5(211)-one (11-47); 4-(2,6-dichlomobenzyl)-7-(4-(frifluomomethioxy)phenyl)>3,4 dihydrobenz[f][ 1,4]oxazepin-5(211)-one (11-48); 4-(2,6-difluorabenzy)-7-(4-(trifluoomethoxy)pkenyl)-3,4-dihydrobenzofJ[1 ,4]oxszepin 5(211)-one (11-49); 25 4-(2-(1H-pyrazol-1-yt)ethyl)-7-(4-(trifluoromethoxy)pkenyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one (11-50); (2S,1 aS)-2-amino-7-(4-(frifluomomethyl)pheayl)-2,3,1 1, 11 a tetrahydhnbenzo[fjpy-rrolo[2, 1-o][1 ,4]oxazepin-5(1R)-one (11-51); 79 4-(2-(pyridin-2-yl)ethyl)-7-(4-(trifluoroinethoxy)pheniy)-3,4 dihydrobenzo[t][ 1 ,4]oxezepin-5(2B)-o-ne (11-54); 4-(2-fluorobenzyl)-7-(4-(tfrfluo-romethoxy)phenyl)-3,4-dihydrobenzo[t] [1 ,4]oxazepin 5(211)-one (11-57); 5 (R)-7-(4-(trifluxoromethyl)phenyl)-2,3,1 1,1 1a-teirabydiobenzo[flpyrrolo[2,1 c [1,4joxazepin-5(1B)-one (11-59); 4-(pyrimidini-2-ylmetliyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[ 4 1 ,4]oxazepin-5(211)-one (11-61); 4-(4-fluolobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrob~o[ff1 ,4]oxazepin 10 5(211)-one (11-62); 4-((1-methyl- 1H-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3 ,4 dihydrobenzo[f][ 1,4]oxazepin-5(211-one (11-64); 4-((5-ohloropyrimidin-2-yl)methyl)-7-(4-Qrifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1 ,4]oxazepiu-S(2HJI-one (H-65); 15 4-(pyridin-4ylmethyl)-7-(4-(frifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5(2H)-one (11-67); 4-((5-cyclopropyl-1,3 ,4-oxadiazol-2-yl)methyl)-7-(4-(trifluowomethoxy)pheyl)-3,4 dittydrobenzo[f][ 1,4]oxazepin-5(2H)-one (11-68)-) 4-(2-(pyrixnicin-2-yloxy)ethiy)-7-(4-(trifluomomethoxy)pheny)-3 ,4 20 dihydrobenzo[fjl[1,4]oxazepiri-5(211)-one (H1-69); 4-(pyridin-3-ybnethy1)-7-(4-(trifluoromethoxy)pheuy)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(211)-oue (U1-70); 4-(pyridin-2-yhmethy1)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[fJ[1 ,4]oxazepin-5(2H1)-one (H1-72); 25 4-(pyrhnidin-2-ylmethyl)-7-(4-(frifluorometoxy)paenyl)-3,A dihydrobenzo(f][1 ,4]oxazepin-5(2H)-one (11-73); 4-((3-meffiylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fJ[1 ,4joxazepin-5(2H)-one (11-75); 80 (RL)-2-(2,2,2-trifluoroethyl)-8-(4-(rifluoxomethyl)PbenyI)-3A4,2,12a-tefrahydro-1H benofjpyrazino[2, 1-c][1 ,4]oxazepin-6(2H)-one (101-83); 4-(pyrinicin-2-ylmethyl)-7-p-tolyl-3,4-dhlydrobeuzo[][1,4]oxazepin-5(21)-oue (11-87); 7-(4-cblomPhenYl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H) 5 one (11-88); 7-(4-isopropyIpheny)-4-(yrimidin-2-yhmethyfl-3,4-dihydrobenzo[f] [1,4]oxazepin 5(28)-one (11-89); 7-(4-ethylphenyl)-4-(jpyrinidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one 10 7-(4-oyolopropylphenyl}-4-(pyriindin-2-yimethyl)-3,4-dihydrobenzo[t][1 ,4]oxazepin 5(211)-one (11-92); (RL)4-(I-(PYrimidin-2-Yl)ethYl)-7-(4-Qrifluorometbyl)phenyl)-3,4 dibydrobenzo~fJ[ 1,4]oxazepiu-5(2H1)-one (11-95); 7-(4-isobutoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-diydrobenzo[f][1,4]oxazepi-n 15 5(28)-one (11-97); 7-(4-tert-butylpheny1)-4-(pyinidin-2-yhraethyI)-3,4-diliydrobenzo[fJ[1,4]oxazepin 5(28)-one (11-98); 7-(4-oyolopropoxyphenyl)-4-(pyrimidiu-2-yhnethyl)-3,4-dihydrobeizo[f][1 ,4]oxazepiu 5(28)-one (11-102); 20 7-(4-fluorophenyl)-4-(pyrimidin-2-yhuethyl)-3,4-dihydrobenzo[f)[1,4]oxzpin-5(21) one (11-104); 7-(2-fluoro-4-(trdttuororuethyl)phenyl)-4-(pyrimidin-2-ybnethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (1[-105); 7-(3-fluoro-4-(2,2,2-trifluoroethoxy)phenyt)-4-(pyrimidin-2-ylmethyl)-3,4 25 dihydrobenzo[ ]1,4]oxazepin-5(2H)-one (11-106); 4-(PYrimidin-2-YlmcthY1)-7-(4-{2,2,2-trifluoroethoxy)phenyI)-3,4 dihydrobenzo[fff I,4]oxazepin-5(28)-one (1[107); 7-(2-chloro-4-(trifluoromethyI)pheny1)-4-(pyrimidin-2-yLmetby1)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (11-1 10); 81 7-(4-(triluoromethioxy)phenyl)-4-((4-(trifluoromethlyl)pyrhnidin-2-yl)metb~yl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (11-113); 7-(4-(trffliuoromethoxy)phenyl)-.(5-(6-(trifluoromethyl)pyridin-3-yl)pyrimidin-2 yl)methiyl)-3,4-dihydrobenzo[fJ[1,4]oxazepin-5(2H)-one (11-115); 5 7-QI-cbloro-2-fluorophcnyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1 ,4]oxazepin 5(211)-one (H-1 17); 1-(4-(5-oxo-4-(pyrimidiu-2-yhunethyl)-2,3,45-tetrAhydrobenz[f]f1,4]oxazepin-7 yl)phenyl)cyolopentanecarbonitrile (11-122); 7-(4-ethoxyphenyl)-4-(pyrinidin-2-ylmethyl)-3,4-diiydrobenzo[fJ[1 ,4]oxazepiri-5(2H) 10 one (I1-123); 7-(4-(difluomomethyl)phenyl)-4-{pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][ 1,4joxazepin-5(211)-o-ne (11-124); 4-Qnfidazo[1 5 2-ajpyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (11-129); 15 4-((4-mozpholinopyrhilin-2-yl)methyl)-7-(4-(tzifluorornethoxy)phenyl)-3,4 dihydrobenzo[ff 1 ,4]oxazepin-5(211)-one (11-133); 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-diiydrabenzo[f] [1 ,4]oxazepin-5(211)-one (11-134); 4-(inaidazo[1 ,2-a]pyridin-2-yhnetliyl)-7-(4-(tifluomomethyl)p-henyl)-3,4 20 dihydrobenzo[fJ[1,4]oxazepin-5(211-one (H-135); 7-(3-tluowo-4-Qtrifuomomethyl)phenyl)-4-(pyrimidia-2-ylmethlyl)-3,4 dihydrobenzo[f][1 ,4joxazepin-5(211)-one (11-136); 4-((4-methoxYPYrin'idin-2-Yl)methyl)-7-$--(trifluomamethoxy)phenyl)-3,4 dihydrobenzo[f][1 A]oxazepin-5(2H)-one (11-137); 25 4-((4-methylpyrimidin-2-yl)methyi)-7-(4-(trifluoroniethoxy)pheyl)-34 dihydrobenzo[ ]1 ,4]oxazepin-5(2H1)-one (11-138); 4-((4-(piperidin-1-yl)pyrimidin-2-yl)methyl)-7-(4-(trifluoromethox)phenyQ)-3,4 dihYdrobenzo[fj[1 ,4joxazepin-5(2H)-one (11-139); 82 4-((4-(dimethylamino)pyriniidin-2-yl)methyl)-7-(4-(trifiuoromethoxy)pkienyl)-3,4 dihydrobenzo[flf1,4)oxazepin-5(2H)-one (11-140); 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydmobenzo[fJ[1 ,4]oxazepin-5(21*}-one (H 141); 5 4-((3-methoxypyridin-2-yJ)methyl)-7-(4-(trifluorometoxy)phenyl)-3 ,4 dihydrobenzo[f][1,4]oxazepin-5(211I)-one (H-143); 7-(4-(cyclabutylmnethoxy)phenyl)-4-(pyrimidiu-2-ylmethyl)-3,4 dihydrobe-nzo[fl[1,4]oxazepin-5(2I11)-one (11-144); 7-(2-methyl-4-(trifluomomethyl)phenyl)-4-(pyriniidiut-2-ylmethyl)-3,4 10 dihydrobenzo[f][1 ,4]oxazepin-5(2J3)-one (11-145); 7-(2-methyl-4-(trifluoroniethoxy)phenyl)-4-(pyrimidin-2-yhnethyl)-3,4 dihydrobenzo[fJ[ 1,4]oxazepin-5 (211)one (11-146); 4-((1-(difluoromethyl)-1H-pyrazol-3-yl)methy[)-7-(4-(trifhzoromethoxy)phenyl)-3,4 dihydrobenzo[fff I,4]oxezepin-5 (211)-one (11-147); 15 7-(4-Qrifluoromethoxy)phenyl)-4-((3-(trifluoromethyl)-11-pyrazol-1 -yl)rnethyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(211)-one (11-148); 4-Qpyrimnidin-2-ylmethyl)-7-(4-(2,2,2-trifluoroetkyl)pheuyl)-3,4 dihydrobenazo[fJ[1,4]oxazepin-5(2H)-one (11-150); 4-(pyridin-2-ylmethy1)-7-(4-(2,2,2-trifluomethylpheny1)-3,4 20 dihydrobenzo[f)[1 ,4]oxazepin-5(211)-one (TI- 151); 4-((1-cyclopentyl-1H-pyrazol-3-yl)methyl)-7-(4-(triluoromehoxy)pheyL)-3,4 dihydroberzo[fJ[1 ,4]oxazepin-5(2H)-one (11-152); 4-((1-ethyl-111-pyrazol-3-yl)methyl)-7-(4-(frifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5(211)-one (11-153); 25 4-((1-methyl-1E-imidazol4-yl)methyl)-7-{4-Qxifluoromethoxy)phenyL)-3,4 dihydroberizo[fJ[1 ,4joxazepin-5(2H)-one (11-154); 4-((4-ntethyl-1H-pyrazol-1 -yl)methyfj-7-(4-(trifluorometkoxy)phenyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5(211)-one 011-155); 83 4-((4-cliloro-1H-pyrazol-1-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo~f][1,4]oxazepin-5(2H)-one (11-15 6); 7-(4-(difluoromethyl)phenyl)A-(pyridin-2-ynethyF)-3,4-dihydroDbenzo[f][1,4]oxazepin 5(211-one (11-157); 5 7-(4-chloro-3-fluomophenyl)-4-(pyridin-2-ylmethyl)-3,4-dihydrobenzo[fj[1,4]oxazepin 5(211)-one (H-158); '7-(4-(difluommiethoxyphenYlA-(PYridn-2-yhmethy)-3,4-dihydrobenzo[ L[,4]oxazepiu 5(211)-one (11-159); 4-((1-methyl-1 E-pyrazol-4-yl)meth34)-7-(4-Qtrifluoromethoxy)phenyl)-3,4 10 dihydroberizo[t][1 ,4]oxazepin-5(211-one (11-160); 4-(pyrimidin-2-ylmethyl)-7-(2,3,4-trifluorophenyl)-3,4-dihydrobenzo[fj [1 ,4]oxazepin 5(211)-one (J1-162); 7-(3,4-difluomophenyl)-4-(pyimidin-2-ylmetlyl)-3,4-dihydrobenzo[f] [l4loxazepin 5(211)-one (11-163); 15 4-((3-fluoropyridin-2-y1)methy1)-7-(4-(frifluomomethoxy)phenyl)-3,4 dihydrobenzo[fffl ,4]oxazepia-5(2H)-one (11-164); 4-benzyl-9-fluoro-7-(4-(trifiuowomethoxy)phenyl)-3,4-dihydrobenzo[f] [1 ,4]oxazepin 5(211)-one (U-165); 4-benzyl-9-fluoro-7-(4-(trifluowomethyl)phenyl)-3,4-diydrobenzo[f][1 ,4]oxazepin 20 5(211)-one (11-166); 4-benzyl-8-fluoro-7-(4-(trifiuoroinethoxy)phenyl)-3,4-dihydrobenzo[f] [1 ,4]oxazepin 5(211-one (11-1 67); 4-benzyl-8-fluomo-7-(4-(trifluomomethyl)phenyl)-3A-dihydrobenzo[fj[1 ,4]oxazepin 5(211)-one (11-168); 25 7-(4-ohlowo-3-fluorophenyl)-4-((3-fluowopyridin-2-yi)methyl)-3,4 dihydroDbenzo[ ]1,4]oxazepin-5(21-one (11-169); 7-(2-fluoro-4-(tiifluoromethyl)phenyl)A-((3-fluawpyridin-2-yl)methyl)-3,4 clihyclrobenzo[fJ[1,A] oxazepin-5 (211)-one (11-170); 84 4-(5-oxo-4-(pyrimiciin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[fj[1 ,4]oxazepin-7-yI)phenyl trilkomomethanesulfonate (11-171); 4-((5-methylpyrazin-2-yl)methyl)-7-(4-(trfluowometkoxy)pheniyl)-3,4 dihydrobenzo[fJ[1,4]oxezepin-5(2H1-)-one (H-172); 5 2,2,3,34tetradeutero-A-(pyriinidin-2-ylmethyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[fJ[ 1,4]oxazepin-5(2H)-one (11-174); 4-((6-methylpyrazin-2-yl)methyl)-7-(4-(trifluomomethoxy)pheuyl)-3,4 dihydrobenzo[f][1 ,4]oxazepin-5 (211)-one (11-175); 4-((3-fluoropyridin-2-yl)miethyl)-7-(4-(tifluoromethyl)phenyl)-3,4 10 dihydrobenz[f][1,4]oxazepin-5(2H)-one (11-176); N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f] [1 ,43oxazepin-4(5fl) yl)ethyl)benzenesulfonamide (11-177); N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyL)-2,3-dihydrobenzo[f] [1,4]oxazepin-4(51} yl)ethyl)cyclopropanesulfonamide (11-179); 15 4-((1-methyl-JH-ixnidazol-2-yI)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[ 1,4]oxazepin-5(211)-one (11-186); 4-((1-benzyl-lJ-imidazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fl[ 1,4]oxazepin-5(2H}.one (11-187); 4-(imidazo[1,2-a]pyridin-2-ylmethyl)-7-(4-Qrifluomomethoxy)phenyl)-3,4 20 dihydrobenzo[fjl ,4]oxazepin-5(2H)-one (H-189); N-oyolopwopyl-3-(5-oxo-7-(4--(trifluoromethoxy)phenyl)-2,3 dihydroberizo[f][1,4]oxazepin-4(511}.yl)propane-1-sulfoaamide (11-190); N-(2-(5-oxo-7-(4-(tfluoromethoxy)phenyl)-2 3 3-dihydrobenzo[f][ 1,4]oxazepin-4(1) yI)ethyl)pyriiidine-2-caboxamfide (11-192); 25 7-(4-(4-fluo-ropheuoxy)phenyl)-4-(pyrinidiu-2-ylmethyl)-3,4 dihydrobenzo[fJ[ 1,4]oxazepin-5(211)-one (11-193); 7-(4-plienoxyphenyl)-4-(pyriniidin-2-ylmethyl)-3,4-dbydobenz[f] [1 ,4]oxazepin-5(21-1) one (11-194); and 85 7-(3-phenoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f[1,4]oxazepin-5(2H) one (H-195); or a phannaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof 5 [01501 In other embodiments, the disclosure provides compounds of Formula II: (RO)n- 0 .. R2 RR3 (R7~ O R4 wherein: m is 0 or 1; 10 n is 0, 1, 2 or 3: each R is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH 3

)

3 , -o-R20, -S-R 2 O, -C(O)-R 0 , -C(0)-OR, -N(R)(R 2 ), -C(O) N(e)(e), -N(R2)-C(O)-RO, -N(Ra)-C(0)-ORE, -N(RO)-S(O)2-R?, -S(O)2 R, -O-S(0) 2

-R

0 , -S(0) 2 -N(R)(Re 2 ), C 14 alkyl, C 24 alkenyl, C24 alkynyl, 15 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said Ci alkyl, C24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, . heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C14 alkyl, cycloalkyl, 20 -N(R 2 )(R), -C(O)-R, -C(O)-OR 2 0 , -C(O)-N(R)(Re), -CN and -0-a;

R

2 is -C1 4 alkylene-R, -L-R 5 , -L-C 14 alkylene-R 5 , -C14 alkylene-L-R or -C14 alkylene-L-Ci4 alkylene-R 5 ; L is -0-, -S-, -C(O)-, -NHS(O) 2 -, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-; each R 3 is independently hydrogen, deuterium, CI-15 alkyl, cycloalkyl, aryl, 25 heteroaryl or heterocyclyl; wherein said C1.15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 86

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 4 )(R), -C(O)-R, -C(Q)-ORW, -C(O)-N(R)(Re), -CN and -O-R"; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 5 independently selected from the group consisting of halo, -NO 2 , C1-s alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2)(R), -C(O)-Rw, -C(O)-0R, -C(O)-N(R)(Re), -CN and -O-R 2; and wherein said Ci-6 alkyl, aralkyl, cycloalkyl, aryl, 10 heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2

)(R

2 ), -C(O)-Re, -C(O)-OR 0 , -C(O)-N(R")(Re), -CN and -0 R; 15 or R 2 and one of R3 can join togetherwith the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1

.

15 alkyl, -O-R 2 , -N(Re)(Re), -N(R 2

)-C(O)-OR

2 and -C(O)-ORa; and 20 wherein said C1-1.5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; each RW is independently hydrogen, deuterium, Ci 4 s alkyl, CIA alkoxy, -C(O) OR, -C(O)-N(R 2

)(R

2 ), -N(RW)-S(0)2-Ra, cycloalkyl, aryl, heteroaryl or 25 heterocyclyl; wherein said Cs 1 5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Rt)(Re), -C(O)-R 0 , -C(O)-OR2, -C(O)-N(R 2 )(R), -CN and -0-Ra 0 30 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 87 independently selected from the group consisting of halo, -NO 2 , CI- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re 2 ), -C(0)-R , -C(O)-OR , -C(O)-N(R)(R ), -CN and

-O-R

0 ; and 5 wherein said Ci- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO2, -N(Re)(Re), -C(Q)-R 0 , -C(O)-0R 0 , -C(O)-N(R 2 0 X3), 10 -CN and -0-R0; or two R 3 or two R 4 together with the carbon atom to which they are attached form an oxo;

R

5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally 15 substituted with one, two or three substituents independently selected from the group consisting of C1 alkyl, C 2 . alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R 2 ), -N(Re)-S(0) 2

-R

0 , -N(R C(O)-R2f, -C(O)-Re, -C(O)-OR 20 , -C(O)-N(R)(Re), -CN and -O-R 0 ; wherein said CI4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl 20 are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , CI4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R", -C(O)-OR 0 , -C(O)-N(R 0 )(R2), -CN and -O-R2; and wherein said CIJ alkyl, cycloalkyl, aryl, heterocyclyl or 25 heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 eN), -C(O)

R

20 , -C(O)-ORe, -C(O)-N(R 2 %(Re ), -CN, -S(O) 2 -R and 30 R 7 is halo or CI4 alkyl; 88 Ra and Ra are in each instance independently selected from the group consisting of hydrogen, C-is alkyl, C 2 -Is alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C-is alkyl, C 2 -s alkenyl, C 2 -is alkynyl, cycloalkyl, 5 heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CI 4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 R?, -CN, C 1 -3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 10 wherein said heteroaryl is optionally further substituted with Ci 4 alkyl or cycloalkyl; or when Re and R? are attached to a common nitrogen atom R and Rm 2 May join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of 15 hydroxyl, halo, C 4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2, -S(0)21R?6, -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R0 is independently selected from the group consisting of hydrogen, C 14 alkyl, aryl and cycloalkyl; and wherein the C 14 alkyl, aryl and cycloalkyl may be further substituted with 20 from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or pro drug thereof, provided the compound is not tert-butyl 6-oxo-8-phenyl-3,4,12,12a-tetrahydro 25 1H-benzo[fjpyrazino[2,1-c][1,4]oxazepine-2(6H)-carboxylate, tert-butyl 6-oxo-9 phenyl-3,4,12,12a-tetrahydro-1H-benzo[fjpyrazino[2,1-c](1,4]oxazepine-2(6Hl) carboxylate, 8-phenyl-3,4,12,12a-tetrahydro-1H-benzo[flpyrazino[2,1 c][1,4]oxazepin-6(2H)-one, or 9-phenyl-3,4,12,12a-tetrahydro-1H benzo[fjpyrazino[2,1-c][1,4]oxazepin-6(2H)-one. 30 [0151] In some embodiments, R 2 is -C 1 4 alkylcne-R or -C 1 -6 alkylene-L-R. [0152] In some embodiments, R is cycloalkyl, aryl, heteroaryl or heterocyclyl; 89 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Ci.4 alkyl, halo, cycloalkyl, heterocyclyl, heteroaryl, -N(R 2 t)(R,

-C(O)-OR

2 O, -CN and -0-0; 5 wherein said C1. alkyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, C14 alkyl and aryl; and wherein said C14 alkyl is optionally further substituted with one, two or three halo. 10 [0153] In some embodiments, R 2 and one of R 3 can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of CIis alkyl, -0-Ra, -N(R)(R) and -C(0)-OR20; and 15 wherein said CI.15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl. AO [0154] In some embodiments, R2 s'.~ F C C 0 2 0 20 CI /0 N '/"~ ' N, % N N N't ~

N

9oN 90 \ N N NN-V F N F PF N N N 5< N N N N FFCF FF NN N F N N FN NN N N 1 ~ 1 N\ N~ or~ F~o 10~~~~N RN aud onFfi~tgte ihtecro tm owihte r tahdfr AN F NY 2t/h9N~~N NW -*, Fb N F F F h91 F F F N" N-/ N N F NN \ -F FN/N or H N O (0155] In some embodiments, n is 1, 2 or 3; and each R 0 is independently selected from the group consisting of halo, -O-R, -O 5 S(O)2-R 0 , C 1

.

4 alkyl and cycloalkyl; and wherein said alkyl is optionally substituted with one, two or three halo; and Ra is independently selected from the group consisting of C-CI 5 alkyl and cycloalkyl; and wherein the alkyl is optionally substituted with one, two or three halo or 10 cycloalkyl. [01561 In some embodiments, n is 1, 2 or 3; and each R' 0 is independently 2-fluoro, 3 fluoro, 4-fluoro, 2-chloro, 4-chloro, 2-methyl, 4-methyl, 4-ethyl, 4-isopropyl, 4-tert-butyl, 4-difluoromethyl, 4-trifluoromethyl, 4-cyclopropyl, 4-isobutoxy, 4-difluoromethoxy, 4 trifluoromethoxy, 4-(2,2,2-trifluoroethoxy), 4-trifluoromethylsulfoxyl, 4-(2,2,2 15 trifluoroethyl), 4-cyclopropoxy or 4-cyclobutylmethoxy. [0157 In some embodiments, each R3 is independently hydrogen, deuterium or C 1 .15 alkyl optionally substituted with heteroaryl; or R2 and one of R3 can join together with the atom to which they are attached to form a heterocyclyl; 20 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of CI-is alkyl, -N(R 2 )(R2) and -N(R 2

)-C(O)-OR

0 ; and wherein said CI-Is alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting 25 of halo and heteroaryl; and 92 R2 and R are in each instance independently selected from the group consisting of hydrogen, C 1 -Cis alkyl and heteroaryl. [0158] In some embodiments, each R? is independently hydrogen, deuterium or Cx.1.

5 alkyl optionally substituted with heteroaryl. 5 [01591 In some embodiments, each R? is independently hydrogen, deuterium, methyl, isopropyl or pyridin-2-ylnethyl. [0160] In some embodiments, each R 4 is independently hydrogen, deuterium or C 1

-

15 alkyl. [0161] In some embodiments, each R 4 is independently hydrogen, deuterium or methyl. 10 [0162] In some embodiments, m is 0. [01631 In some embodiments, m is 1; and R 7 is halo. [0164] In some embodiments, m is 1; and R 7 is fluoro. [0165] In certain embodiments, the disclosure provides compounds of Formula I: (RIO)n- I N'R2 R

FR

3 R4 15 1II wherein: nis 0, 1,2, 3,4 or5: each R 0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SF,, -Si(CH 3

)

3 , -O-R2, -- S-IR, -C(O)-R 2 , -C(O)-OR 20 , -N(R)(R 2 ), -C(O) 20 N(R 2 )(Re), -N(R 2 )-C(O)-R?, -N(R)-C(O)-OR", -N(R)-S(O) 2 -R, -S(0)2 RZ, -O-S(Ort 2 0 , -S(O) 2 -N(R)(Re), C 1

.

4 alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1

.

4 alkyl, C2 4 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 25 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1

.

4 aLkyl, C.3 haloalkyl, cycloalkyl, -N(R20)R), -C(0)-RO, -C(O)-OR?, -C(O)-N(ReW), -CN and -0-R?; 93

R

2 is -L-R, -L-Ci- alkylene-R, -C14 alkylene-L-Ror -C14 alkylene-L-CI 4 alkylene-R; wherein each -CI alkylene is optionally substituted by one substituent independently selected from the group consisting of C2 alkynyl, halo, 5 -NO 2 , -CN, -0-Rt, -N(R 2 )(R ), -C(O)-R, -C(O)-ORF, -C(0) N(Rt)(Re), -N(RY)-S(O) 2 -R , cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents 10 independently selected from the group consisting of Ci- alkyl, CZ alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2

)(R

2 ), -C(O)-R , -C(O)-OR 0 , -C(O)-N(R 2 )(R), -CN and -0-et; L is -O-, -S-, -NHS()r, -S(0)2NH-, -C(O)NH- or -NHC(O)-, provided that when 15 R 2 is -L-R or -L- 1 CI alkylene-R2, then L is not -0-, -S-, -NHS(0) 2 - or -NHC(O)-; each R 3 is independently hydrogen, deuterium, CI-1s alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said CI- 1 5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 20 -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Rt)(Rt), -C(O)-Rt, -C(0)-OR2, -C(O)-N(R 2 )(Rt), -CN and -0-R; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally father substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 25 C14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Rn)( 2 R), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(Rt)(RE), -CN and -0-R?; and wherein said CI6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally farther substituted 30 with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2 R), 94

-C(O)-R

2 , -C(O)-OR, -C(O)-N(R 2 )(Rz), -CN and -0 Re; each R 4 is independently hydrogen, deuterium, C1.15 alkyl, Ci 4 alkoxy, -C(O)

OR

2 , -C(O)-N(R)(R), -N(R)-S(0)2-R2, cycloalkyl, aryl, heteroaryl or 5 heterocyclyl; wherein said Ci4s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 0 aR), -C(O)-Ra, -C(O)-OR, -C(O)-N(R)R 2 e), -CN and -0- 0 ; 10 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R 2 R), -C(O)-R 20 , -C(O)-OR 2 , -C(O)-N(R 2 )(Re), -CN and 15 -0-R 0 ; and wherein said Crc- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , 20 -N(R)(R), -C(O)-R 0 , -C(O)-OR, -C(O)-N(R)(R , -CN and -O-R2; or two Rt or two R4 together with the carbon atom to which they are attached form an oxo; R? is cycloalkyl, aryl, heteroaryl or heterocyclyl; 25 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Ci-6 alkyl, C 24 alkynyl, halo, -NO 2 , cyoloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)R), -N(R)-S(0)2-Re, -N(R 2 > C(O)-R, -C(O)-R, -C(O)-OR 0 , -C(O)-N(R 2 )(RE), -CN and -O-R; 30 wherein said C 1 .6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 95 independently selected from the group consisting of halo, -NO 2 , C1 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R),

-C(O)-R

0 , -C(O)-ORY, -C(O)-N(Ra? Xn), -CN and -O-R 2 0 ; and wherein said C3 alkyl, cycloalkyl, aryl, heterocyclyl or 5 heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF3, -N(R 2 )(Re), -C(0) R, -C(O)-ORt, -C(O)-N(R 2 )(Re), -CN, -S(O) 2

-R

0 and -0-R 20 10 R?' and R? 2 are in each instance independently selected from the group consisting of hydrogen, Ci-is alkyl, C2-is alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the Ci-15 alkyl, C2-Is alkenyl, C2-Is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or 15 three substituents independently selected from the group consisting of hydroxyl, halo, C4 alkyl, acylamino, oxo, -NO2, -S(O) 2 R, -CN, C1 alkoxy, -CF3, -OCF3, -OCH2CF3, -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C4 20 alkyl or cycloalkyl; or when R and R2 are attached to a common nitrogen atom R and R may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CIA alkyl, aralkyl, aryloxy, aralkyloxy, acylanino, -NO2, 25 -S(O) 2

R

6 , -CN, C 1

.

3 alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C14 alkyl, aryl and cycloalkyl; and wherein the C-4 alkyl, aryl and cycloalcyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting 30 of hydroxyl, halo, C14 alkoxy, -CF3 and -OCF3; 96 or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0166 In other embodiments, the disclosure provides compounds of Formula III: N O AO

F"R

3 O R R R4 5 III wherein: nis0,1,2or3: each R0is independently selected from the group consisting of halo, -NO 2 , -CN, -SFS, -Si(CH)3, -O-R0, -S-R2, -C(O)-R 0 , -C(O)-0R 2 , -N(R)(Re 2 ), -C(O) 10 N(Re)(R), -N(R)-C(O)-R 2, -N(R2)-C(0)-OR?2, -N(Re)-S(O)2-R?6, -S(O).2 R2, -O-S(O)2rR2, -S(O)2-N(R)(R 2 ), C 1 . alkyl, C 24 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1

.

6 alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 15 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, Cp- 6 alkyl, cycloalkyl,

-N(R

2

)(R

2 ), -C(O)-R 2 , -C(O)-0R", -C(O)-N(R)(Re), -CN and -O-R0 R2 is -L-R 5 , -L-C 1 _ alkylene-R 5 , -C 1 .- alkylene-L-R' or -C 1

.

6 alkyleae-L-C 1

.

6 alkylene-R 5 ; 20 L is -0-, -S-, -C(O)-, -NHS(0)2-, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-; each R3 is independently hydrogen, deuterium, C 1

.

15 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 1

.

15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 25 -N02, cycloalkyl, aryl, heterocyclyl, heteroaryl, -Ne()(Rf), -C(O)-0,

-C(Q)-

0 0

(

, -C(O)-N(R)(R 2 ), -CN and -0-R 21; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 97 C-- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(R), -C(0)-R, -C(O)-OR, -C(O)-N(R 2 )(Re), -CN and -0-Km; and wherein said C1.4 alkyl, aralkyl, cycloalkyl, aryl, 5 heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2 )(R),

-C(O)-R

2 0 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -0 10 each R! is independently hydrogen, deuterium, CI5 alkyl, C14 alkoxy, -C(0) OR, -C(O)-N(RE)(R 2 ), -N(R 2 t)-S(O) 2 -RY, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C-5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 15 -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2)(Re), -C(O)-R0 -C(O)-OR, -C(O)-N(R 2 )(R), -CN and -0-R; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 20 C4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R 2 ), -C(O)-R 0 , -C(O)-OR 0 , -C(0)-N(Re)(Re), -ON and -0-K; and wherein said CI- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted 25 with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , -N(RW (R), -C(O)-Ra, -C(0)-ORr, -C(0)-NU(R 12g) -CN and -0-R; or two R 3 or two R4 together with the carbon atom to which they are attached form 30 an oxo; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; 98 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Ci alkyl, C2.4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -N(R 2 )-S(O)2-R 2 , -N(R) 5 C(O)-R?, -C(O)-R 0 , -C(O)-0R 0 , -C(O)-N(R 2 )(Re), -CN and -O-R 0 ; wherein said C 1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Ci6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), 10 -C(O)-R 0 , -C(O)-OR, -C(O)-N(Ra)(Re), -CN and -O-RO; and wherein said C 1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(Re), -C(0) 15 R2, -C(O)-OR 0 , -C(O)-N(R)(R 2 ), -CN, -S(O)2-R 0 and 20-0 Ra and R? are in each instance independently selected from the group consisting of hydrogen, CI-15 alkyl, Cr15 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 20 wherein the CI-is ailcyl, C2-is alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CiA alkyl, acylamino, oxo, -NO2, -S(O) 2

R

2 , -CN, C1.3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and 25 heteroaryl; and wherein said heteroaryl is optionally further substituted with CIA alkyl or cycloalkyl; or when R 2 and R are attached to a common nitrogen atom R 2 and R" may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 30 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO2,

-S(O)

2 Re, -CN, C1-3 alkoxy, -CF 3 , -OCF3, aryl, heteroaryl and cycloalkyl; and 99 each R 26 is independently selected from the group consisting of hydrogen, C 1 4 alkyl, aryl and cycloalkyl; and wherein the Ci 4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting 5 of hydroxyl, halo, Ci 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0167] In some embodiments, R2 is -C(O)-R' or -C(O)-Ci. alkylene-R 5 ; and R is cycloalkyl, aryl or heteroaryl; 10 wherein said cycloalkyl or heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1.o alkyl, halo and -C(Q)-OR. [0168] In some embodiments, RW is cycloalkyl, aryl or heteroaryl; wherein said cycloalkyl or heteroaryl are optionally substituted with one, two or 15 three substituents independently selected from the group consisting of C 1

.

4 alkyl, halo and -C(O)-OR 20 . [0169] In some embodiments, each -C 1

.

4 alkylene of R 2 is unsubstituted. oN 0 ~ N 0 [0170] In some embodiments, R2 is N' 0 0 0 H 0H F N H N N 20 N N or [0171] In some embodiments, n is 1; and

R

10 is -O-R or CI 4 alkyl; 100 wherein said alkyl is optionally substituted with one, two or three halo; and R2 0 is CI-C1 5 alkyl; wherein the alkyl is optionally substituted with one, two or three halo. [0172] In some embodiments, n is 1; and R1 0 is 4-trifluoromethyl or 5 4-trifluoromethoxy. [0173J In some embodiments, the compound is selected from the group consisting of: pyrimidin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepi-4() yl)methanone (HI-1); phenyl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) 10 yl)methanone (MI-4); (1-methylcyclopropyl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzolf][1,4]oxazepin-4(5H)-yl)methanone (I1-10); (3,3-difluorocyclobutyl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)methanone (111-11); 15 (1-methyl-1H-pyrazol-4-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (11-12); (lH-pyrazol-3-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj[l,4]oxazepin 4(5I)-yl)methanone (11-15); pyrazin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepin-4(5H) 20 yl)methanone (111-23); pyridazin-3-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin4(5H) yl)methanone (111-24); 2-(pyridin-2-yl)-1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)ethanone (IM-29); 25 2-(pyrhmidin-2-yl)-1-(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)ethanone (HI-30); (1-methyl-1H-imidazol-5-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (111-32); 101 (IH-imidazol-2-yl)(7-(4-(trifluoromethy)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepin 4(5H)-yl)methanone (1II-33); (1-methyl-iH-imidazol-2-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepiu-4(5H)-yl)methanone (III-37); 5 (R)-(2-methyl-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) yl)(pyrinmidin-2-yl)methanone (111-38); tert-butyl 2-(7-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[fj[1,4]oxazepine-4 carbonyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate (III-40); (IH-1,2,4-triazol-3-yl)(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 10 4(5H)-yl)methanone (II-50); and (1,5-dimethyl-1H-pyrazol-3-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (1II-58); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. 15 [01741 In certain embodiments, the disclosure provides compounds of Formula IV: O IR2 NN (RI1). '1 IV wherein: n is 0, 1, 2, 3, 4 or 5: 20 each R' 0 is independently selected from the group consisting of halo, -NO2, -CN, -SFs, -Si(CH3)3, -0-Ra, -S-RaO, -C(O)-RaO, -C(O)-Oea, -N(Re)(R), -C(O) N2R)(RS), -N(Re)-C(O)-NR, -N(R)-C(O)-OR , -N(R)-S()2-R2 , -S(O)2

R

0 , -O-S(O),, - O)-N()e), C 1 -6 alkyl, C 2 4 alkenyl, C 24 alkynyl, cycloalkyl, ryl, heteroaryl and heterocyclyl; and 25 wherein said C 1 -6 alkyl, C 2 4 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1 - alkyl, C 1 3 haloalkyl, 102 cycloalkyl, -N( 2 0)W' ), -C(O)-Ra, -C(O)-OR 0 , -C(O)-N(R )(R ), -CN and -O-R 0 R2 is -C 1

.

4 alkylene-R 5 , -L-R', -L-CI 4 alkylene-R', -C 1 .- alkylene-L-R' or -C 1 -6 alkylene-L-Ci4 alkylene-R; 5 wherein each -C 14 alkylene is optionally substituted by one substituent independently selected from the group consisting of C24 alkynyl, halo, -NO2, -CN, -O-R 0 , -N(R 2 4 gRe), -C(O)-R 20 , -C(Q)-OR 2 6 , -C(O) N(Ra)(1R), -N(R 2

)-S(O)

2

-R

2 , cycloalkyl, aryl, heteroaryl or heterocyclyl; and 10 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 .6 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R )(R?), -C(O)-R , -C(O)-OR , -C(O)-N(R )(R), -CN and 15 -0- 0 ; L is -0-, -S-, -C(O)-, -NHS(O) 2 -, -S(0)2NH-, -C(O)NH- or -NHC(O)-, provided that when R 2 is -L-R' or -- C14 alkylene-R, then L is not -0-, -S-, -NHS(O) 2 - or -NHC(O)-; R5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; 20 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 6 alkyl, C24 alkynyl, halo, -NO2, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 20 )(R), -N(Rt)-S(O) 2 -R, -N(Rg C(O)-R2, -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -O-Ra 0 ; 25 wherein said C14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1.6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(RY), -C(O)-R , -C(O)-ORa, -C(O)-N(Re)(R ), -CN and -O-R0; and 30 wherein said C.4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 103 or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R)(RO), -C(O)

R

0 , -C(O)-0R 0 , -C(o)-N(e)(R), -CN, -S(0)2-R and -O-a 5 R' and Re are in each instance independently selected from the group consisting of hydrogen, C 1

-

1 5 alkyl, C 2 -, alkenyl, C 2

-

1 5 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; whereinthe C,- 15 alkyl, C-is alkenyl, C 2 -is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or 10 three substituents independently selected from the group consisting of hydroxyl, halo, Ci 4 alkyl, acylamino, oxo, -NO 2 , -S(O)20R, -CN, C1.3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C 1 4 15 alkyl or cycloalkyl; or when R 20 and R 2 are attached to a common nitrogen atom R 20 and R may join to form a heterocyclic or heteroaryl ring which is then optionally substituted.with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , 20 -S(O) 2

R

2 6 , -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, CI4 alkyl, aryl and cycloalkyl; and wherein the CI 4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting 25 of hydroxyl, halo, Ci 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0175] In other embodiments, the disclosure provides compounds of Formula IV: 104 N (Ri0)n -t IV nisO, 1,2or3: each R0 is independently selected from the group consisting of halo, -NO 2 , -CN, 5 -SF 5 , -Si(CH3)3, -O-Ra, -S-R2, -C(O)-R 0 , -C(O)-ORO, -N(R2)(RP), -C(0) N(R)(R), -N(R)-C(0)-RO, -N(R)-C(O)-OR?2, -N(R')-S(O)r-R26, -S(0)r R0, -O-S(O)r-R0, -S(O)-N(R)(Re), Ci 4 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said CI 4 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, 10 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, CI-3 alkyl, cycloalkyl, -N(R )(R 2 ), -C(O)-R2, -C(O)-OR2, -C(O)-N(R)(R 2 2 ), -CN and -O-R R2 is -C14 alkylene-R 5 , -L-R 5 , -L-C 14 alkylene-R5, -C 1 6 alkylene-L-R or -C1 15 alkylene-L-C 14 alkylene-R 5 ; L is -0-, -S-, -C(0)-, -NHS(O) 2 -, -S(0)2NH-, -C(O)NH- or -NHC(O)-; S(O)R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from 20 the group consisting of Ci- alkyl, C 2

.

4 alkynyl, halo, -NO2, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -N(R)-S(O) 2 -R, -N(R) C(O)-R, -C(O)-R 2 0 , -C(O)-OR20, -C(O)-N(R)(Re), -CN and -O-R20; wherein said Cj4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 25 independently selected from the group consisting of halo, -NO 2 , C16 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -C(O)-R2, -C(O)-OR20, -C(O)-N(R 2 )e), -CN and -O-0; and wherein said CI alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 105 or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R2)(R), -C(O) R, -C(O)-0R 20 , -C(O)-N(R 2 )(Re), -CN, -S(O)-R 20 and -O-R; 5 R and R2 are in each instance independently selected from the group consisting of hydrogen, Ci- 15 alkyl, C 2

-

1 5 alkenyl, C 2

-

15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C-i 5 alkyl, C 2 -is alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or 10 three substituents independently selected from the group consisting of hydroxyl, halo, CI 4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 R, -CN, CI-3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with Ci 4 15 alkyl or cycloalkyl; or when R and R0 are attached to a common nitrogen atom R and RP mayjoin to form a heterocyclic or heteroaryl ring which is then optionally substituted-with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , 20 -S(O) 2 R6, -CN, C 1 -3 alkoxy, -ClF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group consisting of hydrogen, CI 4 alkyl, aryl and cycloalkyl; and wherein the C 1 4 alky], aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting 25 of hydroxyl, halo, CIA alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [01761 In some embodiments, each -C 1

.

4 alkylene of R2 is unsubstituted. [0177J In certain embodiments, the disclosure provides compounds of Formula V: 106

(R

1 O)n A N wherein: A is cycloalkenyl; 5 n is 0, 1,2, 3, 4 or 5; each R1 0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH3)3, -O-R0, -S-R0, -C(O)-RO, -C(O)-OR20, -N(RF)(R), -C(O)

N(R

20 )(R), -N(R 2

)-C(O)-R?

2 , -N(Re)-C(O)-OR, -N(R 2 )-S(0)rR 2 6 , -S(0)2

R

20 , -0-S(O) 2 -R, -S(0)rN(R 0 )(Re), C 1 . alkyl, C24 alkenyl, C24 alkynyl, 10 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1.4 alkyl, C2.4 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C1.6 alkyl, C 1

.

3 haloalkyl, 15 cycloalkyl, -N(R 2

)(R

2 ), -C(O)-R 20 , -C(O)-ORZ, -C(O)-N(RY)(R), -CN and -O-R0

R

2 is -C1.4 alkylene-R, -L-R 5 , -L-C 1 - alkylene-R 5 , -C 1

.

4 alkylene-L-R or -C1 alkylene-L-C 1

.

4 alkylene-R 5 ; wherein each -C1-6 alkylene is optionally substituted by one substituent 20 independently selected from the group consisting of C24 alkynyl, halo,

-NO

2 , -CN, -O-R , -N(R)(R), -C(O)-R 2 , -C(O)-OR 6 , -C(O)

N(R

2 )(RP), -N(R 2

)-S(O)

2

-R

20 , cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are 25 optionally substituted with one, two or three substituents independently selected from the group consisting of C1.6 alkyl, C24 alkynyl, halo, -NO2, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(Re)(R), -CN and 107 L is -0-, -S-, -C(0)-, -NHS(O)2-, -S(O)2NH-, -C(O)NH- or -NHC(O)-, provided that when R2 is -L-R or -L-C 1 -6 alkylene-R', then L is not -0-, -S-, -NHS(0)r or -NHC(O)-; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; 5 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 .6 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -N(2)-S(0)2-R, -N 20)_ C(O)-R2, -C(0)-R, -C(0)-OR 0 , -C(0)-N(R0)R , -CN and -O-Ra 10 wherein said C4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re),

-C(O)-R

0 , -C(0)-OR , -C(O)-N(R)(R ), -CN and -0-R; and 15 wherein said C 1

.

4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(RE), -C(O) R20, -C(O)-OR0, -C(O)-N(R)(R 2 ), -CN, -S(0) 2 -R? and 20 -O-R2; Ra 0 and R? are in each instance independently selected from the group consisting of hydrogen, C-is alkyl, C2-is alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the Cl-is alkyl, C2-15 alkenyl, C 2

-

15 alkynyl, cycloalkyl, 25 heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CI 4 alkyl, acylanino, oxo, -NO2, -S(0) 2

R

2 6 , -CN, C1-3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 30 wherein said heteroaryl is optionally further substituted with C1.4 alkyl or cycloalkyl; or 108 when R 0 and R? are attached to a common nitrogen atom .

0 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, aralkyl, aryloxy, aralkyloxy, acylaminuo, -NO 2 , 5 -S(0) 2 R2, -CN, C1-3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C 14 alkyl, aryl and cycloalkyl; and wherein the CI4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting 10 of hydroxyl, halo, Ca4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0178] In other embodiments, the disclosure provides compounds of FormulaV: (RO). A 0 ,R 2 N' 15 V wherein: A is cycloalkenyl; n is 0, 1, 2 or 3: each R 10 is independently'selected from the group consisting of halo, -NO 2 , -CN, 20 -SFs, -Si(CH3)3, -O-R, -S-R 2 , -C(O)-R, -C(O)-O 2 , -N(Rt)(R 2 ), -C(O) N(R -() , CNR)-C(0)-RD, -N(R0)-C(0)-OR2, -N(R)-S(0)2-R2, -S()2 2, -O-S(O)2-R?, -S(%)2-N(R)(R.), Ces alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said CI-4 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, 25 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, CI-6 alkyl, cycloalkyl, -N(R.)(e), -C(O)-.

0 , -C(O)-OH., -C(O)-N(R 2

)(

0 R), -CN and -0-R; R2 is -C4l -L-R 5 , alkylene-RS, -C alkylene-L-R or -Cas 30 alkylene-L-C alkylene-R'; 109 L is -0-, -S-, -C(O)-, -NHS(O) 2 -, -S(0) 2 NH-, -C(O)NH- or -NHC(O)-; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from 5 the group consisting of C 1 . alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -N(R 2

)-S(O)

2

-R

2 , -N(R 2

)

C(O)-R

2 , -C(O)-RO, -C(O)-ORa, -C(O)-N(R 2 )(Re), -CN and -0-R wherein said C 1 . alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 10 independently selected from the group consisting of halo, -NO 2 ,

C

1

.

4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Rn)(RE),

-C(O)-R

0 , -C(O)-OR 0 , -C(O)-N(R")R), -CN and -0-Ra; and wherein said C 1 . alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 15 or three substituents independently selected from the group consisting of halo, aryl, -NO2, -CF3, -N(R)(R), -C(O) R, -C(O)-0R 2 , -C(O)-N(R)(Re), -CN, -S(O) 2 -R?" and -O-Ra R2 and R2 are in each instance independently selected from the group consisting 20 of hydrogen, C 1 5 alkyl, C2-15 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C-is alkyl, Cris alkenyl, C2-1s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 25 hydroxyl, halo, C 14 alkyl, acylamino, oxo, -NO2, -S(0) 2

R

2 , -CN, CI-a alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH2, aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C14 alkyl or cycloalkyl; or 30 whea Ra and R are attached to a common nitrogen atom R and R2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 110 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO2,

-S(O)R

2 , -CN, C 1

-

3 alkoxy, -CF3, -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C 14 5 alkyl, aryl and cycloalkyl; and wherein the C- alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, 10 mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0179] In some embodiments, R2 is -C1.6 alkylene-R 5 . [0180] In some embodiments, it 5 is heteroaryl. [0181] In some embodiments, each -C1.6 alkylene of R is unsubstituted. [0182] In some embodiments, R 2 is 15 [0183] In some embodiments, A is cyclohex-1-enyl. [0184] In some embodiments, A is cyclohex-1-enyl; n is 0 or 1; and R 0 is 4-methyl or 4-tert-butyl. [0185] In some embodiments, the compound is selected from the group consisting of: 7-(4-tert-butylcyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 20 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (V-1); 7-cyclohexenyl-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (V-3); and 7-(4-methylcyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (V-5); 25 or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0186] In certain embodiments, the disclosure provides compounds of Formula VI: I1

(R

10 ) B O ,R2 vi) VI wherein: B is heterocyclylor heteroaryl; 5 n is 0, 1, 2,3, 4 or 5: each R10 is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH3) 3 , -OR, -S-R72, -C(O)-R, -C(Q)-OR0, -N(R)(R?), -C(O)

N(R

2

)(R

2 ), -N(R 2 )-C(O)-R?, -N(RZ)-C(O)-ORn, -N(Re)-S(O) 2

-R

2 6, -S(0)2 RY, -O-S(O)2-R2, -S(O) 2

-N(R

2 )(Re), C16 alkyl, C 24 alkenyl, C24 alkynyl, 10 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said Ci,6 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl. are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 14 alkyl, CIa haloalkyl, 15 cycloalkyl, -N(R)(R 2 ), -C(O)-R 2 , -C(O)-0R, -C(O)-N(Re)(R 2 ), -CN and -0-R; R2 is -C16 alkylene-R 5 , -L-R , L-C, 4 alkylene-R, -C.6 alkylene-L-R or -C6 alkylene-L-C 1 4 alkylene-R'; wherein each -C1.6 alkylene is optionally substituted by one substituent 20 independently selected from the group consisting of C2m alkynyl, halo,

-NO

2 , -CN, -O-R, -N(R 0

)(R

2 ), -C(O)-RY', -C(O)-OR26, -C(O)

N(R

2 )(Re), -N(R 2

)-S(O)

2 -RY, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are 25 optionally substituted with one, two or three substituents independently selected from the group consisting of C1 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -C(O)-R20, -C(0)-OR, -C(O)-N(R)(R2), -CN and -0-1 112 L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(0) 2 NH-, -C(O)NH- or -NHC(O)-, provided that when R 2 is -L-R 5 or -L-C 14 alkylene-R 5 , then L is not -0-, -S-, -NHS(O) 2 - or -NHC(O)-;

R

5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; 5 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1.6 alkyl, C 24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )( ), -N(R2)-S(0)2-R, -N(R) C(O)-R, -C(O)-R 2 , -C(O)-OR , -C(O)-N(Re)(Re), -CN and -0-R; 10 wherein said C 1 . alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -C(O)-R, -C(O)-0R 0 , -C(O)-N(R)(Re), -CN and -0-R; and 15 wherein said C 1 6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(Re),-C(O) R3 -C(Q)-OR 0 , -C(O)-N(R eR 2 ), -CN, -S(O) 2

-R

0 and 20 -0-R 20 ;

R

0 and R are in each instance independently selected from the group consisting of hydrogen, Ci-is alkyl, C2-Is alkenyl, C 2

-

15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C-is alkyl, C2-is alkenyl, C2-15 alkynyl, cycloalkyl, 25 heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, acylanino, oxo, -NO 2 , -S(O) 2 R, -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 30 wherein said heteroaryl is optionally further substituted with CIA alkyl or cycloalkyl; or 113 when R and R? 2 are attached to a common nitrogen atom RP and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C-4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , 5 -S(0) 2

R

2 6 , -CN, C1.3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C 1 4 alkyl, aryl and cycloalkyl; and wherein the C 1 4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting 10 of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0187] In other embodiments, the disclosure provides compounds of Formula VI: ) B O N 15 VI wherein: B is heterocyclyl or heteroaryl; n is 0, 1, 2 or 3: each R 0 is independently selected from the group consisting of halo, -NO 2 , -CN, 20 -SF,, -Si(CH) 3 , -O-R 0 , -S-R2 0 , -C(0)-R 0 , -C(O)-OR 2 0 , -N(R 20 )RY), -C(O)

N(R

2 )(Re), -N(R2h-C(O)-R 2 , -N(R)-C(O)-OR 2 , -N(R)-S(O)2-R, -S(O)2

R

0 , -O-S(O) 2

-R

2 , -S(O)rN(R)(R), C 1 .6 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1.6 alkyl, C 24 alkenyl, C 2

.

4 alkynyl, cycloalkyl, aryl, 25 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C1.4 alkyl, cycloalkyl, -N(R")(R), -C(O)-R, -C(O)-OR, -C(O)-N(R 2 )(Re), -CN and -O-R; R is -C1.4 alkylene-R, -I-R, -I-C 1

.

4 alkylene-R 5 , -C1.4 alkylene-L-R 5 or -C1-6 30 alkylene-L-C 1 .4 alkylene-R'; 114 L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(0)2NH-, -C(O)NH- or -NHC(O)-; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from 5 the group consisting of C14 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R ), -N(R)-S(O)2-R, -N(R 2 C(O)-R 2 , -C(O)-R, -0(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -- R 0 ; wherein said Ca alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 10 independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R ) -C(O)-Ra 2 , -C(O)-OA, -C(O)-N(R)(R 2 ), -CN and -O-R; and wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 15 or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(Rn)(R2), -C(0)

R

2 , -C(O)-OR, -C(O)-N(R)(R 2 ), -CN, -S(0) 2 -R0 and R2 and R 2 are in each instance independently selected from the group consisting 20 of hydrogen, C1-Is alkyl, C 2

-

15 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the Cl-15 alkyl, C 2

-

15 alkenyl, C2-Is alkynyl, cycloalkyl, heterocyclyl, aryl and hetero aryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 25 hydroxyl, halo, CA alkyl, acylamino, oxo, -NO 2 , -S(0) 2 Re, -CN, C alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with Ci.. alkyl or cycloalkyl; or 30 when R 0 and R are attached to a common nitrogen atom R and R m 2 May join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 115 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CIA alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2 R?, -CN, C 13 alkoxy, -CFs, -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C14 5 alkyl, aryl and cycloalkyl; and wherein the C1A alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF3 and -OCF3; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, 10 mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [01881 In some embodiments, B is heteroaryl. [0189] In some embodiments, B is 2-oxo-1,2-dihydropyridin-4-yl, pyridin-4-yl, pyridin 2-yl, thiazol-4-yl or thiophen-2-yl. [0190] In some embodiments, each -C 1 - alkylene of R 2 is unsubstituted. 15 [0191] In some embodiments, R2 is -C 1 4 alkylene-Rt. [0192] In some embodiments, R3 is heteroaryl. N; [0193] In some embodiments, R2 is N [0194] In some embodiments, n is 1; R9 is cycloalkyl, -- R0 or C alkyl; 20 wherein said alkyl is optionally substituted with one, two or three halo; and Re0 is Csais alkyl. [0195] In some embodiments, n is 1; RO is -0-R 2 0 or C1A alkyl; wherein said alkyl is optionally substituted with one, two or three halo; and 25 R 20 is CrC 1 s allcyl. 116 [0196] In some embodiments, B is 2-oxo-1,2-dihydropyridin-4-yl, pyridin-4-yl, 5 (trifluoromethyl)pyridin-2-yl, 2-isopropylthiazol-4-yl, 5-(trifluoromethyl)thiophen-2-y1 or 5-cyclopropylthiophen-2-yl. [0197] In some embodiments, the compound is selected from the group consisting of: 5 7-(2-tert-butoxypyridin4-yl)4-(pyridin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H1)-one (VI-4); 7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (VI-12); 4-(pyridin-2-ylmethyl)-7-(5-(trifluoromethyl)pyridin-2-yl)-3,4 10 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (VI-26); 7-(2-isopropylthiazol-4-yl)-4-(pyridia-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(211)-one (VI-30); 4-(pyridin-2-ylmethyl)-7-(5-(trifluoromethyl)thiophen-2-yl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (VI-31); 15 7-(5-cyclopropylthiophien-2-yl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (VI-32); 7-(5-cyclopropylthiophien-2-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (VI-36); and 4-(pyrimidin-2-ylmethyl)-7-(5-(trifluoromethyl)thiophen-2-yl)-3,4 20 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (VI-37); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0198] In certain embodiments, the disclosure provides compounds of Formula VIII:

(R

1 )n N, 25 VIII wherein: n is 0, 1, 2, 3,4 or 5; 117 represents a single, double or triple bond; each R1 0 is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH 3

)

3 , -O-Re, -S-R 2 , -C(O)-R, -C(O)-OR 20 , -N(R 2 )(Rt), -C(O) N(Ra)(Re), -N(R 2 )-C(O)-R 2 , -NR)C(O)-OR 2 , -N(R 0

)-S(O)-R

2 6 , -S(O)2 5 R0, -O-S(O) 2

-R

20 , -S(O) 2

-N(R

2 )(Re), C1.4 alkyl, C2-4 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1 .6 alkyl, C 24 alkenyl, C2A alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 10 -NO 2 , aryl, heterocyclyl, heteroaryl, C1.4 alkyl, C1 haloalkyl, cycloalkyl, -N(R)(R 2 ), -C(O)-R 2 , -C(O)-OR 2 0 , -C(O)-N(R 2 0 )(e), -CN and -O-R ; R2 is -C 1 -6 alkylene-R 5 , -L-R 5 , - 1 CI-6 alkylene-R', -C1- alkylene-L-R or -C1-6 alkylene-L-C 1 .4 alkylene-R 5 ; wherein each -C14 alkylene is optionally substituted by one substituent 15 independently selected from the group consisting of C24 alkynyl, halo, -NO2, -CN, -O-Re, -N(R)(Re), -C(O)-RI, -C(0)-OR?6, -C(0) N(R)(R), -N(Ra)-S(O) 2

-R

0 , cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are 20 optionally substituted with one, two or three substituents independently selected from the group consisting of C1.6 alkyl, C2-4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(e), -C(O)-Re, -C(O)-OR 2 , -C(O)-N(R 2 )(Re), -CN and

-O-

20 ; 25 L is -0-, -S-, -C(0)-, -NHS(0)r, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-, provided that when R 2 is -L-R 5 or -L-C 1 alkylene-R', then L is not -0-, -S-, -NHS(0) 2 - or -NHC(O)-; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally 30 substituted with one, two or three substituents independently selected from the group consisting of Cj-6 aLkyl, C2.4 alkynyl, halo, -NO 2 , cycloalkyl, 118 aryl, heterocyclyl, heteroaryl, -N(R 20

)(R

2 ), -N(R )-S(O) 2

-R

20 , -N(R 2

O)

C(O)-R

22 , -C(O)-R2 0 , -C(O)-OR, -C(0)-N(R 0

)(R

2 ), -CN, oxo and -0

R.

20 ; wherein said C- alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl 5 are optionally father substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 0

)(R

2 ),

-C(O)-R

20 , -C(O)-OR 2 0 , -C(O)-N(R 2 0

)(R

2 ), -CN and -0- 20 ; and wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or 10 heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 0 X)(), -C(O)

R

20 , -C(O)-OR 2 0 , -C(O)-N(R 2 0

)(R

2 ), -CN, -S(0) 2 -R2 0 and -- 20 -0-B.; 15 R.

20 and R are in each instance independently selected from the group consisting of hydrogen, C1 alkyl, C2-6 alkenyl, C2 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C1 alkyl, C24 alkenyl, C24 alkynyl, cycloaLkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three 20 substituents independently selected from the group consisting of hydroxyl, halo, C4 alkyl, acylamino, oxo, -NO 2 -S(0) 2

R

6 , -CN, C1-3 alkoxy, -CF 3 ,

-OCF

3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C4 alkyl or cycloalkyl; or 25 when R 20 and R" 2 are attached to a common nitrogen atom 20 and R 2 may join to form a heterocyclic or hetemaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

2 6 , -CN, C3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and 30 each R 26 is independently selected from the group consisting of hydrogen, C4 alkyl, aryl and cycloalkyl; 119 wherein the C 1 4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkoxy, -CF3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of 5 stereoisomers or tautomer thereof. [0199] In some embodiments, each -C 14 alkylene of R2 is unsubstituted. [0200] In some embodiments, R2 is N , F or [0201] In some embodiments, n is 0 or I; and R' 0 is 4-trifluoromethyl or 4-trifluoromethoxy. 10 [0202] In some embodiments, the compound is selected from the group consisting of: 4-(pyrimidin-2-ylmethyl)-7-((4-(trifluoromethoxy)phenyl)ethynyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(21)-one (VflI-4); 7-(phenylethynyl)-4-(pyrinidin-2-ylmethyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(211)-one (VIII-5); 15 4-(pyrimidin-2-ylmethyl)-7-((4-(trifluoromethyl)phenyl)ethynyl)-3,4 dihydrobenzo[fl[1,4]oxazepin-5(2H)-one (VUI-6); 4-(pyridin-2-yhnethyl)-7-(4-(trifluoromethyl)phenethyl)-3,4 dihydrobenzo[f]1,4]oxazepin-5(2H)-one (VEI-7); 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluorornethyl)phenethyl)-3,4 20 dihydrobenzo[fj[I,4]oxazepin-5(2)-one (VIII-8); 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluommethyl)phenethyl)-3,4 dihydrobenzo[f[1,4]oxazepin-5(211)-one (VIII-9); (E)-4-benzyl-7-(4-(trifluoromethy)styryl)-3,4-dihydrobenzo[fj{1,4]oxazepin-5(21)-one (VII-10); and 25 4-benzyl-7-(4-(trifluoromethyl)phenethyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (VIE-11); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. 120 [0203] In other embodiments, the disclosure provides compounds of Formula VIIIA: (R10 N N VIIIA wherein: 5 n is 0, 1, 2 or 3: each Ro is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH 3

)

3 , -O-RO, -S-R 0 , -C(O)-R 20 , -C(O)-OR 20 , -N(R)(R), -C(O)

N(R

0

)(R

2 ), -N(R 0

)-C(O)-R?

2 , -N(R2)-C(O)-OR 22 , -N(R 0

)-S(O)

2

-R

2 , -S(0) 2 R?, -O-S(0)2-R 0 , -S(0) 2

-N(R

2 )(Re), C14 alkyl, C24 alkenyl, C24 alkynyl, 10 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said Ci- alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

_NO

2 , phenyl, heterocyclyl, heteroaryl, Ci- alkyl, cycloalkyl, 15 -N(R 2

)(R

2 ), -C(O)-R, -C(O)-OR 0 , -C(O)-N(R 2 )(Rn), -CN and -0-R;

R

2 is -C1-s alkylene-R', -L-R, -L-CIa alkylene-R, -C14 alkylene-L-R5 or -C1-6 alkylene-L-C 1 - alkylene-R'; L is -0-, -S-, -C(0)-, -NIS(0)2-, -S(O) 2 N1H-, -C(O)NH- or -NHC(O)-; R' is cycloalkyl, aryl, heteroaryl or heteweyclyl; 20 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Ci- alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R 2 ), -N(Re)-S(0) 2

-R

0 , -N(Re)

C(O)-R

2 , -C(0)-kR, -C(O)-OR 0 , -C(O)-N(R2)(Re), -CN and -0-Rn; 25 wherein said Ci- alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Ci6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 0 RE),

-C(O)-R

20 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -Q-R 2 ; and 121 wherein said CI6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 20 )(Re), -C(O) 5 R2, -C(O)-0R 20 , -C(0)-N(R 2 0

)(R

2 ), -CN, -S(O) 2

-R

20 and -0-R 20 ;

R

20 and R2 are in each instance independently selected from the group consisting of hydrogen, CI- 1 s alkyl, C 2 -is alkenyl, C 2

-

1 s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 10 wherein the C 1

-

1 5 alkyl, C 2

-

1 5 alkenyl, C 2 -is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkyl, acylamino, oxo, -NO 2, -S(0) 2 Re, -CN, C 1

,.

3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and 15 heteroaryl; and wherein said heteroaryl is optionally further substituted with Ci 4 alkyl or cycloalkyl; or when R 2 0 and R 2 are attached to a common nitrogen atom R 20 and R2 may join: to form a heterocyclic or heteroaryl ring which is then optionally substituted with 20 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CI 4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(0)2Re, -CN, C 1

-

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, C 1 -4 alkyl, aryl and cycloalkyl; and 25 wherein the C 14 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stercoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. 30 102041 In some embodiments, R2 is -C 1 6 alkylene-R'. [0205] In some embodiments, R5 is heteroaryl. 122 N [0206] In some embodiments, R 2 is [02071 In some embodiments, n is 0 or 1;

R

0 is -0-.

0 or C 14 alkyl; wherein the alkyl is optionally substituted with three halo; and 5 R is CIrC alkyl; and wherein the alkyl is optionally substituted with one, two or three halo. 10208] In some embodiments, n is 0 or 1; and R 0 is 4-trifluoromethyl or 4-trifluoromethoxy. [02091 In some embodiments, the compound is selected from the group consisting of: 10 4-(pyriniidin-2-ylmethyl)-7-((4-(trifluoromethoxy)phenyl)ethynyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (VIII-4); 7-(phenylethyny1)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(21)-one (VIII-5); and 4-(pyrimidin-2-ylmethyl)-7-((4-(trifluoromethyl)phenyl)ethynyl)-3,4 15 dihydrobenzotfj[1,4]oxazepin-5(2H)-one (VIII-6); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0210J In certain embodiments, the disclosure provides compounds of Formula IX: O--'PR2 20 IX wherein: n is 0, 1, 2, 3,4 or 5; each R"0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SF-5, -Si(CH3)a, -O-R'O, -S-Ra', -C(0)-R, -C(O)-OWa, -N(R)(R), -C(O) 25 N(R 2

)(R

2 ), -N(R 2 )-C(Q)-R 2 , -N(R)-C(O)-ORD 2 , -N(R )-S(0)r-R, -S(0)2 R, -0-S(O) 2 -Ra, 0

-S(O)

2

-N(R

2

)(R

2 ), C 1 s alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 123 wherein said CI4 alkyl, C 24 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , aryl, heterocyclyl, heteroaryl, C1 alkyl, C14 haloalkyl, cycloalkyl, 5 -N(R)(R0 ), -C(O)-R 0 , -C(O)-OR , -C(O)-N(R 2 )(R), -CN and -O-R0; R2 is -Ci-e alkylene-R 5 , -L-R 5 , -L-Ci-. alkylene-R 5 , -Cj4 alkylene-L-R 5 or -C1 alkylene-L-C14 alkylene-R 5 ; wherein each -CI4 alkylene is optionally substituted by one substituent independently selected from the group consisting of C 24 alcynyl, halo, 10 -NO 2 , -CN, -O-R, -N(R 2

)(R

2 ), -C(O)-R 20 , -C(O)-OR 6 , -C(O)

N(R

2 )(Re), -N(R 2 )-S(O)2-R, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents 15 independently selected from the group consisting of C1 alkyl, C 24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 )(R), -C(O)-R 0 , -C(O)-OR 0 , -C(O)-N(Re)(Re), -CN and -0-0.; L is -O-, -S-, -C(O)-, -NHS(O)2-, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-, provided 20 that when R 2 is -L-Rs or -L-C 14 alkylene-R 5 , then L is not -0-, -S-, -NHS(O)2- or -NHC(O)-;

R

5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from 25 the group consisting of C1 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )R), -N(R)-S(0) 2 -R, -N(ROe C(O)-R2, -C(O)-R, -C(O)-OR 0 , -C(O)-N(R)(R 2 ), -CN, oxo and -O wherein said C 14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl 30 are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, 124

C

1

.

4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re),

-C(O)-R

0 , -C(O)-0R 0 , -C(Q)-N(R)(R 2 ), -CN and -O-R 0 ; and wherein said CI6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 5 or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2

)(R

2 ), -C(O)

R

20 , -C(O)-OB, -C(O)-N(R 2

)(R

2 ), -CN, -S(O) 2 -R and

R

20 and Re are in each instance independently selected from the group consisting 10 of hydrogen, CI4 alkyl, C2 alkenyl, C2 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the CI- alkyl, C 2 6 alkenyl, Cu alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, 15 halo, C 14 alkyl, acylamino, oxo, -NO 2 , -S(O)R26, -CN, C 1

-

3 alkoxy, -CFs,

-OCF

3 , -OCH 2

CF

3 , -C(O)-NH2, aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C-4 alkyl or cycloalkyl; or when R 20 and R are attached to a common nitrogen atom R 0 and R 2 may join to 20 form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO2, -S(0) 2

R?

6 , -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R is independently selected from the group consisting of hydrogen, C 1 4 25 alkyl, aryl and cycloalkyl; wherein the C 1 4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of 30 stereoisomers or tautomer thereof. [02111 In other embodiments, the disclosure provides compounds of Formula IX: 125

(R

1 )n|- O 0,R O-2 Ix wherein: n is0, 1,2 or 3: 5 each R'o is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH 3 ), -O-R 2 , -S-R, -C(O)-R', -C(O)-ORO, -N(R 2 )(R), -C(O)

N(R

2 )(Re), -N(Re)-C(O)-R, -N(R)-C(O)-OR, -N(R)-S(O)2-R, -s(o)2 Ro, -0-S(0)2-Ro, -S(O)2-N(R 0

)(R

2 ), Ci 4 alkyl, C 24 alkenryl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 10 wherein said C 1 .6 alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1

.

6 alkyl, cycloalkIyl, -N(Re)(R), -C(O)-R, -C(0)-OR 2 0 , -C(O)-N(R 0 )(R2), -CN and -0-R 2 ; 15 R 2 is -C1i. alkylene-R 5 , -L-R 5 , -L-C 1 -6 alkylene-R 5 , -C1-6 alkylene-L-R 5 or -C1.4 alkylene-L-C 1 .- alkylene-R ; L is -0-, -S-, -C(O)-, -NHS(O) 2 -, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-; RW is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally 20 substituted with one, two or three substituents independently selected from the group consisting of C14 alkyl, C 2

.

4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -N(R )-S(O) 2

-R

0 , -N(R 0

)

C(O)-R

2 , -C(O)- 0 , -C(O)-OR , -C(0)-N(R 20 )(R), -CN and -O-R; wherein said C1.4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl 25 are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Cie. alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N( )(Re), -C(O)-R', -C(O)-OR 0 , -C(O)-N(R 2 ")(e), -CN and -0-R 0 ; and 126 wherein said C1- alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(R), -C(0) 5 R 2 O, -C(O)-R 0 , -C(0)-N(R 0

)(R

2 ), -CN, -S(0)2rRI( and -O-R ' Ra and R are in each instance independently selected from the group consisting of hydrogen, C 1

-

15 alkyl, C2-15 alkenyl, C2-15 alkynYl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 10 wherein the C1-15 alkyl, C2-1s alkenyl, C2-Is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci 4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 R0, -CN, C13 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and 15 heteroaryl; and wherein said heteroaryl is optionally further substituted with CI 4 alkyl or cycloalkyl; or when RP and R 2 are attached to a common nitrogen atom R 0 and R? may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 20 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2 R0, -CN, C1-3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, Ci4 alkyl, aryl and cycloalkyl; and 25 wherein the C14 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkoxy, -CF 3 and -OCF3; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. 30 [0212] In some embodiments, each -C1.4 alkylene of R 2 is unsubstituted. [02131 In some embodiments, R 2 is -C1.6 alkylene-R'. 127 10214] In some embodiments, R 2 is not benzyl. [02151 In some embodiments, R5 is heteroaryl; wherein said heteroaryl is optionally further substituted with halo. N !: [02161 In some embodiments, R 2 is selected from the group consisting of N / 5 and Cl [0217] In some embodiments, R" is 4-trifluoromethyl. [0218] In some embodiments, the compound is selected from the group consisting of: 2-((pyrmidin-2-.yl)methyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H benzo[b][1,4,5]oxathiazepin-sulfone (IX-2); and 10 2-((5-chloropyrimidin-2-yl)methyl)-8-(4-(trifluoromethy)phenyl)-3,4-dihydro-2H benzo[b][1,4,5]oxathiazepin-sulfone (IX-3); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0219] In certain embodiments, the disclosure provides compounds of Formula X: (RIO)-- R2 N N R4 15

R

6

R

4 X wherein: n is 0, 1, 2, 3,4 or 5; Rio is independently selected from the group consisting of halo, -NO 2 , -CN, -SF 5 , 20 -Si(CH 3

)

3 , -O-Rr, -S-R 0 , -C(O)-R 2 0 , -C(O)-OR 0 , -N(R 20

)(R

2 ), -C(O) N(R2)(e), -N(R)-C(O)-R22, -N(RM)C(0)-OR22, -N(Re)-S(0)'2-R", -S(0)z

R

20 , -O-S(O) 2

-E

0 , -S(0) 2

-N(R

2 )(R?), C 1 - alkyl, C 2 4 alkenyl, C24 alkynyl, cycloalkyl, ary1, heteroaryl and heterocyclyl; and wherein said C1 alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, 25 heteroaryl or heterocyclyl are optionally substituted with one, two or three 128 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C1.6 alkyl, CIahaloalkyl, cycloalkyl, -N(R 20

)(R

2 ), -C(O)-R 20 , -C(O)-OR 2 0 , -C(O)-N(R 2 0

)(R

2 ), -CN and -O-R20; 5 R2 is -C 1

-

6 alkylene-R, -L-R', -L-C 1 -6 alkylene-R 5 , -CI4 alkylene-L-R or -C1. alkylene-L-CI-6 alkylene-R 5 ; wherein each -C1.6 alkylene is optionally substituted by one substituent independently selected from the group consisting of C2A alkynyl, halo,

-NO

2 , -CN, -O-R 20 , -N(R 2 0

)(R

2 ), -C(O)-R 2 0 , -C(O)-OR 2 6 , -C(O) 10 N( 2 )(ke), -N(R2)-S(0) 2 -R2 0 , cycloalkyl, aryl, hetermaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1.6 alkyl, C24 15 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(

20

)(R

2 ), -C(O)-R 2 0 , -C(O)-OR 20 , -C(O)-N(R 2 0 )(Re), -CN and

-O-

2 0 ; L is -0-, -S-, -C(O)-, -NHS(O)2-, -S(0) 2 NH-, -C(O)NH- or -NHC(O)-, provided that when R is -L-R or -L-C 1 - alkylene-R, then L is not -0-, -S-, -NHS(O)2- or 20 -NHC(0)-; each R is independently hydrogen, deuterium, CI.15 alkyl, C1.4 alkoxy, -C(O)

OR

2 6 , -C(O)-N(R 26

(R

2 ), -N(R 2 0

)-S(O)

2 -R0, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said CI.15 alkyl is optionally substituted with one, two or three 25 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 0 )(), -C(O)-R 2 0 ,

-C(O)-O

20 , -C(O)-N(R 20 )R), -CN and -0-k0 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 30 independently selected from the group consisting of halo, -NO 2 , C1.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 129

-N(R

2 0

)(R

22 ), -C(O)-R, 20

-C(O)-OR

20 , -C(O)-N(R 20

)(R

22 ), -CN and -- 0; and wherein said C4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted 5 with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , -N(Re)(R), -C(O)-R O, -C(O)-O00, -C(O)-N(Re)(e), -CN and -0-0; or two R 4 together with the carbon atom to which they are attached form an oxo; 10 R? is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Cj4 alkyl, C2.4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, hetero aryl, -N(R 2

)(R

2 ), -N(R)-S(O) 2 -RO, -N(R) 15 C(O)-R? 2 , -C(Q)-R 20 , -C(O)-OR, -C(O)-N(R)(Re), -CN and -O-R; wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R )(R 2 ), 20 -C(O)-R, -C(O)-OR 0 , -C(O)-N(R 0 )(Re), -CN and -0-R 0 ; and wherein said C 1 - alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(R), -C(O) 25 R2, -C(O)-ORO, -C(O)-N(R 2 )RE), -CN, -S(0) 2

-R

0 and -O-R O; R is hydrogen, Cio alkyl or cycloalkyl; wherein said C1 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 30 -NO 2 , -N(R 2

)(

22 ), -C(O)-R, -C(O)-OR 20 , -C(O)-N(R 2 )(Re), -CN and -0-e; 130 R20 and R22 are in each instance independently selected from the group consisting of hydrogen, C-is alkyl, C2-is alkenyl, C 2 -Is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C- 15 alkyl, C 2

-

15 alkenyl, C 2

-

15 alkynyl, cycloalkyl, 5 heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, acylamino, oxo, -NO 2 , -S(0) 2 Re, -CN, C1.

3 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 10 wherein said heteroaryl is optionally further substituted with C 1 .4 alkyl or cycloalkyl; or when R2 and R22 are attached to a common nitrogen atom R 20 and R 22 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of 15 hydroxyl, halo, C 1 4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO2,

-S(O)

2

R

6 , -CN, C 1

-

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 6 is independently selected from the group consisting of hydrogen,.C 4 alkyl, aryl and cycloalkyl; and wherein the C 1 4 alkyl, aryl and cycloalkyl. may be further substituted with 20 from I to 3 sub stituents independently selected from the group consisting of hydroxyl, halo, CIA alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [02201 In other embodiments, the disclosure provides compounds of Formula X:

(R'

0 ),- 0 O ,R2 N' N R4 25

R

8

R

4 x wherein: nis0, 1,2or3; 131 Rio is independently selected from the group consisting of halo, -NO 2 , -CN, -SF 5 , -Si(CH3) 3 , -0-R, -S-R2 0 , -C(O)-R 0 , -C(O)-OR 0 , -N(R)(R 2 ), -C(O)

N(R

2

)(R

2 ), -N(R 2 0

)-C(O)-R

2 , -N(R 2 )-C(O)-OR , -N(R 2

)-S(O)

2

-R

2 , -S(0) 2 R 2 , -O-S(0) 2

-R

0 , -S(0)2-N(Rt)R 2 ), C 14 alkyl, C2 alkenyl, C 2 4 alkynyl, 5 cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 14 alkyl, C 2 4 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1 .6 alkyl, cycloalkyl, 10 -N(R 2 )(Re), -C(O)-R 0 , -C(O)-OR 0 , -C(0)-N(R 20 XRe), -CN and -O-R; R2 is -C 14 alkylene-R 5 , -L-R 5 , -L-C 1 4 alkylene-R, -Cj4 alkylene-L-R or -C 14 alkylene-L-C 1 4 alkylene-R; L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-; each R 4 is independently hydrogen, deuterium, C 1 .. s alkyl, C 1 4 alkoxy, -C(O) 15 OR 26 , -C(O)-N(R5(RM), -N(R 2 )-S(0) 2 -R, cycloalkyl, aryl, heteroarylor heterocyclyl; wherein said C 1 .. s alkyl is optionally substituted with one, two orthree substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R), -C(O)-RO, 20 -C(O)-OR 2 , -C(O)-N(R(RE ), -CN and -O-R; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Cr4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 25 -N(R 2 )(Re ), -C(O)-R 2 , -C(O)-0 0 , -C(O)-N(R)(RE), -CN and -O-RO; and wherein said C1 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected 30 from the group consisting of hydroxyl, halo, -NO 2 , 132 -N(RE)(R), -C(O)-Ra, -C(O)-OR0, -C(O)-N(R)(R), -CN and -O-R; or two Re together with the carbon atom to which they are attached form an oxo;

R

5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; 5 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C14 alkyl, C24 alkynyl, halo, -NO 2 , cycloalcyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -N(R 2 )-S(0) 2 -R, -N(Re) C(O)-R?, -C(O)-Re, -C(0)-OR 2 0 , -C(O)-N(Re)(R), -CN and -0-k; 10 wherein said CI- alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R, -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -O-R; and 15 wherein said C14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(R), -C(0)

R

20 , -C(O)-OR 0 , -C(O)-N(Re)(R 2 ), -CN, -S(O),-R and 20 -O-R; R is hydrogen, C1-15 alkyl, -C(O)-R?, -C(O)-Ok , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said Cs1.5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 25 -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R3), -C(O)-R, -C(O)-OR', -C(O)-N(R)(R 2 ), -CN and -0- 4 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 30 CI4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 133 -N(R )(R 2 ), -C(O)-R", -C(O)-OR, -C(O)-N(R)(R), -CN and -O-RO; and wherein said C 1 .6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally finther substituted 5 with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2 )(Re),

-C(O)-R

0 , -C(O)-OR?, -C(O)-N(R 2 )(Re), -CN and -0 Ra 2 0 R2 and Re are in each instance independently selected from the group consisting 10 of hydrogen, C 1

-

15 alkyl, C 2

-

15 alkenyl, C 2

-

15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C1-15 alkyl, C2-is alkenyl, C 2

-

15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 15 hydroxyl, halo, C1 4 alkyl, acylamino, oxo, -NO 2 , -S(0) 2

R

6 , -CN, Ci..2 alkoxy, -CF 3 , -OCF 3 , -OCH 2 CF3, -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with CIA alkyl or cycloalkyl; or 20 when R and Ra are attached to a common nitrogen atom R? 0 and R may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CjA alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

6 , -CN, C1- alkoxy, -CF3, -OCF3, aryl, heteroaryl and cycloalkyl; and 25 each R 2 is independently selected from the group consisting of hydrogen, C14 alkyl, aryl and cycloalkyl; and wherein the CA alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, CA alkoxy, -CF 3 and -OCF 3 ; 30 or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. 134 - [0221J In some embodiments, each -C 1

.

4 alkylene of R2 is unsubstituted. [0222] In some embodiments, R2 is -C 1

.

4 alkylene-R. [0223] In some embodiments, R5 is aryl. [02241 In some embodiments, R is or 5 [0225] In some embodiments, R 0 is 4-trifluoromethyl or 4-trifluoromethoxy. [02261 In some embodiments, each R 4 is independently hydrogen, deuterium or C 1 -6 alkyl optionally substituted with heteroaryl, or two R 4 together with the carbon atom to which they are attached form an oxo. [0227] In some embodiments, two R4 together with the carbon atom to which they are 10 attached form an oxo. [0228] In some embodiments, R 6 is hydrogen or C 1

.

4 alkyl. [0229] In some embodiments, R 6 is hydrogen or methyl. [0230] In some embodiments, the compound is selected from the group consisting of: 4-(2-(benzyloxy)ethyl)-1-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H 15 benzo[e][1,4]diazepine-2,5-dione (X-7); 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-IH-benzo[e][1,4]diazepine-2,5-dione (X-8); 4-benzyl-1-methyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-1H-benzole][1,4]diazepine 2,5-dione (X-1 1); and 20 5-benzyl-8-(4-(trifluoromethyl)phenyl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-6(5H) one (X-12); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0231) In certain embodiments, the disclosure provides compounds of Formula XII: 135 0 (R-O)n N XII wherein: Z' and Z 2 are each independently selected from the group consisting of CR 7 and S N;

Z

4 is CR 7 or N; provided that only one of Z', Z 2 and Z 4 is N; n is 0, 1,2, 3, 4 or 5; each R 10 is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH 3 )3, -O-Ra, -S-R?, -C(O)-R 0 , -C(O)-OR 2 ", -N(RY)(R), -C(O) 10 N(R 2 )(Re), -N(R 2

)-C(O)-R

2 , -N()-C(O)-OR 2 , -N(R 2

)-S(O)

2

-R

6 , -S(0)2 R, -Q-S(O) 2 -RO, -S(O) 2

-N(R)(R

2 ), C 1 .6 alkyl, C 24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1 . alkyl, C24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 15 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 14 alkyl, C 1 -3 haloalkyl, cycloalkyl, -N(R)(RE), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R 2

R

2 ), -CN and -O-R 0 ; R2 is -C 1 6 alkylene-R 5 , -L-R, -L-C 14 alkylene-R 5 , -C.

6 alkylene-L-R or -C 1 . 20 alkylene-L-C 14 alkylene-R 5 ; wherein each -C 14 alkylene is optionally substituted by one substituent independently selected from the group consisting of C 24 alkynyl, halo,

-NO

2 , -CN, -O-Re, -N(R 2 )(R?), -C(O)-R 2 0 , -C(O)-OR26, -C(O)

N(R

2 XR?), -N(R)-S(O) 2 -RZ, cycloalkyl, aryl, heteroaryl or 25 heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 14 aLkyl, C 24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, 136

-N(R

2

)(R

2 ), -C(O)-R 2 , -C(O)-OR2, -C(O)-N(R 2 )(Re), -CN and 0e L is -0-, -S-, -C(O)-, -NHS(O)2-, -S(O) 2 NH-, -C(O)NH- or -NHC(0)-, provided that when R2 is -IrR or -IkC- alkylene-R, then L is not -0-, -S-, -NHS(O) 2 - or 5 -NHC(O)-; R5 is cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of Cj alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, 10 aryl, heterocyclyl, heteroaryl, -N(R)(Re), -N(R 0

)-S(O)-R

0 , -N(R 2 0

)

C(O)-R

2 , -C(O)-a, -C(O)-OR2, -C(O)-N(R)(Re), -CN and -O-a; wherein said C1- alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally father substituted with one, two or three substituents independently selected from the group consisting ofhalo-.-NO 2 , 15 C1 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 20 )Re),

-C(O)-R

0 , -C(O)-OR 0 , -C(O)-N(Re)(R 2 ), -CN and -O-R 0 ; and wherein said CI alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally father substituted with one, two or three substituents independently selected from the group 20 consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(R), -C(0) Ra 2 , -C(O)-OR, -C(O)-N(R)(R 2 ), -CN, -S(0)-R 2 0 and -O-RE; R? is hydrogen, halo or Cj alkyl; a 0 and Re are in each instance independently selected from the group consisting 25 of hydrogen, Ci-is alkyl, C2-15 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the CI-is alkyl, C2-5 alkenyl, C2-s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 30 hydroxyl, halo, C4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 R, -CN, CI.3 137 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C 1

.

4 alkyl or cycloalkyl; or 5 when R 20 and R are attached to a common nitrogen atom R 20 and R? may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 1

.

4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S()

2

R

2 6, -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteraryl and cycloalkyl; and 10 each R 26 is independently selected from the group consisting of hydrogen, Ci 4 alkyl, aryl and cycloalkyl; and wherein the Ci 4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF3; 15 or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof [0232] In other embodiments, the disclosure provides compounds of Formula XII: (RW0)n 0 R2 0, XII 20 wherein: Z' and Z 2 are each independently selected from the group consisting of CR 7 and N;

Z

4 is CR 7 or N; provided that only one of Z', Z 2 and Z4 is N; n is 0, 1, 2 or 3: 25 each R 1 0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SF5, -Si(CH3)3, -0-Re, -8-R2', -C(O)-R20, -C(0)-OR20, -N(R0)(R?2), -C(O)

N(R

2 )(R), -N(R 2

)-C(O)-R

2 , -N(R20)-C(O)-0OR 2 , -N(R 2

)-S(O)

2

-R

2 6 , -S(0)2 R2 0 , -Q-S(O)2R 2 0 , -S(0)2-N(R 2 N)R), C 1

.

6 alkyl, C24 alkenyl, C 2

-

4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 138 wherein said C1. alkyl, C2.4 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, heteroaryl or hetercyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C14 alkyl, cycloalkyl, 5 -N(R 2

)(R

2 ), -C(O)-R 0 , -C(O)-OR 2 , -C(O)-N(R 2 )(Re), -CN and -O-R 0 ; R2 is -C1.6 alkylene-R, -L-R 5 , -L-C 1 alkylene-R, -C 1

.

6 alkylene-L-R' or -C14 alkylene-L-C 14 alkylene-R 5 ; L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(O)2NH-, -C(O)NH- or -NHC(O)-; R' is cycloalkyl, aryl, heteroaryl or heterocyclyl; 10 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2

)(R

2 ), -N(R 2 )-S(0)2-R 2 , -N(R)

C(O)-R

2 , -C(O)-R 20 , -C(O)-OR 2 , -C(O)-N(R')(Re), -CN and -O-R 0 ; 15 wherein said C1.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(RY), -C(O)-R, -C(O)-OR 0 , -C(O)-N(R)(Rn), -CN and -0-a; and 20 wherein said C1.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 )(R), -C(0) R", -C(O)-OR 0 , -C(O)-N(R)(R 2 e), -CN, -S(O) 2 -" and 25 -O-R;

R

7 is hydrogen, halo or Ci6 alkyl; R and R? are in each instance independently selected from the group consisting of hydrogen, Ci alkyl, C-is alkenyl, Cz-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 30 wherein the Ci-is alkyl, C2-15 alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or 139 three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, acylamino, oxo, -NO2 -S(O) 2

R

2 6 , -CN, C 1

-

3 alkoxy, -CFI, -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 5 wherein said heteroaryl is optionally further substituted with Ci4 alkyl or cycloalkyl; or when R 2 0 and R2 are attached to a common nitrogen atom R2 0 and R2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of 10 hydroxyl, halo, CI4 ailcyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

2 6 , -CN, C 1

-

3 alkoxy, -CF 3 , -OCF3, aryl, heteroaryl and cycloalkyl; and each R26 is independently selected from the group consisting of hydrogen, Ci 4 alkyl, aryl and cycloalkyl; and wherein the C 14 alkyl, aryl and cycloalkyl may be further substituted'with 15 from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, CiA alkoxy, -CF 3 and -OCF3; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or pro drug thereof [0233] In some embodiments, R2 is -Cj.6 alkylene-R' or -Ci-6 alkylene-L-C.

6 alkylene 20 R. [02341 In some embodiments, each -C1.6 alkylene of R2 is unsubstituted. 102351 In some embodiments, RW is cycloalkyl, aryl or heteroaryl; wherein said heteroaryl is optionally substituted with one, two or three substituents independently selected from the group consisting of C 1

.

4 alkyl, halo 25 and -o-R? 0 . ... N N [02361 In some embodiments, R2 is , N , N....N or 140 [0237] In some embodiments, n is 0 or 1; R" is -0-RP 0 or C1.4 alkyl; wherein the alkIyl is optionally substituted with three halo; and

R

20 is C1-C 15 alkyl; and 5 wherein the alkyl is optionally substituted with one, two or three halo. [0238J In some embodiments, n is 0 or 1; and RI' is 4-trifluoromethyl or 4-trifluoromethoxy. [0239] In some embodiments, the compound is selected from the group consisting of: 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3-f][1,4]oxazepin-5(2H) 10 one (XI-1); 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[2,3-fl[1,4]oxazepin-5(2Hf) one (XII-2); 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydropyrido[2,3-f][1,4]oxazepin-5(2H)-one (XII-3); 15 4-(pyrinidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3f][1,4]oxazepin-5(2H)-one (XI-5); 4-((4-methylpyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido[4,3-fj[1,4]oxazepin-5(2HE)-one (XII-8); 4-(cyclopropylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3 20 fj[1,4]oxazepin-5(2H)-one (XII-9); 4-((3-methoxypyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydropyrido[4,3-fj[1,4]oxazepin-5(2H)-one (XI-10); 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3 f][1,4]oxazepin-5(2H)-one (XII-1 1); and 25 4-((4-methoxypyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido[4,3-fj[1,4]oxazepin-5(2H)-one (XII-14); or a phannaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. 141 [0240] In certain embodiments, the disclosure provides compounds of Formula XIII: (RIO), 1Q 1 R 2 XIII wherein: 5 Q is a -O-Co2 alkylene- or -NR1-Co.2 alkylene-; n is 1, 2, 3, 4 or 5;

R

0 is halo, -NO 2 , -CN, -SF 5 , -Si(CH3) 3 , -O-R-, -S-R 0 , -C(O)-R2 0 , -C(O)-OR 2 0 , -N(R)(Re 2 ), -C(O)-N(R)(R 2 ), -N(R 2 )-C(O)-R, -N(R 2 )-C(O)-0R, -N(R 2 0

)

S(O)-R

2 6 , -S(0) 2

-R

20 , -O-S(O)2-R0, -S(0) 2

-N(R

0

)(R?

2 ), C1- alkyl, C24 alkenyl, 10 C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said Ci- alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo;

-NO

2 , aryl, heterocyclyl, heteroaryl, C.6 alkyl, Ci, haloalky1, cycloalkyl, 15 -N(R 2 )(R"), -C(O)-R", -C(0)-OR 2 0 , -C(O)-N(R 2 0 )(R), -CN and -O-R2; R2 is -C -L-R, alkylene-R , -Ci.6 alkylene-L-R or -Ci-6 alkylene-L-C6 alkylene-R 5 ; wherein each -CI- alkylene is optionally substituted by one substituent independently selected from the group consisting of C24 alkynyl, halo, 20 -NO 2 , -CN, -O-kR, -N(R 2 )(R2), -C(O)- 0 0, -C(O)-OR 6 , -C(O)

N(R

2 )(Re), -N(R 2

)-S(O)

2 -R?, cycloa[kyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents 25 independently selected from the group consisting of C- alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2 0 )(R"), -C(O)-R, -C(O)-ORO, -C(O)-N(R 2 )(Re), -CN and -O-R20 142 L is -0-, -S-, -C(O)-, -NHS(0) 2 -, -S(0) 2 NH-, -C(O)NH- or -NHC(O)-, provided that when R? is -L-R or -L-C 1 alkylene-R, then L is not -0-, -S-, -NHS(O) 2 - or -NHC(O)-; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; 5 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(R 2 ), -N(R2)-S(O) 2

-R

20 , -N(R 20

)

C(O)-R

2 , -C(O)-_RB , -C(O)-OR 0 , -C(Q)-N(RW)(R ), -CN, oxo and -0 10 R 2 wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R2 0 )( ), 15 -C(O)-RO, -C(O)-OR0, -C(O)-N(Re)(RW), -CN and -O-R2 0 ; and wherein said C4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 20 )(R2), -C(0) 20 R?, -C(O)-ORO, -C(O)-N( 2 )(R?), -CN, -S(0) 2

-R

2 0 and -0-R?; R is hydrogen or Cj4 alkyl;

R

0 and Re are in each instance independently selected from the group consisting of hydrogen, C1 alkyl, C2 alkenyl, C2 alkynyl, cycloalkyl, heterocyclyl, aryl 25 and heteroaryl; wherein the CI alkyl, C2 alkenyl, C2 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl arc optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 e, -CN, C4 alkoxy, -CF 3 , 30 -OCF 3 , -OCH2CF 3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 143 wherein said heteroaryl is optionally further substituted with CM alkyl or cycloalkyl; or when R0 and R are attached to a common nitrogen atom R and R? 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 5 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Cim alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO2, -S(0)2A, -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 26 is independently selected from the group consisting of hydrogen, Ci4 alkyl, aryl and cycloalkyl; 10 wherein the C14 alkyl, aryl and cyclo alkyl maybe further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. 15 [0241] In other embodiments, the disclosure provides compounds of Formula X[II: 0 (RIO)n-R o XIII wherein: Q is a -O-Co2 alkylene- or -NR'"-Co- 2 alkylene-; 20 n is 1, 2 or 3; R'O is halo, -NO 2 , -CN, -SFs, -Si(CH 3

)

3 , -O-R 20 , -S-RO, -C(0)-R 2 0 , -C(O)-OR2 -N(R2)(R), -C(0)-N(R2)(R"2), -N(R20)-C(O)-R?2, -N(R20)-C(0)-ORD, -N(R2 0)_ S(0) 2 -R', -S(0) 2

-R

20 , -O-S(0)2-R 20 , -S(O) 2

-N(R

2 0

)(R

2 ), C14 alkyl, C 24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 25 wherein said Ci alkyl, C24 alkenyl, C24 ailcynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C.6, alkyl, cycloalkyl,

-N(R

20

)(R

2 ), -C(O)-RO, -C(0)-OR 2 0 , -C(O)-N(R 2 0 Re), -CN and -O-R 20 ; 144

R

2 is -C1-6 alkylene-Rs, -IR5, -L-CI-. alkylene-R', -C1.6 alkylene-L-R or -Ci-1 alkylene-L-CI-6 alkylene-R'; L is -O-, -S-, -C(O)-, -NHS(0) 2 -, -S(O) 2 NH-, -C(O)NH- or -NHC(O)-; R is cycloalkyl, aryl, heteroaryl or heterocyclyl; 5 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 -6 alkyl, C 24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R'(R 22 ), -N(R)-S(O) 2 0R, -N(R ) C(O)-R, -C(O)-R 2 0 , -C(O)-OR2, -C(O)-N(R20)(Re), -CN and -O-R; 10 wherein said C 1

-

6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three sub stituents independently selected from the group consisting of halo, -NO 2 , C1.4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(RY)(R), -C(O)-., -C(O)-OR 2 0 , -C(O)-N(R 2 0 )(Re), -CN and -O-R 20 ; and 15 wherein said C 1 -6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 2 t)(R 2 ), -C(O) Ra, -C(O)-OR 20 , -C(O)-N(R 2

)(R

2 ), -CN, -S(O)2-R 20 and 20 -O-R2 0 R' is hydrogen or C1.4 alkyl; Re and R2 are in each instance independently selected from the group consisting of hydrogen, C1-1s alkyl, C2-15 alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 25 wherein the C1-15 alkyl, Cris alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci.4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2

R

26 , -CN, C13 alkoxy, -CF 3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and 30 heteroaryl; and 145 wherein said heteroaryl is optionally further substituted with C 1 4 alkyl or cycloalkyl; or when RP and R 2 2 are attached to a common nitrogen atom RP and R 22 may join to form a heterocyclic or hetemaryl ring which is then optionally substituted with 5 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Cj4 alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2

R

6 , -CN, Cm alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 2 is independently selected from the group consisting of hydrogen, CIA alkyl, aryl and cycloalkyl; and 10 wherein the C 14 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C-4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof 15 [0242] In some embodiments, Q is a -0-, -NH- or -NR'-. [02431 In some embodiments, R" is methyl [0244] In some embodiments, each -CI alkylene of R 2 is unsubstituted. [02451 In some embodiments, R2 is -C1. alkylene-R 5 . [02461 In soine embodiments, RW is heteroaryl. 20 [0247] In some embodiments, R 2 is or [0248] In some embodiments, n is 1;

R

1 0 is -0- 0 ; Ra is Cr1CI5 alkyl; and wherein the alkyl is optionally substituted with one, two or three halo. 25 [02491 In some embodiments, RO is 4-trifluoromethoxy. [0250] In some embodiments, the compound is selected from the group consisting of: 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenylamino)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (XIII-1); 146 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenoxy)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (XIII-2); 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenylamino)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (XII-3); 5 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenylamino)-3,4 dihydrobenzo[f][1,4]oxazepin-5(21)-one (XIII-4); 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenylamino)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (XIII-6); and 7-(methyl(4-(trifluoromethoxy)phenyl)amino)-4-(pyrimidin-2-ylmethyl)-3,4 10 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (XII-10); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof. [0251] In certain alternative embodiments, the disclosure provides compounds of Formula IB: Y'NIR23 R RQ Xz 15 4 IB wherein: R is aryl, cycloalkenyl, heterocyclyl or heteroaryl; wherein said aryl, cycloalkenyl, heterocyclyl or heteroaryl are optionally 20 substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH3)3, -O-R20, -S-R2, -C(O)-R 20 ,

-C(O)-OR

20 , -N(R 2

)(R

2 2 ), -C(O)-N(R 2 0

)R

22 ), -NR 2

)-C(O)-R

22 , -N 0

)-C(O)

OR

22 , -N(R 20

)-S(O)

2 -R2, -S(0) 2

-R

20 , -S(O) 2

-N(R

2 0)(R 22 ), C 1 .6 alkyl, C 24 alkenyl,

C

24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and 25 wherein said C 1 -6 alkyl, C 24 alkenyl, C 24 alCynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 147

-NO

2 , phenyl, heterocyclyl, heteroaryl, C1.4 alkyl, cycloalkyl,

-N(R

2 )(e), -C(0)-R, -C(0)-OR2, -C(O)-N(Re)(Re), -CN and -O-R; R2 is hydrogen, Ci.s alkyl, -C(O)-R, -C(O)-OR 2 6 , -C(O)-N(Re)(Rh,

-N(R)-S(O)

2 -RO, cycloalkyl, aryl, heteroaryl or heterocyclyl; 5 wherein said C1.1s alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1. alkyl, C2-4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-RO, -C(O)- , -C(O)-N(R)(2), -CN and -O-Re 10 wherein said C1. alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1. 6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re),

-C(O)-R

2 , -C(O)-OR 0 , -C(O)-N(R)(Re), -CN and -0-RE; and 15 wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CF 3 , -N(R)(Re), -C(O)- 0 , -C(O)-Ole, -C(O)-N(Rz)(t), -CN, -S(O) 2 -e and -0 20 R?; Q is a covalent bond or C2 alkynylene; Y is -C(0)-, -CH 2 -, -C(NR 5 )- or -S(0)2-; X is -O- or -NR-; each Rt is independently hydrogen, Ci-s alkyl, cycloalkyl, aryl, heteroaryl or 25 heterocyclyl; wherein said Ci-s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R, -C(O)-Oe, -C(O)-N(R 2 )(R), -CN and -0-R; 30 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 148 independently selected from the group consisting of halo, -NO 2 , Ci4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2

)(R?

2 ), -C(O)-R20, -C(O)-OR0, -C(O)-N(R 2 0

)R

22 ), -CN and -0-R 2 0 ; and 5 wherein said C 14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R)(R),

-C(O)-R

20 , -C(O)-OR 20, -C(O)-N(R 2 ")(R), -CN and -0 10 or R 2 and one of R 3 can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of CI-s 15 alkyl, -O-R, -N(R)(R 2 ), -N(R 2 t)-C(O)-0R 0 and -C(O)-OR 20 ; and wherein said Cl-s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; each R 4 is independently hydrogen, C1 alkyl, CA alkoxy, -C(Q)-OR 6 , 20 -C(O)-N(Rt)(R), -N(R 2 )-S(0) 2

-R

2 0 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said CIIs alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -C(O)-R

-C(O)-OR

2 , -C(O)-N(R)(R), -CN and -O-R 20 ; 25 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Ci.a alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2

)(R

2 ), -C(O)-R0, -C(O)-OR 0 , -C(O)-N(R )(R), -CN and 30 -0-Re; and 149 wherein said C]- alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , 5 -N(R)(R), -C(O)-R 0 , -C(O)-OR, -C(O)-N(R)(R), -CN and -0- 0 ; or two R 3 or two R 4 together with the carbon atom to which they are attached form an oxo; R is hydrogen, C 1

.

15 alkyl, C 1 4 alkoxy, -C(0)-O-Re 6 , -C(O)-N(R 2

)(R

2 10 -N(R)-S(O) 2 -R, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C- 15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Re)(R"), -C(O)-R 0 ,

-C(O)-OR

0 , -C(O)-N(ROX 2 2 ), -CN and -0-R 20 ; 15 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , CI-6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2

)(R

2 ), -C(O)-R 0 , -C(O)-OR, -C(O)-N(R)(R 2 e), -CN and 20 -O-R; and wherein said C1. alkyl, araikyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , 25 -N(Re)(R), -C(O)-R , -C(O)-OR 2 , -C(O)-N(R)(R 2 ), -CN and -O-Ra; or R 2 and R can join together with the atom to which they are attached to form a heterocyclyl or heteroaryl; wherein said heterocyclyl or heteroaryl is optionally substituted with one, 30 two or three substituents independently selected from the group consisting 150 of Cl 1 is alkyl, cycloalkyl, heteroaryl, -O-RO, -N(R 2 )(Re),

-N(R

2 )-C(O)-OR20 and -C(O)-0R 0 ; and wherein said Cl- 1 5 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting 5 of halo and heteroaryl;

R

6 is hydrogen, Cis alkyl, -C(O)- 2 0 , -C(O)-OR 2 6 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said CI..is alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 10 -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 0 )(R2), -C(O)-RaO, -C(O)-ORe, -C(O)-N(R 0

R

2 ), -CN and -0-R?; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 15 Co4 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

2

)(R

2 ), -C(O)-R 0 , -C(O)-OR, -C(O)-N(R)(R 2 ), -CN and -0-R 0 0; and wherein said C 1 - alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted 20 with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R)R 2 e), -C(O)-R, -C(O)-OR, -C(O)-N(R)(R 2 ), -CN and -O

R

0 ; R. and R7 are in each instance independently selected from the group consisting 25 of hydrogen, Cl-15 alkyl, C2-I, alkenyl, C2-,s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroary; wherein the Ci-Is alkyl, C2-15 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 30 hydroxyl, halo, C 14 alkyl, acylamino, -NO 2 , -S(0) 2

R

26 , -CN, CI-3 alkoxy,

-CF

3 , -OCF 3 , -OCH2CF 3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 151 wherein said heteroaryl is optionally further substituted with C 1 4 alkyl or cycloalkyl; or when R20 and R22 are attached to a common nitrogen atom R 20 and R2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 5 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci 4 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(O)2R?, -CN, C 1 - alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and R2 and R 2 8 are in each instance independently selected from the group consisting of hydrogen., Ci 4 alkyl, aryl and cycloalkyl; and 10 wherein the Ci 4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or pro drug thereof. 15 [0252] In certain alternative embodiments, when Y is -C(O)-, X is -0-, each R4 is hydrogen, R2 and R3 together with the atom to which they are attached form a piperazine which is optionally substituted with tert-butoxycarbonyl and Q is a bond, then R' is not unsubstituted phenyl or morpholinyl; and that when Y is -S(O) 2 -, X is -0-, 2 is benzyl, each R3 is hydrogen, Z 4 is C-Q-R', Q is a bond and R is aryl or heteroaryl, then both R4 20 are hydrogen. [02531 In certain alternative embodiments, the disclosure provides compounds of Formula HA: (RI)n-- | O ,R2 NR3 Ra R4 IIA 25 wherein: nis0, 1,2 or3: each R O is independently selected from the group consisting of halo, -NO 2 , -CN, -SF, -Si(CH3), -O-Re, -S-R0, -C(O)-R2, -C(O)-O2, -N( 0e), -C(O)-N(R2)(e), -N(RW)-C(O)-Re, -N(R2)-C(0)-OR , -N(R2)-S(O)2-Re, 152

-S(O)

2

-R

0 , -S(O) 2

-N(R

20 )(R), C 1 .6 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C1.4 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 5 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, CI4 alkyl, cycloalkyl,

-N(R

2 )(R), -C(O)-R, -C(O)-OR 0 , -C(0)-N(R 2 )Re), -CN and -O-R0; R2 is hydrogen, Ci.is alkyl, -C(O)-R 0 , -C(O)-OR 6 , -C(O)-N(R)(R 8 ),

-N(R

2

)-S(O)

2 -RY, cycloalkyl, aryl, heteroaryl or heterocyclyl; 10 wherein said Cl1 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C14 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R20, -C(O)-ORZ, -C(O)-N(R 2 )(RP), -CN and -O-Re; 15 wherein said C1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , CI alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-Ra, -C(O)-OR, -C(O)-N(R 2 )(Rf), -CN and -O-R0; and 20 wherein said Ci alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CF 3 , -N(R)(Re), -C(O)-RO,

-C(O)-OR

0 , -C(O)-N(R)(R 2 ), -CN, -S(O) 2 -Ra and -0 25 R2 each R3 is independently hydrogen, C.i15 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1.1s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 30 -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(Rt)(Re), -C(O)-R 2 , -C(O)-OR, -C(O)-N(R 2 )(RP), -CN and -0- 0 ; 153 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 5 -N(Re)(R 2 ), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R)(R 2 ), -CN and -O-R 0 ; and wherein said C1 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected 10 from the group consisting of halo, -NO 2 , -N(R)(R 2 ), -C(O)-R20, -C(O)-OR2, -C(O)-N(R)(R), -CN and -0 R 20 or R2 and one of RW can join together with the atom to which they are attached to form a heterocyclyl; 15 wherein said heterocyclyl is optionally substituted with one, two or three substituents independently selected from the group consisting of Ci-Is alkyl, -O-R, -N(R)(R"), -N(R 2

)-C(O)-OR

2 0 and -C(O)-OR 0 ; and wherein said CI-15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting 20 of halo and heteraryl; each R 4 is independently hydrogen, CI- aLkyl, C1A alkoxy, -C(O)-OR',

-C(O)-N(R)(R

2 ), -N(R 2

)-S(O)

2

-R

2 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said CI-1s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 25 -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(RE), -C(O)-R 2 , -C(O)-OR', -C(O)-N(R)(R 2 ), -CN and -0-R 20 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 30 CI alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, 154

-N(R

2 0

)(R

2 2 ), -C(O)-R 20 , -C(O)-OF?, -C(O)-N(R 2 )(Re), -CN and -Q-R0; and wherein said C1.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted 5 with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , -N(R)(Re 2 ), -C(O)-_RI, -C(O)-OR 20 , -C(O)-N(Re)(R) -CN and -0-R"; RP and R2 are in each instance independently selected from the group consisting 10 of hydrogen, C 1 -Is alkyl, C2-is alkenyl, 2-Cis alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C- 15 alkyl, C2-15 alkenyl, C2-Is alcynyl, cycloalky, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 15 hydroxyl, halo, Ci 4 alkyl, acylamino, -NO2, -S(O) 2 Re, -CN, C1-3 alkoxy,

-CF

3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C14 alkyl or cycloalkyl; or when RP and R? 2 are attached to a common nitrogen atom R 2 and e 2 may join to 20 form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(0) 2 Re, -CN, C1-3 alkoxy, -CF 3 , -OCF3, aryl, heteroaryl and cycloalkyl; and R2 and R2 are in each instance independently selected from the group consisting 25 of hydrogen, Cia alkyl, aryl and cycloalkyl; and wherein the Ci4 alcyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, CIA alkoxy, -CF 3 and -OCF3; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, 30 mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0254] In some embodiments, R2 is hydrogen or Cl-15 alkyl; 155 wherein said alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, heterocyclyl, heteroaryl, cycloalkyl and -0-0; wherein said aryl, heterocyclyl or heteroaryl are optionally further 5 substituted with one, two or three substituents independently selected from the group consisting of halo, C1.6 alkyl, heterocyclyl, heteroaryl, cycloalkyl, -C(O)-0R 2 0 , -CN and -O-R 2 ; and wherein said C14 alkylor heteroaryl are optionally further substituted with one, two or three substituents 10 independently selected from the group consisting of halo and -CF 3 ; or R2 and one of R? can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three 15 substituents independently selected from the group consisting of CIs alkyl, -N(R 2 0

)(R

22 ) and -N(R 2 )-C(0)-OR 2 0 ; and wherein said CI-s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; and 20 Re and R22 are in each instance independently selected from the group consisting of hydrogen, CI-CIS alkyl and heteroaryL. [0255] In some embodiments, R2 is hydrogen, F FFCF 156/ 1561 0 0 N - N 0N N 0-FFFF FF N-.. F \ O CY(F1 5 N , N-N N-r FN F ; /r R2 and one of R5 together with the carbon atoms to which they are attached form a N$ rN j , /NH2 N fNH2 'N % N tNQ NJ NN -- tN/ NiF t'NP NXF FN \NDC N 0or H N - ,N O 10 or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorpha. and/or prodrug thereof. [0256] In some embodiments, n is 1 or 2; and 157 each R' 0 is independently selected from the group consisting of halo, -O-R20, C 14 alkyl and cycloalkyl; and wherein said alkyl is optionally substituted with one, two or three halo; and

R

20 is independently selected from the group consisting of C-C 1 5 alkyl and 5 cycloalkyl; and wherein the alkyl is optionally substituted with one, two or three halo. [0257J In some embodiments, n is I or 2; and each R 0 is independently selected from the group consisting of 2-fluoro, 3-fluoro, 4-fluoro, 2-chloro, 4-chloro, 4-ethyl, 4 isopropyl, 4-tert-butyl, 4-trifluoromethyl, 4-cyclopropyl, 4-isobutoxy, 4-trifluoromethoxy, 10 4-(2,2,2-trifluoroethoxy) and 4-cyclopropoxy. [02581 In some embodiments, each Ra is independently hydrogen or Cl- 15 alkyl; or R? and one of R? can join together with the atom to which they are attached to form a heterocyclyl; wherein said heterocyclyl is optionally substituted with one, two or three 15 substituents independently selected from the group consisting of C 1 .Is alkyl, -N(R 20

)(R

22 ) and -N(R 2 0 )-C(O)-ORa; and wherein said Cx.1s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo and heteroaryl; and 20 R 20 and R 2 2 are in each instance independently selected from the group consisting of hydrogen, C-C 1 , allcyl and heteroaryl. [02591 In some embodiments, each R3 is independently hydrogen or C-1 alkyl. [02601 In some embodiments, each R3 is independently hydrogen, methyl or isopropyl. [0261] In some embodiments, the compound is selected from the group consisting of 25 4-((3-methyloxetan-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[t][1,4]oxazepin-5(2H)-one; 4-(2-(pyrrolidin-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[I,4]oxazepin-5(2H)-one; 158 4-((5-cyclobutyl-1 ,3,4-oxadiazo1-2-yI)methyl)-7-(4-(trifluommethoxy)pheny)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(21)-one; 4-((2,3-dihydwobenzoNb][1 ,4]dioxin-6-y1)methy1)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f][ 1,4]oxazepini-5(2H)-one; 5 4-(2,2-difluotuetlayl)-7-(4-(trifluoromethoxy)pheny9)-3,4-dihydrobenzo f[1,4]oxazepin 5(211)-one; 4-(quinolin-2-ylxnethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1 ,4joxazepin-5 (211)-one; (R)-2-(pyrimidin-2-ylmethyl)-8-(4-(trifluoromethyl)phenyl)-3,4, 12, 12a-tetrahydro- 1H 10 benzo[flpyrazino(2,1-ofl1,4joxazepin-6(2K)-one; 4-(cyclopropylmethyl)-7-(4-(frifluoromethoxy)phenyl)-3,4 dihydrobenzo[fJ[1 ,4]oxazepin-5(211)-one; 4-(2-inethoxyetbhyl)-7-(4-(trifluomomethoxy)phenyl)-3,4-dihydrobenzo[fj[1 ,4]oxazepin 5(211)-one; 15 (8)-3-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[fJ[1,4]oxazepin-5(211)-one; (R)-3-methyl.4-(pyrimidin-2-ylmethyJ)-7-(4-(trifluoromethyl)phenyl)-3,4 dikydrobenzo[t][ 1,4]oxazepin-5(211-one; 6-((5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo~f] [2,4]oxcazepin-4(5U) 20 yl)methylpicolinonilrile; 7-(4-(trifluoromethoxy)phenyl)-4-((6-(trifluoromethyl)pyrilin-2-yl)methyl)-3,4 dihydrobenzo[f][1 ,4)oxazepin-5(2H1)-ne; 7-(4-(trifluoromethoxy)phenyl)-4-((6-(trifluoromethy)pyridin-3-yl)nethyl)-34 dihydrobenzo[f][1 ,4joxazepin-5(2H)-one; 25 4-((6-nxethylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5 (211)-one; (R)-3-methyl-7-(4-(trifluoromethyl)phenyl)-3 ,4-cdihydrobenzo[f][1 ,4joxazepin-5(2ff-one; (2R,1 1 aS)-2-wnino-7-(4-(tifluoromethy)pheny)-2,3,1 1,11 a tetmahydrobenzo[flpyirrolo[2, 1-c] [1 ,4]oxazepin-5(1 1)-one; 159 (R)*-2-(2,2-difuoroethyl)-8-(4-(trifluoromethyl)pheayl)-34 12j12a-tetrahydro-1H benzo [f]pyrazino [2, 1-c-] [I4]oxazepin-6(2T1)-one; (R)-2-etkyl-8-(4-(frifluoromethyl)phenyl)-3,44 2, 12a-tetrahydro-ll1 beuzo[f]pyrazino[2,1-e][1 ,4]oxazepin.-6(28)-one; 5 (S)-2-(2,2-difluoroethyO)-8-(4-(trifluoromethyl)phenyl)-3,4, 12,12a-tetrahydro-IE benzo[f]pyrazino[2, I-o]tl,4]oxazepin-6(2H)-one; (S)-2-ethyl-8-(4-(trifluoromethyl)pheayl)-3,4j12, 12a-tetrahydro-1 H benzo[fjjpyrazino[2,1-cJ [ 1,4]oxazepin-6(21{j)-oae; 4-(PYrazin-2-Ylmethyl)-7-(4-Qrifluoromethoxy)phenyl)-3,4 10 dihydrobcnzo[f][1,4]oxazepin-5(211)-one; 4-((5-miethlyloxazol-2-yl)nethiyl)-7-(4-(trifiuoromethoxy)phenyl)-3 .4 dlihydrobeuzo[fl [ I,4]oxazepin-5(2H)-one; 7-(4-(trifluoromethoxy)phenyl)-4-(2-{2,5,5-trimethyl- 1,3-dioxan-2-yl)ethyl)-3,4 dihydrobenzo[f][ 1 ,4]oxazepin-5(2E)-one; 15 tert-butyl (2R,1 IaR)-5-oxo-7-(4-(trifluoromehiyl)phenyl)-1 ,2,3,5,1 1,1 la hexahydrobenzo[f]pyrrolo[2,1 -d][ 1,4]oxazepin-2-ylcarbamate; 4-((5-(pyricliu-2-yl)isoxazol-3-yl)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f][1I,4]oxazepin-5(21) -one; 4-((4,6-dimiethoxypyrimidin-2-yl)methyl)-7-(4-}trifluoromethoxy)pheayl)-3 ,4 20 dihydrobenza[f][1I,4]oxazepin-5(2H)-one; ethyl 3-((5-oxo-7-(4-(trifluozvmethoxy)pheuy)-2,3-lihydnbenzo[f][1 ,4]oxazepin-4(511) yt)methyl)berrzoate; 4-(2-(pyrimidin-2-yl)ethyl)-7-(4-(trifluoromethoxy)phenyi)-3,4 dihydrobenzo [1I,4]oxazepin-5(2H)-one; 25 4-(3,4-difluorobenzyl)-7-(4-(tifluoromethoxy)phenyl)-3,4-dihydrobenzo[J [1 ,4]oxazepia 5(2ff)-one; 4-methyl-7-(4-(frifluoromethoxy)phenyl)-3,4-dihydrobenzcot] [1 ,4]oxazepiut-5(2H)-one; 4-(2-chlorobenzy1)-7-(4-(trifluoromethoxy~phenyi)-3,4-dihydrobenzo[f] [I,4]oxazepin 5(211)-one; 160 4-(2,6-dichlorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fJ[1 ,4]oxazcpin-5(2B)-one; 4-(2,6-difluorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrvbenzo[f][ 1,4]oxazepin 5(2*1)-one; 5 4-(2-(] H-pyrazol-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1 ,4]oxazezpin-5(211)-oue; (2S, I11 aS)-2-amino-7-(4-(trifluoromethyl)phenyl)-2,3, 11,11 a tetrahydrobenazo[f]pyrrolo[2, 1 -c][ 1,4]oxazepin-5(1 11-one; 4-(2-(pyridin-2-yl)ethyl)-7-(4-(trifluoromethoxy)pheayl)-3,4 10 dihydrobenzo[f][1 ,4]oxazepin-5(2H)-one; 4-(2-flxorobenzyl)-7-(4-(trifluoromethoxy)phenyl)3 ,4-dihydrobenzo[f]1 ,4]oxazepia 5(211)-one; (R)-7-(4-(trifluoromethyl)phenyl)-2,3,1 1,11 a-tetrahydrubenzorflpyrrolo [2,1 c] [1,Ajoxazepin-5(111)-one; 15 4-(pyrinidiu-2-ylmethyl)-7-(4-(trifluoromethy)phenyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5(211)-one; 4-(4-fluorobenzyl)-7-(4-(trifluoroxnethoxy)phenyJ)-3,4-dihydrobenazo[f] [1 ,4]oxazepin 5(211)-one; 4-((1-methyl-IH-pyrazol-3-yl)methyl)-7-(4-(trifiuoromethoxy)pheny)-3,4 20 dihydrobenzo[f][1 ,4]oxazepin-5 (211)one; 4-((5-chloropyriiidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5 (211)-one; 4-(pyridixi-4-ylinethyl)-7-(4-(trifluoromethoxy)pheuyl)-3,4 dihydrobenzo[ff 1 ,4joxazepin-5 (2*1)-one; 25 4-((5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][ 1,4]oxazepin-5 (211-one; 4-(2-(pyrimidin-2-yloxy)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzolf][ 1,4]oxazepin-5 (211)-one; 161 4-(Pyridin-3-ylmetby1)-7-(4-(triluorometioxy)pkeny)-3,4 dihydrobenzo[fJ[1 ,4]oxazepin-5(211)-one; 4-(pyridin-2-ylmethy1)-7-(4-(trifuoromethoxy)pheny)-3,4 dihydrobenzo[f][1I,4]oxazepin-5(2H)-one 5 4-(pyrimidin-2-ylimthyI)-7-(4-(trifluoromiethoxy)pheny)-3,4 dihydrobenzo[fl[I ,4]oxazepin-5(21T)-one; 4-((3-mnethylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[ff 1 ,4]oxazepin-5 (211)-one; (S)-3-isopropyl-7-(4-(trifluorometliyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2ff) 10 one; (R)-2-(2,2,24tritluoroethyl)-8-(4-(trifiuomomethyl)phenyl)-3,4, 12,I2a-tetrahyclro-1H benzoffpyiazino [2, 1-c][1 ,4]oxazepin-6(211)-one; 4-jpydimidin-2-ylmethyl)-7-p-tolyl-3,4-dihydrobenzoftj[ 1,4]oxazepin-5(2fl)-one; 7-(4-cblomophenyI)-4-qpyrimidin-2-ylxnetby1)-3,4-dihydrobenzo[f][1,4]oxzepin-5(21) 15 one; 7-(4-isopropylphenyl)-4-(pyrimidin-2-yhnethyl)-3,4-dihydrobenzo[fJ[l ,4]oxazepin 5(211)-one; 7-(4-ethylphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenz[f]1,4]oxazepin-5(2i one; 20 7-(4-cyclopropylphenyl)-4-(pyriniidin-2-ymethyl)-3,4-dihydrobenzo[f][1 ,4]oxazepin 5(211)-one; (R)-4-(1 -(pyrinidin-2-yl)ethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobeuzotf][I ,43oxwzepin-5(2H)-one; 7-(4-isobutoxphenyl)4-(pyrimidin-2-ylmnethyl)-3 ,4-dihyckobenzo[f][1 ,4]oxazepin 25 5(211)-one; 7-4tr-uypeil-4(yiii-- ehl)34dhdoezl1 ,4]oxazepin 5(211-one; 7-(4-oyolopropoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1 4]oxazepin 5(211)-one; 162 7-(4-fluorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H) one; 7-(2-fluoro-4-(trifluoromethyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one; 5 7-(3-fluoro4-(2,2,2-trifluoroethoxy)phenyl)-4-(pyrimidin-2-ylnethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one; 4-(pyrimidin-2-ylmethyl)-7-(4-(2,2,2-trifluoroethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one; 7-(2-chloro-4-(trifluoromethyl)phenyl)-4-(pyrimidin-2-ylmethy)-3,4 10 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one; 7-(4-(trifluoromethoxy)phenyl)-4-((4-(trifluoromethyl)pyrimidin-2-yl)methyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one; 7-(4-(trifluommethoxy)phenyl)-4-((5-(6-(trifluoromethyl)pyridin-3-yl)pyrimidin-2 yl)methyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H)-one; 15 7-(4-chloro-2-fluorophenyl)-4-(pyrimidin-2-yhnethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one; and 4-(imidazo[1,2-a]pyridin-2-yhnethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of 20 stereoisomers, tautomer, polymorph and/or prodrug thereof. [0262] In certain alternative embodiments, the disclosure provides compounds of Formula IA: (RIO), R2 N N' -0 hIA 25 wherein: n is 0, 1, 2 or 3: each R'* is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH 3

)

3 , -O-R 2 , -S- 20 , -C(O)-R 20 , -C(O)-0R 2 0 , -N(R 2 0

)(R

22 ), 163 -C(O)-N(Re)(e), -N(RE)-C(O)-R 2, -N(Ra)-C(O)-OR , -N(RW)-S(O)r-R26,

-S(O)

2

-R

0 , -S(O)rN(R 2 0 )(Ra), CI.6 alkyl, C 2 4 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said Ci.

6 alkyl, C24 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, 5 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1 .- alkyl, cycloalkyl,

-N(R

2

)(R

2 ), -C(0)-Rr, -C(O)-OR, -C(0)-N(R 2 )(Rn), -CN and -0- 20 ;

R

2 is hydrogen, C 1

.I

5 alkyl, -C(O)-R 2 , -C(0)-OR , -C(O)-N(R2)(R), 10 -N(R 2 )-S(0) 2 - , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C.

1 , s alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 .6 alkyl, C 24 alkiynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R 0 , 15 -C(O)-OR t , -C(0)-N(R 2 )(R), -CN and -O-R 0 ; wherein said C 1 . alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

1 -6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(RY), 20 -C(O)-R 0 , -C(O)-OR, -C(0)-N(R)(Re), -CN and -0- 0 ; and wherein said C1. alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -N02, -CF 3 , -N(R 2 )(R), -C(O)-R , 25 -C(0)-OR, -C(O)-N(R)(R 2 ), -CN, -S(O)-R 20 and -0 a 0 RM and R2 are in each instance independently selected from the group consisting of hydrogen, C 1

-

1 5 alkyl, C2-is alkenyl, C 2

-

1 5 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroatyl; 30 wherein the C 1

-

1 5 alkyl, C-is alkenyl, C2-1 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or 164 three substituents independently selected from the group consisting of hydroxyl, halo, C4 alkyl, acylamino, -NO 2 , -S(0)2R3, -CN, C 1

-

3 alkoxy,

-CF

3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C14 5 alkyl or cycloalkyl; or when R 20 and R are attached to a common nitrogen atom R? 0 and Re may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 , 10 -S(O) 2

R

6 , -CN, C 1 - alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and R and R 2 s are in each instance independently selected from the group consisting of hydrogen, C-4 alkyl, aryl and cycloalkyl; and wherein the C- alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting 15 of hydroxyl, halo, C4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0263) In some embodiments, R2 is -C(O)-R 20 ; and

R

2 is heteroaryl. 0 N 20 [0264] In some embodiments,.R 2 is N , [02651 In some embodiments, n is 1; and R'O is -O-R?; and Ra is C 1

-C

1 s alkyl; and wherein the alkyl is optionally substituted with one, two or three halo. 25 [0266] In some embodiments, n is 1; and RWO is 4-trifluoromethoxy. [0267] In some embodiments, the compound is pyrimidin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzof][1,4]oxazepin 4(5H)-yl)methanone 165 r, or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymoiph and/or prodrug thereof. [02681 In certain alternative embodiments, the disclosure provides compounds of Formula IV: 5 (RN IV wherein: n is 0, 1, 2 or 3: each R 10 is independently selected from the group consisting of halo, -NO 2 , -CN, 10 -SF 5 , -Si(CH 3 )3, -0-RY, -S-R, -C(O)-R 2 , -C(O)-OR 0 , -N(Ra)(Re), -C(O)-N(Ra)(e), -N(Re)-C(O)-Re, -N(R?)-C(O)-OR2, -N(R)-S(O)2-Re, -S(0) 2

-R

0 , -S(O) 2

-N(R(R"

2 ), Ci-6 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C14 alkyl, C24 alkenyl, C24 aLkynyl, cycloalkyl, aryl, 15 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C1.4 alkyl, cycloalkyl,

-N(R

0

)(R

2 ), -C(O)-R 0 , -C(O)-OR, -C(O)-N(R 0 )(R), -CN and -0- 0 ; R is hydrogen, Ci-is alkyl, -C(Q)-Ra, -C(O)-OR 2 , -C(O)-N(R 2

)(R

2 ), 20 -N(R 2

)-S(O)

2

-R

0 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 1

-

15 alkyl, cycloalkyl, aryl, bheteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(RRe), -C(O)-RY, 25 -C(O)-0R, -C(O)-N(R)(R 2 e), -CN and -O-R2; wherein said CI 4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , 166

C

1

.

4 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R), -C(O)-RW, -C(O)-QO, -C(O)-N(R 20 )(R), -CN and -O-RO; and wherein said C1.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 5 or three substituents independently selected from the group consisting of halo, -NO2, -CF 3 , -N(R)(Re), -C(O)-R 0 , -C(O)-0R 0 , -C(O)-N(R)(R 2 ), -CN, -S(0) 2

-R

0 and-O RO RE and R are in each instance independently selected from the group consisting 10 of hydrogen, C 1

-

15 alkyl, C2-1s alkenyl, C 2

-

15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C1-15 alkyl, C2-Is alkenyl, C 2

-

1 5 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 15 hydroxyl, halo, CIa alkyl, acylamino, -NO 2 , -S(O) 2

R

6 , -CN, C1.3 alkoxy,

-CF

3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C 1

.

4 alkyl or cycloalkyl; or when Re and Re are attached to a common nitrogen atom RO and R m2 May join to 20 form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C14 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(O)2R, -CN, C 1

.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and

R

2 and R are in each instance independently selected from the group consisting 25 of hydrogen, Ci 4 alkyl, aryl and cycloalkyl; and wherein the C-4 alkyl, aryl and cycloalkyl may be further substituted with from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, CI4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, 30 mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. 167 [0269] In certain alternative embodiments, the disclosure provides compounds of FormulaV:

(R

10 )n A O ,R2 N. N V 5 wherein: A is cycloalkenyl; n is 0, 1, 2 or 3: each R 10 is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH3) 3 , -O-R", -S-Ra, -C(0)-RO, -C(O)-OR 0 , -N(Re)(R 2 ), 10 -C(O)-N(R)XR), -N(R 2 )-C(O)-R", -N(R")-C(O)-OR 2 , -N(R 0 )-S(0) 2

-R

6 ,

-S(O)

2

-R

0 , -S(O) 2 -N(R")(R?), C 1

.

4 alkyl, C24 alkenyl, C 24 alkynyl, cycloalkiyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1

.

6 alkyl, C 2 4 alkenyl, C2A alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 15 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C1-6 alkyl, cycloalkyl, -N(R 2

)(R

2 ), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -O-R 0 ; R2 is hydrogen, Cs 1

.

5 alkyl, -C(O)-R 0 , -C(O)-OR 6 , -C(O)-N(R5(RMt),

-N(R)-S(O)

2 -RW, cyclo alkyl, aryl, heteroaryl or heterocyclyl; 20 wherein said Cs alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 . alkyl, C 2 4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -C(O)-R, -C(O)-0R 0 , -C(O)-N(Rf(R 2 ), -CN, oxo and -O-R 0 ; 25 wherein said C 1 . alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R2), -C(O)-RY, -C(O)-0R 0 , -C(O)-N(R 2

)(R

2 ), -CN and -O-Re; and 168 wherein said C1.6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CF 3 , -N(R 2 0 )(R2), -C(O)-R 2 0 , 5 -C(O)-OR 2 0 , -C(O)-N(R 2 0

)

2 2 ), -CN, -S(O) 2

-R

20 and -0 R20 R20 and R2 are in each instance independently selected from the group consisting of hydrogen, C1-is alkyl, C2-Is alkenyl, C2-is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 10 wherein the C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, CIA alkyl, acylarnino, -N0 2 , -S(O)R 2 6 , -CN, C3 alkoxy,

-CF

3 , -OCF 3 , -OCH2CF3, -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 15 wherein said heteroaryl is optionally further substituted with CA alkyl or cycloalkyl; or when 20 and R3 2 are attached to a common nitrogen atom R 20 and R 22 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of 20 hydroxyl, halo, C4 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 ,

-S(O)

2 Re, -CN, C alkoxy, -CF 3 , -OCF3, aryl, heteroaryl and cycloalkyl; and R26 and R8 are in each instance independently selected from the group consisting of hydrogen, CA alkyl, aryl and cycloalkyl; and wherein the C14 alkyl, aryl and cycloalkyl maybe further substituted with 25 from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, CIA alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [02701 In some embodiments, A is cyclohex-l-enyl. 30 [0271] In some embodiments, R? is C1.5 alkyl; wherein said alkyl is optionally substituted with heteroaryl. 169 [0272] In some embodiments, R is N [0273] In some embodiments, n is 0 or 1; and R is Cia alkyl. [02741 In some embodiments, A is cyclohex-I-enyl; 5 n is 0 or 1; and R" is 4-methyl or 4-tert-butyl. [0275] In some embodiments, the compound is selected from the group consisting of 7-(4-tert-butylcyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one; 10 7-cyclohexenyl-4-(pyrimidin-2-ynethyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H).one; and 7-(4-methylcyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4Joxazepin-5(2H)-one; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of 15 stereoisomers, tautomer, polymorph and/or prodrug thereof. [0276] In certain alternative embodiments, the disclosure provides compounds of Formula VI:

(R

10 ). B 0 R2 N 0 VI 20 wherein: B is heterocyclyl or heteroaryl; n is 0, 1,2 or 3: each R' is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, -Si(CH 3

)

3 , -0-R 20 , -S-R 20 , -C(O)-R 20 , -C(O)-OR 20 , -N(R 0 )(Re 2 ), 25 -C(O)-N(R 2 )(Re), -N(R 2 o)-C(O)-Rn, -N( 2

)-C(O)-OR

22 , -N(R 20

)-S(O)

2

-R

26 , -S(O)2-R 20 , -S(O)2-N(K2)(R 2 2 ), C1-6 alkyl, C24 alkenyl, C2 4 alkynyl, cycloaLkyl, aryl, hetermaryl and heterocyclyl; and 170 wherein said C1j5 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, CI4 alkyl, cycloalkyl, 5 -N(R)(R 2 ), -C(O)-R, -C(O)-OR 20 , -C(O)-N(R)(Re), -CN and -0-R 0 ; R is hydrogen, CI-15 alkyl, -C(O)-R 20 , -C(O)-OR, -C(O)-NQ(R e)

-N(R

2

)-S(O)

2

-R

0 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C1-15 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently 10 selected from the group consisting of C 14 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(O)-R? 2 , -0(O)-OR 0 , -C(O)-N(R)(R 2 ), -CN, oxo and -0- 0 ; wherein said C4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 15 independently selected from the group consisting of halo, -NO 2 , C1 alkyl, cycloalkyl, aryl, heterocycLyl, heteroaryl, -N(Re)(Re),

-C(O)-R

0 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -0- 20 ; and wherein said CI4 ailcyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 20 or three substituents independently selected from the group consisting of halo, -NO 2 , -CF 3 , -N(R)(R?), -C(O)-R 20 , -C(O)-OR, -C(O)-N(R 2 )(Re), -CN, -S(O) 2

-R

20 and -0

R

0 ;

R

20 and RM are in each instance independently selected from the group consisting 25 of hydrogen, C1-15 alkyl, C2-is alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and wherein the Cl-15 alkyl, C2-is alkenyl, C2-1s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of 30 hydroxyl, halo, C14 alkyl, acylamino, -NO 2 , -S(0) 2

R

6 , -CN, C.3 alkoxy,

-CF

3 , -OCF3, -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; 171 wherein said heteroaryl is optionally further substituted with C 1 4 alkyl or cycloalkyl; or when R 20 and R? are attached to a common nitrogen atom R 20 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 5 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 4 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylarmino, -NO 2 ,

-S(O)

2

R

2 , -CN, C1.

3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and R and R 2 8 are in each instance independently selected from the group consisting of hydrogen, C.

4 1 alkyl, aryl and cycloalkyl; and 10 wherein the C, 4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. 15 [0277] In some embodiments, B is heterocyclyl. [0278] In some embodiments, B is 2-oxo-1,2-dihydropyridin-4-yl. [02791 In some embodiments, B is heteroaryl. [02801 In some embodiments, B is pyridin-4-yl. [0281] In some embodiments, R2 is C- 1 5 alkyl; 20 wherein said alkyl is optionally substituted with heteroaryl. [0282] In some embodiments, R2 is [0283] In some embodiments, n is 1; R'" is -O-R2' or C 1 4 alkyl; and R2 is C-Cis alkyl. 25 [0284] In some embodiments, B is 2-tert-butoxypyridin-4-yl. [0285] In some embodiments, B is 1-methyl-2-oxo-1,2-dihydropyridin-4-yl. [0286] In some embodiments, the compound is selected from the group consisting of 172 7-(2-tert-butoxypyridin-4-yl)-4-(pyridin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one; and 7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[fj{1,4]oxazepin-5(2H)-one; 5 or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0287] In certain alternative embodiments, the disclosure provides compounds of Formula VIlA:

(R''

0 )i N 0 N'2 10 VIIIA wherein: n is 0, 1, 2 or 3: each R 0 is independently selected from the group consisting of halo, -NO 2 , -CN, -SF5, -Si(CH3)3, -0-R0, -S-R0, -C(0)-R0, -C(0)-ORO, _-N(Re)(R), 15 -C(O)-N(R)(R 2 ), -N(Rc)-C(O)-R, -N(R 2 )-C(O)-OR , -N(R)-S(O) 2

-R

6 , -S(0) 2

-R

0 , -S(0)2-N(Rm)(R ), CI.6 alkyl, C24 alkenyl, C24 alkynyl, cycloalky1, aryl, heteroaryl and heterocyclyl; and wherein said C1.4 alkyl, C24 alkenyl, C 24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three 20 substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1 -6 alkyl, cycloalkyl,

-N(R

2 )(Re), -C(O)-R 0 , -C(O)-OR 0 , -C(O)-N(R 2 )(e), -CN and -0-R 2 ;

R

2 is hydrogen, Ci..15 alkyl, -C(O)-R 2 , -C(O)-0R, -C(O)-N(e)(R), -N(e)-S(O) 2

-R

2 , cycloalkyl, aryl, heteroaryl or heterocyclyl; 25 wherein said Ci.15 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C1.6 alkyl, C24 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(e), -C(O)-R 0 ,

-C(O)-OR

'

, -C(O)-N(R 2 )(RM), -CN, oxo and -0-R; 173 wherein said C 1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), 5 -C(O)-R 2 0 , -C(O)-OR" 0 , -C(O)-N(R 0 )(Re 2 ), -CN and -O-R 0 ; and wherein said C 14 alkyl, cycloaUkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CF 3 , -N(R 2 )(Re), -C(O)-RO, 10 -C(O)-OR 0 , -C(O)-N(R 2 )(R ), -CN, -S(0) 2

-R

0 and -0 Re; RY and Rf are in each instance independently selected from the group consisting of hydrogen, C 1 -is alkyl, C 2

-

1 5 alkenyl, C2-15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 15 wherein the CI-15 alkyl, C 2

-

15 alkenyl, C2-Is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, acylamino, -NO 2 , -S(Q) 2

R

6 , -CN, C1.3 alkoxy,

-CF

3 , -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and 20 wherein said heteroaryl is optionally further substituted with CI4 alkyl or cycloalkyl; or when R 0 and R 2 are attached to a common nitrogen atom R 0 and R 2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of 25 hydroxyl, halo, Ci4 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO2, -S(0) 2

R

2 , -CN, C1..3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and Re and R 28 are in each instance independently selected from the group consisting of hydrogen, CI4 alkyl, aryl and cycloalkyl; and wherein the C14 alkyl, aryl and cycloalkyl may be further substituted with 30 from I to 3 substituents independently selected from the group consisting of hydroxyl, halo, CiA alkoxy, -CF 3 and -OCF 3 ; 174 or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0288J In some embodiments, R2 is C 1

.

15 alkyl; wherein said alkyl is optionally substituted with heteroaryl. N 5 [02891 In some embodiments, R2 is N [0290] In some embodiments, n is 0 or 1; Rio is -O-R or C 1 4 alkyl; wherein the alkyl is optionally substituted with three halo; and R20 is C-C 15 alkyl; and 10 wherein the alkyl is optionally substituted with one, two or three halo. [02911 In some embodiments, n is 0 or 1; and R'O is 4-trifluoromethyl or 4 trifluoromethoxy. (02921 In some embodiments, the compound is selected from the group consisting of 4-(pyrimidin-2-ylmethyl)-7-((4-(trifluoromethoxy)phenyl)ethynyl)-3,4 15 dihydrobenzo[f][1,4]oxazepin-5(2H)-one; 7-(phenylethynyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[t][1,4]oxazepin-5(2H) one; and 4-(pyrinidin-2-ylmethyl)-7-((4-(trifluoromethyl)phenyl)ethynyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one; 20 or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0293] In certain alternative embodiments, the disclosure provides compounds of Formula IX: (Rio0 NR2 'S 25 IX wherein: 175 n is 0, 1, 2 or 3: each R 10 is independently selected from the group consisting of halo, -NO 2 , -CN,

-SF

5 , -Si(CH3)3, -O-R2, -S-R 2 , -C(O)-R 20 , -C(O)-OR 2 0 , -N(R 0 )(R) -C(O)-N(R)(Ra) -N(R20)-C(0)-RO, -N(Re)-C(O)-OR", -N(Re)-S(O)rRe, 5 -S(0) 2

-R

20 , -S(O) 2 -N(R)(Re 2 ), C- 6 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 14 alkyl, C24 alkenyl, C24 alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, 10 -NO 2 , phenyl, heterocyclyl, heteroaryl, C 14 alkyl, cycloalkyl,

-N(R)(R

2 ), -C(O)-R 0 , -C(O)-OR 0 , -C(O)-N(R 2 )(Re), -CN and -0-R;

R

2 is hydrogen, C-1 alkyl, -C(O)-R 2 0 , -C(O)-OR 2 , -C(O)-N(R 2 )(R),

-N(R

2 0

)-S(O)

2 -R, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 115 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are 15 optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 . alkyl, C 24 alkynyl, halo, -NO2, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Ra), -C(O)-R 0 , -C(O)-0R 2 , -C(O)-N(R)(R 2 ), -CN, oxo and -O-R; wherein said C 14 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl 20 are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 ,

C

14 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(R ), -C(O)-R2, -C(O)-0R 2 , -C(O)-N(R 0 )(Re), -CN and -0-R?; and wherein said C1-6 alkyl, cycloalkyl, aryl, heterocyclyl or 25 heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -CF 3 , -N(R)(Re), -C(O)-R 2 , -C(O)-0R 0 , -C(O)-N(R)(R 2 ), -CN, -S(0) 2 -R and -0 R1; 176 R2 and R2 are in each instance independently selected from the group consisting of hydrogen, C1-15 alkyl, C2-Is alkenyl, C2-1, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the CI-15 alkyl, C2-1s alkenyl, C2-is alkynyl, cycloalkyl, 5 heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, acylamino, -NOz -S(0) 2 Re 6 , -CN, CI.3 alkoxy, -CF3, -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C4 10 alkyl or cycloalkyl; or when R2 and R2 are attached to a common nitrogen atom R 20 and R2 may join to form a hetero cyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C1. alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO2, 15 -S(O) 2 Re, -CN, CI13 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and R? and R 2 are in each instance independently selected from the group consisting of hydrogen, C14 alkyl, aryl and cycloalkyl; and wherein the C1.4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting 20 of hydroxyl, halo, Ci4 alkoxy, -CF 3 and -OCF3; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [02941 In some embodiments, R2 is CI1 alkyl; wherein said alkyl is optionally substituted with heteroaryl; and 25 wherein said heteroaryl is optionally further substituted with halo. N, [02951 In some embodiments, B? is selected from the group consisting of N and [0296] In some embodiments, R 0 is 4-trifluoromethyl. 177 [0297] In some embodiments, the compound is selected from the group consisting of: 2-((pyrimidin-2-yl)methyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H benzo[b][1,4,5]oxathiazepin-sulfone; and 2-((5-chloropyrimidin-2-yl)methyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H 5 benzo[b][1,4,5]oxathiazepin-sulfone; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [0298] In certain alternative embodiments, the disclosure provides compounds of Formula X: (RIO)n- | ,R2 N N R 4 10 R6 R 4 X wherein: nis 0, 1,2 or 3; RiG is independently selected from the group consisting of halo, -NO 2 , -CN, -SFs, 15 -Si(CH3)3, -O-R0, -S-R20, -C(0)-R", -C(0)-OR O -N(R20)(e), -C(O)

N(R

2 )(Re), -N(R 2

)-C(O)-R

2 , -N(RI)-C(O)-OR 2 , -N(R)-S(O) 2

-R

2 , -S(0) 2 R 20 , -S(0) 2

-N(R")(R

2 ), C 14 alkyl, C 2 4 alkenyl, C 24 ailcynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1

.

4 alkyl, C 2 4 alkenyl, C 2 4 alkynyl, cycloalkyl, aryl, 20 heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , phenyl, heterocyclyl, heteroaryl, C 1 - alkyl, cycloalkyl,

-N(R

2

)(R

2 ), -C(O)-R 2 , -C(O)-OR 0 , -C(O)-N(R 2 )(R), -CN and -0-R? 0 ; R2 is hydrogen, C 1

..

1 5 alkyl, -C(O)-R 0 , -C(O)-OR 6 , -C(O)-N(Re)(R 2 S), 25 -N(R 2

)-S(O)

2 -R, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said Ci 4 s alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 24 6 aAlyl, C 24 alkynyl, halo, -NO 2 , 178 cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(RO), -C(O)-Re, -C(O)-ORa, -C(O)-N(R 2 )(R?), -CN, oxo and -0-R 2 0 ; wherein said C 1 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 5 independently selected from the group consisting of halo, -NO 2 , CIs alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R)(Re), -C(0)-R 0 , -C(O)-OR 0 , -C(O)-N(R 2 )(R), -CN and -0-R; and wherein said C. alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two 10 or three substituents independently selected from the group consisting of halo, -NO 2 , -CF 3 , -N(RE)(Re), -C(O)-R, -C(0)-OR, -C(O)-N(R 2 )(R0), -CN, -S(O)2-RO and -0 each R 4 is independently hydrogen, C1-is alkyl, Ci4 alkoxy, -C(O)-OR 6 , 15 -C(O)-N(R 6 )(R), -N(R 2

)-S(O)

2 -R, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said CI1s alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(RE), -C(O)-R -C(O)-OR, -C(0)-N(R)(R 2 ), -CN and -O-R2; 20 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , Ci6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R)(R?

2 ), -C(0)-R, -C(O)-OR 2 , -C(O)-N(R 2 )(R), -CN and 25 -0-Re; and wherein said C14 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2 , 30 -N(R)(R), -C(O)-R 0 , -C(O)-OR", -C(O)-N(R")(Ra), -CN and -O-R; 179 or two R together with the carbon atom to which they are attached form an oxo;

R

6 is hydrogen, CI-s5 alkyl, -C(O)-R 2 , -C(O)-OR?, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 1 5s alkyl is optionally substituted with one, two or three 5 substituents independently selected from the group consisting of halo,

-NO

2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 )(Re), -C(0)-R2 0 ,

-C(O)-OR

2 0 , -C(O)-N(R 2 0

)(R

2 ), -CN and -O-R 2 0 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents 10 independently selected from the group consisting of halo, -NO 2 , C1.6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl,

-N(R

20 )(R 2 ), -C(O)-R 20 , -C(O)-OR 2 0 , -C(O)-N(R 2 0)(Re), -CN and -0-R20; and wherein said C1.6 alkyl, aralkyl, cycloalkyl, aryl, 15 heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , -N(R 2 0

)R

2 ), -C(0)- 20 , -C(O)-OR 20 , ,C(0)-N(R 2 c)(Rn), -CN and -0

R

20 ; 20 R 20 and R are in each instance independently selected from the group consisting of hydrogen, C 1

-

1 5 alkyl, C2-Is alkenyl, C2 1 s alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the C i-is alkyl, C2-is alkenyl, C2-Is alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or 25 three substituents independently selected from the group consisting of hydroxyl, halo, C 3 4 alkyl, acylamino, -NO 2, -S(0) 2

R

2 6 , -CN, C1.3 alkoxy, -CF3, -OCF 3 , -OCH 2

CF

3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C 1

.

4 alkyl or cycloalkyl; or 30 when R 2 0 and R are attached to a common nitrogen atom R 20 and R2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with 180 one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci4 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(0) 2 R26, -CN, C-3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and

R

6 and R0 8 are in each instance independently selected from the group consisting 5 of hydrogen, C1.4 alkyl, aryl and cycloalkyl; and wherein the C1.4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C 1

.

4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, 10 mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. [02991 In some embodiments, R 2 is C .1, alkyl; wherein the alkyl is optionally substituted with aryl or -0-R? 0 ; and 20 is C1-C15 alkyl; wherein the alkyl is optionally substituted with aryl. 15 [0300] In some embodiments, R2 isCI or [0301] In some embodiments, RI is 4-trifluoromethyl or 4-trifluoromethoxy. [03021 In some embodiments, two R 4 together with the carbon atom to which they are attached form an oxo. [0303] In some embodiments, Re is hydrogen or C1i alkyl. 20 [0304] In some embodiments, R 6 is hydrogen or methyl. [0305] In some embodiments, the compound is selected from the group consisting of 4-(2-(benzyloxy)ethyl)-1-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-IH benzo[e][ 1,4]diazepine-2,5-dione; and 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5 25 dione; or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof. 181 (0306] In some embodiments of Formula I and each of the other formulas disclosed herein, R 20 and R 2 2 are in each instance independently selected from the group consisting of hydrogen, C 1 .s alkyl, C2-s alkenyl, C2.6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 5 wherein the C1 alkyl, C2.4 alkenyl, C 2 -6 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, C 14 alkyl, acylamino, -NO 2 , -S(O)2Re, -CN, C13 alkoxy, -CF 3 , -OCF 3 , -OCH 2 CF, -C(O)

NH

2 , aryl, cycloalkyl and heteroaryl; and 10 wherein said heteroaryl is optionally further substituted with CIA alkyl or cycloalkyl; or when R 20 and R2 are attached to a common nitrogen atom R 20 and R 22 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Cl4 15 alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(0) 2 R0, -CN, C1 alkoxy,

-CF

3 , -OCF 3 , aryl, heteroaryl and cycloalkyl. [0307] In certain embodiments, R 20 is hydrogen or C1- alkyl; wherein the Clz alkyl is optionally substituted with one, two or three halo. [03081 In certain embodiments, R 2 0 is hydrogen. In other embodiments, R 2 0 is -CF 3 . 20 4. Further Embodiments [0309] In some embodiments, the compounds provided by the present disclosure are effective in the treatment of conditions or diseases known to respond to administration of late sodium channel blockers, including but not limited to cardiovascular diseases such as 25 atrial and ventricular arrhythmias, including atrial fibrillation, Prinzmetal's (variant) angina, stable angina, unstable angina, ischemia and reperfusion injury in cardiac, kidney, liver and the brain, exercise induced angina, pulmonary hypertension, congestive heart disease including diastolic and systolic heart failure, and myocardial infarction. In some embodiments, compounds provided by the present disclosure which function as late 30 sodium channel blockers may be used in the treatment of diseases affecting the neuromuscular system resulting in pain, itching, seizures, or paralysis, or in the treatment 182 of diabetes or reduced insulin sensitivity, and disease states related to diabetes, such as diabetic peripheral neuropathy. [03101 Certain compounds of the disclosure may also possess a sufficient activity in modulating neuronal sodium channels, i.e., Na, 1.1., 1 1.3, 1.5, 1.7, and/or 1.8, and 5 may have appropriate pharmacokinetic properties such that they may be active with regard to the central and/or peripheral nervous system. Consequently, some compounds of the disclosure may also be of use in the treatment of epilepsy or pain or itching or heachache of a neuropathic origin. [0311] In one embodiment, this disclosure provides a method of treating a disease state 10 in a mammal that is alleviable by treatment with an agent capable of reducing late sodium current, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I, IA, IB, II, IIA, IB, III, IIA, IV, V, VI, VIII, VIIIA, IX, X, XII or XIII or other formulas or compounds disclosed herein. In another embodiment, the disease state is a cardiovascular disease selected from one or more of 15 atrial and ventricular arhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension, and intermittent 20 claudication. [03121 In another embodiment, the disease state is diabetes or diabetic peripheral neuropathy. In a further embodiment, the disease state results in one or more of neuropathic pain, epilepsy, heachache, seizures, or paralysis. [0313] In one embodiment, this disclosure provides a method of treating diabetes in a 25 mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I, IA, IB, II, IIA, IB, III, IIIA, IV, V, VI, VIII, VIIIA, IX, X, XII or XIII or other formulas or compounds disclosed herein. Diabetes mellitus is a disease characterized by hyperglycemia; altered metabolism of lipids, carbohydrates and proteins; and an increased risk of complications from vascular disease. 30 Diabetes is an increasing public health problem, as it is associated with both increasing age and obesity. [03141 There are two major types of diabetes mellitus: 1) Type I, also known as insulin 183 dependent diabetes (IDDM) and 2) Type H, also known as insulin independent or non insulin dependent diabetes (NIDDM). Both types of diabetes mellitus are due to insufficient amounts of circulating insulin and/or a decrease in the response of peripheral tissue to insulin. 5 [0315] Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them. The complications of Type I diabetes include heart disease and stroke; retinopathy (eye disease); kidney disease nephropathyy); neuropathy (nerve damage); as well as maintenance of good skin, foot and oral health. 10 [03161 Type H diabetes results from the body's inability to either produce enough insulin or the cells inability to use the insulin that is naturally produced by the body. The condition where the body is not able to optimally use insulin is called insulin resistance. Type II diabetes is often accompanied by high blood pressure and this may contribute to heart disease. In patients with type 11 diabetes mellitus, stress, infection, and medications 15 (such as corticosteroids) can also lead to severely elevated blood sugar levels. Accompanied by dehydration, severe blood sugar elevation in patients with type H diabetes can lead to an increase in blood osmolality (hyperosmolar state). This condition can lead to coma. [03171 It has been suggested that ranolazine (RANEXA*, a selective inhibitor of INaL) 20 may be an antidiabetic agent that causes 0-cell preservation and enhances insulin secretion in a glucose-dependent manner in diabetic mice (see, Y. Ning et al. J Pharmacol Exp Ther. 2011, 337(1), 50-8). Therefore it is contemplated that the compounds of Formula I, IA, TB, II, HA, 111I, M IA, IV, V, VI, VIII, VIlHA, DC, X, XI or XI or other formulas or compounds disclosed herein can be used as antidiabetic agents for the 25 treatment of diabetes. 5. Pharmaceutical Compositions andAdministrafon [03181 Compounds provided in accordance with the present disclosure are usually administered in the form of pharmaceutical compositions. This disclosure therefore 30 provides pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt or ester thereof, and 184 one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. The pharmaceutical compositions may be administered alone or in combination with other therapeutic agents. 5 Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985); and Modem Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.) [0319] The pharmaceutical compositions may be administered in either single or 10 multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporate d by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for 15 example, or an artery-inserted cylindrical polymer. [0320] One mode for administration is parenteral, particularly by injection. The forms in which the novel compositions of the present disclosure may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile 20 aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection, but less preferred in the context of the present disclosure. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, 25 such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlIorobutanol, phenol, sorbic acid, thimerosal, and the like. [0321] Sterile injectable solutions are prepared by incorporating a compound according 30 to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the 185 required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution 5 thereof Preferably, for parenteral administration, sterile injectable solutions are prepared containing a therapeutically effective amount, e.g., 0.1 to 700 mg, of a compound described herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of 10 administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient the severity of the patient's symptoms, and the like. [0322] Oral administration is another route for administration of compounds in accordance with the disclosure. Administration maybe via capsule or enteric coated 15 tablets, or the like. In making the pharmaceutical compositions that include at least one compound described herein, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the 20 active ingredient Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders. 25 [0323] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending 30 agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents. [0324] The compositions of the disclosure can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by 186 employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and 5 5,616,345. Another formulation for use in the methods of the present disclosure employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present disclosure in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 10 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. [0325J The compositions are preferably formulated in a unit dosage form. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of 15 active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, ampoule). The compounds are generally administered in a pharmaceutically effective amount. Preferably, for oral administration, each dosage unit contains from 1 mg to 2 g, or alternatively, or 100 mg to 500 mg, of a compound described herein, and for parenteral administration, preferably 20 from 0.1 mg to 700 mg, or alternatively, 0.1 mg to 100 mg, of a compound a compound described herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, 25 weight, and response of the individual patient, the severity of the patient's symptoms, and the like. [0326] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present disclosure. When 30 referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. 187 [0327J The tablets or pills of the present disclosure may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of 5 an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and 10 cellulose acetate. [0328 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably, the compositions are administered 15 by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably 20 orally or nasally, from devices that deliver the formulation in an appropriate manner. Combination Therapy [0329] Patients being treated by administration of the late sodium channel blockers of the disclosure often exhibit diseases or conditions that benefit from treatment with other therapeutic agents. These diseases or conditions can be of cardiovascular nature or can be 25 related to pulmonary disorders, metabolic disorders, gastrointestinal disorders and the like. Additionally, some coronary patients being treated by administration of the late sodium channel blockers of the disclosure exhibit conditions that can benefit from treatment with therapeutic agents that are antibiotics, analgesics, and/or antidepressants and anti-anxiety agents. 188 Cardiovascular Agent Combination Therapy [0330] Cardiovascular related diseases or conditions that can benefit from a combination treatment of the late sodium channel blockers of the disclosure with other therapeutic agents include, without limitation, angina including stable angina, unstable 5 angina (UA), exercised-induced angina, variant angina, arrhythmias, intermittent claudication, myocardial infarction including non-STE myocardial infarction (NSTEMI), pulmonary hypertension including pulmonary arterial hypertension, heart failure including congestive (or chronic) heart failure and diastolic heart failure and heart failure with preserved ejection fraction (diastolic dysfunction), acute heart failure, or recurrent 10 ischemia. [0331] Therapeutic agents suitable for treating cardiovascular related diseases or conditions include anti-anginals, heart failure agents, antithrombotic agents, antiarrhythmic agents, antihypertensive agents, and lipid lowering agents. [03321 The co-administration of the late sodium channel blockers of the disclosure with 15 therapeutic agents suitable for treating cardiovascular related conditions allows enhancement in the standard of care therapy the patient is currently receiving. In some embodiments, the late sodium channel blockers of the disclosure are co-administered with ranolazine (RANEXA*). And-anginals 20 [03331 Anti-anginals include beta-blockers, calcium channel blockers, and nitrates. Beta blockers reduce the hearts need for oxygen by reducing its workload resulting in a decreased heart rate and less vigorous heart contraction. Examples of beta-blockers include acebutolol (Sectral), atenolol (Tenormin*), betaxolol (Kerlone*), bisoprolol/hydrochlorothiazide (Ziac*), bisoprolol (Zebeta), carteolol (Cartrol*), 25 esmolol (Brevibloc), labetalol (Normodyne* Trandate'), metoprolol (Lopressor, Toprol* XL), nadolol (Corgard), propranolol (lnderal"), sotalol (Betapace"), and timolol (Blocadren"). [0334] Nitrates dilate the arteries and veins thereby increasing coronary blood flow and decreasing blood pressure. Examples of nitrates include nitroglycerin, nitrate patches, 30 isosorbide dinitrate, and isosorbide-5-mononitrate. 189 [0335 Calcium channel blockers prevent the normal flow of calcium into the cells of the heart and blood vessels causing the blood vessels to relax thereby increasing the supply of blood and oxygen to the heart. Examples of calcium channel blockers include amlodipine (NorvasO, Lotrel), bepridil (Vascor*), diltiazem (Cardizem*, Tiazac), 5 felodipine (Plendil), nifedipine (Adalat, Procardia*), nimodipine (Nimotopt), nisoldipine (Sular), verapamil (Calan*, Isoptin* Verelan"), and nicardipine. Heart Failure Agents [03361 Agents used to treat heart failure include diuretics, ACE inhibitors, vasodilators, and cardiac glycosides. Diuretics eliminate excess fluids in the tissues and circulation 10 thereby relieving many of the symptoms of heart failure. Examples of diuretics include hydrochlorothiazide, metolazone (Zaroxolyn*), furosemide (Lasix*), bumetanide (Bumex*), spironolactone (Aldactone*), and eplerenone (Inspra*). [0337] Angiotensin converting enzyme (ACE) inhibitors reduce the workload on the heart by expanding the blood vessels and decreasing resistance to blood flow. Examples 15 of ACE inhibitors include benazepril (Lotensin®), captopril (Capoten), enalapril (Vasotec*), fbsinopril (Monopril*), lisinopril (Prinivil*, Zestril*), moexipril (Univasc*), perindopril (Aceon"), quinapril (Accuprilo), ramipril (Altace"), and trandolapril (Mavik*). [03381 Vasodilators reduce pressure on the blood vessels by making them relax and 20 expand. Examples of vasodilators include hydralazine, diazoxide, prazosin, clonidine, and methyldopa. ACE inhibitors, nitrates, potassium channel activators, and calcium channel blockers also act as vasodilators. [0339] Cardiac glycosides are compounds that increase the force of the heart's contractions. These compounds strengthen the pumping capacity of the heart and improve 25 irregular heartbeat activity. Examples of cardiac glycosides include digitalis, digoxin, and digitoxin. Antithrombotic Agents [0340] Antithrombotics inhibit the clotting ability of the blood. There are three main types of antithrombotics - platelet inhibitors, anticoagulants, and thrombolytic agents. 190 [0341J Platelet inhibitors inhibit the clotting activity of platelets, thereby reducing clotting in the arteries. Examples of platelet inhibitors include acetylsalicylic acid (aspirin), ticlopidine, clopidogrel (Plavixt), prasugrel (Effient*), dipyridamole, cilostazol, persantine sulfinpyrazone, dipyridamole, indomethacin, and glycoprotein llb/llla 5 inhibitors, such as abciximab, tirofiban, and eptifibatide (Integrelin*). Beta blockers and calcium channel blockers also have a platelet-inhibiting effect. [03421 Anticoagulants prevent blood clots from growing larger and prevent the formation of new clots. Examples of anticoagulants include bivalirudin (Angiomax), warfarin (Coumadin*), unfractionated heparin, low molecular weight heparin, danaparoid, 10 lepiradin, and argatroban. [0343] Thrombolytic agents act to break down an existing blood clot. Examples of thrombolytic agents include streptokinase, urokinase, and tenecteplase (TNK), and tissue plasminogen activator (t-PA). Antiarrhythmic agents 15 [0344] Antiarrhythmic agents are used to treat disorders of the heart rate and rhythm. Examples of antiarrhythmic agents include amiodarone, dronedarone, quinidine, procainamide, lidocaine, and propafenone. Cardiac glycosides and beta blockers are also used as antiarrhythmic agents. [0345] Combinations with amiodarone and dronedarone are of particular interest (see 20 U.S. Patent Application Publication No. 2010/0056536 and U.S. Patent Application Publication No. 2011/0183990, the entirety of which are incorporated herein). Antihypertensive agents [0346] Antihypertensive agents are used to treat hypertension, a condition in which the blood pressure is consistently higher than normal. Hypertension is associated with many 25 aspects of cardiovascular disease, including congestive heart failure, atherosclerosis, and clot formation. Examples of antihypertensive agents include alpha-1-adrenergic antagonists, such as prazosin (Minipress*), doxazosin mesylate (Cardura), prazosin hydrochloride (Minipress*), prazosin, polythiazide (Minizide*), and terazosin hydrochloride (Hytrin ; beta-adrenergic antagonists, such as propranolol (Inderal*), 30 nadolol (Corgard*, timolol (Blocadren*), metoprolol (Lopressor), and pindolol (Visken"); central alpha-adrenoceptor agonists, such as clonidine hydrochloride 191 (Catapres*), clonidine hydrochloride and chlorthalidone (Clorpres*, Combipres*), guanabenz Acetate (Wytensin), guanfacine hydrochloride (renex*), methyldopa (Aldomet*), methyldopa and chlorothiazide (Aldoclor*), methyldopa and hydrochlorothiazide (Aldoril*); combined alpha/beta-adrenergic antagonists, such as 5 labetalol (Normodyne*, Trandate*), carvedilol (Coreg*); adrenergic neuron blocking agents, such as guanethidine (Ismelin*), reserpine (Serpasil*); central nervous system acting antihypertensives, such as clonidine (Catapres*), methyldopa (Aldomett), guanabenz (Wytensin); anti-angiotensin II agents; ACE inhibitors, such as perindopril (Aceon*) captopril (Capoten), enalapril (Vasotec"), lisinopril (Prinivil, Zestrii ; 10 angiotensin-H receptor antagonists, such as candesartan (Atacand*), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar*), teknisartan (Micardis*), valsartan (Diovan*); calcium channel blockers, such as verapamil (Calan* Isoptin), diltiazem (Cardizem*), nifedipine (Adalat*, Procardia); diuretics; direct vasodilators, such as nitroprusside (Nipride"), diazoxide (Hyperstat* IV), hydralazine (Apresoline), minoxidil 15 (Loniten), verapamil; and potassium channel activators, such as aprikalim, bimakalim, cromakalim, emakalim, nicorandil, and pinacidil. Lzpid Lowering Agents [0347] Lipid lowering agents are used to lower the amounts of cholesterol or fatty sugars present in the blood. Examples of lipid lowering agents include bezafibrate 20 (Bezalip*), ciprofibrate (Modalim), and statins, such as atorvastatin (Lipitor*), fluvastatin (Lescol*), lovastatin (Mevacor*, Altocor*), mevastatin, pitavastatin (Livalo*, Pitava*) pravastatin (Lipostat), rosuvastatin (Crestor, and simvastatin (Zocor*). [0348] In this disclosure, the patient presenting with an acute coronary disease event often suffers from secondary medical conditions such as one or more of a metabolic 25 disorder, a pulmonary disorder, a peripheral vascular disorder, or a gastrointestinal disorder. Such patients can benefit from treatment of a combination therapy comprising administering to the patient a compound as disclosed herein (e.g., Formula I, IA, IB, II, JIA, IB, IH, IlA, TV, V, VI, VIII, VIllA, IX, X, XI or XII) in combination with at least one therapeutic agent. 192 Pulmonary Disorders Combination Therapy [0349] Pulmonary disorder refers to any disease or condition related to the lungs. Examples of pulmonary disorders include, without limitation, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. 5 [0350] Examples of therapeutics agents used to treat pulmonary disorders include bronchodilators including beta2 agonists and anticholinergics, corticosteroids, and electrolyte supplements. Specific examples of therapeutic agents used to treat pulmonary disorders include epinephrine, terbutaline (Brethaire" Bricanyt*), albuterol (Proventil"), salmeterol (Serevent, Serevent Diskus*), theophylline, ipratropium bromide (Atrovent*), 10 tiotropium (Spiriva), methylprednisolone (Solu-Medrol*, Medrol*), magnesium, and potassium. Metabolic Disorders Combination Therapy [0351] Examples of metabolic disorders include, without limitation, diabetes, including type I and type II diabetes, metabolic syndrome, dyslipidemia, obesity, glucose 15 intolerance, hypertension, elevated serum cholesterol, and elevated triglycerides. 103521 Examples of therapeutic agents used to treat metabolic disorders include antihypertensive agents and lipid lowering agents, as described in the section "Cardiovascular Agent Combination Therapy" above. Additional therapeutic agents used to treat metabolic disorders include insulin, sulfonylureas, biguanides, alpha-glucosidase 20 inhibitors, and incretin mimetics. Peripheral Vascular Disorders Combination Therapy [0353] Peripheral vascular disorders are disorders related to the blood vessels (arteries and veins) located outside the heart and brain, including, for example peripheral arterial disease (PAD), a condition that develops when the arteries that supply blood to the 25 internal organs, arms, and legs become completely or partially blocked as a result of atherosclerosis. Gastrointestinal Disorders Combination Therapy [03541 Gastrointestinal disorders refer to diseases and conditions associated with the gastrointestinal tract. Examples of gastrointestinal disorders include gastroesophageal 193 reflux disease (GERD), inflammatory bowel disease (IBD), gastroenteritis, gastritis and peptic ulcer disease, and pancreatitis. [03551 Examples of therapeutic agents used to treat gastrointestinal disorders include proton pump inhibitors, such as pantoprazole (Protonix*), lansoprazole (Prevacid*, 5 esomeprazole (Nexium), omeprazole (Prilosec), rabeprazole; H2 blockers, such as cimetidine (ragamet), ranitidine (Zantac"), famotidine (Pepcido), nizatidine (Axidt); prostaglandins, such as misoprostol (Cytotec"); sucralfate; and antacids. Antibiotics, analgesics, antidepressants and and-anxiety agents Combination Therapy [0356] Patients presenting with an acute coronary disease event may exhibit conditions 10 that benefit from administration of therapeutic agent or agents that are antibiotics, analgesics, antidepressant and anti-anxiety agents in combination with a compound as disclosed herein (e.g., Formula I, IA, IB, 1I, IIA, IB, III, IA, IV, V, VI, VIII, VHIA, DX, X, XII or XIII). Antibiotics 15 [0357] Antibiotics are therapeutic agents that kill, or stop the growth of, microorganisms, including both bacteria and fingi. Example of antibiotic agents include p-Lactam antibiotics, including penicillins (amoxicillin), cephalosporins, such as cefazolin, cefuroxime, cefadroxil (Duricef*), cephalexin (Keflex'), cephradine (Velosef*, cefaclor (Ceclor), cefuroxime axtel (Ceftin), cefprozil (Cefzil*), loracarbef 20 (Lorabid , cefixime (Suprax*), cefpodoxime proxetil (Vantin , ceftibuten (Cedax*), cefdinir (Omnicef*), ceftriaxone (Rocephint), carbapenems, and monobactarns; tetracyclines, such as tetracycline; macrolide antibiotics, such as erythromycin; aminoglycosides, such as gentamicin, tobramycin, amikacin; quinolones such as ciprofloxacin; cyclic peptides, such as vancomycin, streptogramins, polymyxins; 25 lincosamides, such as clindamycin; oxazolidinoes, such as linezolid; and sulfa antibiotics, such as sulfisoxazole. Analgesics [0358] Analgesics are therapeutic agents that are used to relieve pain. Examples of analgesics include opiates and morphinominimetics, such as fentanyl and morphine; 30 paracetamol; NSAIDs, and COX-2 inhibitors. Given the abilty of the late sodium channel blockers of the disclosure to treat neuropathic pain via inhibition of the Nav 1.7 and 1.8 194 sodium channels, combination with analgesics are particularly invisioned. See U.S. Patent Application Publication 20090203707. Antidepressant and Anti-anxiety agents [0359J Antidepressant and anti-anxiety agents include those agents used to treat anxiety 5 disorders, depression, and those used as sedatives and tranquillers. Examples of antidepressant and anti-anxiety agents include benzodiazepines, such as diazepam, lorazepam, and midazolam; enzodiazepines; barbiturates; glutethimide; chloral hydrate; meprobamate; sertraline (Zoloft, Lustral* Apo-Sertral, Asentra*, Gladem*, Serlift*, Stimuloton*); escitalopram (Lexaproo, Cipralex®); fluoxetine (Prozac, Sarafem* 10 Fluctin, Fontex* Prodep, Fludepo, Lovan"); venlafaxine (Effexor*XR, Efexor*); citalopram (Celexa", Cipramil*, Talohexane*); paroxetine (Paxilo, Seroxat*, Aropax*); trazodone (Desyrel*); amitriptyline (ELavil*); and bupropion (Wellbutrin*, Zyban*). [0360 Accordingly, one aspect of the disclosure provides for a composition comprising the late sodium channel blockers of the disclosure and at least one therapeutic agent. In 15 an alternative embodiment, the composition comprises the late sodium channel blockers of the disclosure and at least two therapeutic agents. In further alternative embodiments, the composition comprises the late sodium channel blockers of the disclosure and at least three therapeutic agents, the late sodium channel blockers of the disclosure and at least four therapeutic agents, or the late sodium channel blockers of the disclosure and at least 20 five therapeutic agents. [0361] The methods of combination therapy include co-administration of a single formulation containing the the late sodium channel blockers of the disclosure and therapeutic agent or agents, essentially contemporaneous administration of more than one formulation comprising the late sodium channel blocker of the disclosure and therapeutic 25 agent or agents, and consecutive administration of a late sodium channel blocker of the disclosure and therapeutic agent or agents, in any order, wherein preferably there is a time period where the late sodium channel blocker of the disclosure and therapeutic agent or agents simultaneously exert their therapeutic affect. 30 6. Synthesis ofExample Compounds 195 [03621 The compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical 5 compounds described herein, e.g. compounds having structures described by one or more of Formula I, IA, I3, 11, IIA, 1IB, III, IIIA, IV, V, VI, VIII, VIIIA, IX, X, XII or XIII or other formulas or compounds disclosed herein, may be accomplished as described in the following examples. If available, reagents maybe purchased commercially, e.g. from Sigma Aldrich or other chemical suppliers. 10 General Syntheses [0363] Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to 15 result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using 20 published methods. For synthesizing compounds which are embodiments of the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. 25 Synthetic Reaction Parameters [0364] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process 30 conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skiLled in the art by routine optimization procedures. 196 [0365J Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well 5 known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein. [0366] Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure 10 stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can 15 be separated using, for example, chiral column chromatography, chiral resolving agents, and the like. [0367] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such 20 as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by. procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals 25 (Elsevier Science Publishers, 1989) organic Reactions, Volumes 140 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5* Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). [03681 The terms "solvent," "inert organic solvent" or "inert solvent" refer to a solvent 30 inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the 197 solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen. [03691 The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%). 5 Synthesis of the Compounds ofFormula I [0370] The compounds of Formula I (and Formula IA, IB, 11, IIA, IIB, I, IA, IV, V, VI, VIIVIIIA, IX, X, XII or XIII) are typically prepared by first providing the molecular core 1-1 and then attaching the desired -Q-R' substituents using suitable coupling conditions (e.g., Suzuki coupling) and the desired -R 2 substituents using suitable 10 substitution conditions. These processes are show below in Scheme I for the synthesis of a compound of Formula I, wherein -Q-R' is at either Za or Z 4 in each of Formulas 1-1, 1 2, 1-3 and I shown in Scheme 1, wherein the bromo and/or -Q-R' is at either Z 3 or Z 4 in each of the Formulas shown in Scheme 1. Scheme 1 Z '-NH Pd-cat, base, solvent ,Z 1 " -NH R 3 heat or microwave irradiation R3 X - R4R 4 RIQ'B(OH)2 or R Q -- X 11 4 O 1-3 4

LG-R

2

LG-R

2 Z1 ' -N ,"R2 Pd-cat, base. solvent 1 Y NoR2 Z R3 heat or microwave irradiation Z3' R3 B r -- - R , Q 15 R 4 R B(OH)2 or RR 4 1 R4 ORI [0371] In general, a halogenated compound of formula 1-1, in this case a brominated compound, is reacted with an appropriately substituted boronic acid derivative of formula

R'Q-B(OH)

2 or a boronic ester thereof, in an inert solvent, for example aqueous NN 20 dimethylformamide, in the presence of a mild base, for example potassium carbonate or sodium bicarbonate. The reaction is typically conducted in the presence of a metal 198 catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(I), at a temperature of about 120-170"C, for about 10 minutes to about 1 hour or at a lower temperature, i.e., 90-110"C for2 to 5 days. When the reaction is substantially complete, the product of Formula I is isolated by conventional means. 5 [0372] It will be appreciated that the R 2 subsitutent can be modified or added either before (as shown in Scheme 1) or after the addition of the R' moiety. The R 2 moiety may be coupled to the core 1-1 under substitution reaction conditions with an appropriate reagent of formula LG-R 2 (where LG is a leaving group such as a halo, hydroxyl, alkoxy or the like) as shown in Scheme 1. Typical substitution reaction conditions include the 10 presence of a base, such as ssium carbonate, sodium bicarbonate, triethylamine, and the like, in a polar aprotic solvent, such as NN-dimethylformamide, and optionally an elevated temperature of about 100-1 50*C or in a microwave. Also, in the case where the R2 substituent contains a heteroaryl ring, the heteroaryl ring may be synthesized and cyclized before or after addition of the -Q-R' portion. 15 Optional Core Synthesis [0373] In certain embodiments, the core may be synthesized before or after addition of the -Q-R' subsitutent (Scheme 2). For example, such alternative routes for the synthesis of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one compounds of Formula 2-8 (i.e., Formula IA, II, IA, IIB, IV, V, VI VIII, X, XII and XIII) are shown in Scheme 2, below, wherein 20 the bromo and/or -Q-R' is at either Z 3 or Z 4 in each of the Formulas shown in Scheme 2. 199 Scheme 2 PG HN -R 0O .R 0 R3 R 3 R ' OH 2-2 R4 RQB(oH)2 R HATU. DI PEA . PG XH Pd-cat, base, RI PG XH '2 F F heat or microwave F 2-1 2-3 Irradlation 2-4 NaH PG

R

1

Z

2 X~R 2-5 deprotect 0 0 0 NaNs Z- N NH R RQB(oH) NH R r ' r R3 Pd-cat, base, R

R

4 heat or microwave X R4 2-7 2-8 4 Irradiation 2-64 heat/mivrowave

LG-R

2 R 23 209 f [03741 In one embodiment, compounds of Formula 2-3 can be provided from 5 compounds of Formula 2-1 via aide formation with a suitably protected amino alcohol 2-2, where PG is a protecting group, such as benzyl. Compounds of Formula 2-3 are coupled with an appropriately substituted boronic acid derivative of formula R'Q-H(OH)2 or a boronic ester thereof, under typical coupling reaction conditions. Typical coupling reaction conditions an inert solvent, for example aqueous NN-dimethylformamide, in the 10 presence of a mild base, for example potassium carbonate or sodium bicarbonate. The reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II), at a temperature of 200 about 120-170*C, for about 10 minutes to about 1 hour or at a lower temperature, i.e., 90 110*C for 2 to 5 days. When the reaction is substantially complete, the compounds of Formula 2-4 can be isolated by conventional means. Compounds of Formula 2-4 are cyclized to afford compounds of Formula 2-5 using sodium hydride, in a suitable solvent, 5 such as dimethylformamide. Deprotection under suitable conditions provides compounds of Formula 2-6. [03751 In another embodiment, compounds of Formula 2-8 are prepared from commercially available compounds of Formula 2-7 using sodium azide. Compounds of Formula 2-6 can be obtained from compounds of Formula 2-8 via reaction with an 10 appropriately substituted boronic acid derivative of formula R 1

Q-B(OH)

2 or a boronic ester thereof, under typical coupling reaction conditions as described above. [03761 The R2 moiety may be coupled to compounds of Formula 2-6 under substitution reaction conditions with an appropriate reagent of formula LG-R 2 (where LG is a leaving group such as a halo, hydroxyl, alkoxy or the like) as shown in Scheme 1 to afford 3,4 15 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one compounds of Formula 2-9. Typical substitution reaction conditions include the presence of a base, such as ssium carbonate, sodium bicarbonate, triethylamine, and the like, in a polar aprotic solvent, such as NN dimethylformamide, and optionally an elevated temperature of about 100-150"C or in a microwave. 20 [03771 2,3,4,5-Tetrahydrobenzo[fj[1,4]oxazepine compounds of Formula 3-2 (i.e., Formula III and IIIA) are synthesized from compounds of Formula 2-6 as shown in Scheme 3, below, wherein -Q-R is at either C7 or C8 in each of the Formulas shown in Scheme 2. Scheme 3 0 R reduction R--R R hea m r w v R 25 2- 3-1 R4 3-2 R' [03781 In one embodiment, compounds of Formula 3-1 can be provided from the reduction of compounds of Formula 2-6 via amide formation with a suitably protected amino alcohol 2-2, where PG is a protecting group, such as benzyI. The R2 moiety may 201 be coupled to compounds of Formula 2-6 under substitution reaction conditions with an appropriate reagent of formula LG-R 2 (where LG is a leaving group such as a halo, hydroxyl, alkoxy or the like) as shown in Scheme 1 to afford compounds of Formula 3-2. [0379] Compounds of Formula 4-3 (i.e., Formula IX) are synthesized as shown in 5 Scheme 4, below, wherein -Q-R' is at either C7 or C8 in each of the Formulas shown in Scheme 2. Scheme 4

H

2 N i HOR 4 'a RR 0 OR 3

R

3 -C] 4-2 t Rio' H R4 Br OH Pd-cat, base, OH F F0 hetR v 4-1 4- radiation 4-4 NaH RR LG-R 2 R4LT R R4 R 10 [0380 In one embodiment, compounds of Formula 4-3 can be provided from compounds of Formula 4-1 via sulfonamide formation with an amino alcohol 4-2. Compounds of Formula 4-3 are coupled with an appropriately substituted boronic acid derivative of formula R 1 Q-B(OH)2 or a boronic ester thereof, under typical coupling reaction conditions as discussed in Scheme 2. Compounds of Formula 4-4 are cyclized to 15 afford compounds of Formula 5-5 using sodium hydride, in a suitable solvent, such as dimethylformamide. [03811 The R? moiety may be coupled to compounds of Formula 4-5 under substitution reaction conditions with an appropriate reagent of formula LG-R 2 (where LG is a leaving group such as a halo, hydroxyl, alkoxy or the like) as shown in Scheme 1 to afford 20 compounds of Formula 4-6. Typical substitution reaction conditions include the presence of a base, such as ssium carbonate, sodium bicarbonate, triethylamine, and the like, in a polar aprotic solvent, such as NN-dimethylformamide, and optionally an elevated temperature of about 100-150 "C or in a microwave. [0382] It will also be appreciated that the addition of any substituent may result in the 202 production of a number of isomeric products any or all of which may be isolated and purified using conventional techniques. Examples 5 [03831 The following examples are included to demonstrate preferred embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the 10 present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure. List of abbreviations and acronyms. Abbreviation Meaning *C Degree Celcius anal Analytical ATP Adenosine-5'-triphosphate ATX II Anemonia sulcata toxin ACN Acetonitrile CHO Chinese hamster ovary conc. Concentrated d Doublet DABCO 1,4-Diazabicyclo[2.2.2]octane dd Doublet of doublets DCM Dichloromethane DIPEA NN-diisopropylethylamine DMF Dimethylformamide DMSO Dimethylsulfoxide dppf 1,1'-Bis(diphenylphosphino)ferrocene EA Ethyl alcohol ECF Extracellular fluid EDTA Ethylenediaminetetraacetic acid EGTA Ethylene glycol tetraacetic acid equiv/eq Equivalents ESI Electrospray ionization Ac Acetate Et Ethyl g Grams HEPES (4-(2-Hydroxyethyl)-l-piperazineethanesulfonic acid) HATU 2-(7-Aza-1lH-Benzotriazole -1-yl)-1,1,3,3 tetramethyluronium hexafluorophosphate hERG human Ether-A-go-go Related Gene 203 HIPLC High-performance liquid chromatography h Hours Hz Hertz ICSO The half maximal inhibitory concentration IMR-32 Human neuroblastoma cell line I Coupling constant Kg Kilogram kHz Kilohertz LCMS/LC-MS Liquid chromatography-mass spectrometry M Molar m multiplet m/z mass-to-charge ratio M+ Mass peak M+H Mass peak plus hydrogen Me Methyl mg Milligram MHz Megahertz min/m Minute mIl/mL Milliliter mM Millimolar mmol Millimole nmol Nanomole mOsmol Milliosmole MRM Magnetic Resonance Microscopy MS Mass spectroscopy ins Millisecond mV Millivolt mw Microwave N Normal mol Mole NMR Nuclear magnetic resonance pA Picoamps Ph Phenyl prep Preparative q.s. Quantity sufficient to achieve a stated function Rf Retention factor RT/rt Room temperature s Second s Singlet SEM Standard error of the mean t Triplet TB Tonic Block TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran TLC Thin layer chromatography TTX Tetrodotoxin UIDB Use Dependent Block WT Wild type 6 Chemical shift 204 jig Microgram pU pd Microliter pM Micromolar pm Micrometer pmol Micromole EXAMPLES Example 1 7-(4-(triflnoromethoxy)phenyl)-3,4-dihydrobenzo[fJ [1,4]oxazepin-5(2H)-one 5 (Compound 11-74) F F0O F NH N F 3 CO B NaNs Br NH B(OH)2

CH

3 S0 3 H Pd(dppf)C 2 , NaHCOaHJ O*C ~ rt 1-A DMF, H 2 0, 8O0C 11-74 [03841 Commercially available 6-bromochroman-4-one (1.0g, 3 mmol) was dissolved in 10 10 mL methanesulfonic acid. The solution was cooled using an ice bath and sodium azide (0.30 g, 4.5 mmol) was added over a period of 45 min. The mixture was stirred at RT for 16 h. The mixture was neutralized using cone. HC. The resulting solid was filtered and washed with water to afford Comound -A as analytically pure sample. [0385] For the Suzuki coupling reaction the following conditions were applied: To a 15 suspension of Compound 1-A (1 eq), the substituted boronic acid or boronate ester (1.2 eq) and base sodium bicarbonate (3 eq) in solvent (DMF:water in the ratio of 4:1) was added palladium catalyst Pd(dppf)C 2 (10 mol%) and heated at 80 *C for 2-4h. The reaction progress was followed by LC and after completion, the reaction mixture was filtered through celite, washed with ethyl acetate. The filtrate was concentrated the filtrate 20 and purified by prep TLC/ prep HPLC or column chromatography to afford Compound U-74. 205 Example 2 4-(pyrimidin-2-ylmethyl)-7-((4-(trifluoromethyl)pheny)ethynyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound VIH-6) F F

-

3 . F N 1-ADMF 0, 8 0

N

F

3 FN NN 0 I j ~Pd(dppf)Cla, NaHCO3 z 1- DMF, H20, 80 C14 J 2-A w-A N/N NN NaH, DMFA rt 0 5 vill-s [0386] Compound 2-A was prepared from Compound 1-A according to Example 1 using 1-ethynyl-4-(trifluoromethyl)benzene in place of the boronic acid. [03871 To a solution of 2-A (1 eq) in DMF was added the corresponding halide (1.3 eq). To the mixture was added sodium hydride (60% dispersion in oil, 2 mmol) and stirred at 10 room temperature for 10 min, followed by heating at 80 "C for 24h. The reaction mixture was quenched with water, extracted with ethyl acetate (100 mL). The organic layer was washed with water, brine and dried over sodium sulphate and concentrated And purified using prep TLC/ prep HPLC or column chromatography to afford Compound VMI-6. [0388] 'H-NMR (CDC1 3 ) 6 8.71 (d, 2H, J=4.4 Hz), 8.20 (d, 1H, J=2.4 Hz), 7.55-7.59 15 (i, 5H), 7.20 (t, 1H,J= 4.8 Hz), 7.01 (d, 1H, J=8.4 Hz), 5.08 (s, 2H), 4.58 (t, 2H, J= 4.6 Hz), 3.76 (t, 2H, J =5.0 Hz); MS m/z 424.1 (M+H). 206 Example 3 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo [f] [1,4]oxazepin-5(2H)-one (Compound 11-72) F3CO 0 a 5 [0389] Compound H-72 was prepared according to Example I using the appropriate starting materials. 'H-NMR (CDC1s) 88.81 (d, 111, J= 5.6 Hz), 8.27 (t, IH, J= 7.8 Hz), 8.07 (d, 1H, J= 8.4 Hz), 8.02 (d, 1H, J= 2.4 Hz), 7.75 (t, 1H,J= 6.4 Hz), 7.65 (dd, III, J =8.6, 2.6 Hz), 7.58 (dd, 2H, J= 4.8, 2.8 Hz ), 7.28 (d, 2, J= 8.4 Hz), 7.12 (d, 1H, J= 8.4 Hz), 5.24 (s, 2H), 4.39 (t, 2H, J= 5.0 Hz), 3.85 (t, 2H, J= 5.0 Hz); MS /nlz 415.1 10 (M+H). Example 4 4-(pyridin-3-ylmethyl)-7-(4-(trifluoromethoxy)pheny])-3,4 dihydrobenzo f1 [1,4]oxazepin-5(2H)-one (Compound 11-70)

F

3 CO 0 N N NN/ 15 [0390] Compound 11-70 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CDC 3 ) 8 9.00 (s, 1H), 8.75 (d, IH, J= 5.2 Hz), 8.47 (d, 1H, J= 7.6 Hz), 8.05 (d, 13, J= 2.4 Hz), 7.83 (dd, IH, J= 7.8, 5.4 Hz), 7.66 (dd, 1H, J= 8.8, 2.4 Hz), 7.60 (d, 211, J= 8.4 Hz), 7.28 (d, 2H, J= 8.4 Hz), 7.13 (d, 1H, J= 8.0 Hz), 4.99 (s, 2H), 4.37 (t, 2H, J= 5.0 Hz), 3.67 (t, 2H, J= 5.0 Hz); MS ink 415.1 (M+H). 20 Example 5 4-(2-(pyrimidin-2-yloxy)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzof] [1,4]oxazepin-S(2H)-one (Compound 11-69)

N

F

3 CO O \ NN 207 [0391] Compound 11-69 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CDCl 3 ) 8 8.53 (d, 2H, J=4.8 Hz), 8.03 (dI, 1H, J=24 Hz), 7.58-7.61 (m, 3H), 7.27 (d, 2H, J= 5.2 Hz), 7.07 (d, 1H, J= 8.0 Hz), 6.97 (t, 1H1, J=4.8 Hz), 4.66 (t, 2H, J= 4.8 Hz), 4.51 (t, 211, J= 5.2 Hz), 4.07 (t, 2H, J= 5.0 Hz), 3.78 (t 2H, 5 J= 5.0 Hz); MS m/z 468.0 (M+Na). Example 6 4-(4-fluorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzof] [1,4]oxazepin 5(211)-one (Compound 11-62) FaOCO F 10 [03921 Compound 11-62 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CDC 3 ) 8 8.10 (d, 1H, J= 2.8 Hz), 7.60-7.63 (m, 311), 7.35 (dd, 2H, J= 8.4, 1.2 Hz), 7.28 (d, 2H, J=8.0 Hz), 7.03-7.09 (m, 3H), 4.82 (s, 2H), 4.22 (t, 2H, J= 5.2 Hz), 3.51 (t, 2H, J =5.2 Hz); MS mz 432.1 (M+H). Example 7 15 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzoff] [1,4joxazepin-5(2H)-one (Compound H-61)

F

3 0. a NNtI [0393] Compound 11-61 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CDCl 3 ) 8 8.80 (d, 2H, J = 5.2 Hz), 8.19 (d, 1HI, J= 2.8 Hz), 20 7.66-7.71 (m, 5H), 7.33 (t, IH, J= 5.0 Hz), 7.13 (d, IH, J= 8A Hz), 5.14 (s,2H), 4.59 (t, 2H, J=4.8 Hz), 3.81 (t, 2H, J= 5.0 Hz); MS m/z 400.1 (M+H). 208 Example 8 4-(2-fluorobenzyl)--7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one (Compound H-57) F

F

3 CO 0 NN 5 [0394] Compound 11-57 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CDCI) 8 8.07 (d, 1H, J= 2.4 Hz), 7.58-7.61 (m, 3H), 7.49 7.51 (m, 1H), 7.26-7.31 (m, 3H), 7.16 (t, 1H, J= 7.6 Hz), 7.07-7.18 (ma, 2H), 4.92 (s, 211), 4.29 (t, 2H, J= 4.8 Hz), 3.61 (t, 2H, J= 5.0 Hz); MS m/z 432.1 (M+H). Example 9 10 4-(2-(pyridin-2-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound U-54) FsCO 0 Z N [0395] Compound 11-54 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CDC1 3 ) 8 8.57 (d, 1H, J= 4.8 Hz), 8.03 (d, III, J= 2.4 Hz), 15 7.67-7.69 (m, 1H), 7.57-7.61 (m, 3H), 7.20-7.33 (m, 4H), 7.04 (d, 1H, J =8.8 Hz), 4.19 (t, 2H, J= 4.8 Hz), 4.06 (t, 2H, J= 7.4 Hz), 3.51 (t, 2H, J= 5.0 Hz), 3.24 (t, 2H, J= 6.8 Hz); MS n/z 429.1 (M+H). Example 10 4-(2-(1H-pyrazol-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 20 dihydrobenzo[f] [1,4Joxazepin-5(2H)-one (Compound U-50)

F

3 CO 1 O N-N 209 [0396] Compound 11-50 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CDCl 3 ) 6 8.02 (d, 1H, J= 2.4 Hz), 7.58-7.64 (m, 4H), 7.47 (d, 1H, J= 1.6 Hz), 7.28 (d, 2H, J=8.8 Hz), 7.04 (d, 1H, J= 8.4 Hz), 6.30 (t, 1H, J=2.2 Hz), 4.55 (t, 2H, J= 5.8 Hz), 4.11 (t, 2H, J- 5.A Hz), 3.96 (t, 2H, J =5.0 Hz), 3.28 (t, 2H, 5 J=5.O Hz); MS m/z 418.1 (M+H). Example 11 4-(2,6-difluorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 1-49) F

F

3 CO ~ F FsCO 10 [0397] Compound H-49 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CDC1a) & 8.08 (d, 1H,J= 2.4 Hz), 7.57-7.61 (M,, 3H1), 7.26 7.33 (ni, 3H), 7.05 (d, 1H, J= 8.4 Hz), 6.95 (t, 21, J= 8.0 Hz), 4.98 (s, 211), 4.23 (t, 2H, J =4.8 Hz), 3.59 (t, 2H, J= 4.8 Hz); MS m/z 450.1 (M+H). Example 12 15 4-(2,6-dichlorobenzyl)-7-(4-(trifIuoromethoxy)phenyl)-3,4 dihydrobenzo [f] 1,4] oxazepin-5(2H)-one (Compound H-48) CI

F

8 CO 0 N N N [03981 Compound 11-48 was prepared according to Example I using the appropriate starting materials. 1 H-NMR (CDCla) 8 8.06 (d, 1H, J= 2.4 Hz), 7.59-7.62 (m, 311), 7.40 20 (d, 2H, J= 8.0 Hz), 7.25-7.29 (m, 3H), 7.06 (d, IH, J= 8.4 Hz), 5.24 (s, 2H), 4.07 (t, 2H, J= 5.0 Hz), 3.42 (t, 2H, J= 5.2 Hz); MS m/z 483.0 (M+H). 210 Example 13 4-(2-chlorobenzyI)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[ff[1,4]oxazepin-5(2fl)-one (Compound 11-47) FCO o 5 [0399] Compound 11-47 was prepared according to Example ] using the appropriate starting materials. 'H-NMR (CDCI 3 ) 8 8.10 (d, 1H, J= 2.4 Hz), 7.60-7.64 (m, 3H), 747 (dd, 1H, J= 7.0, 2.2 Hz), 741 (dd, 1H, J=7.4, 1.8 Hz), 7.26-7.30 (m, 4H), 7.09 (d, 1H, J = 8.4 Hz), 5.01 (s, 2H), 4.28 (t, 2H, J= 5.0 Hz), 3.58 (t, 2H, J= 5.2 Hz); MS n/z 448.1 (M+H). 10 Example 14 7-(phenylethynyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin-5(ZH) one (Compound VXI--5) N [0400] Compound VIII-5 was prepared according to Example 2 using the appropriate 15 starting materials. 'H-NMR (CD 3 0D) 8 8.76 (d, 2H, J= 4.8 Hz), 7.92 (d, 1H, J= 2.4 Hz), 7.60 (dd, 1H, J= 8.6, 1.8 Hz), 7.48-7.51 (m, 2H), 7.35-7.39 (m, 4H), 7.07 (d, 1H, J= 8.8 Hz), 5.05 (s, 2H), 4.59 (t, 2H, J= 4.8 Hz), 3.83 (t, 2H, J= 4.8 Hz); MS ink 356.1 (M+H). Example 15 4-(pyrinidin-2-ylmethyl)-7-((4-(trifluoromethoxy)phenyl)ethynyl)-3,4 20 dihydrobenzo [f] (1,41 oxazepin-5(2H1)-one (Compound VIU-4)

F

3 CO NN 0 211 [04011 Compound VIM4 was prepared according to Example 2 using the appropriate starting materials. 1 H-NMR (CD 3 0D) 38.76 (d, 2H, J= 7.2 Hz), 7.95 (d, 1H, J= 2A Hz), 7.59-7.63 (n, 3H), 7.38 (t, 1H, J= 5.0 Hz), 7.29 (d, 2H, J= 8.4 Hz), 7.08 (d, 1H, J= 8.8 Hz), 5.05 (s, 2H), 4.60 (t, 211, J= 5.0 Hz), 3.83 (t, 2H, J= 4.8 Hz); MS m/z 440.1 (M+H). 5 Example 16 4-(2-(pyrimidin-2-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-44) F3CO I N [0402] Compound H-44 was prepared according to Example 1 using the appropriate 10 starting materials. 'H-NMR (CDCl 3 ) 8 8.70 (d, 2H, J=5.2 Hz), 8.00 (d, 1H, J=2.4 Hz), 7.56-7.59 (m, 3H), 7.26(d, 211, J= 8.4 Hz), 7.20 (t, 1H, J= 5.2 Hz), 7.04 (d, 1H, J= 8.8 Hz), 4.36 (t, 2H, J= 5.0 Hz), 4.16 (t, 2H, J= 7.0 Hz), 3.59 (t, 2H, J= 5.0 Hz), 3.38 (t, 2H, J =6.0 Hz); MS nz 430.1 (M+H). Example 17 15 4-((4,6-dimethoxypyrimidin-2-y)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[fj [1,4]oxazepin-5(2H)-one (Compound 1-42)

F

3 CO N OMe N OMe [04031 Compound 11-42 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CD 3 OD) 8 8.00 (d, 1H, J= 2.4 Hz), 7.76 (dd, 1HI, J= 8.2, 20 2.6 Hz), 7.69 (dd, 2H, J= 6.8, 2.0 Hz), 7.34 (d, 2H, J= 8.0 Hz), 7.16 (d, 1H, J= 8.8 Hz), 6.11 (s, 1H), 4.87 (s, 2H), 4.58 (t, 211, J= 5.0 Hz), 3.93 (s, 6H), 3.84 (t, 2H, J= 5.2 Hz); MS n/z 476.1 (M+H). 212 Example 18 4-((5-methyloxazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound H-33)

F

3 CO0 5 [0404) Compound 11-33 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.00 (d, IH, J= 2.4 Hz), 7.77 (dd, 1H, J= 8.4, 2.4 Hz), 731(d, 2H, J= 8.8 Hz), 7.34 (d, 2H, J = 8.0 Hz), 7.15 (d, 1H, J= 8.4 Hz), 6.81 (d, 1H, J= 0.8 Hz), 4.93 (s, 2H), 4.43 (t, 2H, J= 5.2 Hz), 3.76 (t, 2H, J= 5.2 Hz), 2.34 (d, 3H, J =0.8 Hz); MS m/z 419.1 (M+H). 10 Example 19 4-(pyrazin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4joxazepin-5(2H)-one (Compound U-31) FCO N [0405] Compound 1-31 was prepared according to Example 1 using the appropriate 15 starting materials. 'H-NMR (CD 3 0D) 8 8.71 (d, 1H, J= 0.8 Hz), 8.60 (t, 1H, J= 2.0 Hz), 8.53 (d, 1H, J= 2.4 Hz), 7.99 (d, 1H, J= 2.4 Hz), 7.77 (dd, 1H, J= 8.4, 2.4 Hz), 7.72 (dd, 2H,J=6.6,2.2Hz), 7.34 (d, 2H, J=8.0 Hz), 7.15 (d, 1HJ= 8.4 Hz), 5.01 (s, 2H), 4.47 (t, 2H, J= 5.2 Hz), 3.82 (t, 2H, J= 5.0 Hz); MS ink 416.1 (M+H). Example 20 20 4-((6-methylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4joxazepin-5(2H)-one (Compound f-17)

F

3 CO 0 [0406] Compound 11-17 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CD 3 0D) 88.28 (t, 1H, J= 7.8 Hz), 8.00 (t, 1H, J= 2.4 Hz), 213 7.81 (dd, 1H, J= 8.2,2.6 Hz), 7.68-7.73 (m, 4H), 7.35 (dd, 2H, J=8.6, 1.0 Hz), 7.20 (d, 1H,J= 8.8 Hz), 5.09 (s, 211), 4.50 (t, 2H,J= 5.0 Hz), 3.86 (t, 2H,J=5.0 Hz), 2.77 (s, 3H); MS mz 429.1 (M+H). Example 21 5 7-(4-(trifluoromethoxy)phenyl)-4-((6-(trifloromethyl)pyridin-2-yl)methyl)-3,4 dlhydrobenzo[ft][1,4]oxazepin-5(2H)-one (Compound 11-15) FsCO o N CF 3 [0407] Compound 1-15 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 7.98-8.04 (m, 2H), 7.68-7.77 (m, 5H), 733 (d, 10 2H, J= 8.0 Hz), 7.14 (d, 1H, J= 8.4 Hz), 5.01 (s, 2H), 4.48 (t, 2HJ= 5.2 Hz), 3.80 (t, 2H, J =5.2 Hz); MS m/z 483.] (M+H). Example 22 6-((5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[1][1,4]oxazepin-4(5H) yl)methyl)picolinonitrile (Compound 11-14) F3O N CN 15 [0010 [0408] Compound 11-14 was prepared according to Example 1 using the appropriate starting materials. 1 H-NMR (CD 3 0D)8 7.96-8.00 (in, 2H), 7.69-7.79 (m, 5H), 733 (d, 2H, J= 8.0 Hz), 7.15 (d, 1H,J= 8.4 Hz), 4.98 (s, 2H), 4.46 (t, 2H, J=5.2 Hz), 3.79 (t, 2H, J=~5.0 Hz); MS m/z 440.1 (M+H). 20 Example 23 4-(cyclopropylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fl [1,4]oxazepin-5(2H)-one (Compound H-10) F3CO2 214 [0409] Compound 11-10 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CDaOD) 87.92 (d, lH, J=2.8 Hz), 7.69-7.75 (m, 3H), 7.34 (d, 2H, J=8.0 Hz), 7.13 (d, 1H, J= 8.4 Hz), 4.48 (t, 2H, J= 5.2 Hz), 3.70 (t, 2H, J= 5.2 Hz), 3.53 (d, 2H, J=6.8 Hz), 1.13-1.18 (m, 1H), 0.57-0.61 (M, 2H), 0.35-0.40 (m, 21); 5 MS mz 378.1 (M+H). Example 24 4-(quinolin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzof] [1,4] oxazepin-5(2H)-one (Compound 11-7)

F

3 CO O N NI 10 [0410] Compound 11-7 was prepared according to Example 1 using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.35 (d, 1H, J= 8.8 Hz), 8.02-8.05 (i, 211), 7.93 (d, 1H, J=7.6 Hz), 7.72-7.79 (m, 4H), 7.60 (d, 2H, J= 8.4 Hz), 7.35 (d, 2H, J= 8.0.Hz), 7.16 (d, IH, J= 8.8 Hz), 5.15 (s, 2H), 4.43 (t, 2H, J= 5.2 Hz), 3.79 (t, 2H, J= 5.0 Hz);. MS n/z 465.1 (M+H). 15 Example 25 7-(3-fluoro-4-(trifluoromethylophenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-130) F F F O N N % F N [0411] 7-Bromo-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (1.0g, 4.13mmol) was 20 dissolved in DMF (10 ml) cooled down in a ice/water bath and treated with sodium hydride (60% dispersion) (363mg, 9.08mmol) portion wise. After 10 min a solution of 2 (chloromethyl)pyrimidine hydrochloride (813mg, 4.96mmol) in DMF (4ml) was added, the reaction mixture warmed up to room temperature and quenched with 12 mL of water after it was complete. The reaction mixture was extracted with EtOAc and water and the 25 organic phase was dried, evaporated and purified by silica gel chromatography (95% 215 DCM/MeOH) to afford 7-bromo-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one. (04121 Similar procedure to Example 1 for the synthesis of 7-(4,4,5,5-tetramethyl-1,3,2 dioxaborolan-2-yl)-3,4-dihydrobenzo[fj [1,4]oxazepin-5(2H)-one was followed to obtain 5 the title compound using instead of 7-bromo-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H) one. [0413] A mixture of 7-bromo-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (50mg, 0.15mmol), 2-(3-fluoro-4 (trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (52mg, 0.18mmol), 10 cesium carbonate (146mg, 0.45mmol), 1,1' bis(diphenylphosphino)ferrocene]dichloropalladium (10mg, 0.015 mmol) was dissolved in a degassed mixture of DMF and water 3/1.5 (4.5 mL). The mixture was heated in microwave at 85 0 C for 40 min. The mixture was poured into EtOAc and washed with water and brine. The organic layer was collected, dried over sodium sulfate and loaded 15 onto silica gel. A flash column (5% MeOH in EtOAc) and reverse phase chromatography gave 7-(3-fluoro-4-(trifluoromethyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one. [04141 MS found for C 21

H

15

FAN

3 0 2 as (M+H)* 418.13. 'IH NMR (400 MHz, DMSO ds): 5: 8.78 (d, J=4.0Hz, 2H), 8.09 (d, .- 12.0Hz, 1H), 7.91 (dd, J=2.4, 8.0Hz, 1$), 7.85 20 7.80 (m, 2H), 7.70 (d, J1=8.4Hz, 1H), 7.41 (t, .=4.8Hz, iH), 7.17 (d, .J=8.4Hz, 1H), 4.98 (s, 2H), 4.55 (t, J=4.8Hz, 2H), 3.79 (t, J=4.8Hz, 2H). Example 26 7-(4-(difluoromethyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dthydrobenzo[f] [1,41 oxazepin-5(2H)-one (Compound 11-124) F F O N N D 25 [0415] Compound 11-124 was prepared according to Example 25 using 4 (difluoromethyl)phenylboronic acid. MS found for C21H17F2N302 as (M+H)* 382.15. 'H NMR (400 MHz, DMSO -4): 8: 8.77 (d, r=4.8Hz, 2M), 8.00 (d, J-2.4Hz0, IN), 7.84-7.77 216 (M, 4H), 7.63 (d, J=7.6Hz, 2H), 7.40 (t, J=5.2Hz, 1H), 7.15 (d, J=8.8Hz, 111), 7.06 (t, J=56.4Hz, 1H), 4.98 (s, 2H), 4.52 (t, J=4.4Hz, 21), 3.77 (t, J=5.2Hz, 2H). Example 27 7-(4-cyclopentylphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4] oxazepin 5 5(2H)-one (Compound 11-120) O ND NN [0416] Compound 11-120 was prepared according to Example 25 using 4 cyclopentylphenylboronic acid. MS found for C25H25N302 as (M+H)* 4002. 'H NMR (400 MHz, DMSO -d 6 ): 8: 8.77 (d, J=4.8Hz, 2H), 7.90 (d, J=2.4Hz, 1H), 7.74 (dd, J=2.4, 10 8.8 Hz, 1H), 7.52 (d, t8.4Hz, 2H), 7.40 (t, J=4.8Hz, 111), 7.30 (d, .J=8.0Hz, 2H), 7.10 (d, J=8.8Hz, 1H), 4.97 (s, 2H), 4.48 (t, J=4.4Hz, 2H), 3.74 (t, .1=5.2Hz, 2ff), 3.00-2.96 (n, 1H), 2.01-1.97 (m, 2H), 1.78-1.51 (m, 6H). Example 28 7-(4-chloro-3-fluorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4 15 dihydrobenzo [fj [1,4] oxazepin-5(2H)-one (Compound H-131) CN Nk [0417] Compound H-131 was prepared according to Example 25 using 4-chloro-3 fluorophenylboronic acid. MS found for C20HI5CLFN302 as (M+H 384.09. 'H NMR (400 MHz, DMSO-d): 8: 8.78 (d, .J=5.2Hz, 2H), 7.99 (d, J=2.4Hz0, 1H), 7.83 (dd, J=2.0 20 8.0 Hz, 1H), 7.72 (d, J=8.8Hz, 1H), 7.62 (t, .J=8.0Hz, 1H), 7.51 (dd, J=1.2-8.4 Hz, 1H), 7.42 (t, .J=4.8Hz, 1), 7.13 (d, J='8.0Hz, iH), 4.98 (s, 2H), 4.52 (t, J=4.8Hz, 2H), 3.77 (t, .T=4.8Hz, 2H). 217 Example 29 7-(2-tert-butoxypyridin-4-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,41 oxazepin-5(2H)-one (Compound VI-2) N O N ND >Ko 5 [04181 To a mixture of 4-bromo-2-tert-butoxypyridine (1.0 g, 4.34 mmol), bis(pinacolato)diboron (1.32 g, 5.22 mmol), potassium acetate (1.28 g, 13.0 mmol), [1,1' bis(diphenylphosphino)ferrocene]dichloropalladium methylene choloride complex (310 mg, 0.43 mmol) was suspended with degassed dioxane (15 mL) and heated at 85 *C for 60 min. The reaction mixture was diluted with EtOAc, washed with water and brine, dried 10 (MgS(0)4), filtered and concentrated. The concentrate was purified by flash chromatography on silica gel eluding with 33% percent ethyl acetate/iexanes to afford the compound 2-tert-butoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine.. [0419] Similar procedure as in Example 25 was followed to obtain the title compound using 2-tert-butoxy-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)pyridine that was 15 previously prepared. [0420] MS found for C23H24N403 as (M+H)* 405.13. 1 HNMR (400MHz, DMSO d 6 ): 8: 8.77 (d, J=4.8Hz, 21), 8.14 (d,.1=5.6Hz, 1H), 8.03 (d, J=2.4Hz, 11), 7.88 (dd, J=24-8.4 Hz, 1H), 7.40 (t, J=4.8Hz, 1H), 7.18 (d, J=5.6Hz, 1H), 7.12 (d, .J=8.4Hz, 1HI), 6.89 (s, 1fH), 4.97 (s, 2H), 4.53 (t, J=4.8Hz, 2H), 3.77 (t, J=4.4Hz, 2H), 1.54 (s, 9H). 20 Example 30 7-(5-methylthiophen-2-yl).4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f[[1,4loxazepin-5(2H1)-one (Compound VI-20) S O N N N [0421] A mixture of 4-(pyrimidia-2-ylnethyl)-7-(4,4,5,5-tetramethyl-1,3,2 25 dioxaborolan-2-yl)-3,4-dihydrobenzo[f][ 1,4]oxazepin-5(2H)-one (50mg, 0. 13mmol), 2 218 bromo-5-methylthiophene (28mg, 0.156mmol), cesium carbonate (128mg, 0.39mmol), 1,l'-Bis(diphenylphosphino)ferrocene]dichloropalladium (9mg, 0.013 mmol) was dissolved in a degassed mixture of DMF and water 311.5 (4.5ml). The mixture was heated in microwave at 850C for 40min. The mixture was poured into EtOAc and washed with 5 water and brine. The organic layer was collected, dried over sodium sulfate and loaded onto silica gel. A flash column (5% MeOH in EtOAc) and reverse phase chromatography gave 7-(5-methylthiophen-2-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one. [0422] MS found for C19H17N302S as (M+H)+ 352.09. 'H NMR (400 MHz, DMSO 10 d): 1 H-NMR (DMSO) 8: 8.70 (d, .=4.0Hz, 2H), 7.80 (d,J=2.OHz, 1H), 7.68 (dd, J=2.0 8A Hz, 1H), 7.40 (t, J-4.8Hz, 1H), 7.23 (d, J=3.2Hz, 1H), 7.05 (d, J=8.4Hz, IH), 6.77 (d, J=2.8Hz, 111), 4.95 (s, 2H), 4.46 (t, J=4.8Hz, 2H), 3.73 (tfJ=4.8Hz, 2H), 2.48 (s, 31). Example 31 1-(4-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[fJ[1,4]oxazepin-7 15 yl)phenyl)cyclopentanecarbonitrile (Compound H.-122) N % [0423] To a solution of 2-(4-bromophenyl)acetonitrile (1.0 g, 5.10 mmol) and 1,4 dibromobutane (0.67 ml, 5.6 mmol) in THF (10 ml) was added potassium bis (trimethylsilyl) amide(2.23 g, 11.2 mmol) and tetra-n-butylammonium bromide (164mg, 20 0.51 mmol). The mixture was stirred for 2 h and then quenched with IN HCL. Ethyl acetate was added, the layers separated and the organic layer was washed with water and brine. Drying, solvent evaporation and flash chromatography (silica gel, 20% EtOAc/hexanes) gave 1-(4-bromophenyl)cyclopentanecarbonitrile. [04241 Similar procedure as in Example 30 was followed to obtain the title compound 25 using 1-(4-bromophenyl)cyclopentanecarbonitrile. [04251 MS found for C26H24N402 as (M+H)* 425.21. 'H NMR (400MHz, DMS0 d6): 'H-NMR (DMSO) 8: 8.72 (d, J=4.0Hz, 211), 7.90 (d, J=2.4z, 1H), 7.74 (dd, J=2.4 8.8 Hz, 1H), 7.63 (d, J=r8.4Hz, 2ff), 7.50 (d, J=84AHz, 2ff), 7.35 (t, .=4.8Hz, 1H), 7.08 (d, 219 J=8.8Hz, 1H), 4.92 (s, 211), 4.45 (t, J=4AHz, 2H), 3.71 (t, J=4.8Hz, 2H), 2.37-2.34 (m, 2H), 2.05-2.02 (m, 211), 1.85-1.83 (m, 4H). Example 32 7-(4-ethoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4loxazepin 5 5(2H)-one (Compound H-123) [04261 Compound 1-123 was prepared according to Example 30 using 1-bromo-4 ethoxybenzene. MS found for C22H21N303 as (M+H)* 376.15. 'H NMR (400MHz, DMSO-d): 8: 8.77 (d, J=5.2Hz, 2H), 7.86 (d, J=2.4HzO, 1H), 7.71 (dd, J=2.8-8.4 Hz, 10 1H), 7.54 (d, J=8.8Hz, 2H), 7.40 (t, J=4.8Hz, 1H), 7.08 (d, J=8.0Hz, 111), 6.97 (d, J=8.4Hz, 211), 4.96 (s, 2H), 4.47 (t, J=4.8Hz, 2H), 4.06-4.01 (m, 2H), 3.74 (t, Ji=4.4Hz, 2H), 1.34-1.30 (m, 3H). Example 33 7-(4-(difluoromethoxy)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4-. 15 dihydrobenzo[f][1,]oxazepin-5(2H)-one (Compound 1-119) F O EQ N 0/t [0427] Compound 11-119 was prepared according to Example 30 using 1-bromo-4 (difluoromethoxy)benzene. MS found for C21H17F2N303 as (M+H)* 398.13. 'H NMR (400MHz, DMSO-d 6 ): 1 H-NMR (DMSO) 8: 8.77 (d, J=4.8Hz, 2H), 7.92 (d, J=2.OHzO, 20 1H), 7.77 (dd, J=2.4-8.4 Hz, 1H), 7.68 (d, J=8.4Hz, 2W), 7.40 (t, .J=4.8Hz, 11), 7.26 (t, .J=74.0Hz, 2H), 7.23 (d, J=8.8Hz, 1H), 7.12 (d, J=8.4Hz, 1H), 4.97 (s, 211), 4.50 (t, .=4.8Hz, 2H), 3.75 (t, J=4.8Hz, 2H). 220 Example 34 4-(4-fluorobenzyl)-7-(1-methyl-2-oxo-1,2-dihydropyridin-4-y)-3,4 dihydrobenzolfJll,41oxazepin-5(2H)-one (Compound VI-22) a N O 5 [0428] Compound VI-22 was prepared according to Example 30 using 1 (chloromethyl)-4-fluorobenzene and 4-bromo-1-methylpyridin-2(1H)-one. MS found for C22H19FN203 as (M+H)* 379.27 'H NMR (400MHz, DMSO-d): 8: 8.01 (d, J=2.4Hz, 1H), 7.83 (dd, J==2.0-8.4 Hz, 1H), 7.75 (d, J=6.8Hz, 1H), 7.42-7.38 (m, 2H), 7.17 (t, J-9.2Hz, 211), 7.10 (d, J=8.0Hz, 111), 6.63 (s, 1H), 6.56 (dd, J=2.0-7.2 Hz, 1H), 4.74 (s, 10 2H), 4.27 (t, .=4.8Hz, 2H), 3.56 (t, J=4.8Hz, 2H), 3.42 (s, 3H). Example 35 7-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4] oxazepin-5(2H)-one (Compound VI-23) 15 [0429] Compound VI-23 was prepared according to Example 30 using 5-bromo-1 isopropyl-2-methyl-1H-imidazole. MS found for C21H23N502 as (M+H)+ 378.14 'H NMR (400MHz, DMSO-d 6 ): 6: 8.77 (d, J1=4.8Hz, 2H), 8.15 (s, 1H), 7.63 (d, .J=2.0Hz, 1H), 7.40 (t, J=4.8Hz, 2H), 7.10 (d, J=8.0Hz, 1H), 6.68 (s, 111), 4.95 (s, 2), 4.52 (t, /=4.8Hz, 1H), 4.32-4.29 (s, 1H), 3.77 (t, J=4.8Hz, 2H1), 2.41 (s, 3H), 1.34 (d, J=6.8Hz, 20 6H). 221 Example 36 7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-4-(pyrimidin-2-ylmethy)-3,4 dihydrobenzolfj [1,4] oxazepin-5(2H)-one (Compound VI-13) 0 N O N N N NN 5 [0430] A mixture of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (200 mg, 0.69 mmol), 4-bromo-1 methylpyridin-2(1H)-one (156mg, 0.83mmol), cesium carbonate (674mg, 2.07 mmol), 1,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium (49 mg, 0.069 mmol) was dissolved in a degassed mixture of DMF and water 3/1.5 (4.5mL). The mixture was 10 heated in microwave at 850C for 40min. The mixture was poured into EtOAc and washed with water and brine. The organic layer was collected, dried over sodium sulfate and loaded onto silica gel. A flash column (5% MeOH in EtOAc) and reverse phase chromatography gave 7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one. 15 [04311 7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-3,4-dihydrobenzo[fj[1,4]oxazepin 5(211)-one (50mg, 0.185mmol) was dissolved in DMF (3 mL) and cooled down iii a ice/water bath and treated with sodium hydride (60% dispersion) (17mg, 0Ammol) portion wise. After 10 min a solution of 2-{chloromethyl)pyrimidine hydrochloride (37mg, 0.22mmol) in DMF (2mL) was added and the reaction mixture was warmed up to 20 room temperature and quenched with 6mL of water after it was complete. The reaction mixture was extracted with EtOAc and water and the organic phase was dried, evaporated and purified by silica gel chromatography (95% DCM/MeOH) and then purified by reverse phase chromatography to afford 7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-4 (pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[t[1,4]oxazepin-5(2H)-one. 25 [0432] MS found for C20H18N403 as (M+H)* 363.19. 'H NMR (400MHz, DMSO-d 6 ) 8: 8.77 (d, J=5.2Hz, 2H), 7.99 (d, J=f2.8HzO, 1H), 7.83 (dd, J=2A-8.4 Hz, 1H), 7.73 (d, .7.2Hz, 1H), 7.40 (t, J-5.2Hz, 1H), 7.12 (d, J=8.8Hz, 1H), 6.60 (d, J=1.6Hz, 1H), 6.53 (dd, J=2.0-7.2 Hz, 1H), 4.97 (s, 2H), 4.54 (t, J=4.8Hz, 2H), 3.77 (t, .=4.4Hz, 2H), 3.42 (s, 3H). 222 Example 37 7-(1-methyl-2-oxo-1,2-dihydropyridin4-y)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-12) 0 N 0 N 5 [0433] Compound VI-12 was prepared according to Example 36 using 2 (chloromethylpyridine hydrochloride. MS found for C21H19N303 as (M+H)* 362.18. 1 H NMR (400MHz, DMSO-d): 8: 8.73 (s, 111), 8.25 (s, 111), 7.99 (s, 1H), 7.84-7.75 (m, 4H), 7.12 (d, J=8.OHz, 1H), 6.60-6.53 (m, 2H), 5.02 (s, 2H), 4.44 (s, 2H), 3.79 (s, 2H), 3.41(s, 3H). 10 Example 38 7-(2-tert-butoxypyridin-4-y)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4] oxazepin-5(2H)-one (Compound VI-4) >k% IV N - ~ v O [0434] Compound VI-4 was prepared according to Example 36 using 7-bromo-3,4 15 dihydrobenzo[f][ 1,4]oxazepin-5(21)-one, 2-tert-butoxy-4-(4,4,5,5-tetramethyl- 1,3,2 dioxaborolan-2-yl)pyridine and 2-(chloromethyl)pyridine hydrochloride. [0435] MS found for C24H25N303 as (M+H)* 404.18. 'H NMR (400MHz, DMSO d 6 ): 8: 8.52 (d, J=4.8Hz, 1H), 8.15 (d, .J=5.2Hz, 110, 8.03 (d, J=2.4Hz, 1H), 7.87 (dd, J=2.0-8.0 Hz, 1H), 7.79-7.75 (m, 1H), 7.35 (d,J=8.OHz, 1H), 7.29 (dd, J=4.8-6.8 Hz, 1H), 20 721 (d, J=5.6Hz, 1H), 7.12 (d, .8.4Hz, 1H), 6.91 (s, 1H), 4.85 (s, 2H), 4.39(t, J=4.4Hz, 2H), 3.69 (t, J-4.8Hz, 211), 1.54 (s, 9H). 223 Example 39 7-(2-oxo-1,2-dlhydropyridin-4-yl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4) oxazepin-5(ZH)-one (Compound VI-3) 0 HN O) N, N N 5 [0436] Compound VI-3 was generated after the acidic hydrolysis of Compound VI4 with formic acid. MS found for C20H17N303 as (M+H)+ 348.13 'IH NMR (400MHz, DMSO-d 6 ): 8: 11.56 (s, 1H), 8.52 (d, r4.8Hz, 1H), 7.98 (d, J=2.4Hz, 1H), 7.82-7.75 (m, 2H), 7.42 (d, J=r6.8Hz, 1ff), 7.35 (d, J=7.6Hz, 1H), 7.28 (dd, J=4.8-6.8 Hz, 1H), 7.11 (d, J=8.8Hz, 1H), 6.53 (s, 1H), 6A7 (dd, J=1.6-6.4 Hz, 1H), 4.85 (s, 2H), 4.39 (t, J=4.4Hz, 10 2H), 3.69 (t, J=4.4Hz, 2H). Example 40 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] 11,41 oxazepin-5(2H)-one (Compound H-73)

F

3 CO ND N N 0 1) DMF H +e 0 90 0Q 2h + C1 + N a O H (10 M ) 2) C xo nO a~ ~ 2) Dfoxans ~ . ic 1-A 40-A rL; 4h; 95% 40 0 Pd(dppf)CI 2 (DCM adduct) (0.02 eq) Or ~~F %1H ,Tlu n r r H20 (5/2.5/2.5) F w DH 83C*,Z2h;78% 40-B 0 11-73 4 C Diae .t 4hn 92%I 15 11-7 U-734 c 224 [0437] To a solution of Compound 1-A (20 g, 0.083 mol, 1 eq.) and Compound 40-A (25 g, 0.15 mol, 1.8 eq.) in DMF (150 mL), NaOH solution (20 mI, IOM, 5 eq.) was slowly added at room temperature (slightly exothermic) and stirred at r.t. for 10 min, followed by heating at 95 *C for 2h. After cooling the reaction mixture, ethyl acetate (200 5 mL) was added and the organic layer was separated. The organics was washed with water (20 mL), brine, dried over sodium sulphate and concentrated. 10438] The residue was dissolved in 1,4-dioxane (50 mL) and to this 4N HClin dioxane (50 mL) and conc. HCl (2mL) was added and stirred at room temperature for 4h, filtered the precipitate, washed with ethyl acetate and dried. Compound 40-B obtained (30 g) 10 was a light yellow solid. [0439] To the bromide (15 g, 0.04 mol, I eq), boronic acid (12.5 g, 0.06 mol, 1.5 eq) and potassium carbonate (22 g, 0.16 mol, 4 eq) in a round bottom flask, solvent (150 mL, toluene/isopropano/water: 2/1/1) was added and stirred under nitrogen for 10 min. To the above solution the palladium catalyst (1 g, 0.012 mol, 0.02 eq) was added and heated 15 at 85 "C for 2h. The reaction mixture was diluted with ethyl acetate, separated the organic layer and filtered the organic layer through a plug of celite and silica gel and concentrated. Column purification on silica gel using ethyl acetate/hexane as eluent provided Compound 11-73 (13 g). [0440] To a solution of Compound 11-73 (26 g) in 1,4-dioxane (25 mL), 4N 20 HCI/dioxane (25 mL) was added followed by conc. HC (2 mL) and stirred at room temperature for 4h. Solvent was distilled off, dichloromethane was added and distilled off and to the residue, ethyl acetate (150 mL) was added and stirred at room temperature overnight and filtered the precipitate, washed with ethyl acetate, hexane and dried under vacuum. Compound H-73-HCI obtained (24.8 g) was a white solid. 25 [0441] 'H-NMR(CDCl 3 ) 88.72 (d, 2H,J= 5.2 Hz), 8.17 (d, 1H,J=2.4 Hz), 7.59-7.63 (m, 3H), 7.26 (d, 2H, J= 3.2 Hz), 7.22 (t, 1H, J= 4.8 Hz), 7.10 (d, 1H, J= 8.4 Hz), 5.10 (s, 2H), 4.56 (t, 2H, J= 5.0 Hz), 3.77 (t, 2H, J= 5.0 Hz); MS n/z 416.1 (M+H). 225 Example 41 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[fj [1,4]oxazepin-5(2H)-one (Compound 11-128) F F F 0 NH BrF C F 3 C 0 BrN H 1LB(OH)2 , 5 5 Pd(dppf)C 2 , K 2 CO3 [0442] 7-Bromo-3,4-dihydrobenzojfj[1,4]oxazepin-5(2H)-one (2.0 g), 4 trifluoromethoxyphenylboronic acid (2.2 g) and potassium carbonate (2.0 g) were combined in a mixture of toluene (20 mL), isopropanol (10 mL) and water (10 mL) and the resulting suspension was degassed with nitrogen. Palladium chloride dppf complex 10 was added (0.42 g) and the reaction was heated overnight at 85 *C. After cooling aqueous layer was discarded and the organic layer was diluted 2-fold with ethyl acetate, dried over MgS(0) 4 and concentrated. Recrystallization was conducted by dissolving in a minimum necessary amount of dichloromethane and cashing with excess hexane, resulting in 7-(4 (trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one as a grey solid 15 (1.43 g). [0443] 'HNMR: 8.42 (t, 1H); 8.12 (d, 1H); 7.86 -7.76 (i, 5H); 7.13 (d, 1H); 4.38 (t, 2H); 3.37 (quartet, 2H). Example 42 4-(imidazo[1,2-alpyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 20 dihydrobenzo[fj [1,4]oxazepin-5(2H)-one (Compound 11-129) F F F / 0 N 2-) 226 FaC N F 3 C N [0444] 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[fj[1,4joxazepin-5(2H)-one (50 mg) was dissolved in dry THF and the NaH suspension (6 mg, 60% in oil) was added, 5 followed shortly by 2-(chloromethyl)imidazo[1,2-a]pyridine (29 mg) and stirred overnight at room temperature. Worked up with ethyl acetate and pH 7 buffer organic layer dried over MgS(0) 4 and concentrated. Purification was conducted on normal phase

(CH

2 Cl 2 /10% EtOH in ethyl acetate gradient) followed by reverse-phase (ACN / H20, 0.1% TFA). Resulting glassy solid was dissolved in dioxane, diluted 10-fold with 0.iN 10 HCl and lyophilized resulting in 4-(imidazo[1,2-alpyridin-2-ylmethyl)-7-(4 (trifiuoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one hydrochloride salt as a white solid (42.2 mg). [04451 'H NMR: 7.95 (s, 1H); 7.53 (d, 2H); 7.36 (m, 2H); 7.31 (d, 211); 7.20 (di, 1H); 5.30 (s, 2H); 2.16 (s, 3H); "F NMR: -58.36 (s); MS (]ES+): 391.0 (base peak, M+H*); 15 803.2 (2M+Na). Example 43 8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-sulfone (Compound IX-1) F F F NNH 0 227 oMF oP-F FdI(p4 F HO% NHNSM~ft.fY.tIt~ F0 It F 43A 4.H 43 227 [04461 To a cooled (0"C) solution of Compound 43-A (1.368 g, 5.0 mmol) in anhydrous THF (10 mL) was added dropwise 2-aminoethanol (1.833 g, 30.0 mmol) in THF (10 mL) with stir. After completion of addition, the reaction mixture was allowed to warm to room temperature overnight. The mixture was concentrated in vaccuo, taken up 5 in EA-H 2 0 (100-50 mL), transferred to separation funnel, the aqueous layer was extracted with EA (50 mL x 3), combined organic phase was washed with 0.1 N HC (100 mL x 2), dried, concentrated to give Compound 43-B (1.355 g). LCMS m/z 226.0 (M-+H), 228.0 (M+H+2), anal HPLC > 98%. It was used directly in the next step without further purification. 10 [04471 To a solution of Compound 43-B (920 mg, 3.11 mmol) and 4 trifluoromethylphenylboronic acid Compound 43-C (886 mg, 4.66 mmol) in DM1 (6 mL) was added K2CO3 (1.932 g, 13.98 mmol), triethylamine (1 mL) and H20 (1 mL). The reaction mixture was stirred for 5 min under an atmosphere of dry N 2 . PdC 2 (dppf) (68 mg, 0.09 mmol) was added and the resulting mixture was heated at 13 0"C for 30 min in a 15 Biotage microwave. The reaction mixture was cooled, diluted with EtOAc (30 nL), filtered through a layer of celite, washed with 20% DMF in EtOAc (60 mL), combined filtrate concentrated in vaccuo. To the resulting slurry was added 1% MOH in CH 2 C12 (10 mL), filtered and the filtrate was subjected to Yamazen chromatography, eluting with a gradient of EtOAc in CH 2 Cl 2 to afford the desired product Compound 43-D (823'mg, 20 2.26 mmol, 73%). LCMS m/z 364.1 (M+E), anal HPLC > 92% in purity. [0448] To a cooled (0"C) solution of Compound 43-D (73 mg, 0.20 mmol) in anhydrous DMF (3 mL) was added 95%NaH (10 mg, 0.40 mmol) in 3 portions and the resulting mixture was allowed to warm to room temperature under an atmosphere of N 2 for 3 h. The reaction was quenched with solid NH 4 C (159 mg, 3.0 mmol), then EtOAc 25 H20 (30 mL and 10 mL) was added, transferred to a separation funnel. The aqueous layer was extracted with EtOAc (3 x 10 mL), combined organic phase dried (MgS(0) 4 ), concentrated. The crude mixture was subjected to Yamazen chromatography, eluting with a gradient of EtOAc in CH 2 Cl 2 (0% to 25%) to afford Compound IX-1 (34 mg, 0.10 mmol, 50%). 30 104491 LCMS m/z 344.0 (M+H), anal HPLC > 96% in purity. 'H NMR (400 MFz; DMSO-d6) 8 7.97 (d, J=2.3 Hz, 1H); 7.93 (dd, J=8.3, 2.4 Hz, 1H); 7.90 (s, 1H); 7.85 (m, 4H); 7.35 (d, J= 8.2 Hz, 1H); 4.14 (i, 2H); 3.47 (m, 2H). "F NMR (400 MHz; DMSO-d6) 6 -61.50 (s, 3F). 228 Example 44 2-((5-chloropyrimidin-2-yl)methyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H benzo[b][1,4,5]oxathiazepin-sulfone (Compound IX-3) F F F N ON F F F F F 0 Cs 2

CO

3 , TEA, DMF, F O N 8 'NH mw 130"C, 30min NC 5 IX-1 IX-3 [0450] A mixture of chloromethyl-5-chloropyrimidine (82 mg, 0.50 mmol), Compound IX-1 (17 mg, 0.05 mmol), K 2

CO

3 (169 mg, 1.22 mmol), triethylamine (0.5 mL) anhydrous DMF (3 mL) in a Biotage microwave vial was capped and irradiated at 130 *C 10 for 30 min in a Biotage microwave. The reaction was cooled, taken up in BtOAc (30 mL), filtered through a silica gel plug and concentrated. The crude mixture was subjected to Gilson preparative HPLC, eluting with a gradient of ACN in H20 (5% to 95%) to afford Compound IX-3 (19 mg, 0.04 mmol, 80%). [04511 LCMS m/z 470.0 (M+H), 472.0 (M+H+2), anal HPLC > 98% in purity, 1 H 15 NMR (400 MHz; acetone-d6) 8.77 (s, 2H); 8.04 (d, J= 2.3 Hz, 1H); 7.95 (m, 3H); 7.84 (d, J= 4 Hz, 2H ); 7.37 (d, J=8.4 Hz, 1H); 4.57 (s, 2H); 4.41 (m, 2H); 4.00 (m, 2H). 'F NMR (400 Mlz; acetone -d6) -63.62 (s, 3F). Example 45 S-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-benzo[b] [1,4,5]oxathiazepin-sulfone 20 (Compound IX-5) F O Fy 22 F N S-H

K

0 ) 229 [0452] Compound IX-5 was prepared according to Example 44 using the appropriate starting materials [miz 360.1, M+H]. Example 46 2-(2,2,2-trifluoroeth-1-yl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H 5 benzo[b][1,4,5]oxathiazepin-sulfone (Compound IX-4) F F F N F (0453] Compound IX-4 was prepared according to Example 44 using the appropriate starting materials [m/z 426.1, M+H]. Example 47 10 2-(2,2,2-trifluoroeth-1-yl)-8-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H benzo[b][1,4,5]oxathiazepin-sulfone (Compound IX-7) F 0 N FF FF N N NF [04541 Compound JX-7 was prepared according to Example 44 using the appropriate starting materials. 15 Example 48 2-((pyrimidin-2-yl)methyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2U benzo[b] [1,4,5]oxathiazepin-sulfone (Compound IX-2) F F F N [04551 Compound IX-2 was prepared according to Example 44 using the appropriate 20 starting materials [m/z 436.1, M+H]. 230 Example 49 2-((pyrimidin-2-yl)methyl)-S-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H benzo[b][1,4,5]oxathiazepin-sulfone (Compound IX-6) F O N 5 [0456] Compound IX-6 was prepared according to Example 44 using the appropriate starting materials. Example 50 2-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)methyl)-S-(4-(trifluoromethoxy)phenyl)-3,4 dihydro-2H-benzo(b] (1,4,5]oxathlazepin-sulfone (Compound IX-8) 10 Ia) [04571 Compound IX-8 was prepared according to Example 44 using the appropriate starting materials. Example 51 2-(cyclopropylmethyl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2 15 benzo[b](1,4,5]oxathiazepin-sulfone (Compound IX-9) F F F N [0458J Compound IX-9 was prepared according to Example 44 using the appropriate starting materials. 231 Example 52 2-(2-methoxyeth-1-yl)-8-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H benzo [b] [1,4,5]oxathiazepin-sulfone (Compound IX-10) F F F O O SN 5 [0459] Compound IX-10 was prepared according to Example 44 using the appropriate starting materials [m/z 402.1, M+H]. Example 53 4-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzoff] [1,4]oxazepin-5(2H)-one (Compound H-4) FaCO OO N N-N 10 [0460] Compound 11-4 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD30D) S 8.01 (d, 1H, J= 2.0 Hz), 7.78 (dd, 1H, J=8.8, 2.4 Hz), 7.71 (d, 2H, J= 8.4 Hz), 7.35 (d, 2H, J= 8.0 Hz), 7.16 (d, 1H, J 8.8 Hz), 5.07 (s, 2H), 4.49 (t, 211, J= 5.0 Hz), 3.75-3.83 (m, 3H), 2.41-2.47 (m, 4H), 15 2.00-2.21 (m, 2H); MS inz 460.1 (M+1). Example 54 4-((3-methylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound H-75) 0 0 20 [04611 Compound 11-75 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 OD) 6 8.35 (d, 1H, J=4.8 Hz), 8.00 (d, 1H, J= 2.4 Hz), 7.70-7.77 (m, 3H), 7.66 (d, 1H, J= 7.6 Hz), 7.35 (d, 1H, J= 8.0 232 Hz), 7.26-7.29 (m, 21), 7.13 (d, 1H, J= 8.0 Hz), 5.01 (s, 2H), 4.25 (t, 2H, J= 5.2 Hz), 3.68 (t, 211, J= 5.2 Hz), 2.43 (s, 3H); MS m/z 429.1 (M+H). Example 55 7-(2-fluoro-4-(trifluoromethyl)pheny)-4-(pyrimidin-2-ymethyl)-3,4 5 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 1-105) FsC ND N N F [0462] Compound 11-105 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMRt (CD 3 0D) 8 8.76 (d, 211, J= 4.8 Hz), 8.02 (s, 1H), 7.71-7.75 (m, 2R), 7.54-7.59 (m, 211), 7.38 (t, 1H, J= 4.8 Hz), 7.18 (d, IH, J 10 = 8.4 Hz), 5.07 (s, 2H), 4.62 (t, 2H, J=4.8 Hz), 3.86 (t, 2H, J=4.8 Hz); MS mz 418.1 (M+H). Example 56 7-(2-chloro-4-(triflnoromethyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-110) NN N N~ 15 C I [04631 Compound 1-110 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.76 (d, 2H, J= 4.8 Hz), 7.88 (d, 1H, J=2.4 Hz), 7.82 (s, 1H), 7.69 (d, 1H, J= 7.6 Hz), 7.60-7.63 (in, 2H), 7.38 (t, 1H, J=5.0 Hz), 7.17 (d, 1H, J 8.0 Hz), 5.07 (s, 21), 4.62 (t, 211, J= 4.8 Hz), 3.86 (t 20 2H, J=4.8 Hz); MS m/z 434.0 (M+H). 233 Example 57 7-(4-(trifluoromethoxy)phenyl)-4-((4-(trifluoromethyl)pyrimidin-2-y)methyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound H--113) FaCO 0 CF 3 I NN K-) 5 [04641 Compound H-113 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD30D) 8 9.08 (d, IH, J= 5.2 Hz), 8.01 (d, IHI, J= 2.0 Hz), 7.76-7.79 (m, 2H), 7.71 (d, 2H, J= 9.2 Hz), 7.34 (d, 211, J =8.0 Hz), 7.17 (d, 1H, J= 8.4 Hz), 5.16 (s, 2H), 4.63 (t, 2H, J= 5.0 Hz), 3.88 (t, 2H,J= 4.8 Hz); MS m/z 484.1 (M+H). 10 Example 58 7-(4-(trifluoromethoxy)phenyl)-4-((3-(trifluoromethyl)pyridin-2-yl)methyl)-3,4 dlhydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 11-126)

F

3 C FaCO 0 -~ N ND [04651 Compound H-126 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. 'H-NMR (CD 3 OD) 8 8.74 (d, 1H, J=5.2 Hz), 8.13 (d, 1H, J=7.6 Hz), 8.01 (d, 1H, J= 6.4 Hz), 7.77 (dd, 1H, J=8.2, 2.2Hz), 7.71 (d, 2H,J= 8.4 Hz), 7.48 (dd, 1H, J= 7A, 5.0 Hz), 7.34 (d, 2H, J= 8.4 Hz), 7.16 (d, 1H, J 8.8 Hz), 5.18 (s, 2H), 4.57 (t, 2H, J= 4.8 Hz), 3.81 (t, 2H, J= 5.2 Hz); MS m/z 483.1 (M+H). 234 Example 59 4-(oxazol-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound H-127)

F

3 CO N 5 [0466] Compound 11-127 was prepared according to the Examples disclosed herein using the appropriate starting materials. 1 H-NMR (CD 3 0D) 8 8.00 (d, 1H, J= 2.4 Hz), 7.92 (s, 1H), 7.77 (dd, 1H, J= 8.6, 2.2 Hz), 7.72 (d, 2H, J= 8.4 Hz), 7.35 (d,2H, J= 8.0 Hz), 7.14-7.17 (m, 211), 4.99 (s, 2H), 4.44 (t, 2H, J= 5.0 Hz), 3.78 (t, 2H, J=5.0 Hz); MS m/z 405.0 (M+H). 10 Example 60 4-(2-(benzyloxy)ethyl)-1-methyI-7-(4-(trfluoromethoxy)phenyl)-3,4-dihydro-1H benzo[e][1,4]diazepine-2,5-dione (Compound X-7) F N O BrMel 0 HO NH2 t FaCO BH) OMPI Br 0 -z BrNH 2(13 Na 2

CO

3 A OH Md(d 2 r P0 3 I-ft Me Me 0 H 2 OJaun ~OH F C N0 B r DF 3 C O NH0 k- Nz Nr- N I N ANai-!.DMF N Me 0 x-7 Me- 15 [04671 6-Bromo-LH-benzo[d][1,3]oxazine-2,4-dione (5.0 g, 20.66 mmol), iodomethane (1.94 mL, d=2.28, 4A g, 31.0 mmol, 1.5 equiv.) and Na 2

CO

3 (4.38 g, 41.3 mmol, 2 equiv.) were placed in a round bottomed flask. To the flask were added DMF (40 mL) at 235 ambient temperature. The mixture was stirred overnight at room temperature and then filtered through a glass filter. Obtained filtrate was diluted with water to form precipitates. The precipitates were dissolved in EtOAc and the solution was dried over MgS(O)4. The solvent was removed under reduced pressure. At this point, since the conversion was 5 -50%, K 2 C0 3 (14.3 g, 103.3 mmol, 5 equiv.) and iodomethane (2.58 mL, d= 2.28, 41.3 mmol, 2.0 equiv.) were added to the solution of the crude material in DMF. The mixture was heated at 30"C so that the reaction can go to completion and then filtered through a glass filter. Obtained filtrate was diluted with water to form precipitates. Formed precipitates were filtered through a glass filter to give the desired product (6-bromo- 1 10 methyl-IH-benzo[d][1,3]oxazine-2,4-dione). This was used for the subsequent step without further purification. (04681 6-Bromo-l-methyl-lH-benzo[d][1,3]oxazine-2,4-dione (5.29 g, 20.66 mmol) and glycine (1.7 g, 22.73 mmol, 1.1 equiv.) were dissolved in AcOH (100 mL) in a round bottomed flask. The mixture was heated under reflux conditions for 2 hours. The mixture 15 was purified by automated silica-gel column chromatography using EtOAc/hexane gradient as the eluent. The purification give the desired product (7-bromo-1-methyl-3,4 dihydro-1H-benzo[e][1,4]diazepine-2,5-dione, colorless powder, 446.7 mg). [0469] 7-Bromo-1-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (446.7 mg, 1.661 mmol), 4-trifluoromethoxyboronic acid (445.0 mg, 2.159 mmol, 1.3 equiv.) 20 Pd(dppf)ClI2-CH2Cl2 (120.0 mg, 0.166 mmol, 10 mol%) and K 2 C0 3 (482.0 mg, 3.49 mmol, 2.1 equiv.) were dissolved in a mixed solvents, H 2 0/toluene/i-PrOH (2.5 mL: 5 mL: 2.5 mL) in a 10 mL round bottomed flask under a nitrogen atmosphere. The mixture was heated at 60*C for 64 h. The mixture was purified by automated silica-gel column chromatography using EtOAc/hexane gradient as the eluent. The purification give the 25 desired product (1-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-IH benzo[e][1,4]diazepine-2,5-dione, 415.0 mg). 10470] 1-Methyl-7-(4-(trifluoromethoxy)phenyl)--3,4-dihydro-1H benzo[ej[1,4]diazepine-2,5-dione (50.0 mg, 0.143 mmol) and NaH (17 mg, 0.428 mmol, 3.0 equiv.) were placed in a 2-5 mL Smith process vial under a nitrogen atmosphere. To 30 the vial was added DMF (5 mL) to observe hydrogen extiusion. And then ((2 bromoethoxy)methyl)benzene (45 PL, 0.285 mmol, d = 0.135,2 equiv.) was added at room temperature. After stirring for 50 min, the reaction was quenched with AcOH. Resulting mixture was directly injected to a preparative HPLC to give the desired product 236 (4-(2-(benzyloxy)ethyl)-l-methyl-7-(4-(trifluoromethoxy)-phenyl)-3,4-dihydro-1H benzo[e][1,4]diazepine-2,5-dione, 42.7 mg) as a light yellow film. [0471] LCMS (EI: 70 eV) 503 (M*+Na), 486 (M+1). Example 61 5 4-(pyrimidin-2-ylmethyl)-7-(4-(trfluoromethyl)phenyl)-3,4-dibydro-1H benzo[e] [1,4]diazepine-2,5-dione (Compound X-9) F F F O N F -o HA1 NN NN 0SC 0 173Cr>c 0IPE DMFF FM Ii - O - 5 a NH 61D 61-E H 10 [0472] Procedure to 61-B To a mixture of compound 61-A (4.3 80 g, 20.0 imnol), N Boc diamine (5.000 g, 31.2 mnmol) and EDC (5.6 00 g, 38.74 mmnol) in anhydrous CHI 2

CI

2 (80 mL) was added dropwise Hunig's base (10 mL., 56.16 mnmol) with stir. After completion of addition, the reaction mixture was concentrated in vaccuo, taken up in EA H20O (200-100 mL), transferred to separation funnel, the aqueous layer was extracted with 15 EA (100 miL x 3), combined organic phase was washed with 0.1 N HCi (100 mL. x 2), dried, concentrated, column chromnatographed using Yamazen, eluting with EaQAc/n hexane to give compound 61-B (6.386 g, 17.67 mmrol, 88%). LCMS m/z 362.0 (M+H), anal HPLC > 90%. It was used directly in the next step without further purification. [0473] Procedure to Compound 61-C Standard Suzuki coupling as described above, 20 starting from compound 61-B (658 mg, 1.8 mmol), a pale yellow solid 61-D (610 mg, L4 mmrol, 79%) was obtained using Yamazen chromatography eluting with EaOAc/n 237 hexane, LCMS mfz 327.1 (M-t-Butyl), 876.3 (2M+Na), it was used directly in the next step without further purification. [04741 Procedure to Compound 61-D and 61-E To a anhydrous DMF (30 mL) solution of compound C (213 mg, 0.500 mmol) and chloromethyl pyrimidine HC salt 5 (248 mg, 1.50 mmol) was added slowly 95% NaH (65 mg, 2.7 mnmol) and stirred 5 min. Another portion of 95% NaH (55 mg, 2.3 mmol) was added, stirred for 5 min. The crude mixture was quenched by 30% aqueous NH 4 CI (40 nL), extracted with EtOAc (3 x 100 mL), combined organic phase was washed with saturated NaHCO 3 (100 mL), brine (100 mL), dried, concentrated in vaccuo. Reverse-phase HPLC was used to obtain a yellow 10 solid 61-D (75 mg, 0.14 mmol, 29%). LCMS m/z 519.2 (M+H). It was used directly in the next step without further purification. [0475] To a solution of compound 61-D (70 mg, 0.13 mmol) in DCM (5.0 mL) was added TFA (2.0 mL) and stirred overnight. Then it was concentrated in vaccuo, only one single peak in LCMS as compound 61-E, m/z 419.1 (M+H), anal HPLC > 95 in purity. 15 10476] Procedure to compound X-9 To a anhydrous DMF solution (15 mL) of the above compound 61-E (54 mg, 0.13 mmol) was added Hunig's base (2 mL), capped in a Biotage microwave vial and subjected to microwave heating at 150"C for 40 min. The reaction mixture was filtered, concentrated in vaccuo and subjected to Gilson preparative HPLC, eluting with a gradient of ACN in H20 (5% to 95%) to afford X-9 (16 mg, 0.04 20 mmol, 31%). LCMS m/z 399.1 (M+H), anal HPLC > 98% in purity. Example 62 1-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-1H benzo[e] [1,4]diazepin-5(2H1)-one (Compound X-10) F F F 0 N N 238 238 FF F F F ND-. NaEH(OAc) 3 , DCM F

-

N ) HO H 1 H X-9 Paraformaldehyde X-1 0 [0477] Procedure to compound X-10 To a anhydrous DCM solution (3 mL) of the compound X-9 (14 mg, 0.035 mmol) was added paraformaldehyde (0.5 mL) and HzO (1 5 mL), stirred for 5 min, THF (1 mL) was added to help solubility. After 5 min, borohydride (63 mg, 0.31 mmol) was added, stirred for 30 min until the starting material disappeared in LCMS. The crude mixture was quenched by 30% aqueous NHI 4 CI (10 mL), extracted with EtOAc (3 x 30 mL), combined organic phase was washed with saturated NaHCO 3 (30 mL), brine (30 mL), dried, concentrated in vaccuo. Reverse-phase 10 HPLC was used to obtain a yellow solid X-10 (6 mg, 0.0 15 mmol, 42%). LCMS m/z 412.1 (M+H), anal HPLC> 98%. Example 63 4-((1-methyl-1H-imidazol-2-yl)methy[)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-186) A 0N F N N 15 0 0Fjf FjIF Br BH 0 NaH. OlF F [0478] Compound 1-186 was prepared according to the Examples disclosed herein using the appropriate starting materials. The Suzuki coupling was performed under standard conditioned explained in the other procedures using Pd(dppOCl 2 . 20 [0479] Alkylation of the amide was performed using sodium hydride following the standard procedure to provide the final products. 239 [0480] Mass (M+H)+418.1.HNMR (400 MHz; dmso-d 6 ) 87.93 (s, 1H); 7.75 (m, 311); 7.58 (m, 2H); 7.42 (m, 2H1); 4.86 (m, 2H); 4.18 (m, 2H); 3.75 (s, 31); 3.65 (i, 2H). "F NMR (400 MHz; DMSO-d6) 8-57.26 (s, 3F). Example 64 5 4-(2-morpholinoethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dlhydrobenzo[fl] [1,4] oxazepin-5(2H)-one (Compound 11-188) F O N 0 [0481] Compound 11-188 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)*437. 1. 10 Example 65 4-((5-methylpyrazin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound 11-172) N [04821 Compound 11-172 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. Mass (M+H)*430.1. 'HNMR (400 MHz; DMSO-d6) 88.50 (m, 2H); 7.94 (s, 1H); 7.78 (m, 3H); 7.41 (d, J= 8.5 Hz, 21); 7.13 (d, I = 8.1 Hz, 1H); 4.86 (s, 2H); 4.38 (m, 2H); 3.71 (m, 2H); 2.48 (s, 311). "IF NMR (400 MHz; DMSO-d6) 8 -57.26 (s, 3F). Example 66 20 4-((6-methylpyrazin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 1-175) 00 2-40 240 [04831 Compound 11-175 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)*430.1 'HNMR(400 Mz; CD30D) 8 8.48 (s, 111); 8.41 (s, IH ); 7.97 (s, 1H); 7.73 (m, 3H); 7.32 (d, J=8.6Hz, 2H ); 7.13 (d, J = 8.6 Hz, 1H); 4.95 (s, 2H); 4.46 (m, 2H); 3.80 (m, 211); 3.30 (s, 3$. "F 5 NMR (400 Mlz; CD 3 0D) 8 -56.96 (s, 3F). Example 67 4-((1-benzyl-1H-imidazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-187) 9 jNN) 10 [0484J Compound 11-187 was prepared according to the Examples disclosed-herein using the appropriate starting materials. Mass (M+H)*494.1. 'H NMR (400 MHz; dmso d) S 7.00 -8.00 (m, 12H); 5.32(s, 2H); 4.82 (s, 2H); 4.26 (m, 2H); 3.49 (m, 2H). 9 F NMR (400 MHz; DMSO-d6) 8 -57.25 (s, 3F). Example 68 15 4-(imidazo[1,2-alpyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2R)-one (Compound H-189) F I) [0485] Compound H-189 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)+454.1. 'H NMR (400 MHz; dmso 20 d) 6 6.80 -8.50 (m, 12H); 5.36 (s, 2H); 4.82 (m, 21); 4.24 (m, 2H). "F NMR (400 MHz; DMSO-d6) 8 -57.38 (s, 3F). 241 Example 69 tert-butyl 2-(7-(4-(trifllorometbyl)phenyl)-2,3,4,5-tetrahydrobenzo[fJ [1,4] oxazepine 4-carbonyl)-5,6-dihydroimidazo [1,2-a]pyrazine-7(8Hl)-carboxylate (Compound III 40) F F F - N 5 U F ~F FAU N NH - I H - I rtN NHN 82-A 11140 [0486] Decarboxylation of the aide was performed using IM BH 3 in THF for 1-5 days following the standard procedure to provide amine 69-A. This was followed by a standard HATU catalyzed condensation reaction to afford Compound H-40. Mass (M+H) 543.2. 10 Example 70 (5,6,7,8-tetrahydroimidazo[1,2-alpyrazin-2-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dlhydrobenzo[fj [1,4]oxazepin-4(5H1)-y)methanone (Compound MH-42) FF F N H W: N F F FBOC TFA, DCM F 1114011142 15 [0487] Compound I-40 was deprotected using TFA in dichloromethane in a standard procedure to give Compound IH-42. Mass (M+H)* 443.1. 242 Example 71 1-(2-(7-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-4 carbonyl)-5,6-dihydroimidazo[1,2-ajpyrazIn-7(8H)-y)ethanone (Compound 101-48) F F FCN 00 F -Q N-j) Ac 2 F t'/

-

N N' N 11142 5 IM4 [0488] Standard acylation using acetic anhydride at room temperature of Compound M-42 afforded Compound If-48. Mass (M+H)*485.1. Example 72 (1-methyl-1H-imidazol-5-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 10 dihydrobenzo[fj[1,4]oxazepin-4(5I)-yI)methanone (Compound a-32) F F F N N N [0489] Compound m-32 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H) 4 402.1. Example 73 15 (1H-imidazoI-2-yI)(7-(4-(trifluoromethyl)phenyl)-2,3-dibydrobenzo[fj[1,4]oxazepin 4(5H)-yl)methanone (Compound mI-33) F FO0 H F N N 24 243 [0490] Compound HI-33 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 388.1. Example 74 (1-((1H-imidazol-1-yl)methyl)cyclopropyl)(7-(4-(trifluoromethyl)phenyl)-2,3 5 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)methanone (Compound IH-34) P'N F F

N

F [04911 Compound ID-34 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H) 442.1. Example 75 10 (1-methyl-1H-imidazol-2-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f[ [1,4] oxazepin-4(5H)-yl)methanone (Compound H-37) FF O F N [04921 Compound IM-37 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H) 402.1. 15 Example 76 (R)-tert-butyl 2-(7-(4-(trifluoromethyl)phenyl)-2,3,4,5 tetrahydrobenzo[fJ11,4]oxazepine-4-carbonyl)pyrrolidine-1-carboxylate (Compound M-52) F F O F \A F N 244 [0493] Compound Il-52 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H) 491.2. Example 77 (1H-1,2,3-triazol-5-yl)(7-(4-(trifluorometbyl)phenyl)-2,3 5 dThydrobenzo[fJ[1,4]oxazepin-4(5H)-yl)methanone (Compound II-49) FF H F N N N [04941 Compound H1-49 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 389.1. Example 78 10 (1H-1,2,4-triazol-3-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f] [1,4] oxazepin-4(511)-yl)methanone (Compound I-50) F F F N NwN--NH [0495] Compound I-50 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 389.1. 15 Example 79 (3-amino-1H-1,2,4-triazol-5-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzolf] [1,4] oxazepin-4(5HI)-yI)methanone (Compound 111-51) F SFO H F N N NH2

K

0 ) [0496] Compound I-51 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. Mass (M+H)* 404.1. 245 Example 80 (R)-pyrrofidin-2-yI(7-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[fJ [1,4]oxazepin 4(5H)-yl)methanone (Compound m-53) F F OH F N 5 [04971 Compound 111-53 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)*391.1. Example 81 (1-phenyl-iH-1,2,3-triazol-5-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo [f] [1,4] oxazepin-4(5H)-yl)methanone (Compound ]H-54) F S F N) 10 [04981 Compound HI-54 was prepared according to the Examples disclosed herein using the appropriate starting materials. Example 82 (R)-1-(2-(7-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f] [1,4]oxazepine-4 15 carbonyl)pyrrolidin-1-yl)ethanone (Compound H-55) F F 0 O4j F N NN [04991 Compound HI-55 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 433.1. 246 Example 83 (1H-imidazol-2-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzolf] [1,41 oxazepIn-4(5H)-yl)methanone (Compound m-56) F O N 10 1 0 5 [0500] Compound HI-56 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H) 404.1. Example 84 (S)-4-benzyl-3-methyl-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(21H)-one (Compound H-132) F F F O N / 10 0 ~FF HO y H 1) HATU, DIPEA, DMF F N OH 2)4-trifiuommetylplwnyl boronic T acid, dPdC, K 2 Cos. 3) NaH, DMF F O 2chln methylpyrimidine F WA NaH DMFN NBS, NMA, CHOl N 0.- N [0501] A solution of 5-bromo-2-fluorobenzoic acid (1 mmol), benzyl (S)-valinol (1 mmol), HATU (1 mmol) and diisopropylethylamine (3 mmol) in DMF (3 mL) was stirred at room temperature for 30 minutes. The reaction mixture was poured into a 1:1 solution 15 of IM HC1 and brine and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate solution and brine, dried and concentrated. The resided was taken up in a mixture of toluene, isopropanol and water (ImL each) and added to a flask containing 4-trifluoronethylphenyl boronic acid (3 mmol), K 2

CO

3 (3 247 mmol) and dppfPdCl 2 (40 mg) under nitrogen. The reaction mixture was stirred at 90*C for 1 h. The organic layer was separated and concentrated before being purified by flash chromatography (rf= 0.28 in 2:1 hexanes/ethyl acetate) to give a viscous oil. The product was dissolved in DMF (5 mL) and sodium hydride was added (5 mmol). The reaction 5 mixture was stirred at room temperature for 40 minutes and was poured into a 1:1 solution of 1M HCI and brine and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate solution and brine, dried and concentrated before being purified by flash chromatography (rf= 0.59 in 2:1 hexanes/ethyl acetate) to give (S)-4-benzyl-3-methyl-7-(4-(trifluoromethyl)phenyl)-3,4 10 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one as an oil. [0502] To a solution of the above product in chloroform was added NBS (2.5 equiv) and N-methylacetamide (10 mol%). The reaction was stirred for 18 hours at room temperature before being concentrated under vacuum. The residue was dissolved in ethyl acetate (10 mL) and IM NaOH solution was added (10 mL). The mixture was stirred 15 vigorously for 5 minutes and the organic layer was separated, washed with brine and concentrated. Flash chromatography (f = 0.10 in 2:1 hexanes/ethyl acetate) gave the debenzylated product. [0503] To a solution of the above product (20 mg) and 2-chloromethylpyrimidiie HC salt (30 mg) in DMF was added sodium hydride (40 mg) and the reaction was stirred for 1 20 h at room temperature. The reaction mixture was quenched with IM HCl and purified by preparative HPLC to give (S)-3-methyl-4-(pyrimidin-2-ylmethyl)-7-(4 (trifluoromethyl)phenyl)-3,4-dihydrobenzo [fJ[ 1,4]oxazepin-5(2H)-one TFA salt as a white powder. Example 85 25 (2S,llaS)-2-amino-7-(4-(trifluoromethyl)pheny)-2,3,11,11a tetrahydrobenzo[fJpyrrolo[2,1-c] [1,4] oxazepin-5(1HI)-one (Compound 11-51) F F F / 0 N NH2 0 [0504] Compound 11-51 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 1

H

17

F

3

N

2 0 2 x TFA. 363.1 (M+1). 'H NMR 248 (DMSO) 5 8.34 (d, J=2.8 Hz, 1H), 8.20 (br, 3H), 7.85 (m, 511), 7.16 (d, J=8.4 Hz, 1H1), 4.61 (d, J = 12.0 Hz, 11), 4.16 (m, 2H), 3.96 (m, 1H), 3.83 (br, 1H), 3.58 (m, 1H), 2.54 (I, 1H), 1.80 (m, 1H). "F NMR (DMS0) & -61.4 (s, 3F). Example 86 5 (R)-2-(pyrimidin-2-ylmethyl)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro 1H-benzo[fjpyrazino[2,1-el[1,4]oxazepin-6(2H)-one (Compound H-8) FF NNYN F 0 [05051 Compound H-8 was prepared according to the Examples disclosed herein using the appropriate starting materials. C24H2IF 3 N40 2 x 2-TFA. 455.1 (M+1). 10 Example 87 (S)-2-(pyrimidin-2-ylmethyl)-8-(4-(triflnoromethyl)phenyl)-3,4,12,12a-tetrahydro 1H-benzo[f]pyrazino[2,1-c1,4]oxazepin-6(2H)-one (Compound 11-9) F, I N~r F / 0 / N N N- N [0506] Compound 11-9 was prepared according to the Examples disclosed herein using 15 the appropriate starting materials. C241 21

F

3

N

4 0 2 x 2-TFA. 455.1 (M+1). Example 88 (S)-3-methyl-4-(pyrinidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-12) F F F 0 0N N N 20 [0507] Compound H-12 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HsF 3

N

3 0 2 x TFA. 414.1 (M+1). 'H NMR 249 (DMSO) 8 8.77 (d, J = 5.2 Hz, 2H), 8.38 (d, J= 2.4 Hz, IH), 7.85 (in, 511), 7.40 (t, J = 5.0 Hz, 111), 7.20 (d, J=8.4 Hz, 111), 5.10 (J= 17.0 Hz, 1H), 4.79 (d, J= 17.0 Hz, 1H), 4.60 (in, 2H), 4.05 (n, 1H). 1.22 (d, J= 6.8 Hz, 3H). 1 9 F NMR (DMSO) 8 -61.37 (s, 3F). Example 89 5 (R)-3-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dlhydrobenzo[fJ[1,4]oxazepin-5(2H)-one (Compound H-13) F F F O 0N NN (0508] Compound 11-13 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HsF3N302x TFA. 414.1 (M+1). 'H NMR 10 (DMSO) S 8.77 (d, J= 5.2 Hz, 21), 8.38 (d, J= 2.4 Hz, 1H), 7.85 (m, 5H), 7.40 (t, J = 5.0 Hz, 1H), 7.20 (d, J = 8A Hz, 1H), 5.10 (J = 17.0 Hz, IH), 4.79 (d, J= 17.0 Hz, 1H), 4.60 (n, 211), 4.05 (m, 111). 1.22 (d, J=6.8 Hz, 3H). "I NMR (DMSO)8 -61.37 (s, 3F). Example 90 (S)-3-methyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[fj[1,4]oxazepin-5(2H) 15 one (Compound 11-18) F F F 0 NH (0509] Compound 11-18 was prepared according to the Examples disclosed herein using the appropriate starting materials. CnH14F3NO2. 322.1 (M+1). 'H NMR (DMSO) 8 8A1 (d, J= 4.4 Hz, 111), 8.20 (d, J= 1.6 Hz, 1H), 7.85 (m, 5H), 7.16 (d, J =8.4 Hz, 1H), 20 4.22 (m, 2 H), 3.68 (br, 1H), 1.15 (d, J =6.4 Hz, 3H). 250 Example 91 (R)-3-methyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound H-19) F F F 0 NH 5 [0510] Compound 1-19 was prepared according to the Examples disclosed herein using the appropriate starting materials. C7H1jF3N02. 322.1 (M+1). 1H NMR (DMSO) 6 8.41 (d, J=4.4 Hz, 111), 8.20 (d, J= 1.6 Hz, 111), 7.85 (m, SH), 7.16 (d, J = 8.4 Hz, 1H), 4.22 (m, 2 H), 3.68 (br, 1H), 1.15 (d, J = 6.4 Hz, 311). Example 92 10 (2R,11aS)-2-anilno-7-(4-(trifluoromethyl)phenyl)-2,3,11,11a tetrahydrobenzo[f]pyrrolo [2,1-c] [1,4]oxazepin-5(1H)-one (Compound 11-21) F F F / O F 0 N ANH2 0 [0511] Compound I1-21 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 1

H

17

F

3

N

2 0 2 x TFA. 363.1 (M+1). 15 Example 93 (R)-2-(2,2-difluoroethyl)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro4H benzo[f]pyrazino[2,1-e] [1,4]oxazepin-6(2H)-one (Compound 11-22) F F / F N NF F OO 0 [0512] Compound H-22 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. C2 1 HigF 5

N

2 O2 x TFA. 427.1 (M+1). 'H NMR (DMSO) 6 8.22 (d, J = 2.4 Hz, 1H), 7.84 (m, 5H), 7.18 (d, J = 8.4 Hz, 1H), 6.22 (tIm, J 251 55.6 Hz, 1H), 4.53 (m, 1H), 4.27 (m, 1H), 3.97 (br, 2H), 3.62 (mn, 1H), 2.90-2.60 (i, 6H). l 9 F NMR (DMSO) 8 -61.4 (s, 3F), -119.4 (dt, 55.6, 16.2 Hz, 2F). Example 94 (R)-2-ethyl-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1H 5 benzo[fJpyrazino[2,1-e] [1,4joxazepin-6(2H)-one (Compound U-23) F F F / 0 N N [0513] Compound 11-23 was prepared according to the Examples disclosed herein using the appropriate starting materials. C21HnFN2O 2 x TFA. 391.1 (M+1). Example 95 10 (S)-2-(2,2-difluoroethyl)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydr-1H* benzo[fjpyrazino[2,1-c] [1,4]oxazepin-6(2H)-one (Compound 11-24) F F F ON N F [0514] Compound 1-24 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 21

H

1 gFSN20 2 x TFA. 427.1 (M+1). 'H NMR 15 (DMSO) 8 8.22 (d, J = 2A Hz, 1H), 7.84 (m, 5H), 7.18 (d, J = 8.4 Hz, 1H), 6.22 (tm, J= 55.6 Hz, 1H), 4.53 (in, IH), 4.27 (m, 1H), 3.97 (br, 2H), 3.62 (m, 1H), 2.90-2.60 (m, 6H). "F NMR (DMSO) 8 -61.4 (s, 3F), -119.4 (dt, 55.6, 16.2 Hz, 2F). Example 96 (S)-2-ethyl-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1H 20 benzo[f]pyrazino[2,1-c] [1,4]oxazepIn-6(2H)-one (Compound 11-25) FF F / 0 N N 252 [0515] Compound EH-25 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 2 1H21F 3

N

2 0 2 x TFA. 391.1 (M+1). Example 97 (S)-3-isopropyl-7-(4-(triflnoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5 5(2H)-one (Compound 11-77) F F F 0 [0516] Compound 11-77 was prepared according to the Examples disclosed herein using the appropriate starting materials. C19Hi&F 3

NO

2 . 350.1 (M+1). Example 98 10 (R)-3-methy1-4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f] [1,4joxazepin-5(2H)-one (Compound 11-80) F F F 0 N N N [05171 Compound 11-80 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 23

H

19

F

3

N

2 0 2 x TFA. 413.1 (M+1). 15 Example 99 (S)-3-methyl-4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dfhydrobenzo [f] [1,4joxazepin-5(2H)-one (Compound 1-81) F F F N N [0518] Compound 1-81 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. C23H19F3N202 x TFA. 413.1 (M+1). 253 Example 100 4-(1-(pyridin-2-yl)ethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound 11-82) F F FO N t) 5 [0519] Compound 1-82 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HisF 3

N

3 0 2 x TFA. 414.1 (M+1) Example 101 (R)-2-(2,2,2-trifluoroethyl)-8-(4-(trifluoromethy)phenyl)-3,4,12,12a-tetrahydro-H benzo[fjpyrazino[2,1-e] [1,4]oxazepin-6(2H)-one (Compound 11-83) FF F O N N 10 [0520] Compound 11-83 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 21 HisF6N 2 02x TFA. 445.1 (M+1) Example 102 (R)-4-benzyl-2-methyl-7-(4-(trifluoromethyl)phenyl)-3,4 15 dihydrobenzo [f] [1,4]oxazepin-5(2H)-one (Compound 11-85) F F F N0 [0521] Compound 11-85 was prepared according to the Examples disclosed herein using the appropriate starting materials. C24H2OF3NO2 412.1 (M+1). 254 Example 103 (S)-4-benzyl-2-methyl-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(21)-one (Compound 11-86) F F F A0 5 [05221 Compound 11-86 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 2 4H 20 F3NQ 2 .412.1 (M+1). Example 104 (S)-2-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[fl] [1,4Joxazepin-5(2H)-one (Compound H-101) F F F A N N N 10 [0523] Compound 1-101 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HisF 3

N

3 0 2 . 414.1 (M+1) Example 105 2-(pyridin-2-yl)-1-(7-(4-(trifluoromethyl)phenyl)-2,3-dibydrobenzo[f] [1,4]oxazepin 15 4(5H)-yl)ethanone (Compound 111-29) F F N0 F l N [0524] Compound HI-29 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 2 3

H

19

F

3

N

2 0 2 . 413.1 (M+ 1). 255 Example 106 2-(pyrimidin-2-yl)-1-(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzolfj[1,4]oxazepin-4(5H)-yl)ethanone (Compound IH-30) F F O 5 [0525] Compound I-30 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HsF 3

N

3 0 2 . 414.1 (M+1). Example 107 4-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[fj [1,4]oxazepin-7 yl)phenyl trifluoromethanesulfonate (Compound H-171) F 10k 6t1 N 10 [0526] Compound 1-171 was prepared according to the Examples disclosed herein using the appropriate starting materials. C 21

H

1 6

F

3

N

3 0 5 S. 480.1 (M+1). Example 108 (R)-(2-methyl-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepin 15 4(5H)-yl)(pyrimidin-2-yl)methanone (Compound 111-38) O N [0527] Compound 111-38 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HisFN303. 430.1 (M+ 1). 256 Example 109 (S)-(2-methyl-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)(pyrimidin-2-yl)methanone (Compound mI-39) F O N 5 [0528] Compound 1I-39 was prepared according to the Examples disclosed herein using the appropriate starting materials. C22HFN303. 430.1 (M+1). Example 110 Phenyl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj [1,4]oxazepin-4(5H) yl)methanone (Compound M-4) F*O A F N 10 [0529] Compound -4 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C23HaF 3

NO

3 as (M+H)+ 414.1. Example 111 4-(pyrimidin-2-ylmethyl)-7-(4-(2,2,2-trifluoroethyl)phenyl)-3,4 15 dihydrobenzo[fl [1,4joxazepin-5(2H)-one (Compound 11-150) F F F / 0 -- N F N/ [0530] Compound 11-150 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 23 Hi 8

F

3

NO

3 as (M+H)* 414.2. 257 Example 112 4-(pyridin-2-ylmethyl)-7-(4-(2,2,2-trifluoroethyl)phenyl)-3,4 dlhydrobenzof] [1,4]oxazepin-5(2H)-one (Compound 1-151) F 5 [0531] Compound 1-151 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 23

H,

9

F

3

N

2 0 2 as (M+H)* 413.2 'H NMR (400MHz, dnso-d: 8: 8.54 (d, J=5.6 Hz, 1$, 7.96 (d, J=2.4 Hz, [H), 7.80-7.76 (m, 2); 7.67 (d, J = 8.0 Hz, 1H), 7.42-7.28 (m, 411); 7.14 (d, J= 8.4 Hz, 111); 4.86 (a, 2H), 4.38-4.36 (m, 211), 3.72-3.64 (m, 4H). 10 Example 113 (1-methylcyclopropyl)(7-(4-(trifluoromethoxy)pheny)-2,3-dihydrobenzo[fj [1,4] oxazepin-4(5H)-yl)methanone (Compound I-10) F 0 O [0532] Compound HI-10 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. MS found for C 21

H

20

F

3 N0 3 as (M+H)* 392.0. Example 114 (3,3-difluorocyclobutyl)(7-(4-(trfluoromethoxy)pheny)-2,3-dihydrobenzof] [1,4] oxazepin-4(5H)-yl)methauone (Compound HI-11) F},O 0F F O" F j) F 20 [0533] Compound III-11 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 Hi 8

F

5

NO

3 as (M+H)* 428.1. 258 Example 115 (1-methyl-1H-pyrazol-4-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f] [1,4] oxazepIn-4(5)-yl)methanone (Compound MH-12) F}O. 0 F N 5 [0534] Compound MI-12 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 1 HisF 3

N

3 0 3 as (M+E)* 418.1. 'H NMR (400MHz, dmso-d): 8: 8.03 (s, 1H), 7.73-7.41 (m, 71); 7.03 (d, J= 8.0 Hz, 1H), 4.82 (s, 2H), 4.26 (im, 2H); 4.00 (in, 2H); 383 (s, 3). Example 116 10 (1H-pyrazol-3-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f] [1,41 oxazepin-4(5H)-yl)methanone (Compound IH-15) F{F0 .. 0 F NI IN N-NH [0535] Compound 111-15 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 20 Hi 6

F

3

N

3 0 3 as (M+H)* 404.1. 15 Example 117 (1,5-dimethyl-lH-pyrazol-3-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[f] [1,4joxazepin-4(5H)-yl)methanone (Compound 111-58) F{0~ F N N & Y N N-N (0536] Compound HI-58 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. MS found for CnH 2 0F 3

N

3 0 3 as (M+H)* 432.1 259 Example 118 Pyrazin-2-yi(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo(fj (1,4] oxazepin 4(5H)-yomethanone (Compound I-23) F+O O N F N K) N 5 [05371 Compound IH-23 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 1Hi'F 3

N

3 0 3 as (M+H)+ 416.1. Example 119 Pyridazin-3-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f1[1,4]oxazepin 4(SH)-yl)methanone (Compound HI-24) F O O F N 10 i [0538I Compound 111-24 was prepared according to the Examples disclosed herein+ using the appropriate starting materials. MS found for Ci4H 1

F

3

NO

2 as (M+H)* 310.LMS found for C21Hi6F3N303 as (M+H)* 416.1. Example 120 15 4-(pyrimidin-2-ylmethyl)-7-p-tolyl-3,4-dihydrobenzo[f1 ,4]oxazepin-5(2H)-one (Compound H-87) 0 N N NNN [05391 Compound 11-87 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 1

H

19

N

3 0 2 as (M+IH) 346.1 'H 20 NMR (400MHz, dmso-d 6 ): : 8.77 (d, J=5.2Hz, 211), 7.90 (d, J=2,4Hz, IH), 7.75 (dd, J=2.4, 8.8 Hz, 1H), 7.52 (d, J=8.8Hz, 2H), 7.40 (t, J=5.2Hz, 1H), 7.25 (d, J=8.OHz, 2H), 7A2 (d, J=8.4Hz, 111), 4.96 (s, 2H), 4.49-4.47 (m, 2H), 3.75-3.73 (, 211), 2.31 (s, 311). 260 Example 121 7-(4-chlorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one (Compound 11-88) CQ N 0K-) N 5 [0540] Compound 11-88 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 20

H

1 iN 3 0 2 C1 as (M+H 366.1 1H NMR (400MHz, dnso-d 6 ): 8: 8.77 (d, J=5.2Hz, 2H), 7.94 (d, J=2.4Hz, 1H), 7.79 (dd, 1=2.4, 8.8 Hz, 1H), 7.67 (d, J=8.8Hz, 2H), 7.49 (d, J=8.OHz, 211), 7.40 (t, J=5.2Hz, 1H), 7.13 (d, J=8.4Hz, 1H), 4.97 (s, 2H), 4.51-4.49 (m, 2H), 3.77-3.74 (m, 2H). 10 Example 122 7-(4-isopropylpheny)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound 11-89) o N NN K) [0541] Compound 11-89 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. MS found for C23H23NO2 as (M+H)* 374.1 '1H NMR (400MHz, dmso-da): 8: 8.77 (d, J=5.2Hz, 2H), 7.90 (d, J=2.4Hz, 1H), 7.75 (dd, J=2A, 8.8 Hz, 1H), 7.55 (d, J=8.8Hz, 2H), 7.41 (t, J=5.2Hz, 1H), 7.29 (d, J=8.Hz, 2H), 7.11 (d, J=8.4Hz, 1H), 4.96 (s, 2H), 4.49-4.47 (m, 2H), 3.75-3.73 (m, 2H), 2.91 (m, 1H); 1.22 (d, J=7.2 Hz, 6H). 20 Example 123 7-(4-ethylphenyl)-4-(pyrimdin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin-5(2H) one (Compound H-91) o N 261 [05421 Compound 11-91 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C22H 2 1N 3 02 as (M+H)* 360.1 'H NMR (400MHz, dmso-dq): 8: 8.77 (d, J=5.2Hz, 2H), 7.91 (d, J=2.4Hz, 1H), 7.75 (dd, J=2.4, 8.8 Hz, 1H), 7.54 (d, J=8.8Hz, 2H), 7.41 (t, J=5.2Hz, 1H), 7.28 (d, J=8.0Hz, 2H), 5 7.12 (d, J=8.4Hz, 1H), 4.97 (s, 211), 4.49-4.47 (m, 2H), 3.75-3.73 (m, 2H), 2.64 (q, J= 7.6 Hz, 211); 1.20 (d, J = 7.6 Hz, 3H). Example 124 7-(4-cyclopropylphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound H-92) 0 N (I 09-/) 10 [05431 Compound 11-92 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C2H21N 3

O

2 as (M+H)+ 372.1 1H NMR (400MHz, dmso-d4): 8: 8.77 (d, J=5.2Hz, 211), 7.88 (d, J=2.4Hz, 1H), 7.74 (dd, 1=2.4, 8.8 Hz, 1H), 7.50 (d, J=8.8Hz, 211), 7.41 (t, J=5.2Hz, 1H), 7.14 (d, J=8.0Hz, 2H), 15 7.10 (d, J=8.4Hz, 1H), 4.96 (s, 2H), 4.49-4.47 (m, 2H), 3.75-3.73 (m, 2H), 1.94-1.89 (in, 1f); 0.97-0.93 (m, 2H); 0.70-0.66 (m, 2H). Example 125 7-(4-methoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[fj [1,4]oxazepin 5(2H)-one (Compound H-94) 20 0- N 20 A [05441 Compound 11-94 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for CzIHwN 3 0 3 as (M+H)+ 362.1 'H NMR (400MHz, dmso-d 6 ): 8: 8.78 (d, J=5.2Hz, 2H), 7.86 (d, J=2.4Hz, 1H), 7.72 (dd, J=2.4, 8.8 Hz, 1f), 7.56 (d, J=8.8Hz, 2H), 7.41 (t, J=5.2Hz, 1H), 7.10 (d, 1=8.0Hz, 2H), 25 7.00 (d, J=8.4Hz, 1ff), 4.97 (s, 2H), 4.48-4.45 (m, 2H), 3.76 (s, 3H); 3.74-3.72 (m, 2H). 262 Example 126 7-(4-isobutoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one (Compound 11-97) 00 NN 5 [0545] Compound 1-97 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 41 25

N

3 0 3 as (M+H)* 404.1. '11 NMR (400MHz, dmso-ds): 8: 8.78 (d, J=5.2Hz, 2H), 7.85 (d, J=2.4Hz, 1H), 7.72 (dd, J=2.4, 8.8 Hz, 1H), 7.54 (d, J=8.8Hz, 2H), 7.41 (t,J=5.2Hz, 1HR), 7.10 (d, J=8.OHz, 2), 6.99 (d, J=8.AHz, 1H), 4.97 (s, 2H), 4.48-4.46 (m, 2H), 3.76-3.72 (m, 4$; 2.03-1.97 (m, 10 11); 0.97 (d, J= 6.4 Hz, 6H). Example 127 7-(4-tert-butylphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound 11-98) N0N N N DO) 15 [0546] Compound H-98 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C24H 2 5

N

3 0 3 as (M+H)* 404.1 IH NMR (400MHz, dirso-d) 8: 8.78 (d, J=5.2Hz, 2H), 7.91 (d, J=2AHz, 11), 7.75 (dd, J=2.4, 8.8 Hz, 1H), 7.55 (d, J=8.8Hz, 2$), 7.46 (d, J=8.0Hz, 2H1); 7.41 (t, J=5.2Hz, 1H); 7.11(d, J=8.4Hz, 1H), 4.97 (s, 2H), 4.50-4.47 (m, 211), 3.76-3.73 (m, 4H); 1.29 (s, 911). 263 Example 128 7-(4-eyclopropoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-102) 00N O N 5 [0547] Compound H-102 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C23H 2 1N 3 0 3 as (M+H)* 388.1 'H NMR (400MHz, dmso-d): 8: 8.78 (d, J=5.2Hz, 2H), 7.86 (d, J=2.4Hz, 1H), 7.72 (dd, J=2.4, 8.8 Hz, 1f), 7.57 (d, J=8.8Hz, 2H), 7.41 (t, J=5.2Hz, 1H); 7A6 (d, J=8.OHz, 211), 7.11 (m, 3H), 4.97 (s, 2H), 4.48-4.46 (m, 2H), 3.87-3.86 (m, 1H); 3.84-3.74 (mi, 211); 10 0.80-0.75 (m, 2H); 0.67-0.65 (m, 2H). Example 129 7-(4-chloro-2-fluorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 1-117) Cl -a sN~ N1 N / F 15 [0548] Compound H-117 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 20

H

1 sN 3 0 2 FC as (M+H)* 384.1 1H NMR (400MHz, drnso-d 6 ): 6: 8.77 (d, J=5.2Hz, 2H), 7.87 (d, J=2.4Hz, 1H), 7.66 (dd, J=2.4, 8.8 Hz, JH), 7.57-7.51 (m, 2H); 7.41-7.35 (m, 2H); 7.16 (d, J=8.OHz, 1H), 4.97 (s, 2H), 4.54-4.52 (m, 2H), 3.79-3.76 (m, 2H). 20 Example 130 pyrimidin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f] [1,4] oxazepin 4(5H)-yl)methanone (Compound HI-1) F O O N 264 [0549] To a solution of 7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (660 mgs, 2.0 mmol) in THF (6 mL), LOM Borane in THF (6.0 mL, 6.0 mmol) was added and the mixture was heated at 70 "C. After 16h, the mixture was cooled to rt and Methanol (22 mL) and 6.OM HCI (22 mL) was 5 added and stirred at rt for 2h. The reaction mixture was then concentrated and the solids formed were filtered and washed with ether and dried to give 7-(4 (trifluoromethoxy)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine as HCI salt. The above compound (100 mgs, 0.29 mmol), pyrimidine-2-carboxylic acid (47 mgs, 0.38 mmol), HATU (143 mgs, 0.38 mmol), in DMF (I mL) was added NMM (0.1 mL, 0.86 10 mmol) and stirred at 60 *C for 30min.The reaction mixture was then diluted with EtOAc and washed with NaHCO 3 , brine and dried (MgS(0) 4 ). The mixture was the filtered, concentrated and chromatographed (SiO 2 , 50% EtOAc/DCM) to provide the title compound. [0550] MS found for C 21 H1 6

F

3

N

3 0 3 as (M+H)+ 415.9. 'H NMR (400MHz, dmso-d 6 ): 15 mixture of rotomers (-2:1): 'H-NMR (DMSO) of the major rotomer: 6 8.86 (d, J=5.2Hz, 211), 7.77 (d, J=8.8 Hz, 2H), 7.75 (m, 1H); 7.69-7.54 (m, 2H); 7.47-7.40 (m, 2H); 7.11 (d, J = 8.0 Hz, 1H); 4.85 (s, 2H); 4.25-4.03 (m, 411); 3.58-3.56 (m, 2H). Example 131 7-cyclohexenyl-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin-5(2H) 20 one (Compound V-3) 0 N N:N (0551] Compound V-3 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 0

H

2 1

N

3 0 2 as (M+H)* 336.1. Example 132 25 7-(4-methyleyclohex-1-eny1)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4joxazepIn-5(2H)-one (Compound V-5) 26 N 265 [0552] Compound V-5 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C 2 1

H

2 3

N

3 0 2 as (M+H)* 350.1 1H NMR (400MHz, dmso-d): 8: 8.76 (d, J=5.2Hz, 2H), 7.65 (d, J=2.4Hz, 1H), 7.53 (dd, J=2.4, 8.4 Hz, 1H), 7.42-7.39 (m, 1H); 6.98 (d, J=84Hz, 1H); 6.08 (m, 1H); 4.94 (s, 2H), 4.44-4.42 5 (m, 2H), 3.69-3.67 (m, 2H); 2.36-2.23 (m, 4H); 1.81-1.66 (m, 5H); 1.31-1.26 (m, IH). Example 133 7-(4-ethyleyelohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj [1,4loxazepin-5(2H)-one (Compound V-6) 0 NN& 10 [05531 Compound V-6 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS found for C22H2sN302 as (M+H)* 364.1 'H NMR (400MHz, dmso-d 6 ): 8: 8.77 (d, J=5.2Hz, 2H), 7.65 (d, J=2.4Hz, 111), 7.52 (dd, J=2.4, 8.4 Hz, 111), 7.42-7.38 (i, 1H); 6.98 (d, J= 8.4Hz, 1H); 6.09 (m, 1H); 4,94 (s, 2H), 4.44 4.42 (m, 2H), 3.70-3.67 (m, 2H); 2.36-2.25 (m, 3H); 1.84-1.77 (m, 2H); 1.32-1.26 (n, 15 4H); 0.91-0.88 (m, 3H). Example 134 (R)-7-(4-methyleyelohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound V-8) 0~ ~ N.i) '. 20 N 0 N [0554] The racemic 7-(4-methyleyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one was separted using chiral preparative HPLC to give pure enantiomers of Compound V-8 and Compound V-9. [05551 R-enantiomer: MS found for C21H23NO2 as (M+H)+ 350.1 266 Example 135 (S)-7-(4-methylcydohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dlhydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound V-9) A N N 5 [0556] Compound V-9 was prepared according to the Example above. S-enantiomer: MS found for C 21 H23N 3 0 2 as (M+H)+ 350.1 Example 136 3-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzoff] [1,4] oxazepin-5(2H)-one (Compound 11-142) F F NH A N 10 0 ~F 3 C x1:D Br

F

3 CO suzuki F 1) B(OH) 2 A [0557] Synthesis of 6-(4-(trifluoromethoxy)phenyl)chroman-4-one. See previous Suzuki reaction conditions. m/z = 309.0

F

3 CO + 0 FSCOA +3ON pyrrolidine FC 10 + Oi EtOH, reflux A 15 [0558] Synthesis of 3-(pyridin-2-ylmethylene)-6-(4-(trifluoromethoxy)phenyl)chroman 4-one. A solution of 400mg 6-(4-(trifluoromethoxy)phenyl)chroman-4-one (1.3 mmol, 1.0 eq), 150 gL 2-pyridine carboxaldehyde ( 1.6 mmol, 1.2 eg) and 130 ±L pyrrolidine ( 1.6 mmol, 1.2 eq) in 10 mL ethanol was refluxed 3h. The reaction was concentrated and 267 purified on silica gel column eluting with EA:Hex. 160 mg of a yellow solid was collected. m/z= 398.0

F

3 CO 0 F 3 CO 0 N H 2 PdC N N EtOH [05591 Synthesis of 3-(pyridin-2-yhnethyl)-6-(4-(trifluoromethoxy)phenyl)chmnman-4 5 one. A solution of 150 mg 3-(pyridin-2-ylmethylene)-6-(4 (irifluoromethoxy)phenyl)chroman-4-one (0.38 mmol) in 20 rnL EtOH with catalytic Pd/C was stirred under I atm of hydrogen gas for 16 h. The reaction was filtered through celite and the filtrate concentrated. The filtrate was purified on silica gel column eluting with EA:Hex. 85 mg of an off-white solid was collected. m/r= 400. F3CO / O

F

3 CO 0 O N NaN 3 NH

A

0 Amethylsulfonic O 10 (0560] Synthesis of 3-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one. To a solution of 72 mg 3-(pyridin-2-ylmethyl) 6-(4-(trifluoromethoxy)pheny)chroman-4-one (0.18 mmol) in ImL methylsulfonic acid 35 mg sodium azide (0.54 mmol) was added. After lh, reaction was diluted with 5 mL 15 water and neutralized with addition of IN NaOH solution. The precipitate was filter off to afford 65 mg off-white powder of product. m/z= 415.0 Example 137 7-(4-(cyclobutylmethoxy)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepln-5(2H)-one (Compound -U-144) c\Nr 0 A 0 20 [0561] Compound H-144 was prepared according to example 25 using 2-(4 (cyclobutylmethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS found for C25H25N303 as (M+H)+ 416.22 'H NMR (400MHz, dmso-ds): 'H-NMR (DMSO) & 268 8.78 (d,J= 5.2Hz, 2H), 7.86 (d, J=2.OHz, 1ff), 7.72 (dd, J=2.4-8.4Hz, 111), 7.54 (d, J=8.4Hz, 2H), 7.41 (t, J= 5.2Hz, 1H), 7.09 (d, J=8.4Hz, 1 H), 6.99 (d, J=8.8Hz, 211), 4.97 (s, 211), 4A8 (t,J=4.4Hz, 211), 3.97 (d, J=6.8Hz, 2H), 3.74 (t, J=4.8Hz, 2H), 2.75-2.67 (in, 1H), 2.09-2.03 (m, 2H), 1.94-1.79 (m, 4H). 5 Example 138 4-(pyrimidin-2-ylmethyl)-7-(6-(2,2,2-trifluoroethylpyridin-3-yl)-3,4 dlhydrobenzo[f] [1,4] oxazepin-5(2H)-one (Compound VI-24) F NN F I Qi -(\s:) F N [0562] Compound VI-24 was prepared according to example 25 using 5-(4,4,5,5 10 tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2,2,2-trifluoroethyl)pyridine. Example 139 7-(2-methyl-4-(trifluoromethyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-145) F F F

.

o N N 15 [0563] Compound 11-145 was prepared according to example 25 using 2-methyl-4 (trifluoromethyl)phenylboronic acid. MS found for C22H1 8F3N302 as (M+H)+ 414.32 Example 140 7-(2-methyl-4-(trifluoromethoxy)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(211)-one (Compound H-146) F F N 20 [0564] Compound H-146 was prepared according to example 25 using 2-methyl-4 (trifluoromethoxy)phenylboronic acid. MS found for C22H18F3N303 as (M+$)* 430.19 269 '1H NMR (400MHz, dmso-d): 'IH-NMR (DMSO) 8: 8.77 (d, J= 5.2Hz, 2H), 7.64 (d, J=2.4Hz, 111), 7.48 (dd, J=2.4-8.4Hz, 1H), 7A0 (t, .J=4.8HIz, 1H), 7.31 (d, J= 8.4Hz, 2H), 7.23 (d, J=8.8Hz, 1H), 7.11 (d, J=8.4Hz, IH), 4.96 (s, 2H), 4.52 (t, J=4AHz, 2H), 3.78 Ct J=4.4Hz, 2H), 2.25 (s, 311). 5 Example 141 7-(4-(difluoromethyl)phenyl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzof][1,4]oxazepin-5(2H)-one (Compound 11-157) F F / 0 N'N [0565] Compound H-157 was prepared according to example 25 using 4 10 (difluoromethyl)phenylboronic acid. MS found for C22H18F2N202 as (M+H)* 381.20 'H NMR (400MHz, dmso-d 6 ): 'H-NMR (DMSO) 5: 8.54 (s, 1H), 8.02 (s, 1H), 7.85-7.80 (m, 4H), 7.65 (d, J=7.6H1z, 211), 7.38-7.31 (m, 2H), 7.16 (d,1= 8.0Hz, 1M), 7.08 (t J=55.6Hz, 1), 4.87 (s, 2H), 4.40 (s, 211), 3.71 (s, 2H). Example 142 15 4-(pyridin-2-ylmethy1)-7-(2-(trifluoromethyl)pyridin-4-yl)-3,4 dihydrobenzo[f] [1,4]oxazepIn-5(21)-one (Compound VI-25) F F F N NX [0566] Compound VI-25 was prepared according to example 25 using 4-(4,4,5,5 tetramethyl-1,3,2-dioxaborolaa-2-yl)-2-(trifluoromethyl)pyridine. 270 Example 143 7-(4-chloro-3-fluorophenyl)-4-(yridin-2-ylmethy)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound H-158) G1 0 F N 010 5 [0567J Compound 11-158 was prepared according to example 25 using 4-chloro-3 fluorophenylboronic acid. MS found for C21H16CFN202 as (M+H)* 383.17 'H NMR (400MHz, dmso-d6): 'H-NMR (DMSO) 8: 8.60 (d, J= 4.8Hz, IN), 8.01 (d, J=7.2Hz, 1H), 7.94 (d, J=2.4Hz, 1H), 7.79 (dd, J=2.4-8.4Hz, 1H), 7.69 (dd, J= 2.0-10.8Hz, 1H), 7.61 7.47 (m, 4H), 7.09 (d, J=8.4Hz, 1H), 4.90 (s, 2H), 4.36 (t, J=4.8Hz, 2H), 3.69 (t, J=4.8Hz, 10 2H). Example 144 7-(4-(difluoromethoxy)phenyl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4] oxazepin-5(2H)-one (Compound H-159) F F 15 [0568] Compound U1-159 was prepared according to example 25 using 2-(4 (difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS found for C22H 1 3

F

2

N

2 0 3 as (M+H)' 397.22. Example 145 4-(pyridin-2-ylmethyl)-7-(5-(trifluoromethyl)pyridin-2-yl)-3,4 20 dihydrobenzo[f] [1,4] oxazepin-5(2H)-one (Compound VX-26) F F F O N A) N 27 271 [05691 Compound VI-26 was prepared according to example 25 using 2-(4,4,5,5 tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)pyridiue. MS found for C21H16F3N302 as (M+HI) 400.21. Example 146 5 7-(1-methyl-1H-pyrazol-4-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2Hf)-one (Compound VI-27) -N IP [0570] Compound VI-27 was prepared according to example 25 using 1-methyl-4 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. 10 Example 147 7-(1-isopropyl-1R-pyrazol-4-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound VI-28) N [0571] Compound VI-28 was prepared according to example 25 using 1-isopropyl-4 15 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. Example 148 7-(1-methyl-1H-pyrazol-3-yl)-4-(pyridin-2-ylmethyl)-3,4 diiydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-29) N-N o 20 [0572] Compound VI-29 was prepared according to example 25 using 1-methyl-3 (4,4,5,5-tetramethyl-1,3,2-dioxabomlan-2-yl)-1H-pyrazole. 272 Example 149 7-(2-isopropylthiazol-4-yl)-4-(pyridin-2-ylmethyl)-3,4-dihydrobenzofj [1,4] oxazepin 5(2H)-one (Compound VI-30) N 0N 5 [0573] Compound VI-30 was prepared according to example 25 using 2-isopropyl-4 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole. MS found for C2 1H21N302S as (M+H)* 380.20 1H NMR (400MHz, dmso-d 6 ): 1 H-NMR (DMSO) 6:8.53 (d, J= 4.8Hz, 111), 8.26 (d, J=2.OHz, 111), 8.01 (dd, J=2.0-8.8Hz, 111), 7.94 (s, 1H), 7.78 (t, J= 7.2Hz, 111), 7.36-7.28 (m, 2H), 7.09 (d, J=8.0Hz, 1H), 4.85 (s, 2H), 4.36 (t, J=4.4Hz, 2H), 3.66 10 (t, J=4.8Hz, 2H), 1.36 (d, J=6.8Hz, 6H). Example 150 4-(pyrimidin-2-ylmethyl)-7-(2,3,4-trifluorophenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound 11-162) F

N'

F F ND 15 [0574] Compound 11-162 was prepared according to example 25 using 2,3,4 trifluorophenylboronic acid. MS found for C20H14F3N302 as (M+H)* 386.14. Example 151 7-(3,4-difluorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one (Compound 11-163) FN 20 [0575] Compound 11-163 was prepared according to example 25 using 3,4 difluorophenylboronic acid. MS found for C20H15F2N302 as (M+H)* 368.15. 273 Example 152 4-(pyridin-2-ylmethyl)-7-(5-(trifluoromethyl)thiophen-2-yl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-31) F F F N 5 [0576] Compound VI-31 was prepared according to example 29 using 2-bromo-5 (trifluoromethyl)thiophene. MS found for C2OH15F3N2Q2S as (M+HF 405.16 'H NMR (400MHz, dmso-dj): 'IH-NMR (DMSO) 8: 8.53 (d, .= 4.8Hz, 1H), 8.02 (d, J=2.0Hz, 1H), 7.87-7.71 (m, 3H), 7.59 (d, J= 3.2Hz, 1H), 7.37-7.28 (m, 2H), 7.13 (d, J= 8.4Hz, 1H), 4.85 (s, 2H), 4.40 (t, J=4.8Hz, 211), 3.70 (t, .1=4.8Hz, 211). 10 Example 153 7-(5-cyclopropylthiophen-2-yl)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2R)-one (Compound VI-32) S O N [0577] Compound VI-32 was prepared according to example 29 using 2-bromo-5 15 cyclopropylthiophene. MS found for C22H20N2025 as (M+H)+ 377.18 'H NMR (400MHz, dnso-d4): 'H-NMR (DMSO) 8: 8.53 (d, J=4.8Hz, 1H), 7.81-7.76 (m, 2H), 7.68 (dd, J=2A-8.OHz, 1H), 7.36-7.24 (m, 3H), 7.04 (d, J= 8.4Hz, 1H), 6.80 (d, J= 3.6Hz, 111), 4.84 (s, 2H), 4.34 (t, J=5.2Hz, 2H), 3.66 (t, J=5.2Hz, 2H), 2.14-2.10 (m, 1H), 1.02 0.97 (m, 2H), 0.71-0.67 (i, 211). 274 Example 154 7-(2-methylthiazol-4-yl)-4-(pyridin-2-ylmethyl)-3,4-dihydrobenzo[f] 1,4]oxazepin 5(2H)-one (Compound VI-33) N O0 5 [0578J Compound VI-33 was prepared according to example 29 using 4-bromo-2 methylthiazole. Example 155 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5 dione (Compound X-S) F F 0 N 10 H 0 00 0 N'I? F 3 C1, jih 2 !, Br H NBn BrF B(OHh ~-'N-% DMSO, A Pdfdpt)C1, KCO,. [05791 A mixture of 5-bromoisatoic anhydride (1g, 4.13mmol), N-benzylglycine (0.628g, 4.13mmol) and DMSO (3mL) was heated in the microwave at 200*C for one hour. After cooling, the mixture was diluted with water and the precipitate was filtered 15 off, washed with water and dried, giving 4-benzyl-7-bromo-3,4-dihydro-1H benzo[e][1,4]diazepine-2,5-dione (1.4g, 98%) as an off-white powder. [0580] 4-Benzyl-7-bromo-3,4-dihydro-IH-benzo[e}[1,4]diazepiue-2,5-dione (1.4g, 4.05mmol) was combined with 4-(trifluoromethyl)phenylboronic acid (0.77g, 4.05mmol), potassium carbonate (Ig) and [1,1' 20 Bis(diphenylphosphino)ferrocene]dichloropalladium(l) (148 mg, 0.202 mmol) in 5mL DMF. Water (3mL) was added and the mixture was heated under nitrogen atmosphere at 80*C for three hours. After cooling the mixture was diluted with ethyl acetate, washed with water and brine, dried with magnesium sulfate and evaporated. Purification by silica 275 gel chromatography (20-100% ethyl acetate in hexane) followed by recrystallization gave 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (1.25g, 75%) as a white powder. [05811 'H-NMR (DMSO) B: 10.61 (s, IH), 8.13 (d, J=1.6Hz, 111), 7.92 (d, J=8.4Hz, 5 3H), 7.11 (d, J=8.4Hz, 2H), 7.36-7.25 (m, 5H), 7.22 (d, J=8.4Hz, 1H), 4.79 (s, 2H), 3.92 (s, 2H). MS: 411 (MH+ Example 156 4-benzyl-1-methyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro- 11H benzo[e] [1,4] diazepine-2,5-dione (Compound X-11) F F F N N 10 F F F F FN Mel,

K

2

CO

3 N DMF N [0582] 4-Benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydro-IH-benzo[e][1,4]diazepine 2,5-dione (9.80 mg, 0.024 mmol) and K 2 C0 3 (10 mg, 0.072 mmol, 3.0 equiv.) were 15 placed in a 0.5-2 mL Smith process vial under a nitrogen atmosphere. To the vial were added DMF (0.5 mL) and iodomethane (2.25 pL, 0.036 mmol, d = 2.28 g/cmi, 1.5 equiv) at room temperature. After heating, stirred, at 60*C for 2 hours, the reaction mixture was concentrated en vacuo. The resulting crude mixture was diluted with acetonitrile (1 mL), filtered through a syringe filter and injected into a preparative HPLC to give desired 20 product (4-benzyl-1-methyl-7-(4-(trifluoromthyl)phenyl)-3,4-dihydro-H benzo[e][1,4]diazepine-2,5-dione, 1.8 mg) as a yellow film. [0583] 'H-NMR (400 MHz; CD 3 CN) 88.16 (d, 1H, J= 2 Hz), 7.93 (dd, 1H, J=8.4 Hz, 2 Hz), 7.92 (d, 2H, J= 7.8 Hz), 7.82 (d, 2H, J= 7.8 Hz), 7.47 (d, 1H, J= 8.4 Hz), 4.98 (d, iH, J= 15 Hz), 4.73 (d, 1H, J= 15 Hz), 4.10 (d, iH, J= 15 Hz), 3.70 (d, iH, J= 15 Hz), 276 3.37 (s, 3H). ' 9 F-NMR (400 MHz; CD 3 CN) 8 -63.96 (s, 3F). LCMS (EL: 70 eV) 447.1 (M++Na), 425.1 (M++1). Example 157 (S)-3-(2-hydroxyethyl)-1-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H 5 benzo[e] [1,4] diazepine-2,5-dione (Compound X-1) F O 0 F NH OH N -F[OHH dh0 Ff20

NH

2 NHI DMF FF [05841 2-Amino-5-iodobenzoic acid (1.327 g, 5.05 mmol), 4-trifluoromethoxyboronic 10 acid'(1.455 g, 7.07 mmol, 1.4 equiv.), Pd(dppf)CI2-CH 2 Cl 2 (183.0 mg, 0.252 mmol, 5 mol%) and K 2

CO

3 (1.604 g, 11.61 mmol, 2.3 equiv.) were dissolved in a mixture of H20/toluene/i-PrOH (2.5 mL: 5 mL: 2.5 mL) in a 10 mL Smith process vial equipped with a stir bar under a nitrogen atmosphere. The mixture was heated at 90*C for 1 hour. After aqueous workup and removal of volatile solvents en vacuo, the mixture was purified 15 by automated silica-gel column chromatography using an EtOAc/hexane gradient as the eluent. The purification gave the desired product (4-amino-4'-(trifluoromethoxy)biphenyl 3-carboxylic acid, 462.0 mg) as a colorless powder. [0585] To a suspension of 4-amino-4'-(trifluoromethoxy)biphenyl-3-carboxylic acid (462.0 mg, 1.554 mmol) in CH 2

CI

2 (10 mL) in a round bottomed flask was added 20 triethylamine (210 L, 1.492 mmol, d = 0.726 g/cm 3 , 0.96 equiv.). Flask was charged with nitrogen, cooled to 0*C and a solution of triphosgene (148.0 mg, 0A97 mmol, 0.32 equiv.) in 2 mL DCM was added, followed by a solution of N,N-dimethyl-4-aminopyridine (30 mg, 0.246 mmol, 25 mol%) in CH 2 C1 2 (2 mL). Reaction mixture was allowed to stir 2 hours, then quenched with a small portion of 1N HCl. Reaction mixture with resulting 25 precipitate was filtered through a disposable filter funnel and air-dried to give desired 277 product (6-(4-(trifluoromethoxy)phenyl)-1IH-benzo[d][1,3]oxazine-2,4-dione, 348.6 mg) as a colorless solid. [05861 6-(4-(Trifluoromethoxy)phenyl)-1H-benzo[d](1,3]oxazine-2,4-dione (348.6 mg, 1.077 mmol) and K 2

CO

3 (228 mg, 2.153 mmol, 2 equiv.) were placed in a 0.5-2 mL 5 Smith process vial. To the vial was added DMF (3 mL) and iodomethane (101 pL, d= 2.28, 1.615 mmol, 1.5 equiv.) at ambient temperature. The mixture was stirred overnight at room temperature and then filtered through a disposable filter funnel. Obtained filtrate was diluted with water to form precipitates, which were collected on a disposable filter funnel and allowed to air-dry to give desired product (1-methyl-6-(4 10 (trifluoromethoxy)phenyl)-lH-benzo[d][1,3]oxazine-2,4-dione, 357.2 mg) as a colorless solid. [0587] l-Methyl-6-(4-(trifluoromethoxy)phenyl)-1H-benzo[d][1,3]oxazine-2,4-dione (60 mg, 0.178 mmol) and L-homoserine (23.3 mg, 0.196 mmol, 1.1 equiv.) were added to a magnetically stirred 0.5-2 mL Smith process vial containing 0.75 mL glacial acetic acid. 15 Reaction mixture was then heated for 2 hours at 130*C. Excess acetic acid was then removed en vacuo, residue was dissolved into a minimal amount of acetonitrile and purified by reverse-phase preparative HPLC to give the title compound (7.6 mg) following removal of solvent as a clear yellow film. [0588] LCMS (EI: 70 eV) 459.1 (M++Na), 437.1 (M++1) 20 Example 158 1-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H-benzo[eI [1,4jdiazepine-2,5 dione (Compound X-2) F 0 ./0 F N NH F Mel, Ns 2 eCQ, Gtyche *re.~~ H KBOJ DMF GO L (r 25 [05891 6-Bromo-IH-benzo[d][1,3]oxazine-2,4-dione (5.0 g, 20.66 nimol), iodomethane: (1.94 mL, d=2.28,4A g, 31.0 mmol, 1.5 equiv.) and Na2C 3 (4.38 g, 41.3 mmol, 2 278 equiv) were placed in a round bottomed flask. To the flask were added DMF (40 mL) at ambient temperature. The mixture was stirred overnight at room temperature and then filtered through a glass filter. Obtained filtrate was diluted with water to form precipitates. The precipitates were dissolved in EtOAc and the solution was dried over MgS(0) 4 .The 5 solvent was removed under reduced pressure. At this point, since the conversion was -50%, K 2 C0 3 (14.3 g, 103.3 mmol, 5 equiv.) and iodomethane (2.58 mL, d = 2.28, 41.3 mmol, 2.0 equiv.) were added to the solution of the crude material in DMF. The mixture was heated at 300C so that the reaction can go to completion and then filtered through a glass filter. Obtained filtrate was diluted with water to form precipitates. Formed 10 precipitates were filtered through a glass filter to give the desired product (6-bromo-1 methyl- 1H-benzo[d][1,3]oxazine-2,4-dione). This was used for the subsequent step without further purification. [0590] 6-Bromo-1-methyl-1IH-benzo[d][1,3]oxazine-2,4-dione (5.29 g, 20.66 mmol) and glycine (1.7 g, 22.73 nmol, 1.1 equiv.) were dissolved in AcOH (100 mL) in a round 15 bottomed flask. The mixture was heated under reflux conditions for 2 hours. The mixture was purified by automated silica-gel column chromatography using EtOAc/hexane gradient as the eluent. The purification give the desired product (7-bromo-1-methyl-3,4 dihydro-1H-benzo[e][1,4]diazepine-2,5-dione, colorless powder, 446.7 mg). 10591] 7-Bromo-1-methyl-3,4-dihydro-LH-benzo[e][1,4]diazepine-2,5-dione (446.7 mg, 20 1.661 mmol), 4-trifluoromethoxyboronic acid (445.0 mg, 2.159 nimol, 1.3 equiv.) Pd(dppf)Cl 2

-CH

2 Cl 2 (120.0 mg, 0.166 mmol, 10 mol%) and K 2

CO

3 (482.0 mg, 3.49 mmol, 2.1 equiv.) were dissolved in a mixture of H20/toluene/i-PrOH (2.5 mL: 5 mnL: 2.5 mL) in a 10 mL round bottomed flask under a nitrogen atmosphere. The mixture was heated at 60 0 C for 64 hours. The mixture was purified by automated silica-gel column 25 chromatography using EtOAc/hexane gradient as the eluent. Evaporation of solvent en vacuo gave the title compound (415.0 mg) as a white powder. [0592] LCMS (EI: 70 eV) 373.1 (M++Na), 351.1 (M++1) 279 Example 159 1-methyl-4-(pyrimidin-2-ylmethy)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H benzo[e] [1,4J diazepine-2,5-dione (Compound X-3) F O F N N 10 5 F [0593] 1-Methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H benzo[e][1,4]diazepine-2,5-dione (22.9 meg, 0.065 mmnol) and NaHl (15.6 mg, 0.650 mmol, 10.0 equiv.) were placed in a 0.5-2 mL Smith process vial. To the vial was added DMF (0.5 mL) followed by 2-(chlommethyl)pyrimidine hydrochloride (53.9 mng, 0 327 10 mmol, 5 equiv.) was added at room temperature. After stirring for 50 rmin, reaction was quenched with AcOHl. Resulting mixture was filtered and purified via preparative reverse phase HIPLC to give the title compound (2.2 mg) as a clear yellow film. [0594] LCMS (EI: 70 eV) 443.1 (M-H--1) Example 160 15 1-methyl-4-(pyridin-.2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1H benzoEel][1,4]diazepine-.2,5-dione (Compound X-4) SNA F(0 [05951 Compound X-4 was prepared according to the above example using the appropriate staffing materials. 280 Example 161 4-(4-(1H-pyrazol-1-yl)benzyl)-1-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro 1H-benzo [6] [1,4]diazepine-2,5-dione (Compound X-6) FN N% N 5 [0596] Compound X-6 was prepared according to the above example using the appropriate starting materials. Example 162 1-(4-methoxybenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-1IH benzo[e][1,4]dlazepine-2,5-dlone (Compound X-5) F O O F N N:NH

N

10 %oC0 BrN jH FO O~ __ _I ) FN Cs 2 CO DMF Pd(dp CC CP [05971 7-Bromo-3,4-dihydro-1lH-benzo[e][1,4]diazepine-2,5-dione (510.0 mg, 2 mmol) and Cs 2

CO

3 (1.955 nag, 6 mmol, 3 equiv.) were placed in a round bottomed flask. To the reaction vessel was added DMF (10 mL) and 4-methoxybenzyl chloride (273 , 1.615 15 mmol, d = 1.15 g/mL, 1 equiv.) at ambient temperature. The mixture was stirred overnight at room temperature and then filtered through a disposable filter funnel. Resulting filtrate was concentrated en vacuo and purified by automated silica-gel column chromatography using an EtOAc/hexane gradient as the eluent to give the desired product (7-bromo-1-(4-methoxybenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione, 378.3 20 mg) as a colorless solid. 281 [0598] 7-Bmmo-1-methyl-3,4-dihydro-1H-benzoe}[1,4]diazepine-2,5-dione (375.0 mg, 1.007 mmol), 4-trifluoromethoxyboronic acid (270.0 mg, 1.31 mmol, 1.3 equiv.) Pd(dppf)ClrCH2Cl 2 (72.9.0 mg, 0.101 mmol, 10 mol%) and K 2

CO

3 (292.0 mg, 2.116 mmol, 2.1 equiv.) were dissolved in a mixture of H 2 0/toluene/i-PrOH (1.25 mL: 2.5 mL: 5 1.25 mL) in a 2-5 mL Smith process vial equipped with a stir bar under a nitrogen atmosphere. The mixture was heated at 50*C for 17 hours. After aqueous workup and removal of volatile solvents en vacuo, the mixture was purified by automated silica-gel column chromatography using an EtOAc/hexane gradient as the eluent The purification gave the title compound (419 mg) as a colorless powder. 10 [0599] LCMS (EI: 70 eV) 479.1 (M++Na), 457.1 (M++1) Example 163 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dlhydropyrido[4,3-fJ[1,4]oxazepin 5(211)-one (Compound XH-1) F O F N Br OH P t-,,0H Br Nai, DMF Br .- F EDCI. DCM, N %%:N.F rit 0 OH Pd(dppf)C12 Trllisopropano/H20 85 C, 2h F NN 15 F [0600] To 2-bromo-5-fluoroisonicotinic acid (5 g, 22.72 mmol) benzyl amino ethanol (4.20 g, 27.27 mmol, 1.2 eq) was added in the presence of EDCI (5.2 g, 27.27 mmol, 1.2 eq) in dichloromethane (100 mL) and stirred at room temperature for 4h. The reaction 20 mixture was diluted with dichloromethane, washed with water, brine, dried over sodium sulfate and concentrated (5.0 g). The residue (5.0g, 14.16 mmol) was cyclized by 282 dissolving in DMF (20 mL), sodium hydride (1.2 g, 28 mmol) was added and stirred at room temperature for 2h The reaction mixture was neutralized with dil. HCl and extracted with ethyl acetate, washed with water, brine, dried over sodium sulfate and concentrated. Purified by flash chromatography furnished 4.4 g of the cyclized product. 5 [0601] The Suzuki coupling was performed under standard conditioned explained in the other procedures using Pd(dppf)C12. Mass (M+H) 415.1. CDCl 3 : 8.46 (S, 1H), 8.28 (S, 1H), 8.05 (d, J = 8.8 Hz, 2H), 7.42-7.32 (m, 5H), 7.30 (d, J = 8.0 Hz, 2H), 4.86 (s, 21), 4.31 (t, J=4 Hz, 2H), 3.57 (t, J= 4 Hz, 2H) Example 164 10 4-(cyclopropylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3 f][1,4]oxazepln-5(2H)-one (Compound XH-9) F N N) 0_ F{0 0 F{O0 o F N H DMF, NaH F NON XII-4 XII-9 [0602] Alkylation of the amide was performed using sodium hydride following the 15 standard procedure to provide Compound XII-9. Mass (M+H) 379.0. Example 165 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[4,3 f] [1,4]oxazepin-5(21)-one (Compound XH-5) F F " O N 20 [0603] Compound XH1-5 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 417.0. 283 Example 166 4-((3-methoxypyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido(4,3-f][1,4]oxazepin-5(2H)-one (Compound X11-10) F F < 0 5 [06041 Compound XII-10 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)j 446.1. CDC 3 : 8.55 (s, 111), 8.41 (s, 11), 8.22 (s, IH), 7.97 (d, J= 8.2 Hz, 2H), 7.61 (d, J = 2.8 Hz, 2H), 7.30 (d, J= 8.4 Hz, 2ff), 5.12 (s, 21), 4.55 (t, J= 4 Hz, 2H), 4.03 (s, 3H), 3.89 (t, J=4 Hz, 2h). Example 167 10 4-((4-methylpyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido [4,3-f] [1,4]oxazepin-5(2H)-one (Compound XHI-8) F O F [06051 Compound X11-8 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H) 431.1. CDC 3 ; 8.54 (d, J= 4.8 Hz, 15 1H), 8.50 (s, 1H), 8.32 (s, 1H), 80.2 (d, J=8.8 Hz, 211), 7.29 (d, J= 83.4 Hz, 211), 7.08 (d, J =5.2 Hz, 111), 5.05 (s, 2H), 4.72 (t, J= 4.4 Hz, 211), 3.83 (t, J = 4.4 Hz, 2H), 2.52 (s, 3H). Example 168 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 20 dihydropyrido[4,3-fJ[1,4]oxazepin-5(2H)-one (Compound XH-11) F N 284F 284 [0606] Compound XLL-11 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 434.0. CDC1 3 : 8.42 (s, 1H), 8.30 (d, J= 4.4 Hz, 111), 8.23 (s, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.37 (t, J= 8.4 Hz, 111), 7.22 (d, J= 8 Hz, 2H), 7.21 (d, J = 8.4 Hz, 111), 4.99 (s, 2H), 4.53 (t, J = 4.4 Hz, 2H), 3.78 (t, J= 5 4Hz, 2H). Example 169 4-((4-methoxypyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydropyrido[4,3-f][1,4]oxazepin-5(2H)-one (Compound XH-14) FF0 F N N N A1 10 [06071 Compound XH-14 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 447.1. Example 170 4-benzyl-9-fluoro-7-(4-(trifluoromethoxy)phenyl)-3,4-dihyd rob enzo [f] [1,4]oxazepin 5(2H)-one (Compound 11-165) F{ FIO0 F NN 15 F 0 0 NrOH . BrBr FF li OHFAOH F -F CO 0 N F5l-165 285 [06081 Compound 11-165 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 432.1. CDCl 3 :7.80 (s, 1H), 7.53 (d, J=8.8 Hz,2H), 7.37 (dd, J1 = 2.4 Hz, J2= 11.2 Hz, 1H), 7.31 (d, J= 4 Hz, 2H), 7.29-7.20 (n, 5H), 4.79 (s, 2H), 4.21 (t, J = 5.2 Hz, 2H), 3.47 (t, J=5.2 Hz, 2H). 5 Example 171 4-benzyl-9-fluoro-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzoffl [1,4Joxazepin 5(211)-one (Compound 11-166) F F F O r N F 0 0 Br Br 1 N Br N F F OH F

F

3 C0 F 11-166 10 [06091 Compound 11-166 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 416.1. CDCl3:7.87 (s, 1H), 7.63 (s, 4H), 7.42 (dd, JI =1.6 Hz, J2= 10.8 Hz, 1H), 7.32 -7.24 (m, 5H), 4.79 (s, 21), 4.22 (t, J 5.2 Hz, 211), 3.48 (t, J= 5.2 Hz, 2H). Example 172 15 4-benzyl-8-fluoro-7-(4-(trifluoromethoxy)phenyl)-3,4--dihydrobenzo[f][1,4]oxazepin 5(2H)-one (Compound H-167) F{ F N F 286 o 0 Br N HOB

F

3 CO l-167 [06101 Compound H-167 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 432.1. CDCL 3 :8.07 (d, J= 9.2 Hz, 5 1H), 7.58 (d, J=7.6 Hz, 2h), 7.40 -7.32 (m, 5H), 7.28 (d, J=8.4 Hz, 2H), 6.81 (d, J 11.2 Hz, 111), 4.84 (s, 2H), 4.24 (t, J = 4.8 Hz, 2H), 3.54 (t, J = 4.8 Hz, 2H). Example 173 4-benzyl-8-fluoro-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound 1-168) F F F O N 10 F 0 0 0 OH N Br9Br OH FaC o N F 1-168 [0611] Compound 1-168 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 416.1. CDCl 3 :8.11 (d, J = 9.2 Hz, 1H), 7.74 - 7.64 (m, 4H), 7.40 -7.30 (m, 511), 6.83 (d, J= 11.6 Hz, 1H), 4.85 (s, 2H), 15 4.26 (t, J = 4.8 Hz, 2H), 3.56 (t, J = 4.8 Hz, 2H). 287 Example 174 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[2,3-f] [1,41 oxazepin 5(2H)-one (Compound XH-2) F N F~tO 0 00 OHBr Br N < N) FF OH

F

3 CO 0 ~0) 5 Xn-2 [0612] Compound XH-2 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)* 415.1. CDCla: 8.09 (d, J =8.4 Hz, 211), 7.79 (d, J = 8.8 Hz, 111), 7.46 (d, J = 8.8 Hz, 1H), 7.44-7.32 (m, 5H), 7.30 (d, J =8 Hz, 2H), 4.91 (s, 2H), 4.18 (t, J= 5.2 Hz, 211), (t, J= 5.2 Hz, 2H). 10 Example 175 4-benzyl-7-(4-(trfluoromethyl)phenyl)-3,4-dihydropyrido[2,3-fj[1,4oxazepin-5(2H) one (Compound XH-3) F F F N O N0 288 0 0 o H , r B r0 XII-3 [06131 Compound XH-3 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)+ 399.1. CDCl 3 : 8.18 (d, J=8.4 Hz, 2H), 7.84 (d, J= 8.4 Hz, 1H), 7.71 (d, J = 8Hz, 2H), 7.48 (d, J=8 Hz, 1H), 7.46 -7.30 5 (m, 5H), 4.91 (s, 2H), 4.20(t, J = 5.2 Hz, 2H), 3.54 (t, J = 5.2 Hz, 2H). Example 176 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[2,3 f]f1,4]oxazepin-5(2H)-one (Compound XH-6) F{F0 9'0N F O NN F C O F CO 0 N

F

3 CO N 0 N 10 xII [0614] Compound XH-6 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)+417.0. 289 Example 177 4-(pyrmidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4-dihydropyrido[2,3 f][1,4joxazepin-5(2H)-one (Compound XH1-7) FF F IN

F

3 C 0INF 3 C N N NZ NH 00 X 1i-3

F

3 0 IN 0 0 5 X11-7 (0615] Compound XH-7 was prepared according to the Examples disclosed herein using the appropriate starting materials. Mass (M+H)+ 401.0. Example 178 2,2,3,3-tetradeutero-4-(pyrimdin-2-ynethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 10 dihydrobenzo f][1,4]oxazepin-5(2H)-one (Compound 11-174) IF OI I< IN I0 D D 290 Step 1 DO + OJi0k MeOH H Htp2OH N DO DD DD 1X , 0 0 H DH DD Y M Step 3 Br HOO Do

K

2

CO

3 Br N H - XN-V$(O-Ts I D0 Step 4 MeOHHCI 0 Step 50 Br NH D Toluene/Et3N Br DD NH2 D DD 178-A [06161: Step 1: To a solution of 2-aminoethanol (2.0 g, 30 mmol) in methanol (50 mL) at 0 *C, Boc 2 O (6.0 g, 27 mmol) was added slowly and the reaction mixture was stirred at 5 r.t. for 2h. Concentrate the reaction mixture to remove methanol, the residue was dissolved in ethyl acetate, the organic layer was washed with brine, dried over sodium sulfate and concentrated to get the Boc protected amino ethanol (5.0 g) and used directly for the next reaction. (0617] Step 2: To a solution of DABCO (5 g, 45 mmol) in toluene (50 mL), N-Boc-2 10 aminoethanol (5 g, 30 mmol) in toluene was added at room temperature. The reaction mixture was cooled to 0 0 C and benzenesulfonyl chloride (5.8 g, 33 mmol) was added slowly and stirred at room temperature for 2h. Water was added to the reaction mixture, adjust the pH of the mixture to 2-3 by adding 6N HCL. The organic layer was separated, washed with water, sodium bicarbonate, water and brine. Dried over sodium sulfate and 15 concentrated to get an oily product (6.0 g, 70% yield from two steps) which was used directly for the next step. [0618] Step 3: To a solution of protected aminoethanol (6 g, 19.5 mmol) in DMF (20 mL) methyl 5-bromo-2-hydroxybenzoate (3 g, 13 mmol) was added followed by 291 potassium carbonate (3.58 g, 26 mmol) and heated the mixture at 70 0 C for 4 h. Solvent was distilled off, the residue was treated with ethyl acetate. The organic layer was washed with water, brine and concentrated to give an oily product (4 g, 81%) and is used for the next step. 5 [0619] Step 4: To the above oily product in methanol (10 mL) at room temperature HC in methanol (2 ml in 10 mL) was added and heated at 70 0 C for 2h. Solvent was distilled off the residue was treated with ether, filtered the precipitate. The product obtained (2.5 g, 85%) is used for the cyclization step. [06201 Step 5: To the above product (2.5 g, 9 mmol) in toluene (10 mL), triethylamine 10 (4 ml, 36 mmol) was added and heated at 105 *C for 48 h, until the LC-MS no starting material. The reaction mixture was cooled, diluted with methylene chloride, separated the organic layer. Add water to the organic layer and treated with 6N HCl, to adjust the pH 2. The organics were washed with water, brine and dried and concentrated. The residue was treated with dichloromethane and hexane and filtered the product 178-A (2.0 g, 90% 15 yield). 0 F F{O- 0 Br NH FtO Pd(@pf) 2 C2/KzO 3 F NH .+ B(OH) Toluenellsopropanol/H 2 0 D DD 85 0 OC, 2h DD 178-A 178-B 178-C F OD + N - N a H D M F F { N 178-C D 178-D 1M74 DD [06211 Suzuki: To the bromide 178-A (2 g, 8.16 mmol, 1 eq), boronic acid 178-B (2.5 g, 12.2 mmol, 1.5 eq) and potassium carbonate (3.4 g, 24.48 mol, 3 eq) in a round bottom flask, solvent (60 mL, toluene/isopropano/water: 2/1/1) was added and stirred under 20 nitrogen for 10 min. To the above solution the palladium catalyst Pd(dppf)Cl2 (142 mg, 0.16 mmol, 0.02 eq) was added and heated at 85 *C for 2h. The reaction mixture was diluted with ethyl acetate, separated the organic layer and filtered the organic layer through a plug of celite and silica gel and concentrated. Column purification on silica gel using ethyl acetate/hexane as fluent provided 178-C (2 g, 75% yield). 292 [0622 Alkylation: To a solution of 178-C (2 g, 6.12 mmol, 1 eq.) chloromethyl pyrimidine 178-D (1.5 g, 9.17 mmol, 1.5 eq.) in DMF (10 mL), NaH (60% dispersion in oil) (600 mg, 25 mmol, 4 eq.) was slowly added at room temperature (slightly exothermic) and stirred at r.t. for 30 min. The reaction mixture was treated with few drops 5 of HC, diluted the reaction mixture with ethyl acetate and treated with water. The organic layer was separated, washed with brine, dried and concentrated. Column purification on silica gel using ethyl acetate/hexane as eluent provided Compound H-174 (1.8 g, 70% yield). Mass (M+I) 420.1. CDCl 3 :8.65 (d, J=5.2 Hz, 2H), 8.10 (s, 1H), 7.58 -7.50 (m, 311), 7.18 (d, J =8 Hz, 2H), 7.14 (t, J = 5.2 Hz, 1H), 7.02 (d, J= 8.4 Hz, 10 1H), 5.02 (s, 2H). Example 179 4-((3-methyloxetan-3-yl)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-1) F N

F

3 CO A Br F3CO 0 NH N NaH, DMFsrt 11-74 l 15 [06231 4-((3-Methyloxetan-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one was prepared according to Example 25 using 3 (bromomethyl)-3methyloxetane. [06241 1 H-NMR (400 MHz, DMSO) 1.305 (s, 311), 3.618-3.643 (m, 2H), 3.750 (a, 2H), 20 4.183-4.198 (d, 2H, J= 6 Hz), 4.346-4.322 (t, 2H, J,= 4.8 Hz), 4.563-4.577 (d, 2H, J, 5.6 Hz), 7.109-7.131 (d, IH, J= 8.8 Hz), 7.413-7.433 (s, 2H, J=8 Hz), 7.752-7.786 (m, 3H), 7.878-7.883 (d, 1H, J= 2 Hz), MS i/z 407.1 (Nf). 293 Example 180 4-((3-((2-oxopyrrolidin-1-yl)methyl)oxetan-3-y)methyl)-7-(4 (trifluoromethoxy)phenyl)-3,4-dhydrobenzo[f] [1,4] oxazepin-5(2H)-one (Compound U-108) O 5F 0 N j fFaCO Ir F F/CO N 11-74 N814, OMP 18CJA NaiL, 01MF [0625] Compound 180-A and Compound f1-108 was prepared according to Example 25 using (3-(bromomethyl)oxetan-3-yl)methyl methanesulfonate. 10 Example 181 4-(2-(2-oxopyrrolidin-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f [1,41 oxazepin-5(2H)-one (Compound H1-116) F O F N

F

3 CO N NH Br 0N FaCO0 0 N I K IN NaH, DMF. 70 C 11-74 Il-116 15 [0626] Compound 1-116 was prepared according to Example 25 using 1-(2 bromoethyl)pyrrolidin-2-one. 294 Example 182 7-(2-methoxypyrimidin-5-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzof](1,4]oxazepin-5(2H)-one (Compound VI-7) O.1 N N N N. N: 40-0 C0H 3 0 N 0 1 - 3 0 P d (d p p f- H C 6 2 N ~ ' ' 0 I

B(OH)

2 TdueneflFOH2O (311/1 mL)) 40-5 1 2

C

3 700 IC 5 VW-7 [0627] 40-B (0.405 mmol), potassium carbonate (111 mmol) and Palladium chloride dppf catalyst (0.05 mmol) were combined in a mixture of toluene (3 mL), isopropanol (1 mL) and water (1 mL). The resulting suspension was heated at 85 degrees for 2 hours. 10 The reaction mixture was concentrated down and diluted with ethyl acetate and filtered through celite. The filtrate was washed with water. The organic layer was purified by prep HPLC and prep TLC to afford Compound VI-7. Example 183 1-(4-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7 15 yl)phenyl)cyclopropanecarbonitrile (Compound 11-109) N // 0 N N: [0628] Compound II-109 was prepared according to the Examples disclosed herein using the appropriate starting materials. 295 Example 184 N-(2-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[f] [1,41 oxazepin-7-yl) 5-(trifluoromethoxy)phenyl)acetamide (Compound 11-111) F O N yNH 0 5 [0629] Compound 11-111 was prepared according to the Examples disclosed herein using the appropriate starting materials. Example 185 7-(2-(4-methylpiperazin-1-yl)pyrimidin-3-yl)-4-(pyrimidin-2-ymethyl)-3,4 dihydrobenzo[f [1,4] oxazepin-5(2H)-one (Compound VI-14) 10N N N 10 0 [0630] Compound VI-14 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS n/z 432.2 (M). Example 186 4-(pyrimidin-2-ylmethyl)-7-(2-(2,2,2-trifluoroethylamino)pyrimidin-5-yl)-3,4 15 dihydrobenzo[fJ[1,4]oxazepin-5(2H)-one (Compound VI-15) F H [0631] Compound VI-15 was prepared according to the Examples disclosed herein using the appropriate starting materials. 296 Example 187 7-(6-morpholinopyridin-3-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-16) SNN 5 [06321 Compound VI-16 was prepared according to the Examples disclosed herein using the appropriate starting materials. Example 188 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo([[1,4]oxazepin-4(5R) yl)ethyl)ethanesulfonamide (Compound 1-178) F 0 0r F OU N 10 0 fao CT F3 0 FjCO H 0QC,TW 80) 1-74 1-A THF:MeOH 1s8-a FaCO H-SOC F 3CO H FA 4 CH [0633] 11-74 (1.04 mamol) and NaH (3.13 mmol) was stirred in THF (6mL) at 0 degree under -nitrogen. Bromoacetonitrile was added dropwise. The resulting reaction mixture 15 was allowed to slowly warm up to room temperature over the period of 2 hours after which time the reaction mixture was quenched with water and then extracted with dichloromethane. The organic layer was purified by prep HPLC to afford 188-A. [0634] 188-A (0.635 mmol) was dissolved in a mixture of THF:MeOH (4:6 mL). To this was added cobalt chloride (2.49 mmol) and di-tert-butyldicarbonate (1.26 mmol) 297 under nitrogen follow by addition of sodium borohydride (0.762 mmol). The resulting mixture was stirred at ambient temperature overnight. The mixture was filtered through celite and washed with 9:1 mixture of MeOH/H20. The filtrate was washed with saturated NaHCO 3 and then extracted with ethyl acetate. The organic layer was dried 5 over Na 2 S(0) 4 and concentrated down to afford 188-B as an oil which was used without further purifications to make 188-C. [0635] 188-B (200 mg) was combined with TFA (9 mL) and H20 (I mL) and stirred under nitrogen for 2 hours. The reaction mixture was concentrated and used without further purifications to make Compound H-178. 10 [0636] A solution of 188-C (25mg) in dicholoromethane (3 mL) was chilled in an ice bath. To this was added triethylamine (0.1 mL) followed by ethanesulfonyl chloride (0.05 mL). The reaction mixture was stirred under cold conditions for 2 hours after which it was quenched with water. The mixture was extracted with dichloromethane and purified by prep HPLC to afford Compound U.-178. MS i/z 459.1 (M*). 15 Example 189 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(Sf) yl)ethyl)cyclopropanesulfonamide (Compound 11-179) 0 F O HN-9 F><0 F N [0637] Compound 11-179 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. MS m/z 471.1 (M). 298 Example 190 4-fluoro-N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[fj [1,4]oxazepin-4(5H)-yl)ethyl)benzenesulfonamide (Compound H 0 F O O HN- F F N 181) 5 [06381 Compound 11-181 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 525.1 (M*. Example 191 N-(2-(5-oxo-7-(4-(trifluorometboxy)phenyl)-2,3-dihydrobenzo [f] [1,4loxazepin-4(5H) yl)ethyl)cyclopentanesulfonamide (Compound 11-183) 10 [0639] Compound H-183 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 499.1 (M 1 ). Example 192 1-methyl-N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3 15 dihydrobenzo[fJ {1,41oxazepin-4(5H)-yl)ethyl)-1H-imidazole-2-sulfonamide (Compound U-184) 0 N F 0 ~0 N HN-S--( D F N 0 [0640] Compound 11-184 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 511.1 (M). 299 Example 193 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) yl)ethyl)benzenesulfonamide (Compound 11-177) F O0 HN F NO 5 [0641] Compound H-177 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 507.1 (M). Example 194 N-methyl-N-(2-(5-oxo-7-(4-(trlfluoromethoxy)phenyl)-2,3 dihydrobenzo[f[] 1,4]oxazepin-4(5H)-yl)ethyl)benzenesulfonamide (Compound I1 10 182) F N 0 FCO0 NaH, Mel o N K ) DMF N K If-IT7114182 1I-77 IS [0642] Compound 11-182 was prepared according to Example 25 using iodomethane and Compound H-177. 15 Example 195 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H) yl)ethyl)-2-(pyrimidin-2-yl)acetamide (Compound 11-185) HO F N N 0 N 300

F

3 CO NH 2 TFA F 3 CO 0 N N N ,Nc 188-C I-a HATU, DIPEA DMF 106431 188-C (0.054 mmol) was dissolved in DMF (3mL) follow by addition of HATU and DIPEA. The resulting mixture was stirred at room temperature for 3 hours after 5 which water was added and extracted with dichloromethane. The organic was purified by prep HPLC to afford Compound II-185. Example 196 4-((5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-68) N-N [0644] Compound 1I-68 was prepared according to the Examples disclosed herein using-the appropriate starting materials. MS m/z 446.1 (M+H). Example 197 4-(pyridin-4-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 15 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 11-67) ~N [0645] Compound 11-67 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 415.1 (M+H). 301 Example 198 4-((5-chloropyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-34 dihydrobenzo [f] [1,4] oxazepin-5(2R)-one (Compound 11-65) F 0 N C N 5 [0646] Compound 1-65 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 450.0 (M+H). Example 199 4-((1-methyl-lH-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo [f] r1,4]oxazepin-5(2H)-one (Compound H-64) rF N 10 y [0647] Compound 1-64 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 418.1 (M+H). Example 200 4-methyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[][1,4]oxazepin-5(211) 15 one (Compound 11-46) F F [06481 Compound H-46 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 338.1 (M+H), 302 Example 201 4-(3,4-difluorobenzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo [f [1,4]oxazepin-5(2H)-one (Compound 1-45) N,/ -F 5 [06491 Compound H-45 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 450.1 (M+H). Example 202 4-((5-(pyridin-2-yl)isoxazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dlhydrobenzo[f][1,4]oxazepin-5(2)-one (Compound H-41) R 01 0 F N'NNN J N-0 10 [ [0650] Compound 11-41 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 482.1 (M+H). Example 203 7-(4-(trifluoromethoxy)phenyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-3,4 15 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound U-16) F0 -N F N N \ / F F [0651] Compound 11-16 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 483.1 (M+H). 303 Example 204 4-(2-methoxyethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2U)-one (Compound U-11) F N 5 [0652] Compound 11-11 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 382.1 (M+H). Example 205 4-(2,2-difluoroethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo f][l,4]oxazepin-5(2H)-one (Compound H-6) rF F ' 10 [06531 Compound H-6 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 388.1 (M+H). Example 206 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 15 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-5) N 0 [0654] Compound 11-5 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 472.1 (M+H). 304 Example 207 7-(4-fluorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2H)-one (Compound 11-104) N, 5 [0655] Compound H-104 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS min 350.1 (M+H). Example 208 7-(3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-106) F N' 0 NN/ 10 [0656] Compound 3-106 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 448.1 (M+H). Example 209 4-(pyrimidin-2-ylmethyl)-7-(4-(2,2,2-trifluoroethoxy)phenyl)-3,4 15 dihydrobenzo[][1,4]oxazepin-5(2F)-one (Compound fl-107) F N [0657] Compound 11-107 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 430.1 (M+H). 305 Example 210 7-(4-(trifluoromethoxy)phenyl)-4-((5-(6-(trfluoromethyl)pyridin-3-yl)pyrimicdin-2 yl)methyl)-3,4-dihydrobenzo[fj [1,4Joxazepin-5(2H)-one (Compound 11-115) Fy 0 0 F N F 0 5 [06581 Compound 11-115 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS nz 561.1 (M+H). Example 211 4-((4-(pyrrolidin-1-yl)pyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzolfJ[1,4]oxazepin-5(2H)-one (Compound 11-125) 100 F N .' 106591 Compound 11-125 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS nz 485.1 (M+H). Example 212 4-((4-morpholinopyrimidin-2-y)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 15 dihydrobenzo[fj1,4]oxazepin-5(2H)-one (Compound 11-133) 106601 Compound 11-133 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/x 501.1 (M+H). 306 Example 213 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f]11,4]oxazepin-5(2H) one (Compound II-134) F o 0 F F N/ 5 [06611 Compound H-134 was prepared according to the Examples disclosed herein using the appropriate starting materials. 1 H-NMR (CD 3 0D) $ 8.01 (d, 1H, J= 2.4 Hz), 7.72-7.78 (m, 311), 7.31-7.42 (m, 7H), 7.14 (d, 1H, J= 8.0 Hz), 4.85 (s, 2H), 4.25 (t, 2H, J = 5.0 Hz), 3.60 (t, 2H, J= 5.4 Hz); MS m/z 414.1 (M+H). Example 214 10 4-((4-methoxypyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound II-137) F O Os%) [0662] Compound 11-137 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD30D) S 8.41 (d, 11H, J= 6.0 Hz), 15 8.01 (d, 1H, J= 2.4 Hz), 7.77 (dd, 1H, J= 8.8, 2.4 Hz), 7.71 (d, 2H, J= 8.4 Hz), 7.35 (d, 2H, J= 8.0 Hz), 7.17 (d, 1H, J= 8.0 Hz), 6.75 (d, 1H, J =6.0 Hz), 4.97 (s, 2H1), 4.58 (t, 2H, J= 4.8 Hz), 3.95 (s, 31), 3.84 (t, 2H, J= 5.2 Hz); MS ink 446.1 (M+H). Example 215 4-((4-methylpyrimidin-2-yl)methyl)-7-(4.-(trifluoromethoxy)phenyl)-3,4 20 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-138) F O 0 [0663] Compound 11-138 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) $ 8.59 (d, 1H, J= 5.2 Hz), 307 8.02 (d, 1H, J= 2.4 Hz), 7.76 (dd, 1H, J= 8.4, 2.4 Hz), 7.71 (d, 2H, J= 8.4 Hz), 7.34 (d, 2H, J= 8.0 Hz), 7.28 (d, 1H, J= 5.2 Hz), 7.16 (d, 1H, J= 8.4 Hz), 5.03 (s, 2H), 4.59 (t, 2H, J= 5.0 Hz), 3.83 (t, 2H, J= 5.0 Hz)), 2.53 (s, 3H); MS m/z 430.1 (M+H). Example 216 5 4-((4-(piperidin-1-yl)pyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound U-139) O Ni [0664] Compound 11-139 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD30D) 8 8.10 (d, 1H, J= 7.2 Hz), .10 7.98 (d, 1H, J=2.4 Hz), 7.81 (dd, 1H, J= 8.4,2.4 Hz), 7.71 (d, 2H, J= 9.2 Hz), 7.35 (d, 2H, J= 8.0 Hz), 7.20 (d, 1H, J= 8.8 Hz), 7.01 (d, 1H, J= 7.6 Hz), 4.91 (s, 211), 4.56 (t, 2H, J= 5.0 Hz), 4.01 (br, 211), 3.88 (t, 2H, J= 4.8 Hz)), 3.73 (br, 2H), 1.59-1.73 (m, 6H); MS m/z 499.2 (M+H). Example 217 15 4-((4-(dimethylamino)pyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-140) .Nij [0665] Compound 11-140 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD30D) 8 8.14 (d, 1H, J= 7.2 Hz), 20 7.99 (d, 1H,J=2.4 Hz), 7.81 (dd, 1H,J=8.0,2.4Hz), 7.70 (d,2HJ=9.2 Hz), 7.35 (d, 2H, J=8.4 Hz), 7.19 (d, 1H, J=8.4 Hz), 6.93 (d, 1H, J=7.2 Hz), 4.93 (s, 2H), 4.59 (t, 2H,J=5.0Hz), 3.90 (t,2H,J=5.0Hz)), 3.30 (s, 6H); MS m/z 459.1 (M+H). 308 Example 218 4-benzyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f] [1,41 oxazepin-5(211)-one (Compound 11-141) FF F / 0 N ~ N -F ) 5 [06661 Compound 11-141 was prepared according to the Examples disclosed herein using the appropriate starting materials. IH-NMR (CD 3 0D) 5 8.08 (d, 1H, J= 2A Hz), 7.79-7.84 (n, 3H), 7.74 (d, 2H, J= 8.4 Hz), 7.29-7.41 (m, 5H), 7.15 (d, 1H, J= 8.4 Hz), 4.86 (s, 2H), 4.26 (t, 2H, J= 5.2 Hz), 3.60 (t, 2H, J= 5.2 Hz); MS m/z 398.1 (M+H). Example 219 10 4-((3-methoxypyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 11-143) 0 0 0 F O [0667] Compound 1-143 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) & 8.23 (d, 1H, J= 5.6 Hz), 15 8.00 (d, 1H, J= 2.8 Hz), 7.92 (d, 1HI, J= 84 Hz), 7.77 (dd, 1H, J= 8.4, 2.4 Hz), 7.68 7.71 (i, 3H), 7.34 (d, 2H, J= 8.0 Hz), 7.15 (d, 1H, J =8.8 Hz), 5.03 (s, 211), 4.45 (t, 2H, J- 4.8 Hz), 4.05 (s, 311), 3.82 (t, 2H, J= 5.0 Hz); MS m/z 445.1 (M+H). Example 220 4-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 20 dihydrobenzo [f] [1,4]oxazepin-5(211)-one (Compound 11-147) F F NON A 30 309 [0668] Compound 11-147 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.01 (dd, 2H, J= 9.4, 2.6 Hz), 7.76 (dd, H, J=8.2, 26 Hz), 7.72 (d, 2H, J=8.8 Hz), 7.73-7.76 (m, 2H), 7.13 (d, 1H, J=8.4 Hz), 6.54 (d, 1H, J= 2.4 Hz), 4.88 (s, 2H), 4.35 (t, 2H,J=5.0 Hz), 3.69 (t, 5 2H, J =5.0 Hz); MS m/z 454.0 (M+H). Example 221 7-(4-(trifluoromethoxy)phenyl)-4-((3-(trifluoromethyl)-H-pyrazol-1-y)methyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound H-148) F F F ON 10 (0669] Compound 11-148 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 494.0 (M+Na). Example 222 4-((1-cyclopentyl-1H-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo [f] 11,4] oxazepin-5(2H)-one (Compound 11-152) F 0 N 15 {0670] Compound 1-152 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 472.1 (M+H). Example 223 4-((1-ethyl-1H-pyrazol-3-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 20 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-153) Fo 0 N - -t o N 310 310 [0671] Compound 11-153 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 7.99 (d, IN, J= 2.4 Hz), 7.71-7.76 (m, 3H), 7.61 (d, 1H, J= 2.4 Hz), 7.35 (d, 2H, J= 8.0 Hz), 7.12 (d, IH, J= 8.4 Hz), 6.31 (d, IH, J= 2.4 Hz), 4.82 (s, 2H), 4.29 (t, 2H, J= 5.0 Hz), 4.17 (q, 2H, J= 7.2 5 Hz), 3.64 (t, 2H,J= 7A Hz), 1.45 (t, 3H,J= 7.4 Hz); MS m/z 432.1 (M+H). Example 224 4-((1-methyl-1H-imidazol-4-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H1)-one (Compound H-154) F N 10 [0672] Compound 1-154 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 418.1 (M+fH). Example 225 4-((4-methy1-1H-pyrazol-1-y1)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzoff] [1,4]oxazepin-5(2H)-one (Compound 11-155) F><o 0N 15 FN [0673] Compound 11-155 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD30D) 8 7.98 (d, 1H, J= 2.4 Hz), 7.76 (dd, 1H,J= 8.2, 2.6 Hz), 7.71 (d, 2H,J= 8.4 Hz), 7.61 (s, 1H), 7.34-7.37 (m, 311), 7.11 (d, 1H, J= 8.8 Hz), 5.83 (s, 2H), 4.21 (t, 2H, J= 5.0 Hz), 3.76 (t, 2H, J= 5.0 Hz), 20 2.09 (s, 3H); MS m/z 418.1 (M+H). 311 Example 226 4-((4-chloro-1H-pyrazol-1-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fl[1,4oxazepin-5(2H)-one (Compound 11-156) Fl F ro 0 -N C ZC) 5 [06741 Compound H1-156 was prepared according to the Examples disclosed herein using the appropriate starting materials. 1 1-NMR(CD 3 0D) 5 7.99 (d, 1H, J= 2.4 Hz), 7.91 (s, 1f), 7.77 (dd, 1H, J=8.4,2.4 Hz), 7.71 (d, 2H, J=8.8 Hz), 7.52 (s, 11), 7.35 (d, 2H, J= 8.0 Hz), 7.13 (d, 1H, J= 8.8 Hz), 5.85 (s, 2H), 4.29 (t, 2H, J= 5.0 Hz), 3.81 (t, 2H, J= 5.2 Hz); MS mz 438.0 (M+I-). 10 Example 227 4-((1-methyl-1H-pyrazol-4-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 1-160) F F N, -:N [0675] Compound H-160 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. 'H-NMR (CD30D) 5 7.98 (d, 1H, J = 2.8 Hz), 7.67-7.76 (n, 4H), 7.53 (s, 1H), 7.35 (d, 2H,J= 8.0 Hz), 7.12 (d, IH,J= 8.0 Hz), 4.69 (s, 2H), 4.31 (t, 2H, J= 5.2 Hz), 3.87 (s, 3H), 3.62 (t, 2H, J= 5.0 Hz); MS m/z 418.1 (M+H). Example 228 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 20 dihydrobenzo[f][1,4]oxazepin-5(21)-one (Compound 11-164) F F O0 312 [06761 Compound 11-164 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 5 8.37 (d, 1H, J= 4.8 Hz), 8.00 (d, IH, J=2.4 Hz), 7.76 (dd, 1H, J= 8.0, 2.4 Hz), 7.72 (d, 2H, J=8.8 Hz), 7.61 (t, 1H, J=9.2 Hz), 7.38-7.42 (m, 1H), 7.34 (d, 2H, J=8.0 Hz), 7.14 (d, 1H, J=8.0 Hz), 5 5.07 (s, 211), 4.45 (t, 2H, J= 4 .8 Hz), 3.78 (t, 2H, J= 4.8 Hz); MS m/z 433.1 (M+1). Example 229 7-(4-chloro-3-fluorophenyl)-4-((3-fluoropyridin-2-yl)methyl)-3,4 dihydrobenzo[ff[1,4]oxazepin-5(2H)-one (Compound U-169) F CI 0 F-C N 10 10677] Compound 11-169 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.35 (d, 1H, J= 5.2 Hz), 8.00 (s, 1 H), 7.76 (d, 1H, J= 8.4 Hz), 7.61 (t, 1H, J= 9.2 Hz), 7.51-7.55 (in, 2H), 7.38 7.46 (m, 21), 7.14 (d, 1H, J=8.0 Hz), 5.07 (s, 2H), 4.46 (t, 2H, J=4.8 Hz), 3.78 (t, 2H, J = 4.8 Hz); MS m/z 401.1 (M+H). 15 Example 230 7-(2-fluoro-4-(trifluoromethyl)phenyl)-4-((3-fluoropyridin-2-yl)methy)-3,4 dihydrobenzo[f}[1,4]oxazepin-5(2H)-one (Compound 11-170) FF F F / 0 N F O N [0678 Compound 1-170 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. 'H-NMR (CD30D) 5 8.37 (d, 1H, J= 4.8 Hz), 7.99 (s, 1H), 7.70-7.74 (m, 2H), 7.53-7.63 (m, 31), 7.38-7.42 (m, 1H), 7.17 (d, 1H,J= 8.4 Hz), 5.07 (s, 211), 4.49 (t, 2H, J= 5.0 Hz), 3.80 (t, 2H, J= 4.8 Hz); MS m/z 435.1 (M+1H). 313 Example 231 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(triuoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-176) FF F F / 0 N N 5 106791 Compound 11-176 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.36 (d, 1H1, J= 4.4 Hz), 8.06 (s, 1H), 7.71-7.81 (m, 3H), 7.72 (d, 21, J= 8.0 Hz), 7.60 (t, 1H, J= 9.0 Hz), 7.37 7.41 (n, 1 H), 7.15 (d, 1H, J= 8.4 Hz), 5.06 (s, 21), 4.46 (t, 2H, J= 5.0 Hz), 3.78 (t, 2HJ = 4.8 Hz); MS m/z 417.1 (M+H). 10 Example 232 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenylamino)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2fl)-one (Compound XI-1) F e [0680] Compound XIII-1 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. MS m/z 431.1 (M+H). Example 233 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenoxy)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound XI-2) 0O N F 03 0 314 0 N Pd(OAc) 2 , K 3

PO

4 , toluene o N Br N OH 140 0 020min, MW O N +_CO_ FCO N 233-A N NI' I P(tBuhz [0681] 233-A (70 mg, 0.21 mmol), 4-(trifluoromethoxy)phenol (45 mg, 0.252 mmol),

K

3

PO

4 (134 mg, 0.63 mmol), Pd(OAc)2 (3%) and di-tert-butyl(2'4'6' triisopropylbiphenyl-2-yl)phosphine (6%) in toluene (3.5 mL) were put onto microwave 5 at 140 *C for 20 min. The reaction mixture was diluted with EtOAC, filtered through ceilite and washed with EtOAc. The filtrate was concentrated and purified by HPLC followed by prep-TLC (EtOAc) to afford Compound XJI-2 (1.8 mg). MS m/z 432.1 (M+H). Example 234 10 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenylamino)-3,4 dihydrobenzo [0[1,4] oxazepin-5(2H)-one (Compound XI-3) H 0N :)N F F [0682] Compound XIII-3 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 415.1 (M+H). 15 Example 235 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenylamino)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound XI-4) H 0 N F ) Pd 2 (dba) 3 , (R)-BINAP LITNaO'Bu, toluenew Br NNH2 130*C 1In, MWF 0 3 0 F3CO 0 235-A X111-4 315 [0683] 235-A (70 mg, 0.21 mmol), 4-(trifluoromethoxy)aniline (45 mg, 0.252 mmol), NaO'Bu (40mg, 0.42 mmol), Pd 2 (dba)3 (3%) and (R)-BINAP (6%) in toluene (3.5 mL) were put onto microwave at 130 "C for 10 min. The reaction mixture was diluted with EtOAC, filtered through ceilite and washed with EtOAc. The filtrate was concentrated 5 and purified by HPLC to afford Compound XJII-4 (22.8 mg). [06841 'H-NMR (CD 3 0D) 8 8.66 (d, 1H, J=5.21Hz), 8.23 (t, 1H, J=8.0 Hz), 7.78 (d, 1H, J= 8.0 Hz), 7.68 (t, 1H, J= 6.4 Hz), 7.41 (s, 1H), 7.22-7.40 (m, 1ff), 7.06-7.13 (In, 4H), 7.01 (d, 1H, J=8.8 Hz), 5.04 (s, 2H), 4.33 (t, 2H, J= 5.0 Hz), 3.74 (t, 2H, J= 5.4 Hz); MS n/z 430.1 (M+H). 10 Example 236 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenylamino)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound XMI-6) H 0 N F N .. N \/ FF [06851 Compound XLI-6 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. 'H-NMR (CD 3 0D) 5 8.52 (d, 1H, J= 5.2 Hz), 7.84 (t, 1H, J= 7.6 Hz), 7.44-7.50 (m, 4H), 7.29-7.36 (m, 2H), 7.10 (d, 2H, J=8.0 Hz), 7.03 (d, 1H, J= 8.8 Hz), 4.94 (s, 2), 4.29 (t, 21, J=5.2 Hz), 3.68 (t, 2H, J= 5.6 Hz); MS iz 414.1 (M+H). Example 237 20 7-(methy](4-(trifluoronethoxy)phenyl)amino)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzoIf][1,4]oxazepin-5(2H)-one (Compound XIL-10) 1 0N F N [06861 Compound XI-10 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 445.1 (M+H). 316 Example 238 7-(methyl(4-(trifluoromethoxy)phenyl)amino)-4-(pyridin-2-ylmethyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound XIH-12) 0 N< F 9 5 [06871 Compound XIM-12 was prepared according to the Examples disclosed herein using the appropriate starting materials. MS m/z 444.1 (M+H). Example 239 5-benzyl-8-(4-(trifluoromethyl)phenyl)-4H-benzo[f]imidazo[1,2-aJ[1,4]diazepin 6(5H1)-one (Compound X-12) F F F N NN 10 N to ene 120 0 F 0 2392A -s per X-12 [0688] 239-A (0.100g, 0.244mmol), 2, 2-dimethoxyethanamine (lm-L, 9.3mmol) were mixed together, the resulting mixture was stirred at 100*C for 4 hours. When the reaction was cooled down, Water was added dropwise until precipitation was finished. The 15 precipitates were collected by filtration and washed with water to afford 239-B (0.111 g, 92%), MS m/z: 498 (M+ H) 4 . [0689] 239-B (0.104g, 0.209mmol), PPTS (0.525g, 2.09nimol) were added to Toluene (5mL). The resulting mixture was stirred at 120"C overnight, concentrated and purified by preparative HPLC to afford Compound X-12 (0.013g, 14%). MS m/z: 434 (MHf). 317 Example 240 N-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fJ [1,4]oxazepin-4(5H) yl)ethyl)pyrimidine-2-carboxamide (Compound 11-192) N ~ N F N Kssvi + BtACN FG3COh J o xFC A THF;MeOH 11-74

F

5 CO NH-SOC FC O 2 NFA2 , DIPEA o N flA N N N ~DMF N Fi r-' 5 0 [0690] Compound 11-192 was prepared according to Examples 188 and 195 disclosed herein using the appropriate starting materials. MS m/z 473.1 (Mt). Example 241 7-(5-cyclopropylthiophen-2-yl)-4-(pyrimidin-2-ylmethyl)-3,4 10 dihydrobenzo[f][1,4] oxazepin-5(2H)-one (Compound VI-36) N [0691] Compound VI-36 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (DMSO) 88.77 (d, 2H, J= 5.2 Hz), 7.79 (d, 1H, J=2.4 Hz), 7.68 (dd, 1H, J=8.2, 2.6 Hz), 7.40 (t, 1H, J= 5.0 Hz), 7.22 (d, 15 1H, J= 3.2 Hz), 7.04 (d, IH, J= 8.8 Hz), 6.78-6.79 (m, 111), 4.95 (s, 2H), 4.47 (t, 2H, J= 5.0 Hz), 3.73 (t, 2H, J= 5.0 Hz), 2.07-2.13 (m, 1H), 0.96-1.00 (m, 2H), 0.66-0.70 (m, 2); MS m/z 378 (M+H). 318 Example 242 4-(pyrimidin-2-ylmethyl)-7-(5-(trifluoromethy)thiophen-2-yl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-37) F F N 5 [06921 Compound VI-37 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (DMSO) 8 8.70 (d, 2H, J= 5.2 Hz), 7.72 (d, IH, J= 2.4 Hz), 7.61 (dd, 1H, J= 8.2, 2.6 Hz), 7.30 (t, 1H, J= 5.0 Hz), 7.12 (d, 1H, J= 3.2 Hz), 7.01 (d, 1H, J=8.8 Hz), 6.72-6.75 (m, 111), 4.91 (s, 211), 4.42 (t, 2H, J= 5.0 Hz), 3.71 (t, 2H, J= 5.0 Hz), 2.07-2.11 (m, 1H), 0.94-1.1 (m, 2H), 0.64-0.69 (m, 2H); 10 MS m/z 406 (M+H1). Example 243 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenethy)-3,4 dihydrobenzo [f] [1,4joxazepin-5(2H)-one (Compound VfI-8) F3C0N 15 [0693] Compound VIE-8 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.74 (d, 2H, J= 4.8 Hz), 7.51-7.54 (m, 3H), 7.33-7.37 (m, 3H), 7.26 (dd, 1H, J= 8.2, 2.2 Hz), 6.94 (d, 1H, J=8.0 Hz), 5.02 (s, 2H), 4.45 (t, 2H, J= 5.2 Hz), 3.72 (t, 2B, J= 5.2 Hz), 2.91-3.00 (M, 4H); MS mz428.1 (M+H). 20 Example 244 4-((3-fluoropyridin-2-yl)methyl)-7-(4-(trifluoromethyl)phenethyl)-3,4 dihydrobenzo [f] [1,4] oxazepin-5 (210-one (Compound VlI-9) FaC 0 319 319 [0694] Compound VHI-9 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 OD) 5 8.34 (d, 1H, J= 5.2 Hz), 7.50-7.60 (in, 4H), 7.33-7.40 (in, 3H), 7.25 (dd, 1H, J= 8.4, 2.4 Hz), 6.92 (d, 1H, J= 8.0 Hz), 5.01 (d, 2H, J= 1.6 Hz), 4.32 (t, 211, J= 5.2 H1z), 3.66 (t, 2H, J= 5.2 Hz), 2.90-3.00 5 (m, 4H); MS mn/z 445.1 (M+H). Example 245 7-(4-(4-fluorophenoxy)phenyl)-4-(pyrinidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-193) 00 N F> 10 [0695] Compound HE-193 was prepared according to the Examples disclosed herein using the appropriate starting materials. 1 H-NMR (CD 3 CD) 6 8.77 (d, 2H, J= 5.2 Hz), 7.97 (d, 1H, J= 2.0 Hz), 7.73 (dd, 1H, J=8.8, 2.4 Hz), 7.61 (dd, 2H, J =6.8, 2.0 Hz), 7.38 (t, 1H, J= 4.8 Hz), 7.02-7.14 (m, 711), 5.07 (s, 2H), 4.56 (t, 2H, J= 5.0 Hz), 3.82 (t, 211, J=5.0 Hz); MS m/z 442.1 (M+H). 15 Example 246 7-(4-phenoxypheny])-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound H-194) r N. [0696] Compound H-194 was prepared according to the Examples disclosed herein 20 using the appropriate starting materials. 1 H-NMR (CD 3 OD) 5 8.77 (d, 2H, J=5.2 Hz), 7.97 (d, 1H, J= 2.4 Hz), 7.74 (dd, 1H, J= 8.6, 2.6 Hz), 7.61 (dd, 2H, J= 6.8, 2.4 Hz), 7.35-7.39 (in, 3H), 7.10-7.15 (m, 2H), 7.01-7.06 (m, 4H), 5.07 (s, 2H), 4.56 (t, 2H, J= 5.2 Hz), 3.82 (t, 2H, J= 5.0 Hz); MS m/z 424.1 (M+H). 320 Example 247 7-(3-phenoxyphenyl)-4-(pyrinidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2H)-one (Compound H-195) Q N I 5 [0697] Compound H-195 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 8 8.76 (d, 211, J= 5.2 Hz), 7.96 (d, 1H, J= 2.4 Hz), 7.71 (dd, 1H, J= 8.2, 2.6 Hz), 7.34-7.44 (m, 5H), 7.23 (t, 1H, J 2.0 Hz), 7.10-7.14 (m, 2H), 7.02-7.04 (m, 211), 6.93-6.96 (m, 111), 5.06 (s, 211), 4.56 (t, 2H, J= 5.0 Hz), 3.81 (t, 2H, J= 5.2 Hz); MS m/z 424.1 (M+H). 10 Example 248 (E)-4-benzyl-7-(4-(trifluoromethyl)styryl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H) one (Compound VIH-10) FSCA 0 ~0 [0698] Compound VHI-10 was prepared according to the Examples disclosed herein 15 using the appropriate starting materials. MS m/z 424.1 (M+H). Example 249 4-benzyl-7-(4-(trifluoromethy)phenethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin-5(2H) one (Compound VIH-11) F3C 0 N' NN 20 [0699] Compound VIH-11 was prepared according to the Examples disclosed herein using the appropriate starting materials. 'H-NMR (CD 3 0D) 5 7.53-7.54 (m, 3H), 7.26 7.37 (m, 8H), 6.93 (d, 1H, J= 8.0 Hz), 4.82 (s, 2H), 4.16 (t, 2H, J= 5.2 Hz), 3.49 (t, 211, J 5.2 Hz), 2.95-3.02 (m, 4H); MS m/z 426.1 (M+H). 321 Example 250 4-(3-(azetidin-1-ylsulfonyl)propyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f[[1,4]oxazepin-5(2H)-one (Compound U-191) F N 0 F 0N N 00 [ 70-A Copud20Cwa5yteie fo0 opud25-0n ut 250 -B - F CI 5 11-191 [0700] Compound 250-C was synthesized from Compound 250-A and sultone 250-B following general alkylation procedures. Compound 250-C (84 mg, 0.19 mmol) was treated with thionyl chloride at 60 0 C overnight. The resulting mixture was concentrated to afford crude Compound 250-D which was treated with a solution of azetidine (26pL, 2 10 eq) and triethylamine (250 pl) in DCM, the resulting mixture was stirred at room temperature for several hours, concentrated and purified with HPLC to afford Compound I1-191 (42 mg). MS m/z: 485 (MH). Example 251 N-cyclopropyl-3-(5-oxo-7-(4-(trifluorometboxy)phenyl)2,3 15 dihydrobenzo[f][1,4]oxazepin-4(5r)-yl)propane-1-sulfonamide (Compound H-190) F H RJ<O 0 F / NNO [0701] Compound 11-190 was prepared according to the.Examples disclosed herein using the appropriate starting materials. MS m/z: 485 (MH ) 322 [0702] The following compounds were prepared according to the Examples disclosed herein using the appropriate starting materials: 4-(2,2,2-trifluoroethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzoff] [1,4]oxazepin-5(2H)-one (Compound 11-2) MS nz 406.0 (M+H) F 0 . 0N O F F 4-(2-(pyrrolidin-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound H-3) MS m/z 421.1 (M+H) F O O N F N (2S,1laR)-2-amino-7-(4-(trifluoromethyl)phenyl)-2,3,11,lla 10 tetrahydrobenzo[flpyrroIo[2,1-c[1,4oxazepin-5(1H)-one (Compound 11-20) MS m/z: 363 (MI 3 ) FF F - 0 NQ NH2 0 ~ (R)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1H-benzo[fpyrazino[2,1 c] [1,41 oxazepin-6(2H)-one (Compound U-26) MS m/z: 363 (MH*) FF F A 0 N N NH 15 323 (R)-tert-butyl 6-oxo-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-l benzo[fipyrazino [2,1-c] [1,4] oxazepine-2(6H)-carboxylate (Compound 11-27) MS m/z: 463 (MH+ F F F 0 0,~ 5 (S)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1H-benzo[fIpyrazino[2,1 cl [1,4] oxazepin-6(21)-one (Compound 11-28) MS n/z: 363 (MH*) FF F / 0 N )N NH (S)-tert-butyl 6-oxo-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1H benzo[f]pyrazino[2,1-cl[1,4]oxazepine-2(6J)-carboxylate (Compound 11-29) MS m/z: 10 463 (MH*) F F F / 0 N N\ A 0 (2R,1laR)-2-(pyrimidin-2-ylamino)-7-(4-(trifluoromethyl)phenyl)-2,3,11,11a tetrahydrobenzo[f]pyrrolo[2,1-c][1,4]oxazepin-5(1H)-one (Compound 1-30) MS m/z: 441 (MH+) F F F / 0 H NN N 15 0 324 4-((1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)-7-(4 (trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-32) MS m/z 548.1 (M+H) 0 0-0-N F N F N \N F O F F 5 (2S,1laS)-2-(pyrimidin-2-ylamino)-7-(4-(trifluoromethyl)phenyl)-2,3,11,11a tetrahydrobenzofjpyrrolo[2,1-c][1,4]oxazepin-5(1H)-one (Compound 11-34) MS m/z: 441 (Mf) FF F / H N N N 0 7-(4-(trifluoromethoxy)phenyl)-4-(2-(2,5,5-trimethyl-1,3-dioxan-2-yl)ethyl)-3,4 10 dihydrobenzo[f] [1,4joxazepin-5(2H)-one (Compound 11-35) m/z: 480.1 (MH) OC o 0 F N (2R,1laR)-2-(diethylamino)-7-(4-(trifluoromethyl)phenyl)-2,3,11,lla tetrahydrobenzo[f]pyrrolo[2,1-c [1,4]oxazepin-5(1I)-one (Compound 11-36) MS m/z: 419 (MH) F F 0 NoN 15 0 325 (2S,1 laS)-2-(diethylamino)-7-(4-(trifiuoromethyl)phenyl)-2,3,11,la tetrahydrobenzojflpyrrolo[2,1-c] [1,4joxazepin-5(1JH)-one (Compound 11-37) MS m/z: 419 (MH*) F F O N N 0 5 (2R,llaR)-2-amino-7-(4-(trifluoromethyl)phenyl)-2,3,11,lla tetrahydrobenzo[f]pyrrolo[2,1-cl [1,4]oxazepin-5(1H)-one (Compound H-38) MS m/z: 363 (MH*) F F N .NNH2 tert-butyl (2R,11laR)-5-oxo-7-(4-(trifluoromethyl)phenyl)-1,2,3,5,11,lla 10 hexahydrobenzo[flpyrrolol2,1-c][1,4]oxazepin-2-ylcarbamate (Compound 11-39) MS n/z: 463 (MH*) F F,> F / O H 32N JN 326 4-((5-(pyrimidin-2-yl)isoxazol-3-yl)methyl)-7-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f][1,4oxazepin-5(2H)-one (Compound 11-40) MS m/z 483.1 (M+H) 0 NJ) 0 F N N j N-C ethyl 3-((5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fJ[1,4]oxazepin 5 4(5H)-yl)methyl)benzoate (Compound 11-43) m/z: 486.1 (Mf) 0 ro 0 1- 0/ F i F N tert-butyl (2S,1laS)-5-oxo-7-(4-(trifluoromethyl)phenyl)-1,2,3,5,11,lla hexahydrobenzolflpyrrolo[2,1-c] [1,4]oxazepin-2-ylcarbamate (Compound 11-52) MS ink: 463 (MH) FF F / 0 H N N O 10 0 4-((3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)methyl)-7-(4-(trifluoromethoxy)phenyl) 3,4-dihydrobenzo[f][1,4]oxazepin-5(211)-one (Compound 11-53) MS m/z 458.1 (M+H) F 0 O0 No N N N-N 4-(4-(trifluoromethoxy)benzyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 15 dihydrobenzo[f][1,4]oxazepin-5(2H1)-one (Compound 11-55) MSm/z 498.1 (M+H) F 0 0 F 1 N N <9 N-F F F 327 7-(4-(trifluoromethoxy)phenyl)-4-(4-(trifluoromethyl)benzyl)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 11-56) MS n/z 482.1 (M+H) F N- NF F )F (2R,IlaS)-2-hydroxy-7-(4-(trifluoromethyl)phenyl)-2,3,11,lla 5 tetrahydrobenzo[]pyrrolo[2,1-c]1,4]oxazepin-5(1IH)-one (Compound 11-58) MS m/z: 364 (MH*) F F F / .OH N ~ N 0 (R)-7-(4-(trifluorornethyl)phenyl)-2,3,11,11a-tetrahydrobenzo[f]pyrrolo[2,1 cl[1,4]oxazepin-5(1H)-one (Compound 11-59) MS n/z: 348 (MH) F F F / 0 No 10 (S)-7-(4-(trifluoromethyl)phenyl)-2,3,11,lla-tetrahydrobenzo[flpyrrolo[2,1 c] [1,4] oxazepin-5(1H)-one (Compound 11-60) MS m/z: 348 (MHt) F F F / 0 N' N N 0 8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydrobenzo[f] [1,4]oxazino[3,4 15 c] [1,4] oxazepin-6(1H)-one (Compound H-63) MS m/z: 364 (MIt) F F F /~ 0 N O 0 328 2-(2-(5-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzof][1,4]oxazepin-4(5H) yl)ethoxy)pyrimidine-4-carbonitrile (Compound H-66) MS m/z 471.1 (M+H) F 0 0 N( N 4-(2-hydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 5 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-71) MS n/z 368.1 (M+H) F 0 OH F N (R)-3-isopropyl-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f] [1,4]oxazepin 5(2W-one (Compound H-76) MS mz: 349 (MHl) F F NH O 10 (R)-3-isopropyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-78) MS m/z: 442 (MHR) F F N F N N (S)-3-isopropyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzotfj[1,4]oxazepin-5(2H)-one (Compound 11-79) MS m/z: 442 (MH) F < N F oN F

-

0 ) NF40 N 15 329 (S)-2-(2,2,2-trifluoroethyl)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1IH benzo[flpyrazino[2,1-c] [1,4oxazepin-6(2H)-one (Compound 11-84) nz: 445 (MR) FF F N 7-(4-morpholinophenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5 5(2H)-one (Compound 11-90) m/z: 417.2 (MH*) 4 N N N 7-(4-(methylsulfonyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-93) m/z: 410.0 (MH*) 0 0 0N 10 (R)-4-(1-(pyrimidin-2-yl)ethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-95) mz: 414 (MH) F F F O N NN' (S)-4-(1-(pyrimidin-2-yl)ethyl)-7-(4-(trifluoromethy)pheny)-3,4 dihydrobenzo[f] [1,4oxazepin-5(2H)-one (Compound 11-96) nz: 414 (MH) F F 0 NN N' 15 330 7-(4-tert-butoxyphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin 5(2Th)-one (Compound 11-99) m/z: 404.5 (MH-) NN (R)-2-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 5 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-100) nz: 414 (MH) F F F 0 N FN tert-butyl 4-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5 tetrahydrobenzo[f] [1,4]oxazepin-7-yl)phenylcarbamate (Compound 11-103) n/z: 447.1 (MH) Ho 10 N 10 N-(4-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7 yl)phenyl)cyclopropanecarboxamide (Compound 11-112) m/z: 415.2 (MHt H 0 NN N N Q 4-((5-(pyridin-3-yl)pyrimidin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4 15 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound 11-114) MS m/z 493.1 (M+H) N N -N F O N 331 7-(4-(2-hydroxypropan-2-yl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-118) m/z: 390.2 (M[H+) HO HO N N N' 4-(pyrimidin-2-ylmethyl)-7-(4-(2,2,2-trifluoroacetyl)phenyl)-3,4 5 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 1-121) n/z: 428.2 (MH) 0 F N N 4-(pyriuidi-2-ylmethyl)-8-(4-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2T)-one (Compound 1W-1) MS m/z 416.0 (M+H) t N N N F 0 10 4-(pyridin-2-ylmethyl)-8-(4-(trifluoromethoxy)pheny)-3,4 dihydrobenzo[f][1,4oxazepin-5(2H)-one (Compound WV-2) MS m/z 415.1 (M+H) o N FN F 0 4-(pyridin-2-ylmethyl)-8-(3-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound WV-3) MS m/z 399.1 (M+I-H) O N F O 15 332 4-(pyrimidin-2-ylmethyl)-8-(3-(trifluoromethy)phenyl)-3,4 dihydrobenzo[f][1,4oxazepin-5(2H)-one (Compound V-4) MS m/z 400.1 (M+H) 0 N F N F O 4-(pyrimidin-2-ylmethyl)-8-(4-(trifluoromethyl)phenyl)-3,4 5 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound V-5) MS rn/z 400.1 (M+H) O ND N F F F 4-(pyridin-2-ylmethyl)-8-(3-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound WV-6) MS m/z 415.1 (M+H) o N N F O F / 10 4-(pyrimidin-2-ylmethyl)-&-(3-(trifluoromethoxy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2L)-one (Compound V-7) MS m/z 416.1 (M+H) 0 N F 0 N N F O O F 333 4-(pyridin-2-ylmethyl)-S-(4-(trifluoromethy)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound IV-8) MS m/z 399.1 (M+H) c N F / FF 7-(4-tert-butylcyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 5 dihydrobenzo[f][1,4oxazepin-5(21)-one (Compound V-1) m/z: 392.2 (MH*) 0 N 7-cyclopentenyl-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin-5(2H) one (Compound V-2) m/z: 322.1 (MH) 0 N) 10 7-(4,4-dimethylcyclohex-1-enyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fl[1,4]oxazepin-5(2H)-one (Compound V-4) rn/z: 364.2 (MH*) 7-(bicyclo[3.1.1]hept-2-en-3-yl)4(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound V-7) m/z: 348.1 (MH*) 15 334 7-(2-oxo-1,2-dihydropyridin-4-yl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fI[1,4]oxazepin-5(2H)-one (Compound VI-1) mz: 349.1 (MH*) 0 HN O N N-N - NW O tert-butyl 4-(5-oxo-4-(pyrimidin-2-ylmethyl)-2,3,4,5 5 tetrahydrobenzo[fj [1,4]oxazepin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Compound VI-5) m/z: 436.9 (MH*) Oj N 4-(pyrimidin-2-ylmethyl)-7-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-6) MS mlz 431.1 (M+H) F 0 FFWO N N 10I ) 4-(pyrimidin-2-ylmethyl)-7-(6-(trifluoromethy)pyridin-3-yl)-3,4 dihydrobenzo[fj [1,4]oxazepin-5(2H)-one (Compound VI-8) MS nz 401.1 (M+H) F F 0N 7-(6-fluoropyridin-3-yl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[tf [1,4]oxazepin 15 5(2H)-one (Compound VI-9) MS in/z 351.1 (M+H) F NN 335 4-(pyrimidin-2-ylmethyl)-7-(2-(pyrrolidin-1-yI)pyrhidin-5-y)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VI-10) MS m/z 403.1 (M+H) NN

N

7-(2-(piperidin-1-yl)pyrimidin-5-yl)-4-(pyrimidin-2-ylmethyl)-3,4 5 dihydrobenzo[fl[1,4]oxazepin-5(2IH)-one (Compound VI-11) MS m/z 417.1 (M+H) N NN 7-(l-(cyeIopropanecarbonyl)-1,2,3,6-tetrahydropyridin-4-y)-4-(pyrimidin-2 ylmethyl)-3,4-dihydrobenzo[f] [1,4]oxazepin-5(2B)-one (Compound VI-17) m/z: 405.2 (MIt) 0 0) N N, 10j 7-(pyrimidin-2-yl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[fI [1,4]oxazepin 5(2H)-one (Compound VI-18) MS m/z 334.1 (M+H) N O N NN 4-(pyrimidin-2-ymethyl)-7-(5-(trifluoromethyl)pyrimidin-2-y)-3,4 15 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound VI-19) MS m/z 402.1 (M+H) F F F I NN 0N3 336 7-(cyclopropylethyny1)-4-(pyrimidin-2-ylmethyl)-3,4-dfliydrobenzo [f] [1,4 oxazepin 5(2H)-one (Compound VI-1) m/z: 320.2 (MH+) 7-(3,3-dimethylbut-1-ynyl)-4-(pyrimidin-2-ylmethyl)-3,4 5 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound VIH-2) nz: 336.1 (MRt) 09N 7-((1-methyl-1H-imidazol-5-yl)ethynyl)-4-(pyrinidin-2-ylmethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VIII-3) m/z: 360.2 (MH) /l N N 10 4-(imidazo[1,2-a]pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-135) m/z: 438.1 (MH) F F 0 7-(3-fluoro-4-(trifluoromethyl)phenyl)-4-(pyrimidin-2-ylmethyl)-3,4 dihydrobenzo[fl[1,4]oxazepin-5(2H)-one (Compound 11-136) m/z: 418.1 (MH) F F 0 N 15 ) 337 4-(pyrimidin-2-ylmethy)-7-(4-(2,2,2-trifluoroethyl)phenyl)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound 11-150) m/z: 459.2 (Mf) F F NIN F 4-(pyridin-2-ylmethyl)-7-(4-(2,2,2-trifluoroethyl)phenyl)-3,4 5 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound 11-151) m/z: 458.2(MIt) F cyclopropy](7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj [1,4]oxazepin 4(5H)-yl)methanone (Compound HI-8) rm/z: 378 (MH*) F+ 0 F ON 10 (1H-pyrazol-4-y)(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)methanone (Compound I-13) m/z: 404 (MH) F{OO (3,5-dimethyl-1H-pyrazo-4-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzotfl [1,4]oxazepin-4(5H)-yl)methanone (Compound IM-14) m/z: 432.2 15 (MH) F{0O 0 F N O 3038 338 (1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[f] [1,4] oxazepin-4(5H)-yl)methan one (Compound HI-16) m/z: 486.1 (MI-I F F F F .N \I 5 (3-methyl-1H-pyrazol-4-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[f] [1,4]oxazepin-4(5H)-yl)methanone (Compound IH-17) m/z: 418.2 (M) F / N NNH J 1-morpholino-2-(7-(4-(tripluoromethyl)phenyl)-2,3-dihydrobenzo[f] [1,4] oxazepi 10 4(52-yl)ethaone (Compound 3-28) m/z: 421 (MH) F F 0 O N 4-(pyrimidin-2-ylmethyl)-7-(pyrrolidin-1-y)-3,4-dihydrobenzo[f] [1,41 oxazepin 5(21)-one (Compound V-34) MS m/z 325.1 (M+H) 15 44yridin-2-ylmethy)-7-(pyrroldin-1-yI)-3,4-cihydrobenzo [l [1,41 oxazepin-5(2f) one (Compound VI-35) MS m/z 324.1 (M+H-) 339 4-benzyl-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[3,2-f] [1,4] oxazepin 5(2)-one (Compound XII-12) MS m/z 415.1 (M+H) F Y 0 F 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyrido[3,2 5 f] [1,4]oxazepin-5(2H)-one (Compound Xfl-13) MS mfz 417.1 (M+H) rO 4-(pyridin-2-yImethyl)-7-(4-(trifiuoromethoxy)phenoxy)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound XI-5) MS m/z 431.1 (M+H) 0 N FO 10 N-(5-oxo-4-(pyridin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo [f] [1,4] oxazepin-7 yl)benzamide (Compound XHI-7) MS m/z 374.1 (M+H) H 0N 0 e 4-(pyridin-2-ylmethyl)-7-(4-(triftluoromethyl)phenoxy)-3,4 dihydrobenzo[f] [1,4]oxazepin-5(2H)-one (Compound XIH-8) MS m/z 415.1 (M+H) F q 15 F 340 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)benzylamino)-3,4 dihydrobenzo[fj[1,4]oxazepin-5(2H)-one (Compound XIH-9) MS m/z 445.1 (M+H) F NNl 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethoxy)benzylamino)-3,4 5 dihydrobenzo[f]1,4]oxazepin-5(2H)-one (Compound X=I-11) MS m/z 444.1 (M+H) N-(5-oxo-4-(pyridin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)4 (trifluoromethyl)benzamide (Compound XII-13) MS m/z 442.1 (M+H) F F H 0N N N NI 10 7a-(7-(4-(trifluoromethoxy)phenyl)-2,3,4,5-tetrahydrobenzo[f] [1,4loxazepine-4 carbonyl)tetrahtydro-1H-pyrrolizin-3(2H)-one (Compound 111-59) MS m/z 461.4 (M+H) F*O O0 F N N 711t N-(5-oxo-4-(pyridin-2-ylmethyl)-2,3,4,5-tetrahydrobenzo [f] [1,4] oxazepin-7-yl)-4 15 (trifluoromethoxy)benzamide (Compound X1I-14) MS nz 458.1 (M+H) F341 F N N 0 341 4-(pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenethyl)-3,4 dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound VIII-7) MS m/z 427.4 (M+H) F3G N ~ N Example 252 5 [0703] Hard gelatin capsules containing the following ingredients are prepared: Quantity Ingredient (mg/capsule) Active Ingredient 30.0 Starch 305.0 10 Magnesium stearate 5.0 [0704] The above ingredients are mixed and filled into hard gelatin capsules. Example 253 A tablet Formula Is prepared using the ingredients below: Quantity 15 Ingredient (mg/tablet) Active Ingredient 25.0 Cellulose, microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0 20 The components are blended and compressed to form tablets. Example 254 [0705] A dry powder inhaler formulation is prepared containing the following components: Ingredient Weight % 25 Active Ingredient 5 Lactose 95 [07061 The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance. 342 Example 255 [0707] Tablets, each containing 30 mg of active ingredient, are prepared as follows: Quantity Ingredient (mg/tablet) 5 Active Ingredient 30.0 mg Starch 45.0 mg Microcrystalline cellulose 35.0 mg Polyvinylpyrrolidone (as 10% solution in sterile water) 4.0 mg 10 Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1.0 mg Total 120 mg [07081 The active ingredient, starch and cellulose are passed through a No. 20 mesh 15 U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50 "C to 60 'C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are 20 compressed on a tablet machine to yield tablets each weighing 120 mg. Example 256 [07091 Suppositories, each containing 25 mg of active ingredient are made as follows: Ingredient Amount 25 Active Ingredient 25 mg Saturated fatty acid glycerides to 2,000 mg [07101 The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity 30 and allowed to cool. 343 Example 257 [07111 Suspensions, each containing 50 mg of active ingredient per 5.0 mL dose are made as follows: Ingredient Amount 5 Active Ingredient 50.0 mg Xanthan gum 4.0 mg Sodium carboxymethyl cellulose (11%) Microcrystalline cellulose (89%) 50.0 mg Sucrose 1.75 g 10 Sodium benzoate 10.0 mg Flavor and Color q.v. Purified water to 5.0 mL [0712] The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve and then mixed with a previously made solution of the 15 microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume. Example 258 [0713] A subcutaneous formulation may be prepared as follows: 20 Ingredient Quantity Active Ingredient 5.0 mg Corn Oil 1.0 mL Example 259 [0714] An injectable preparation is prepared having the following composition: 25 Ingredients Amount Active ingredient 2.0 mg/mL Mannitol, USP 50 mg/mL Gluconic acid, USP q.s. (pH 5-6) water (distilled, sterile) q.s. to 1.0 mL 30 Nitrogen Gas, NF q.s. 344 Example 260 [07151 A topical preparation is prepared having the following composition: Ingredients grams Active ingredient 0.2-10 5 Span 60 2.0 Tween 60 2.0 Mineral oil 5.0 Petrolatum 0.10 Methyl paraben 0.15 10 Propyl paraben 0.05 BHA (butylated hydroxy anisole) 0.01 Water q.s. tolO0 [0716] All of the above ingredients, except water, are combined and heated to 6000 with stirring. A sufficient quantity of water at 60*C is then added with vigorous stirring 15 to emulsify the ingredients and water then added q.s. 100 g. Example 261 [0717] Sustained Release Composition Ingredient Weight Range% Active ingredient 50-95 20 Microcrystalline cellulose (filler) 1-35 Methacrylic acid copolymer 1-35 Sodium hydroxide 0.1-1.0 Hydroxypropyl methylcellulose 0.5-5.0 Magnesium stearate 0.5-5.0 25 [07181 The sustained release formulations of this disclosure are prepared as follows: compound and pH-dependent binder and any optional excipients are intimately mixed(dry-blended). The dry-blended mixture is then granulated in the presence of an aqueous solution of a strong base which is sprayed into the blended powder. The granulate is dried, screened, mixed with optional lubricants (such as talc or magnesium 30 stearate) and compressed into tablets. Preferred aqueous solutions of strong bases are solutions of alkali metal hydroxides, such as sodium or potassium hydroxide, preferably sodium hydroxide, in water (optionally containing up to 25% of water-miscible solvents such as lower alcohols). 345 [0719] The resulting tablets may be coated with an optional film-forming agent, for identification, taste-masking purposes and to improve ease of swallowing. The film forming agent will typically be present in an amount ranging from between 2% and 4% of the tablet weight. Suitable film-forming agents are well known to the art and include 5 hydroxypropyl methylcellulose, cationic methacrylate copolymers (dimethylaminoethyl methacrylate/ methyl-butyl methacrylate copolymers - Eudragit* E - R6hm. Pharma) and the like. These film-forming agents may optionally contain colorants, plasticizers and other supplemental ingredients. [0720] The compressed tablets preferably have a hardness sufficient to withstand 8 Kp 10 compression. The tablet size will depend primarily upon the amount of compound in the tablet. The tablets will include from 300 to 1100 mg of compound free base. Preferably, the tablets will include amounts of compound free base ranging from 400-600 mg, 650-850 mg and 900-1100 mg. [0721] In order to influence the dissolution rate, the time during which the compound 15 containing powder is wet mixed is controlled. Preferably the total powder mix time, i.e. the time during which the powder is exposed to sodium hydroxide solution, will range from I to 10 minutes and preferably from 2 to 5 minutes. Following granulation, the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60*C. 20 Example 262 [0722] Activity testing is conducted in the Examples below using methods described herein and those well known in the art. Sodium current screening assays: [07231 The late sodium current (Late INa) and peak sodium current (Peak 1Na) assays 25 are performed on an automated electrophysiology platform, QPatch 16X (Sophion Bioscience, Copenhagen, Denmark), which uses the whole cell patch clamp technique to measure currents through the cell membrane of up to 16 cells at a time. The assay uses an HEK293 (human embryonic kidney) cell line heterologously expressing the wild-type human cardiac sodium channel, hNay1.5, purchased from Millipore (Billerica, MA). No 30 beta subunits were coexpressed with the Na channel alpha subunit. Cells are maintained with standard tissue culture procedures and stable channel expression is maintained with 400 gg/nL Geneticin in the culture medium. Cells isolated for use on QPatch are 346 incubated for 5 minutes in Detachin IX (Genlantis, San Diego, USA) at 37 *C to ensure that 80-90% of the cells are single and not part of a cell cluster. Experiments are carried out at 23-25*C. [0724] For both the Late INa and Peak INa assays, series resistance compensation is set 5 to 100% and series resistance and whole-cell compensation are performed automatically. Currents are digitized at 25 kHz and low-pass filtered at 12kHz and 10 kHz for the late and peak ]Na assays, respectively. Currents through open sodium channels are automatically recorded and stored in the Sophion Bioscience Oracle database (Sophion Bioscience, Copenhagen, Denmark). Analysis is performed using QPatch Assay and 10 database software and data are compiled in Excel. [0725] Compound stocks are routinely made by the Gilead Sample Bank in plastic vials to 10 mM in dimethyl sulfoxide (DMSO). In some cases, when compounds are not soluble in DMSO, they are made in 100% ethanol. Stocks are sonicated as necessary. The extracellular solution for screening Late INa is composed of: 140 mM NaCl, 4 mM 15 KCl, 1.8 mM CaCl 2 , 0.75 mM MgCl 2 and 5 mM HEPES with pH adjusted to 7.4 using NaOH. The intracellular solution used to perfuse the inside of the cells for both the Late INa and Peak INa assays contains: 120 mM CsF, 20 mM CsCl, 5 mM EGTA, 5 mM HEPES and pH adjusted to 7.4 with CsOH. Compounds are diluted in extracellular solution to 1 AM in glass vials and then transferred to glass well plates before robotic 20 addition to the cells. The 0 mM Na extracellular solution (ONa-ECF) used at the end of each experiment for the Late INa and Peak INa assays to measure baseline current contains: 140 mM N-methyl-D-glucamine; 4 mM KCl; 1.8 mM CaCl 2 ; 0.75 mM MgCl 2 ; 5 mM HEPES and pH was adjusted to 7.4 with HCl. Late LNa Screening Assay: 25 [0726] For the Late INa assay, sodium channels are activated every 10 seconds (0.1 Hz) by depolarizing the cell membrane to -20 mV for 250 milliseconds (ms) from a holding potential of -120 mV. In response to a -20 mV voltage step, typical bNavl.5 sodium currents activate rapidly to a peak negative current and then inactivate nearly completely within 3-4 ms. 30 [07271 Compounds were tested to detennine their activity in blocking the late sodium current. Late INa was generated by adding 10 pM Tefluthrin (pyrethroid) to the extracellular solution while recording Na currents. To confirm the block of late IN 347 observed using the automated screening method, a second late INa enhancer (ATX-II) and the manual patch clamp method were used. ATX-U and tefluthrin occupy distinct, non overlapping binding sites and modify Na* channel function differently to increase late INa. Compounds tested have been found generally to inhibit the enhanced late IN, caused by 5 either late INa enhancer. For the purposes of the screening, late INa is defined as the mean current between 225 ms and 250 ms after stepping to -20 mV to activateNa channels. After establishing the whole cell recording configuration, late INa activator is added to each well 4 times over a 16-17 minute period so that the late component of the Na current reaches a stable value. Compounds were then added (typically at 1 pM), in the presence 10 of the late INa activator, with 3 additions over the course of 7 or 8 minutes. Measurements were made at the end of exposure to the third compound addition and values were normalized to the current level when all Na t was removed from the extracellular solution after two additions of ONa-ECF. [0728] Results are reported as percent block of late INa. When tested in the assay 15 disclosed above with 10 yM Tefluthrin activating late 1Na, for example Compounds II 105 inhibited (or reduced) the late sodium current by 45% (see Table 1 for additional compound data). The inhibition of Late INa of the cardiac isoform hNa, 1.5 support the use of the compounds of this disclosure to treat atrial arrhythmias, ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, 20 systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable angina, unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, rep erfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension and intermittent claudication. Peak INa Screening Assay: 25 [0729] Compounds were also evaluated for their effect in several other assays, including their effect on Peak INa. Good separation between the concentrations of test compound to reduce late and peak INa is beneficial to enable separation of the desired effect to reduce late INa-induced electrical and mechanical dysfunction from the undesired effect to reduce peak INa, which can lead to slowing or block of conduction of electrical excitation in the 30 heart. It is contemplated that the compounds of Formula I avoid significant block of peak INa. Since the peak INa in the cells used herein can be very large, introducing artifacts in the recording, the concentration of Na in the bath can be reduced to 20 mM and a nonpermeant cation added to compensate for the Nat that was removed to maintain the 348 osmolarity and ionic strength of the solution (see solution details below). Analysis of peak INa generally requires correction for rundown before determining the % block of peak current by the tested compound. [0730] A separate Peak INa screening assay was developed to allow assessment of the 5 effect of compounds on peak INa at both low and high stimulation frequencies in order to identify compounds that are highly selective for block of late INa but do not block peak INa. A low stimulation frequency of 0.1 Hz was used to determine the effect of the test compound when the channel spent most of the time in the resting (closed) state and provides information about Tonic Block (TB). A higher stimulation frequency (3Hz) was 10 used to measure block of the channel when it spent more time in the activated and inactivated states and provided a measure of Use-Dependent Block (UDB). Use dependent block refers to the accumulation of block with increased frequency of channel activation. Block of cardiac peak INa by compounds of this disclosure is increased with an increase in the frequency of stimulation from 0.1 to 1-5 Hz (frequencies encountered 15 either in the normal heart or during tachycardia). It is therefore expected that reduction of peak INa by compounds of this disclosure will be greater at high heart rates, such as those during tachyarrhythnias, than at normal heart rates. As a consequence, compounds of this disclosure may reduce Na+ and Ca 2 t overload due to late INa and abnormal electrical activity and electrical conduction in myocardium that is arrhythmic, especially during 20 ischemia. [07311 The -100 mV holding potential and the 3 Hz stimulation frequency were chosen so that the benchmark compound would have a small but detectable effect under experimental conditions, allowing for direct comparison of new compounds with the benchmark. The extracellular solution for screening Peak INa is composed of: 20 mM 25 NaCl, 120 mM N-methyl-D glucamine, 4 mM KCl, 1.8 mM CaCl 2 , 0.75 mM MgCI 2 and 5 mM HEPES with pH adjusted to 7.4 using HC. The intracellular solution used for the Peak INa assay is the same as outlined for the Late INa assay (see above). [07321 For the peak 1Na assay, Na+ channels were activated by depolarizing the cell membrane to 0 mV for 20 ms from a holding potential of -100 mV. After establishing the 30 whole cell recording configuration, channels were stimulated to open with low frequency stimulation (0.1 Hz) for 7 minutes so that the recording can be monotered and the extent to which the recording has stabilized can be assessed. After this stabilization period the stimulation frequency was increased to 3 Hz for 2 minutes and then returned to 0.1 Hz. 349 Since 3 Hz stimulation causes a small decrease in the peak current even in the absence of compound, this internal control was used for each cell, when no compound is present, to correct the results from 3 Hz stimulation when compound is present. Following 3 Hz stimulation under control conditions, the cell is allowed to recover for 200 seconds before 5 compound is added. The test compound tested at 1 or 3 SM (depending on the % block of late INa at 1 pM) was added 3 times at 60 second intervals, while stimulating the channels to open at 0.1 Hz to monitor the progression of TB. After the third compound addition, a 320 second wait period was imposed to allow for equilibration before the second period of 3 Hz stimulation begins. TB was measured before the second period of 3 10 Hz stimulation. Both TB and U3DB were analyzed by incorporating rundown correction for the peak INa and UDB as calculated by compensating for the small use-dependent effect of the stimulation protocol on peak INa in the absence of compound. Compound I-l105 exhibited peak INa TB of 9% and peak Ia JDB of 11%, both measured at 1 pM. [07331 The above data demonstrates the selectivity of Compound 11-105 to block late 15 INa compared to peak INa (45% versus 9% for peak INa TB; and 45% versus 11% for peak INa UDB) and suggests that Compound II-105 should show minimal to no effects on conduction through the heart (which is driven by peak INa) at concentrations that effectively block late INa. hERG Screening Assay: 20 [0734] Compounds were also tested for their effect to block the hERG K* channel. At least a 3-5-fold separation, preferably 10 fold separation, of ICso values for compounds to inhibit late INa (more potent) and hERG (less potent) indicates that a compound is unlikely to cause QT prolongation and/or proarrhythmic effects at concentrations needed to reduce late I'a. 25 [07351 Compounds were screened to test their activity in blocking the hERG potassium channel at AVIVA Biosciences (San Deigo, CA, USA). The hERG channel is heterologously expressed in a CHO (Chinese Hamster Ovary) cell line. Cells were maintained with standard tissue culture procedures and stable channel expression was maintained with 500 pig/mL G418 in the culture medium. Cells were harvested for testing 30 on the PatchXpress 7000A automated patch clamp with Accumax (Innovative Cell Technologies, San Diego, CA) to isolate single cells. 350 [07361 The following solutions were used for electrophysiological recordings. The external solution contained: 2 mM CaCl 2 ; 2 mM MgCl 2 ; 4 mM KCl; 150 mM NaCl; 10 mM Glucose; 10 mM HEPES (pH 7.4 with lM NaOH; osmolarity, -310 mOsm). The internal solution contained: 140 mM KCl, 10 mM MgCl 2 , 6 mM EGTA, 5 mM HEPES, 5 5 mM ATP (pH adjusted to 7.25 with KOH; osmolarity, -295 mOsm). [0737] hERG channels were activated when the voltage was first stepped to -50 mV for 300 ms from the -80 mV holding potential and then stepped to +20 mV for 5 seconds. At +20 mV the channels open and then largely inactivate, so the currents are relatively small. Upon returning to -50 mV from +20 mV, hERG currents transiently become much larger 10 as inactivation is rapidly removed and then the channel closes. The first step to -50 mV for 300 ins was used as a baseline for measuring the peak amplitude during the step to -50 mV after channel activation. The peak tail current at -50 mV was measured both under control conditions and after addition of compound, each cell serving as its own control. [0738] All compounds were prepared as 10 mM DMSO stocks in glass vials. Stock 15 solutions were mixed by vigorous vortexing and sonication for about 2 minutes at room temperature. For testing, compounds were diluted in glass vials using an intermediate dilution step in pure DMSO and then further diluted to working concentrations in external solution. Dilutions were prepared no longer than 20 minutes before use. [0739] For the electrophysiological recordings, after achieving the whole-cell 20 configuration, cells were monitored for 90 seconds to assess stability and washed with external solution for 66 seconds. The voltage protocol described above was then applied to the cells every 12 seconds and throughout the whole procedure. Only cells with stable recording parameters and meeting specified health criteria were allowed to enter the compound addition procedure. 25 [0740] External solution containing 0.1% DMSO (vehicle) was applied to the cells first to establish the control peak current amplitude. After allowing the current to stabilize for 3 to 5 minutes, I pM and then 10 gM test compounds were applied. Each compound concentration was added 4 times and cells were kept in test solution until the effect of the compound reached steady state or for a maximum of 12 minutes. After addition of test 30 compound, a positive control (1 pM Cisapride) was added and must block >95% of the current for the experiment to be considered valid. Washout in the external solution compartment was performed until the recovery of the current reached steady state. Data 351 were analyzed using DataXpress software and its associated SQL server database, Clampfit (Molecular Devices, Inc., Sunnyvale, USA) and Origin 7 (Originlab Corp.) When tested in the assay disclosed above, Compound 11-105 inhibited (or reduced) the activity of the hERG potassium channel by <10% at 1 pM (see Table I for additional 5 compound data). [0741] Compounds were tested using the above described assay methods. Data are obtained by testing the listed compounds at I pM concentration in the late and peak INa assays (and other concentrations as needed) and at 1 gM and 10 iM for the hERG channel assay. 10 Table 1: Late Ira Assay results No Late Ix. Peak TB Peak UDB 1PM 1ptM I1pM 11-1 25 11-3 15 11-4 30 11-5 26 H-6 16 11-7 34 11-8 21 11-10 43 9 2 11-11 23 11-12 21 11-13 18 H-14 47 7 6 11-15 48 8 8 H-16 19 11-17 59 47 46 11-19 21 352 No Late in Peak TB Peak UDB No' 1pM 1pM 1pM 11-21 18 11-22 30 11-23 25 11-24 23 11-25 25 1-31 51 9 8 11-33 46 10 13 H-35 25 11-39 16 11-41 17 11-42 34 11-43 23 11-44 39 11-45 27 11-46 25 1147 60 13 45 1-48 47 13 53 1149 63 28 44 H-50 48 5 19 H-51 20 11-54 51 13 20 11-57 55 50 41 11-59 15 11-61 41 11-62 49 10 14 353 No Late INa Peak TB Peak UDB No.1pM 1pM 1pM__ 1-64 55' 12 19 n-65 19 1-67 22 11-68 17 11-69 33 1-70 37 11-71 12 11-72 60 22 34 11-73 42 11-74 12 11-75 68 45 59 11-77 21 11-83 31 1-87 22 11-88 41 11-89 28 H-91 54 8 11 11-92 34 H-95 19 11-97 36 11-98 39 11-102 21 11-104 21 11-105 45 9 11 11-106 18 354 No. Late IN Peak TB Peak UDB H-107 18 1[-110 35 11-113 27 1I-115 21 1I-117 37 H-122 19 H-123 21 H-124 17 11-129 33 11-133 23 11-134 69 38 34 H-135 32 11-136 30 1-137 54 28 26 11-138 47 16 23 1-139 31 11-140 32 H-141 73 40 40 11-142 19 11-143 65 H-144 68 34 41 11-145 19 1-146 36 11-147 54 13 6 11-148 17 355 No. Late INa Peak TB Peak UDB 1pM 1pM 1pM 11-150 27 1-151 51 13 14 11-152 23 H-153 56 15 13 H-154 25 1-155 38 13 11 11-156 48 23 13 11-157 43 13 16 11-158 58 34 26 11-159 28 11-160 48 11-162 20 11-163 28 H-164 75 11-165 56 15 30 11-166 53 20 34 11-167 56 20 25 11-168 44 36 47 H-169 65 23 23 11-170 66 36 31 11-171 24 11-172 33 H-174 48 7 18 11-175 53 21 16 11-176 68 45 44 356 No. Late INa Peak TB Peak UDB 1pm iIpM ipM 1-177 22 11-178 19 11-179 21 11-186 55 20 30 11-187 62 9 21 1-189 53 23 28 11-190 18 11-191 25 11-192 15 11-193 70 11-194 63 1-195 66 rn-1 33 III4 35 H O-10 29 n-11 20 I-12 39 10 17 rn-15 50 19 18 III-23 26 III-24 17 III-29 48 11 14 HI-30 16 HI--32 22 mI-33 37 111-37 41 357 No. Late IN, Peak TB Peak UDB 1IM i1pM 1gM I-38 28 111-40 22 rI-50 24 111-58 26 IV-4 14 V-1 24 V-3 23 V-5 49 5 5 VI4 36 VI-i 19 VI-26 28 VI-30 40 VI-31 61 50 42 VI-32 66 28 26 VI-36 47 VI-37 48 VIII-4 61 12 19 VI-5 32 VI-6 38 VI11-7 59 VRI-8 47 VL-9 50 VTII-10 25 VIl-1i 42 IX-2 22 358 NO Late IN. Peak TB Peak UTDB 1 M 1pM 1PM IX-3 27 X-8 50 6 10 X-11 48 17 20 X-12 26 XII-1 53 25 21 XII-2 57 45 64 XII-3 44 51 79 XII-5 25 XII-8 36 XII-9 22 XII-10 45 13 20 XII-11 55 25 24 XII-14 26 XII-1 16 XIII-2 19 XII-3 17 XIII-4 51 8 9 XIII-6 60 8 8 XI-10 22 [0742] The assay results shown in the above table establishes that compounds tested showed activity as modulators of late sodium current, for example by inhibiting (or reducing) the late sodium current. 5 107431 In some embodiments the effects of a compound of Formula I are specific for the late sodium current and show little or no activity with respect to one or more other ion channels. Thus, in some embodiments, a compound having an activity of reducing late 359 sodium current will also exhibit little or no activity with regard to the peak sodium current. In particular embodiments, a compound having an activity of reducing late sodium current will also exhibit little or no activity with regard to the hERG potassium channel. 5 [07441 Table 2 is a summary comparing compound 11-73 and ranolazine ability to block late and peak hNav 1.5 Na* current and hERG W current. The data in Table 2 were obtained in similar but not necessarly contemporaneous experiments. Table 2

IC

50 IM ICso Ratio (fold) Late INa Peak INa hERG Peak INa/Late INa hERG/Late INa 11-73 0.6:t 0.1 52±t:5 5.7 t 0.6 87 10 Ranolazine 6.7* 1.4 428 ±33 13.4 0.5 64 2 [0745] The above data suggests that the compound of Example 1-73 exhibits 10 comparable or improved properties with respect to the tested paramaters. L-type Ca2+ Channel Assay - ChanTest: [07461 Selected compounds were screened for block of the cardiac L-type Ca 2 + channel (hCavl.2, encoded by the human CACNA1C gene and coexpressed with the beta 2 subunit, encoded by the human CACNB2 gene and alpha2deltal, encoded by the 15 CACNA2D1 gene). The Ca 2 + channel is heterologously expressed in a CHO (Chinese Hamster Ovary) cell line. Cells are maintained following standard tissue culture procedures and stable channel expression is maintained with appropriate selection antibiotics in the culture medium. Cells are harvested for testing on the PatchXpress automated patch clamp (Model 7000A, Molecular Devices, Sunnyvale, CA) by washing 20 twice with Hank's Balanced Salt Solution, treating the cells with trypsin and re suspending cells in culture medium (4-6 x 106 cells in 20 mL). Cells in suspension are allowed to recover for 10 minutes in a tissue culture incubator set at 37*C in a humidified 95% air, 5% CO 2 atmosphere. 360 [07471 The following solutions are used for electrophysiological recordings. The external solution contains (mM): 137 NaCl, 4 KC1, 1.8 CaC 2 , 1 MgCI 2 , 10 Glucose, 10 HEPES (pH 7.4 with NaOH). The internal solution contains (mM): 130 Cs Aspartate, 5 MgCl 2 , 10 EGTA, 4 ATP, 0.5 GTP, 10 HEPES, (pH adjusted to 7.2 with N-methyl-D 5 glucamine). [0748] Vehicle is applied to naive cells (n 2, where n= the number cells), for a 5-10 minute exposure interval. Each solution exchange is performed in quadruplicate. At the end of each experiment, a saturating concentration of nifedipine (10 pM) is added to block hCavl.2 current. Leak current is digitally subtracted from the total membrane 10 current record. [0749] Test compound stock solutions are prepared by addition of dimethyl sulfoxide (DMSO) and stored frozen. Each test compound DMSO stock is sonicated (Model 2510/5510, Branson Ultrasonics, Danbury, CT), at ambient room temperature for at least 20 minutes to facilitate dissolution. Test compound concentrations are prepared fresh 15 daily by diluting stock solutions into the standard extracellular physiological saline solution (see above). The maximum percent of DMSO added with compound is 0.1%. All test compound and control solutions are placed in a glass-lined 96-well compound plate before loading on PatchXpress. [0750] Two concentrations (1, 10 pM) of each test compound are applied at five (5) 20 minute intervals via disposable polyethylene micropipette tips to naive cells (n 2, where n = the number cells/concentration). Each test compound concentration is added to the cell in quadruplicate. Total duration of exposure to each test compound concentration is 5 minutes. [0751] Onset and steady state block of hCav.2 (alC/p2/a2 channels is measured 25 using a stimulus voltage pattern consisting of a depolarizing test pulse (duration, 200 ms; amplitude, 10 mV) at 10 s intervals from a -80 mV holding potential. Peak current is measured during a step to 10 mV. [0752] When tested in the assay disclosed above, Compound 11-73 blocked the hCavl.2 late current by 14% and peak current by 32% at I iM concentration. At 10 JIM 30 concentration the compound 11-73 blocked the hCav.2 late current by 47% and the peak current by 79%. 361 Example 263 [0753] Compounds of this disclosure that block cardiac late IN, may also mediate UDB of other Na channel isoforms including the major Na* channel isoforms in peripheral nervous system pain fibers, Nav.7 and 1.8. Compounds of this disclosure that block 5 these channels may also be useful to decrease neuropathic pain. [0754] In particular embodiments, a compound will exhibit a high selectivity for the late sodium current modulatory activity as compared to the activity in one or more other ion channels. The selectivity of a compound may be determined by determining the percentage reduction in late sodium current due to the compound, as measured by the 10 assay described above. The percentage reduction in one other ion channel activity, such as the hERG potassium channel, due to the compound is determined as described above. The selectivity is determined by taking the ratio of (percentage reduction in late sodium current) to (percentage reduction in one other ion channel activity). The assays conducted to measure activities in this regard should be performed as described above, with the 15 compound at a concentration of 10 pM (or at the upper limit of solubility, if less). In particular embodiments, the selectivity of a compound of the disclosure will be at least 5:1, e.g. at least 6:1, at least 7:1, at least 8:1, at least 9:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, or at least 25:1, when comparing the percentage reduction in late sodium current versus percentage reduction of one of the peak sodium current, the bERG 20 potassium channel current. Selectivity data can be calculated based on the values provided in the Examples above. [0755] Evidence supports a role for the tetrodotoxin-sensitive Na.7 in the pathogenesis of pain. In this assay, using whole-cell patch-clamp technique, the effects of compounds of the disclosure on hNa,1.7 (hNay1.7+01 subunits) peak Nat current (INa) are 25 tested as described previously (Rajamani et al, 2009). Cells are continuously maintained using MEM (Gibco-Invitrogen, Carlsbad, CA) supplemented with 10% heat inactivated fetal bovine serum, 1% penicillin-streptomycin, 600 pg/mL geneticin (Gibco-Invitrogen), 2 gg/mL blastocydin (Calbiochem, NJ, USA), and are incubated at 37*C in an atmosphere of 5% CO 2 in air. For recording hNavl.7 INa, HEK293 cells are superfiised with an 30 extracellular solution containing (in mM): 140 NaCI, 3KCl, 10 HEPES, 10 glucose, 1 MgCl 2 , 1 CaCl 2 , pH 7.4 (with NaOH). Patch pipettes are filled with an internal solution containing (in mM): 140 CsF, 10 NaCl, I EGTA, 10 HEPES, pH 7.3 (with CsOH). 362 [0756] Whole-cell INa are recorded as described previously (Rajamani et al, 2009) using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, USA). Signals are filtered at 5 kHz and sampled at 20 kHz. Patch pipettes are formed using borosilicate glass (World Precision Instruments, Sarasota, USA) using a micropipette puller (Dagan Corporation, 5 Minneapolis, USA). The offset potential is zeroed before the pipette is attached to the cell and the voltages are not corrected for the liquid junction potential. In all recordings, 75 80% of the series resistance compensation will be achieved, thus yielding a maximum voltage error of-5 mV and leak currents are cancelled by P/4 subtraction. pCLAMP 10.0 software (Molecular Devices) will be used to generate voltage clamp protocols and 10 acquire data. The membrane potential is held at -100 or -120 mV and the cell dialyzed with the pipette solution for 5-7 minutes before current is recorded, to avoid time dependent shifts in Na* channel gating within the first several minutes after patch rupture. In all experiments, the temperature of experimental solutions will be maintained at 20+1*C using a CL-1 00 bipolar temperature controller (Warner Instruments, Hamden, 15 USA). [0757 Data are analyzed using Clampfit and Microcal Origin (MicroCal, Northampton, USA) software. [0758] When tested in the assay disclosed above, Compound 11-73 blocked the hNa, 1.7 sodium channel isoform with ICso of 5.2 sM at a frequency of 10 Hz. Compound I1-73 20 blocked the hNa, 1.8 sodium channel isoform with a IC 50 of>10 pM at a 10 Hz frequency. At higher frequency of 25 Hz, compound II-73 blocked both hNa, 1.7 and hNa, 1.8 isoforms with IC 5 of 1. 1 and 1.5 pM respectively. The inhibition of either hNa, 1.7 and hNa, 1.8 isoforms or the inhibition of both channels when stimulated at these frequencies support the use of compounds of this disclosure to decrease neuropathic 25 pain. Example 264 Expression of human Nay. eDNA [07591 All experiments with human Nav1.1 are conducted as described (Kablig, et at., PNAS, 105: 9799-9804). Briefly, expression of hNav1.1 is achieved by transient 30 transfection using Qiagen Superfect reagent (5.5 Ig of DNA is transfected at a plasmid mass ratio of 10:1:1 for ai:pi:p2). The human si and P2 cDNAs are cloned into plasmids 363 containing the marker genes DsRed (DsRed-IRES2--hp 1 ) or eGFP (eGFP-IRES2-hp 2 ) flanking an internal ribosome entry site (IRES). Electrophysiology [0760] Whole-cell voltage-clamp recordings are used to measure the biophysical 5 properties of WT and mutant Navl.1 channels, as described previously (Kahlig, 2008). For recording hNavl.1 INa, HEK293 cells are superfused with solution containing (in mM); 145 NaCl, 4 KC, 1.8 CaCI 2 , 1 MgC2, 10 dextrose, 10 HEPES, with a pH of 7.35 and osmolarity of 310 mOsmol/kg. The pipette solution contains (in mM): 110 CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, with a pH of 7.35 with an osmolarity of300 10 mOsmolkg. Cells are allowed to stabilize for 10 min after establishment of the whole-cell configuration before current is measured. Series resistance is compensated 90% to assure that the command potential is reached within microseconds with a voltage error <2 mV. Leak currents are subtracted by using an online P/4 procedure and all currents are low pass Bessel filtered at 5 kcHz and digitized at 50 kHz. 15 (0761) For use-dependent studies, cells are stimulated with depolarizing pulse trains (-10 mV, 5 ms, 300 pulses, 10 and 25Hz) from a holding potential of -120 mV. Currents are then normalized to the peak current recorded in response to the first pulse in each frequency train. For tonic block studies, peak and persistent (late) currents are evaluated in response to a 200 ms depolarization to -10 mV (0.2 Hz) following digital subtraction 20 of currents recorded in the presence and absence of 0.5 JIM tetrodotoxin (TTX). The sodium current termed Late 1Na in the periphery is commonly called persistent 1Na in the CNS. Persistent current is calculated during the final 10 ms of the 200 ms step. Data analysis is performed using Clampfit 9.2 (Axon Instruments, Union City, CA, U.S.A), Excel 2002 (Microsoft, Seattle, WA, U.S.A.), and OriginPro 7.0 (OriginLab, 25 Northampton, MA, U.S.A) software. Results are presented as mean SEM. In vitro Pharmacology [0762] A stock solution of 10mM compound of Formula I is prepared in 0.1 M HCl or DMSO. A fresh dilution of the compound of Formula I in the bath solution is prepared every experimental day and the pH is readjusted to 7.35 as necessary. The final DMSO 30 concentration was kept at 0.1% in all solutions. Direct application of the perfusion 364 solution to the clamped cell is achieved using the Perfusion Pencil system (Automate, Berkeley, CA). Direct cell perfusion is driven by gravity at a flow rate of 350 pL/min using a 250 micron tip. This system sequesters the clamped cell within a perfusion stream and enables complete solution exchange within 1 second. The clamped cell is perfused 5 continuously starting immediately after establishing the whole-cell configuration. Control currents are measured during control solution perfusion. Where appropriate, concentration inhibition curves are fit with the Hill equation: J/.,X = 1/[l+10^(logICso-1)*k], where ICso is the concentration that produces half inhibition and k is the Hill slope factor. [0763] Solutions containing the compounds of the disclosure are perfused for three 10 minutes prior to current recordings to allow equilibrium (tonic) drug block. Tonic block of peak current is measured from this steady-state condition. Use-dependent block of peak current is measured during pulse number 300 of the pulse train, (-10 mV, 5 ms, 300 pulses, 10Hz) from a holding potential of -120 mV. Two sequential pulse train stimulations are averaged to obtain mean current traces for each recording condition. 15 In vivopharnacology [0764] Jugular vein cannulated male Sprague Dawley rats (250 - 350g, Charles River Laboratories, Hollister, CA) are used to study brain penetration of the compounds of the disclosure in vivo. Animal use is approved by the Institutional Animal Care and Use Committee, Gilead Sciences. Three rats per group are infused intravenously with the 20 compound of the disclosure in saline at 85.5 [g/kg/min. After 1, 2.5 or 5 h the animals are sacrificed for plasma and brain collection, and concentrations of the compound of the disclosure are measured by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Brain tissue is homogenated in 1% 2N HCl acidified 5% sodium fluoride (final homogenate is diluted 3-fold). Plasma and brain homogenate 25 samples (50 gl) are precipitated along with deuterated D3-Formula I as an internal standard, vortexed and centrifuged. The supernatant (50 VL) is transferred and diluted with water (450 pl) prior to injection (10 pl). High performance liquid chromatography was performed using a Shimadzu LC-I0AD liquid chromatograph and a Luna C 18(2), 3 pm, 20 x 2.0 mm column with a mobile phase consisting of water containing 0.1% formic 30 acid (solution A) and acetonitrile (solution B) carried out under isocratic conditions (75% solution A, 25% solution B; flow rate 0.300 ml/min). Mass spectrometric analyses are performed using an API3000 mass spectrometer (Applied Biosystems, Foster City, CA) 365 operating in positive ion mode with MRM transition 428.1 > 98. Brain-to-plasma ratios are calculated for each sample as ng compound/g brain divided by ng compound/ml plasma. Example 265 5 Expression of human Nay.2 cDNA [0765] Wild-type (WT) cDNA stably transfected in Chinese hamster ovary (CHO) cells is used to record INa. Unless otherwise noted, all reagents are purchased from Sigma Aldrich ( St Louis, MO, U.S A.). Electrophysiology 10 [0766] Whole-cell voltage-clamp recordings are used to measure the biophysical properties of WT. Briefly, the pipette solution consists of (in mM) 110 CsF, 10 NaF, 20 CsCL, 2 EGTA, 10 HEPES, with a pH of 7.35 and osmolarity of 300 mOsmof/kg. The bath (control) solution contains in (mM): 145 NaCl, 4 KCl, 1.3 CaCl 2 , 1 MgCl 2 , 10 dextrose, 10 HEPES, with a pH of 7.35 and osmolarity of 310 mOsmol/kg. Cells are 15 allowed to stabilize for 10 min after establishment of the whole-cell configuration before current is measured. Series resistance is compensated 90% to assure that the command potential is reached within microseconds with a voltage error <2 mV. Leak currents are subtracted by using an online P14 procedure and all currents are low-pass Bessel filtered at 5 kHz and digitized at 50 kHz. 20 [07671 For clarity, representative ramp currents are low pass filtered off-line at 50 Hz. Specific voltage-clamp protocols assessing channel activation, fast inactivation and availability during repetitive stimulation are used. Results are presented as mean+ SEM.,. [07681 Tonic block of peak current is measured using a step to -10mV (20ms) from a 25 holding potential of -120mV (0.2Hz). Use-dependent block of peak current is measured during pulse number 300 of a pulse train (-10 mV, 5 ms, 300 pulses, 10Hz or 25Hz) from a holding potential of -120 mV. Two sequential pulse train stimulations are averaged to obtain mean current traces for each recording condition, which are then used for offline subtraction and analysis. 30 [07691 For use-dependent studies, cells are stimulated with depolarizing pulse trains ( 10 mV, 5 ms, 300 pulses, 10 and 25Hz) from a holding potential of -120 mV. Currents 366 are then normalized to the peak current recorded in response to the first pulse in each frequency train. For tonic block studies, peak current is evaluated in response to a 20 ms depolarization to -10 mV (0.2 Hz). Data analysis is performed using Clampfit 9.2 (Axon Instruments, Union City, CA, U.S.A), Excel 2002 (Microsoft, Seattle, WA, U.S.A.), and 5 OriginPro 7.0 (OriginLab, Northampton, MA, U.SA) software. Results are presented as mean*+ SEM. In vitro Pharmacology [07701 A stock solution of 10mM compound of Formula I is prepared in 0.1 M HCL or DMSO. A fresh dilution of the compound of Formula I in the bath solution is prepared 10 every experimental day and the pH is readjusted to 7.35 as necessary. The final DMSO concentration was kept at 0.1% in all solutions. Direct application of the perfusion solution to the clamped cell is achieved using the Perfusion Pencil system (Automate, Berkeley, CA). Direct cell perfusion is driven by gravity at a flow rate of 350 Izmin using a 250 micron tip. This system sequesters the clamped cell within a perfusion stream 15 and enables complete solution exchange within 1 second. The clamped cell is perfused continuously starting immediately after establishing the whole-cell configuration. Control currents are measured during control solution perfusion. [07711 Solutions are perfused for three minutes prior to current recordings to allow equilibrium (tonic) drug block. Tonic block of peak currents is measured from this 20 steady-state condition. Three sequential current traces are averaged to obtain a mean current for each recording. The mean current traces are utilized for offline analysis. Use dependent block of peak current is measured during pulse number 300 of the pulse train, (-10 mV, 5 ms, 300 pulses, 10Hz) from a holding potential of -120 mV. Two sequential pulse train stimulations are averaged to obtain mean current traces for each recording 25 condition, which are then used for offline subtraction and analysis Where appropriate, concentration inhibition curves are fit with the Hill equation: Hm= 1/[1+1 0A(logICSo 1)*k], where ICso is the concentration that produces half inhibition and k is the Hill slope factor. Results 30 [0772] Using the above methods it may be demonstrated that the compounds of the disclosure are selective for inhibiting cardiac Late Ina current without inhibiting peak and low frequency currents of brain isoforms NaV 1.1 and 1.2. The compounds of the 367 disclosure may inhibit the very high frequency firing of Na,1.1 and Na,1.2 or demonstrate voltage dependent block of mutant Nav 1.1 and Nav1.2 observed with epilepsy patients. In addition compounds of this disclosure may show activity for inhibition of a panel of Nav1.1 mutant channels associated with the epilepsy and headache (migraine) syndromes 5 GEFS+, SMEI and FHM3 suggesting the ability of the compounds of the disclosure to preferentially block the abnormal increased persistent current carried by these mutant channels. disclosure [07731 When tested in the assay disclosed above for hNa, 1.1 and hNa, 1.2 sodium channel isoforms, Compound 11-73 blocked the hNa, 1.1 sodium channel isoform peak 10 INa with IC0 value of>100 piM at a frequency of 10 Hz and the hNa, 1.2 sodium channel isoform peak )Na with ICso value of> 30 pM at the same frequency. At higher frequency of 25 Hz the compound 11-73 blocked both hNa, 1.1 and hNa, 1.2 isoforms with IC5o of 3.4 pM and 10.1 pM respectively. The inhibition of either hNa, 1.1 and hNa, 1.2 isoforms or the inhibition of both channels when stimulated at these frequencies support 15 the use of compounds of this disclosure to treat patients with epilepsy. Table 3: Late IN, Assay results Late NAV1.1* NAV1.2* RIEART No. INS* UDW1OHZ UDB-10HZ hERG MAPD90 ATX* H-7 34 0 13 -10 H-10 43 -4 9 11-14 47 16 19 11-17 59 <10 H-22 30 3 15 16 11-42 34 2 12 -27 U-46 25 2 16 11-61 41 9 25 <10 -62 11-73 42 10 19 18 -56 11-75 68 35 52 11-83 31 -2 10 21 368 N Late NAV1.1* NAVI.2* ' RG RHEART No. Ir* UDB-10HZ 'UDB-10 Z MAPD90 ATX* 11-88 41 -10 -1 26 -69 11-91 54 -9 -3 11-98 39 -1 -8 <10 -50 11-105 45 -17 1 <10 H-110 35 -4 -2 26 1-117 37 -11 -18 <10 11-129 33 8 7 17 -49 11-138 47 21 40 11-143 65 29 44 11-156 48 -23 rn-1 33 -1 -3 <10 -47 V-5 49 -18 3 VI-4 61 5 18 30 -25 VTI-6 38 6 20 <10 -49 X-8 59 -12 -14 <10 XH1-1 53 -1 -4 XI-8 36 11 11 -34 * %Inhibition at I uM Example 266 Ischemia-induced ST segment elevation in anesthetized rabbits 5 [0774] This study was undertaken to determine the anti-ischemic effects of compounds of the present disclosure in an in vivo rabbit model. Methods: [0775] Female New Zealand rabbits (3.0-4.0 kg) were purchased from Western Oregon Rabbitry. Animals were housed on a 12-h light and dark cycle and received standard 369 laboratory chow and water. All experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by The National Research Council and with the experimental protocol approved by the Institutional Animal Care Committee of Gilead Sciences, Inc. 5 [07761 Rabbits were anesthetized with ketamine (35 mg/kg) and xylazine (5 mg/kg) intramuscular injection (im). A tracheotomy was performed and the trachea was intubated with an endotracheal tube. The animal was ventilated with room air supplemented with oxygen using a pressure control animal ventilator (Kent Scientific Corp., Torrington, CT) at a respiratory rate of 40 strokes/min and peak inspiration pressure of 10 mmH20, which 10 was adjusted to keep blood gases and pH within the physiological range (iSTAT clinic analyzer, Heska Corp.; Waukesha, WI). The left femoral artery was cannulated for the measurement of blood pressure (BP). Blood samples were also withdrawn from femoral artery. The right external jugular vein was cannulated for drug/vehicle administration. Needle electrodes were inserted subcutaneously into the limbs for recording of the surface 15 electrocardiogram (ECG). The heart was exposed via an incision in the 4 intercostal space (4 and /or 5h ribs were cut for a clear surgical vision). The chest was opened and a pericardial cradle was formed using 4 retractors. A coronary artery occluder, comprised of a snare made of 5 cm PE-10 tubing with a 6-0 Prolene polypropylene suture in it, was placed loosely around the left anterior descending artery (LAD) at its origin. Two 20 unipolar electrodes, made with teflon coated silver wire attached to a small patch of filter paper, were attached on the surface of the ischemic and normal regions of the left ventricle to record epicardial electrocardiogram. Reference electrodes were placed in the open incision of the neck. The body temperature of the animal was monitored via a rectal thermometer and maintained at 37-40*C by adjusting the surface temperature of the 25 surgical table. Regional ischemia (15 min) was induced by ligating the LAD followed by 15 min of reperfusion caused by releasing the ligation. The heart was excised at the end of the experiment and the LAD was re-ligated. The ischemic area was visualized by perfusing the heart with 1% Evans blue in saline and calculated as a percentage of total ventricular weight. Rabbits with ischemic area less than 10% or larger than 25% were 30 excluded from the analysis. Animals were randomly assigned to vehicle and test compound groups. Test compounds was dissolved in 5% NMP, 30% PG, 45% PEG 400 and 20% de-ionized water (dH20). Test compound was given as an iv bolus at 0.1, 0.2 370 and 0.4 mg/kg. After 30 min of dosing, the heart was subjected to 15 min of ischemia followed by 15 min of reperfusion. Results: [0777] The compound of Example 11-61 dose-dependently prevented the ischemia 5 induced ST elevation. The area under curve (AUC) for the ST segment height was reduced (vs. control) by 38% and 88% at 0.28 and 0.52 gM plasma concentration of compound of Example 11-61. At the plasma concentration levels studied, compound of Example 11-61 had no significant effect on blood pressure (BP), heart rate (HR) and ECG intervals prior to the ischemia. The data suggests the compound of Example 1-61 10 prevents ischemia-induced myocardial electrical dysfunction in a dose-dependent manner. [0778] Similarly, compound of Example 11-73 dose-dependently prevented the ischemia-induced ST elevation. The area under curve (AUC) for the ST segment height was reduced (vs. control) by 55% and 93% at 0.25 and 0.5 1 ±M respective plasma concentration of compound of Example 11-73. At the plasma concentration levels studied, 15 compound of Example 11-73 had no significant effect on blood pressure (BP), heart rate (HR) and ECG intervals prior to the ischemia. The data suggests the compound of Example 11-73 prevents ischemia-induced myocardial electrical dysfunction in a dose dependent manner. [0779] Reference to any prior art in the specification is not, and should not be taken as, 20 an acknowledgment, or any form of suggestion, that this prior art forms part of the common general knowledge in Australia or any other jurisdiction or that this prior art could reasonably be expected to be ascertained, understood and regarded as relevant by a person skilled in the art. [0780] As used herein, except where the context requires otherwise, the term 25 "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude other additives, components, integers or steps. 371

Claims (8)

1. A compound of Formula III: (R10)n - | ,R2 N R R3 o R 4 R 4 III R2 is -L-R', -L-C 1 - 6 alkylene-R 5 , -C 1 . 6 alkylene-L-R or -CI- 6 alkylene-L-CI. 6 alkylene-R 5 ; wherein each -C 1 - 6 alkylene is optionally substituted by one substituent independently selected from the group consisting of C 2 . 4 alkynyl, halo, -NO 2 , -CN, -O-R 20 , -N(R2)(R ), -C(O)-R20, -C(O)-OR2, -C(O) N(R20)(R ), -N(R2)-S(O) 2 -R20, cycloalkyl, aryl, heteroaryl or heterocyclyl; and wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 . 6 alkyl, C 2 -4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 20 )(R 22 ), -C(O)-R 20 , -C(O)-OR20, -C(O) N(R20)(R 22 ), -CN and -O-R 2 0 ; L is -0-, -S-, -NHS(O) 2 -, -S(0) 2 NH-, -C(O)NH- or -NHC(O)-, provided that when R2 is -L-R 5 or -L-C 1 - 6 alkylene-R 5 , then L is not -0-, -S-, -NHS(O) 2 - or -NHC(O)-; each R 3 is independently hydrogen, deuterium, C 1 . 15 alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said C 1 - 15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, N(R 20)(R ), -C(O)-R 20 , -C(O)-OR20, -C(O)-N(R 2)(R2), -CN and -O-R 20 ; wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , C1. 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 20 )(R 22 ), -C(O) R2', -C(O)-OR 20, -C(O)-N(R2)(R ), -CN and -O-R20; and wherein said C 1 . 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, NO 2 , -N(R 2 0 )(R 22 ), -C(O)-R20, -C(O) OR 2 0 , -C(O)-N(R 20 )(R 2 2 ), -CN and -O-R 2 0 ; each R 4 is independently hydrogen, deuterium, C 1 .- 1 5 alkyl, C4 alkoxy, -C(O) OR6, -C(O)-N(R 2 6 )(R 2 6 ), -N(R 20 )-S(O) 2 -R 2 0 , cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein said Cs 15 alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 0 )(R 2 2 ), C(O)-R20, -C(O)-OR20, -C(O)-N(R 20 )(R 22 ), -CN and -O-R20 wherein said cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , CI. 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R 2 0 )(R 2 ), -C(O)-R20, -C(O) OR20, -C(O)-N(R 20 )(R 22 ), -CN and -O-R 2; and wherein said C 1 . 6 alkyl, aralkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, are optionally further substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, NO 2 , -N(R 20 )(R 22 ), -C(O) R20, -C(O)-OR20, -C(O)-N(R 2 0 )(R 22 ), -CN and -O-R 20 ; or two R 3 or two R 4 together with the carbon atom to which they are attached form an oxo; R' is cycloalkyl, aryl, heteroaryl or heterocyclyl; '1-7'1 wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of C 1 . 6 alkyl, C 2 - 4 alkynyl, halo, -NO 2 , cycloalkyl, aryl, heterocyclyl, heteroaryl, -N(R20)(R ), -N(R2)-S(O) 2 -R20, -N(R ) C(O)-R 2 , -C(O)-R 2 0 , -C(O)-OR 20 , -C(O)-N(R20)(R ), -CN and -O-R20 wherein said C 1 . 6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , CI- 6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, N(R2)(R ), -C(O)-R 20 , -C(O)-OR 2 0 , -C(O)-N(R2)(R ), -CN and -O-R2; and wherein said C 1 - 6 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally further substituted with one, two or three substituents independently selected from the group consisting of halo, aryl, -NO 2 , -CF 3 , -N(R 20 )(R 2 2 ), -C(O) R20, -C(O)-OR20, -C(O)-N(R20)(R ), -CN, -S(O) 2 -R 20 and -O-R 20 ; n is 0, 1, 2, 3, 4 or 5; each R1 0 is independently selected from the group consisting of halo, -NO 2 , CN, -SF 5 , -Si(CH 3 ) 3 , -O-R 20, -S-R2 , -C(O)-R20, -C(O)-OR2, -N(R20)(R ), -C(O) N(R20)(R ), -N(R2 )-C(O)-R , -N(R20)-C(O)-OR , -N(R2)-S(O) 2 -R26, -S(O)2 R 2, -O-S(O) 2 -R20, -S(O) 2 -N(R 20 )(R 2 2 ), Ci-6 alkyl, C24 alkenyl, C 2 - 4 alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein said C 1 . 6 alkyl, C 2 - 4 alkenyl, C2A alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO 2 , phenyl, heterocyclyl, heteroaryl, C 1 .- 6 alkyl, C 1 . 3 haloalkyl, cycloalkyl, -N(R 20)(R ), -C(O)-R 2, -C(O)-OR20, -C(O)-N(R20)(R ), -CN and -O-R 20 ; R20 and R 22 are in each instance independently selected from the group consisting of hydrogen, CI- 15 alkyl, C 2 - 15 alkenyl, C 2 - 15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; 'I7 A wherein the CI- 1 5 alkyl, C 2 - 1 5 alkenyl, C 2 - 15 alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Ci 4 alkyl, acylamino, oxo, -NO 2 , -S(O) 2 R2, -CN, C 1 . 3 alkoxy, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -C(O)-NH 2 , aryl, cycloalkyl and heteroaryl; and wherein said heteroaryl is optionally further substituted with C 14 alkyl or cycloalkyl; or when R 2 0 and R 2 are attached to a common nitrogen atom R 2 0 and R2 may join to form a heterocyclic or heteroaryl ring which is then optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, Cia alkyl, aralkyl, aryloxy, aralkyloxy, acylamino, -NO 2 , -S(O) 2 R26, -CN, C 1 - 3 alkoxy, -CF 3 , -OCF 3 , aryl, heteroaryl and cycloalkyl; and each R 2 6 is independently selected from the group consisting of hydrogen, Ci 4 alkyl, aryl and cycloalkyl; and wherein the Ci 4 alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, Ci 4 alkoxy, -CF 3 and -OCF 3 ; or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof.

2. A compound selected from the group consisting of: pyrimidin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)methanone (III-1); phenyl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[fj[1,4]oxazepin-4(5H) yl)methanone (111-4); (1 -methylcyclopropyl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)methanone (III-10); (3,3-difluorocyclobutyl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo [f] [1,4] oxazepin-4(5H)-yl)methanone (III-11); (1-methyl-i H-pyrazol-4-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)methanone (111-12); (1 H-pyrazol-3 -yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (111-15); pyrazin-2-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)methanone (111-23); pyridazin-3-yl(7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)methanone (111-24); 2-(pyridin-2-yl)- 1 -(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)ethanone (111-29); 2-(pyrimidin-2-yl)-1-(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)ethanone (111-30); (1-methyl-iH-imidazol-5-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (111-32); (1H-imidazol-2-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (111-33); (1-methyl-iH-imidazol-2-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (111-37); (R)-(2-methyl-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin 4(5H)-yl)(pyrimidin-2-yl)methanone (111-38); tert-butyl 2-(7-(4-(trifluoromethyl)phenyl)-2,3,4,5 tetrahydrobenzo[f][1,4]oxazepine-4-carbonyl)-5,6-dihydroimidazo[1,2 a]pyrazine-7(8H)-carboxylate (111-40); (1H-1,2,4-triazol-3-yl)(7-(4-(trifluoromethyl)phenyl)-2,3 dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methanone (111-50); and (1,5-dimethyl-1H-pyrazol-3-yl)(7-(4-(trifluoromethoxy)phenyl)-2,3 dihydrobenzo[fj[1,4]oxazepin-4(5H)-yl)methanone (111-58); or a pharmaceutically acceptable salt, ester, stereoisomer, mixture of stereoisomers or tautomer thereof.

3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound of claim 1 or 2 or a pharmaceutically acceptable salt, thereof.

4. A method of treating a disease state in a mammal that is alleviable by treatment with an agent capable of reducing late sodium current effective in the treatment of conditions or diseases known to respond to administration of late sodium channel blockers, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound according to claim 1 or 2.

5. The method of claim 4, wherein the disease state is a cardiovascular disease selected from one or more of atrial arrhythmias, ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable angina, unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension and intermittent claudication.

6. The method of 4, wherein the disease state is diabetes or diabetic peripheral neuropathy.

7. The method of 4, wherein the disease state results in one or more of neuropathic pain, epilepsy, migraine, seizures or paralysis.

8. Use of a compound according to claim 1 or 2 in the manufacture of a medicament for treating one or more diseases selected from atrial arrhythmias, ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable angina, unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension and intermittent claudication.